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The importance of aquaporins in normal as well as pathophysiological 
conditions has been well established by various studies. Yet these reports also 
highlight the lack and the need of natural regulators that could modulate the 
aquaporin expression. This study attempts to identify natural modulators for 
aquaporins and focuses on the widely prevalent endogenous cellular 
modulators, microRNAs. The entire aquaporin family consists of thirteen 
members classified into two major catergories as classical aquaporins and 
aquaglyceroporins. The initial study explored for possible microRNA regulators 
for the three commonly studied aquaporins, namely aquaporins 1, 2 and 4. 
Using one of the microRNAs that were identified, the study was extended into 
an in vivo animal model. Particular interest was on aquaporins 1 and 4 as they 
were highly implicated in brain associated pathologies. A relatively new 
phenomenon of transcriptional modulation by microRNAs was also explored in 
this study. As two different isoforms of aquaporin 4 were identified in the brain, 
the study investigated the potential to regulate the transcription of the longer 
aquaporin 4 isoform that is considered important in cerebral ischemia. Finally 
an attempt to identify a microRNA based regulator for aquaglyceroporin 9 was 
made for it is also expressed in the brain and considered to be crucial for energy 
metabolism. Thus the use of microRNAs as modulators for aquaporins 1, 2, 4, 
and 9 were explored in this thesis with emphasis on brain aquaporins 1, 4 and 9. 
This study provides evidence of possible microRNAs that could be used to 
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1.1.1 The discovery of aquaporins 
Water makes up more than two thirds of the weight of human body. Diffusion of 
water molecules across the lipid bilayer into or out of a cell is an uninhibited yet 
slow process which was deemed insufficient for cells requiring high water 
permeability, such as red blood cells and kidney epithelial cells [1]. Thus the 
organization of the cellular structures is crucial in controlling the water content in 
both the internal and external environment. Small and neutral molecules can easily 
traverse the lipid bilayers of the cells. Then again charged or polar molecules might 
not be able to do so as the hydrophobic tails of the lipid bilayers create an energetic 
barrier against their movement. Thus such molecules require special pathways and 
often membrane channels play important roles in forming these pathways for 
selective exchange. Although several scientists postulated the presence of water 
channels [1] which would allow the movement of water molecules at a much faster 
rate compared to the simple diffusion process, the identification of the actual water 
channel protein itself eluded many until Peter Agre and his team made a 
serendipitous discovery. The team stumbled upon the water channels when the 
antibodies they were trying to raise against a denatured partially purified Rhesus 
polypeptide, picked up a 28kDa unknown protein [2]. Further experimental studies 
showed that the unknown protein was actually a membrane water channel. It 
became the first functionally defined water channel protein, later named as 
Aquaporin 1 (AQP1) [3]. Since then, studies on the roles of AQPs in physiological  
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as well as patho-physiological conditions have been steadily increasing [4-5]. 
 
1.1.2 The aquaporin family 
AQPs are a family of small hydrophobic, integral membrane proteins that are 
expressed in all living organisms with overall primary sequences of AQPs showing 
about 19 to 52% homology. These integral proteins form transmembrane water 
channels that play critical roles in controlling the water flow into and out of cells 
[3]. To date, 13 different AQPs have been identified in mammals, AQP 0-12. These 
channels facilitate efficient permeation of water, which is of importance in 
preserving the electrochemical potential across the cell membrane. Functional 
studies indicate that most AQPs are capable of permeating water at varying 
degrees. However recent studies show that some AQPs are also capable of 
permeating other small solutes such as anions, urea and glycerol. Thus AQPs have 
been reclassified into three subgroups: classical AQPs, aquaglyceroporins and 
super-AQPs. AQP 0, 1, 2, 4 and 5 are considered to be only permeable to water and 
thus grouped as classical AQPs [3]. Although AQP6 has been proposed to be a pH 
sensitive chloride channel or possibly a nitrate channel [6] and AQP8 has been 
found to be permeable to urea and ammonia [7-8], they are both categorized under 
the classical AQPs. AQPs 3, 7, 9 & 10 are permeable to glycerol and other small 
solutes such as urea, and thus termed as aquaglyceroporins [3]. The two most 
recent additions to the family are AQP11 and AQP12 [9]. These two AQPs have 
been classified as the super-AQPs or subcellular-AQPs. Controversial reports with 
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regards to the water permeability of AQP11 [10-11] exist whereas AQP12 knock-
out models showed no physiological changes under normal conditions [12].  
 
1.1.3 Localization and structure of aquaporins 
1.1.3.1 Localization 
Characterization of the first six AQPs (AQP0–5) was conducted at a relatively 
rapid pace due to their expression in physiologically well-characterized tissues. On 
the other hand, the subsequent seven members (AQP6–12) were relatively new and 
poorly characterized due to their expression in unexpected tissues [13]. AQPs were 
initially found to be mainly expressed in fluid transporting epithelial and 
endothelial cells (Table 1.1). However, a few AQPs have now been identified in 
non-fluid transporting cells such as adipocytes as well.   
 
AQP0, found exclusively in the eye lens, has been implicated in a variety of 
cellular functions such as glycerol transport, cell adhesion and gap junctions. Its 
main role has been considered as regulating the circulation of lens fluid and thus 
maintaining the transparency of the lens since it makes up almost 60% of the lens 
total protein [14]. AQP0 may also be important to transport water, nutrients, or 
oxygen as lenses are devoid of blood vessels. More recently its expression has been 




AQP1 was the first water channel to be identified from erythrocytes nevertheless 
their functional role is not yet elucidated as both wild type and AQP1 null mice 
show no blood abnormalities [16]. However an important functional role in the 
kidneys has been show where its expression is considered crucial for urine 
concentration in humans and rats. Apart from erythrocytes and kidneys, AQP1 is 
also expressed widely in a variety of tissues such as gall bladder, lung, peritoneum, 
lymphatic vessels, secretory granules, eye, ear, testis, ovaries and brain (Table 1.1) 
[17-19].   
 
AQP2 is a vasopressin-sensitive water channel highly expressed at the apical 
membrane of principal cells of the collecting ducts of the kidney. However, unlike 
AQP1, AQP2 is found to be compartmentalized in intracellular vesicles in kidneys 
and gets rapidly translocated to the apical plasma membrane when urine 
concentration is required [20-22]. Mutations in the AQP2 gene lead to abnormal 
trafficking of the protein and results in nephrogenic diabetes insipidus (NDI) (Table 
1.2). In addition to the kidney, AQP2 has been reported to be expressed in the vas 
deferens [23] and less abundantly in the inner ear [24]. 
 
Besides transporting water molecules, human AQP3, mediates movement of small 
non-ionic molecules such as glycerol and thus it is classified as an 
aquaglyceroporin [25]. AQP3 is highly expressed at the basolateral plasma 
membrane of kidney collecting-duct epithelial cells and is considered important for 
urine concentration. Its expression is also observed in the urinary tract, digestive 
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tract, respiratory tract, skin, eye, and brain [26-28]. Osmotic stress seems to 
upregulate the expression of AQP3 gene [26].  
 
In humans, two different isoforms of AQP4 (M1 and M23) have been shown to 
exist due to different transcriptional initiation locations [29]. AQP4 is expressed in 
the collecting ducts, lung, skeletal muscle, stomach, brain, eye and ear [30-32]. 
AQP4 is co-localized with AQP3, in the basolateral membranes of the collecting 
ducts in the kidneys [31] and it is thought to play a role in urine concentration as 
well. It is considered as the major AQP expressed in the central nervous system. In 
the brain where AQP4 is abundantly expressed, it is implicated in the formation of 
brain edema [29, 32-33] 
 
AQP5 exhibits high sequence homology to AQP2. It is highly expressed in the 
salivary glands, gastrointestinal tract, lung, airway glands, pancreas, eye, ear and 
sweat glands [34-37]. Liu et al [38] examined the changes in AQP1 to AQP5 gene 
expression in the fetal lung of a long-gestation species (sheep) and showed that 10 
days of tracheal obstruction, which decreases fluid formation, significantly 
decreased AQP5 mRNA levels, indicating that AQP5 is involved in clearing the 




Table 1.1: Localization of AQPs in various systems.  
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Transition 430 A to G E134G Misrouted 





Transversion 191 C to A A45V Blood Incompatibility 








Premature stop codon 
Truncated protein 
369 C 





1502 G to A  
Splicing error. No transcript 
produced. 
599 C to T R187C 
Non-functional protein. Unable 
to oligomerize. Possibly 
degraded 
588 G to A R187H Not Known 
190 G to A G64R 
No water channel in plasma 
membrane 
646 T to C S216P Non functional protein 
533 G to A A147T Functional protein but misrouted 
471 C to T T126M Functional protein but misrouted 
297 A to G N68S Non-functional protein 
374 C to T T125M 
Reduced functionality due to 
distorted structure 
523 G to A G175R 
Reduced functionality due to 
distorted structure 
Transversion 
149 C to G L22V Reduced functionality 
628 C to G C181W Non- functional protein 
170 A to C Q57P Misrouted proteins 
299 G to T G100V Misrouted 
240 C to A A70D Not Known 
Dominant NDI 
 
Transition G866A E258K 
Functional protein but misrouted 















G347C V59L Unknown 
C206T R12C Unknown 
Transversion G963T G264V Diminished glycerol release 
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AQP6 has been found to be localized as intracellular vesicles within the kidney 
cells [6, 39] and it shows 52% sequence homology to AQP2. However unlike 
AQP2, AQP6 does not seem to have any stimulus for plasma membrane 
trafficking. In fact, the N-terminus of AQP6 seems to contain the signal for 
intracellular trafficking [40]. Although its role in cellular function is not clear, 





AQP7, an aquaglyceroporin, exhibits highest homology to AQP3 [41]. Besides 
allowing the passage of water molecules, it is also capable of transporting glycerol, 
urea and arsenite [42-44]. AQP7 is widely expressed in testis, proximal kidney 
tubules, gastrointestinal tract, immature dendritic cells and the ear [41-44]. 
Although the exact role of AQP7 in these locations, are not clear, in the kidneys it 
is considered involved in glycerol reasbsorption and in the testis it has been 
implicated in volume reduction in maturing spermatids. AQP7 is also highly 
expressed in adipocytes, a non-fluid transporting cell where it probably functions as 
an aquaglyceroporins.  
 
AQP8 has been found to be permeable to urea, ammonia but surprisingly not to 
glycerol [8, 45-46]. It is expressed extensively in many tissues including the 
pancreas, liver, colon, salivary gland, kidney, testis, epididymis, lung, trachea, and 
placenta and predominantly in the gastrointestinal tract [8, 45-49]. AQP8 localized 
in mouse gall-bladder epithelium has been postulated to play a role in the bile 
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synthesis and secretion [50]. In the rat kidney cortex AQP8 was found to be 
localized to the inner mitochondrial membrane, it has been suggested that it may be 
involved in mitochondrial swelling and cell death in certain pathological conditions 
[48]. However a phenotypic analysis of AQP8 knock-out mice showed normal liver 
physiology suggesting a non-significant functional role for AQP8 in the 
mitochondria [51].  
 
AQP9 identified in human leukocytes, is an aquaglyceroporin with broad substrate 
specificity [52]. It has been found to be highly permeable to water and other non-
charged small solutes such as glycerol, urea, lactate, arsentite, purines and 
pyrimidines. The high permeability rate of AQP9 to water and small solutes has 
implicated its role in rapid cellular uptake and exit of metabolites with minimal 
osmotic perturbation [53]. Two
 
isoforms of AQP9 have been detected in the brain 
in astrocytes and midbrain dopaminergic neurons [54]. The longer isoform, similar 
to that identified in the liver, is localised to the plasma membrane while the shorter 
isoform was found to be expressed in the mitochondrial membrane [54].
  
 
Under physiological conditions, the flux of lactate and other metabolites
 
through 
AQP9 may confer an advantage by allowing the mitochondria
 
to adjust to the 
metabolic status of the cytoplasm. However, Yang et al [55] reported non 
significant glycerol permeability in brain mitochondria, casting doubt on the 
expression of mitochondrial AQP9.  AQP9 is also expressed in the testis, intestinal 
wall, liver, lung, spleen and ear (Table 1.1). Expression of AQP9 in the intestinal 
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wall suggests a role in mucus production or secretion [56] whereas expression in 
the spermatocytes, efferent duct and principal cells of the epididymis and vas 
deferens might suggest roles in sperm maturation and storage. AQP9 expressed in 
the hepatocytes has been thought to work together with AQP7 expressed in the 
adipocytes. AQP7 helps with the release of glycerol from the adipocytes while 
AQP9 transports it into the hepatocytes for gluconeogenesis [57].  
 
Human AQP10, the last aquaglyceroporin to be identified to date, is capable of 
transporting water, glycerol and urea [58]. Hybridization studies show that AQP10 
is localized to the absorptive epithelial cells in the small intestine [59] and is 
believed to be participating in the secretion of polypeptide hormones from gastro-
entero-pancreatic cells [60]. 
 
The human genome project revealed a possibility of two additional AQP genes, 
AQP11 and AQP12 [9, 61]. AQP 11 of about 26 kDa in size has been found to be 
widely expressed in the kidney and liver with the highest expression in the testis 
[62]. In the rat brain, AQP11 is expressed in Purkinje cells, hippocampal neurons 
of CA1 and CA2, and cerebral cortical neurons [10]. Localization studies showed 
that AQP11 is retained intracellularly and it is co-localized with an endoplasmic 
reticulum marker. Unlike the other AQPs, AQP11 has only one conserved NPA 




Human AQP12 gene has an open reading frame that encodes a protein of 295 
amino acids with a calculated molecular mass of 31 kDa [63]. Like AQP11, AQP12 
has only one conserved NPA motif. AQP12 has been found to be expressed 
specifically in the acinar cells of the pancreas. This suggests a possible role for 
AQP12 in the synthesis of digestive enzymes. In fact, when pancreatitis was 
induced in AQP12 null mice, using cholecystokinin-8 (CCK-8) analog, the animals 
suffered from severely damaged prancreas [12]. 
   
1.1.3.2 Structure of aquaporins  
An AQP monomer, ranging from 26 to 34 kDa in size, is made up of six membrane 
spanning segments (Figure 1.1A) with three extracellular and two intracellular 
loops [64]. The amino and carboxyl ends of the monomer are embedded within the 
cytoplasm [65]. The two loops B and E act as the hemipores which fold into the 
plasma membrane to form the functional water pore (Figure 1.1B). Within the 
hemipores, two highly conserved hydrophobic amino-acid sequences, Asparagine-
Proline-Alanine (NPA), considered crucial for the movement of water molecules 
exist (Figure 1.2). The more recently discovered AQP11 and AQP12 have been 
shown to possess a variant NPA box. While their second NPA box is conserved, 
the alanine residue in the first box of AQP11 and AQP12 is replaced by cysteine 
and threonine (Figure 1.2) respectively [66]. Although the helices and loops of an 
AQP monomer are capable of folding together, into a structure representing that of 
an hour-glass, to form an independent water channel by itself (Figure 1.3A), freeze-
fracture studies show that each AQP exists as a homo-tetramer (Figure 1.3B) within 
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the plasma membrane  [67]. Thus each AQP contains four functional monomers 
which allow for independent water movement.   
 
1.1.4 Transport of molecules via aquaporins 
1.1.4.1 Water transport 
Each AQP has water permeability of about 3 x 10
9
 water molecules per second. 
Specificity for water movement across the AQP water channels has been postulated 
to occur through two means; size restriction and electrostatic repulsion [68-70]. 
Size restriction itself is caused by two factors. The first and narrowest constriction 
is located close to the opening of the pore towards the extracellular side. This 
region is termed as the aromatic/arginine (ar/R) constriction. In classical AQPs this 
region is approximately 3 Å wide, slightly larger than a single water molecule with 
a diameter of 2.8 Å. The narrowness of the pore allows water molecules to move 
only in a single file with only one water molecule passing through the pore at a 
time (Figure 1.4A). The ar/R constriction is formed by the interaction of four amino 
acids located within the pore [68]. In AQP1 these residues are: F-56 (Phe) located 
in transmembrane (TM) 2, H-180 (His) located in TM5, C-189 (Cys) and R-195 
(Arg) from loop E [69-71].  
 
The second constriction is located within the pore next to the conserved NPA 
region. The two asparagines located within the pore act as hydrogen donors to the 
oxygen atoms of passing permeants. Water that enters this region is re-oriented 
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such that hydrogen bonds between neighbouring water molecules are disrupted. 
This mechanism prevents the formation of a proton wire throughout the pore and 
represents a major energy barrier for proton conductance [69]. The second mode 
for specificity occurs through electrostatic repulsion [68-69]. The electrostatic 
forces from the residues surrounding the NPA region as well as the ar/R region 
enable the exclusion of protons. The conserved arginine and histidine residues 
lining the pores (Figure 1.4B) possess a positive charge and prevent the entry of 
any positively charged molecules or protons into the water channel. [69-71]. 













Figure 1.1: (A) Amino acid sequence of AQP 1. Extracellular loops are 
represented by A, C & E. Intracellular loops are represented by B & E. The amino 
and carboxyl tails are also located intracellularly. Figure was reproduced with 
permission from Preston et al [64]. (B) Hourglass structure of AQP. The hour-
glass figure represents the six transmembrane helices and the conserved hemipore 







       
 
Human_AQP0      GLGSSLRWA-------PGPLHVLQVAMAFGLALATLVQSVGHISGAHVNPAVTFAFLVGS 79 
Human_AQP1      SIGSALGFKYPVGNNQTAVQDNVKVSLAFGLSIATLAQSVGHISGAHLNPAVTLGLLLSC 87 
Human_AQP2      GLGSALNWP-------QALPSVLQIAMAFGLGIGTLVQALGHISGAHINPAVTVACLVGC 79 
Human_AQP3      GCGSVAQVVLSR----GTHGGFLTINLAFGFAVTLGILIAGQVSGAHLNPAVTFAMCFLA 94 
Human_AQP4a     SLGSTINWG---GTEKPLPVDMVLISLCFGLSIATMVQCFGHISGGHINPAVTVAMVCTR 108 
Human_AQP4b     SLGSTINWG---GTEKPLPVDMVLISLCFGLSIATMVQCFGHISGGHINPAVTVAMVCTR 86 
Human_AQP5      GLGSALKWP-------SALPTILQIALAFGLAIGTLAQALGPVSGGHINPAITLALLVGN 80 
Human_AQP6      GVGSVMRWP-------TALPSVLQIAITFNLVTAMAVQVTWKASGAHANPAVTLAFLVGS 93 
Human_AQP7      GLGSVAHMVLN-----KKYGSYLGVNLGFGFGVTMGVHVAGRISGAHMNPAVTFANCALG 105 
Human_AQP8      GCLSVIENG--------TDTGLLQPALAHGLALGLVIATLGNISGGHFNPAVSLAAMLIG 103 
Human_AQP9      GCGCVAQAILSR----GRFGGVITINVGFSMAVAMAIYVAGGVSGGHINPAVSLAMCLFG 95 
Human_AQP10     TQGAVAQAVTSG----ETKGNFFTMFLAGSLAVTIAIYVGGNVSGAHLNPAFSLAMCIVG 93 
Human_AQP11     LCCCTHELQLLS------EQHPAHPTWTLTLVYFFSLVHGLTLVGTSSNPCGVMMQMMLG 110 
Human_AQP12     AREAMRTLVELG-----PWAGDFGPDLLLTLLFLLFLAHGVTLDGASANPTVSLQEFLMA 92 
                     
              
 
           
      --- GMYYTGAGMNPARSFAPAILTGNFT-----------NHWVYWVGPIIGGGLGSLLYDFLLFP---- 225 
      --- AIDYTGCGINPARSFGSAVITHNFS-----------NHWIFWVGPFIGGALAVLIYDFILAP---- 233 
      --- GIHYTGCSMNPARSLAPAVVTGKFD-----------DHWVFWIGPLVGAILGSLLYNYVLFP---- 225 
      --- MGFNSGYAVNPARDFGPRLFTALAGWGSAVFTTGQHWWWVPIVSPLLGSIAGVFVYQLMIGC---- 267 
      --- AINYTGASMNPARSFGPAVIMGNWE-----------NHWIYWVGPIIGAVLAGGLYEYVFCPDVEF 258 
      --- AINYTGASMNPARSFGPAVIMGNWE-----------NHWIYWVGPIIGAVLAGGLYEYVFCPDVEF 236     
      --- GIYFTGCSMNPARSFGPAVVMNRFSP----------AHWVFWVGPIVGAVLAAILYFYLLFP---- 227                     
      --- GIHFTGCSMNPARSFGPAIIIGKFT-----------VHWVFWVGPLMGALLASLIYNFVLFP---- 237      
      --- LGMNTGYAINPARDLPPRIFTFIAGWGKQVFSNGENWWWVPVVAPLLGAYLGGIIYLVFIGS---- 278 
      --- GGPVSGGCMNPARAFGPAVVANHWN-----------FHWIYWLGPLLAGLLVGLLIRCFIGD---- 251 
      --- LGLNSGCAMNPARDLSPRLFTALAGWGFEVFRAGNNFWWIPVVGPLVGAVIGGLIYVLVIEI---- 268 
      --- MGANCGIPLNPARDLGPRLFTYVAGWGPEVFSAGNGWWWVPVVAPLVGATVGTATYQLLVAL---- 266 
      --- GGSLTGAVFNPALALSLHFMCFDEAFP--------QFFIVYWLAPSLGILLMILMFSFFLPW---- 260 
      --- AGPFTSAFFNPALAASVTFACSGHT--------LLEYVQVYWLGPLTGMVLAVLLHQGRLPHLFQR 248 
           
Figure 1.2: Amino acid sequence alignment of human AQPs. Partial sequences 
of the amino acid alignment of the AQP family members is shown here. H2 and H6 
represent the transmembrane helix 1 and 6 respectively. The functional loops that 
form the hemipores are labelled as loop B and E. The conserved NPA region is 
highlighted in red. The non-conserved residues in AQP11 and 12 are highlighted in 















    
Figure 1.3: (A) Crystal structure of human AQP 1 monomer (1H6I). The six 
transmembrane helices, intracellular and extracellular loops can all fold together to 
form fully functional water channel. However in a physiological condition they 
exist as tetramers. (B) Crystal structure of human AQP 1 tetramer (1J4N). The 
AQP tetramer consists of four functional water pores. However the organisation of 
the four monomers into a tetramer results in the formation of a central pore. The 
white spot in the centre signifies the postulated central pore region. All the images 

















Figure 1.4: (A) Transport of water molecules via an AQP 1 monomer. The 
regions of the protein that interact strongest with passing water molecules are 
shown in yellow. (B) Residues that interact with water molecules. Figure shows 
the amino acid residues lining the pore of the water channel. These residues are 
thought to be crucial for the interaction of the water molecules as they pass through 









1.1.4.2 Glycerol, small solutes and ion transport    
Despite the common structural layout, aquaglyceroporins are able to permeate 
glycerol molecules through. This is made possible by changes in several amino 
acids surrounding the pore region. In aquaglyceroporins the aromatic/arginine 
(ar/R) constriction is slightly wider at about 3.4 Å, matching the diameter of a 
glycerol molecule [69-71]. Furthermore the aromatic/arginine (ar/R) region in 
aquaglyceroporins is more hydrophobic than those in classical AQPs. This is due to 
the lack of the histidine molecule and the substitution of the cysteine by a second 
aromatic residue. This feature allows aquaglyceroporins to efficiently conduct 
glycerol, small linear polyols and urea but makes them less efficient as a water 
channel [71-72]. Within the NPA pore itself, the phenylalanine found in classical 
AQPs is replaced with a leucine molecule. This somewhat widens the pore 
diameter enabling passage of glycerol [69, 71-72].  
 
AQP9 an aquaglyceroporin, is also termed as a neutral channel with broad 
spectrum permeability. Apart from water and glycerol, it has been shown to be 
permeable to urea, polyols (glycerol, mannitol, and sorbitol), purines (adenine), 
pyrimidines (uracil and the chemotherapeutic agent 5-fluorouracil), urea analogues 
(thiourea) and monocarboxylates (lactate and β-hydroxybutyrate) [53]. However 
structural studies are needed to determine the crucial amino acid residues which 




AQP6 has been proposed to be an anion channel [6]. It shows permeability to 
various ions such as iodide, bromide and chloride, with the highest permeability for 
nitrates [73]. The pore of AQP6 is lined with hydroxyl-containing residues (Tyr-34 
and Thr-63). Thr-63 is unique to AQP6, because all other aquaporins have 
hydrophobic residues at that site [73]. These residues together with the highly 
conserved asparagine residues (Asn-79 and Asn-193) are considered crucial for 
nitrate permeability. 
 
1.1.4.3 Gas movement 
Apart from water and glycerol a number of other permeants especially gas 
molecules such as oxygen (O2), carbon dioxide (CO2), nitric oxide (NO) , ammonia 
(NH3) and hydrogen peroxide (H2O2) have been reported [70, 74-76]. NO produced 
by endothelial cells was shown to be transported by AQP1 across cell membranes. 
AQP1 is expressed in endothelial and vascular smooth muscle cells. NO transport 
into vascular smooth muscle cells causes dilatation of the renal vasculature and 
other vessels [75]. CO2 is a neutral linear molecule with a diameter similar to that 
of water. Nakhoul et al [74] reported the first experiment on CO2 conductivity in 
AQP1-expressing oocytes. However lots of controversy surrounds this study. They 
concluded that AQP1 expression increased CO2 permeability of oocyte membranes 
[74]. Yet, AQP1 knockout mice used as a physiological model to study CO2 
permeability did not confirm a role for AQP1 in CO2 transport in erythrocytes and 
lung [16]. Although erythrocytes from wild-type mice exhibited seven fold 
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increases in osmotic water permeability than that from null mice, the CO2 
permeability was not significantly different.  
 
As mentioned previously, even though each monomer of an AQP molecule can 
function as an independent water channel, in the cells, they exist as tetramers. The 
organization of the AQP monomers into tetramers results in the formation of a 
central pore (Figure 1.3B). Molecular dynamics simulations showed that the 
hydrophobic central pore was much more permeable to both CO2 and O2 than the 
water pores within the monomeric structure [76-77]. However, it was postulated 
that the energy required for the gas diffusion across the lipid bilayers was much 
lower compared to that of the central pore. Thus the role of the central pore was 
considered to be crucial only in membranes with low intrinsic gas permeability or 
when AQP expression on the lipid bilayers is extensive [69, 76].  
 
1.1.5 Aquaporins in diseases 
While the functional roles and the importance of AQPs within each organ is still 
being worked out, almost every one of them starting with AQP0 to AQP12 have 
been implicated in some kind of disease state. These include congenital cataract, 






One of the leading causes for blindness in humans is the formation of cataract [78]. 
Although cataract formation is often associated with aging, congenital cataract is 
also seen in humans and one of its causes is due to mutations in AQP0 (Table 1.2). 
Mutations in the murine AQP0 gene showed the occurrence of autosomal dominant 
cataract formation [79]. This was also seen in humans where different point 
mutations resulted in dominantly inherited cataracts with
 
differing clinical features 
[80]. The two AQP0 mutations observed in the families were E134G and T138R. 
Both mutations resulted in impaired trafficking of AQP0 to the plasma membrane 
and eventually resulted in the loss of membrane water channel activity. 
Interestingly, these mutations showed different clinical outcomes with E134G 
mutation developing uni-lamellar cataracts which stabilized after birth while 
T138R mutation developed multi-focal opacities which increased
 
throughout life 
[80]. The other AQP reported to be expressed in the lens is AQP1. AQP1 
expression is seen in the epithelial cells located on the anterior surface of the lens. 
Although AQP1 knockout mice did not show any changes in the lens morphology, 
the membrane permeability was reduced by almost 3 fold. Loss of AQP1 
expression was reported to reduce lens transparency and enhance its opacification 








AQPs have more than often been implicated in cancer, especially in cell migration 
[82]. AQP1 is often extensively expressed in the endothelial cells of tumour 
vasculature. AQP1 knockout mice exhibited impaired endothelial cell migration 
due to flawed tumour vasculature formation which eventually resulted in reduced 
tumour growth [83]. The authors proposed that the absence of AQP1 in these mice 
impaired the cancer cell migration. Migrating cells form leading edges known as 
lamellipodia. Rapid water influx is necessary for the formation of these leading 
edges in motile cells and this is regulated by increasing AQP expression at the 
specific locales. A study that investigated AQP-dependent cell migration in kidney 
compared the extent of cellular migration in primary cultures of proximal tubule 
cells. AQP1-deficient mice showed more than 50% reduction in migration but this 
defect was corrected with adenoviral-mediated expression of AQP1 [84]. Others 
have also indicated AQP1 as a member of cell-cycle control proteins which could 
have potential implications in cancer [85].   
 
AQP3, also a glycerol transporter, is highly expressed in the skin epidermis and is 
often associated with skin hydration. However dysregulation of AQP3 expression 
was reported in ovarian, prostate, lung and gastro-intestinal cancers [86-89]. AQP5, 
often highly expressed in lung cancer is associated with poor prognosis. 
Overexpression of AQP5 activated several proliferation associated pathways such 
as epidermal growth factor receptor (EGFR), extracellular receptor kinase 
(ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK) [89].  In fact 
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changes in localisation of AQP1, 3 and 5 were reported in lung cancer tissues with 
potential effects in cancer cell migration and proliferation [89]. Thus modulation of 
AQP1, 3 and 5 expression levels has potential applications in cancer therapeutics.  
 
1.1.5.3 Cerebrovascular disease and edema 
Damage to the brain tissues can occur as a result of stroke, injury or trauma and 
cerebral edema often results as a secondary cause of brain damage. Edema 
formation increases complications and mortality rates mainly due to the space 
restriction imposed by the cranium on the brain. Thus managing edema formation 
could result in favourable circumstances especially in vascular diseases. AQPs 1, 4 
and 9 are extensively expressed in the brain and the central nervous system (CNS) 
with AQP4 being the predominant water channel. Changes in AQP1 and AQP4 
expression have been reported in several stroke studies [90-93]. AQP1 is 
constitutively expressed in the epithelial cells of the choroid plexus and the 
microvascular endothelia of the brain. It is often implicated with the formation of 
cerebrospinal fluid (CSF) [92, 94]. Disruption of this gene resulted in about 25% 
reduction in the production of cerebrospinal fluid as well as the intracranial 
pressure. Although a 25% reduction seems to be minimal, the survival rates of 
AQP1 null mice improved drastically from 25% to 87% [92].  AQP1 was also 
reported to be strongly expressed and co-localized with AQP4 astrocyte end-feet 




In ischemic stroke, AQP4 deletion reduced symptoms of cytotoxic edema 
formation [90]. Yet the authors also emphasized the need for its presence in 
vasogenic edema [91]. This was also evident in hemorrhagic stroke. Deletion of 
AQP4 aggravated the extent of damage caused by hemorrhagic stroke. Importance 
of AQP4 was apparent by the extent of edema formation, blood- brain barrier 
damage and neuronal death [93]. Considering the bidirectional nature of these 
channels, AQP4 is probably equally involved in both clearance and accumulation 
of fluid on a time-dependent manner. An increase in AQP9 expression was 
observed via immunohistochemistry in areas surrounding the ischemic lesion after 
48 hrs [95]. It has been postulated that AQP9 might be involved in lactate 
elimination during acidosis whereas similarities in localization patterns seem to 
indicate that AQP9 might be involved in influencing edematous conditions as well 
[95-96]. These results indicate that AQP1, 4 & 9 together play a key role in 
ischemic stroke. Thus changing the expression levels of these AQPs to suit the 
edematous conditions might be favourable especially in clinical situations.  
 
1.1.5.4 Autoimmune disease 
Neuromyelitis optica is an auto immune disease where autoantibodies generated 
against AQP4 have a tendency to target the optic nerves and spinal cord. The 
damaged optic nerves and spinal cord results in recurrent attacks
 
of blindness and 
paralysis [97]. Serum AQP4 antibodies are often used as a biomarker for diagnostic 
purposes.  While Neuromyelitis optica was thought to mostly affect the optic 
nerves and spinal cord, recent magnetic resonance imaging studies reveal the 
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presence of lesions in the brain as well [97-98]. This emphasizes the need for 
specific modulators of the water channel.  
 
1.1.5.5 Obesity and diabetes  
Aquaglyceroporins 7 and 9 are expressed in the adipose tissue and liver 
respectively [57]. There is compelling evidence for the implication of these two 
AQPs in fat metabolism and metabolic diseases such as obesity and diabetes 
mellitus. AQP7 and 9 participate in the coordination of the fat and glucose 
homeostasis [57]. Plasma glycerol released from adipocytes via AQP7 is 
transported through AQP9 into the liver for gluconeogenesis. In humans, AQP7 is 
expressed in the white adipose tissue while in rat and mouse it is expressed in both 
white and brown adipose tissues [42, 99-100]. Several AQP7 knock-out studies 
using different gene targeting strategies highlighted AQP7‟s involvement in 
developing obesity [101-104]. These studies showed that disruption of the AQP7 
impaired the glycerol transport which leads to progressive adipocyte fat 
accumulation. Polymorphisms present in the AQP7 gene were loosely associated 
with enhanced risks against obesity and diabetes [105]. In obese humans, decreased 
AQP7 expression has been reported. This decrease was speculated to possibly 
result in lowering the glycerol release from adipocytes and thus increasing 
triglyceride re-synthesis which might contribute to obesity [106]. This hypothesis 
was supported by a separate study where development of adult onset obesity 




Recent discovery of AQP7 in the pancreatic beta cells has introduced another 
plausible mechanism for the metabolic disturbances observed in AQP7 knock-out 
models. AQP7 is a beta-cell protein and regulates intra-islet glycerol content and 
glycerol kinase activity, beta-cell mass, insulin production and secretion. AQP7 
knock-out mice displayed increased intra-islet glycerol and islet triglyceride 
concentration but reduced beta-cell mass and insulin content. It has been suggested 
that dysregulation of AQP7 might result in increased glycerol availability for 
gluconeogenesis and thus causing raised glucose levels in type 2 diabetes [107-
110]. AQP7 null mice which developed adult onset obesity also showed 
progressive insulin resistance [107]. This suggests that AQP7 is not only a 
modulator of adiposity but also a key regulator of glucose homeostasis and insulin 
sensitivity.  
 
AQP9 has also been associated with metabolic defects where knock-out models 
showed approximately a 60% increase in plasma glycerol and triglycerides levels 
[111]. Increased levels of AQP9 were reported in the liver of streptozotocin-
induced diabetes mellitus and that its expression was also regulated by insulin 
[112]. However, unlike AQP7, hepatic AQP9 expression level is generally less 
influenced by insulin resistance [112]. Taken together, these findings enhance the 
understanding of the role of these two AQPs in metabolic disorders and the 
possibility of modulating their expression and function as a potential therapy for 




1.1.5.6 Renal diseases 
The renal system expresses eight of the thirteen AQPs. AQP1 is strongly expressed 
in the plasma membrane of the proximal tubules and descending thin limb which 
serves as the principal water channel for transepithelial water permeability in these 
regions [113-115]. Deletion of AQP1 in mice causes polyuria in which the urinary 
osmolality is low and shows no response to vasopressin release or water 
deprivation [113]. Individuals with AQP1 deficiency have also been shown to have 
impaired urinary concentrating ability [115]. In an in vivo model, AQP1 null mice 
subjected to renal artery occlusion-reperfusion showed significant tubule dilation 
indicating tubular injury [116]. These findings highlight the possible implication of 
AQP1 in the renal cell injury.  
 
AQP2 is a vasopressin-sensitive water channel found in the principal cells of the 
collecting duct while AQP3 and AQP4 are localized in the basolateral membrane of 
the collecting duct. Release of vasopressin, in response to dehydration, results in 
translocation of AQP2 to the apical plasma membrane to allow for water 
reabsorption from urine into the principle cells. AQP2 impairment has been 
associated with several water homestasis disorders including congenital NDI [117-
118]. NDI occurs as patients lose their ability to concentrate urine despite normal 
or raised levels of vasopressin. Most cases of NDI results from mutations in 
vasopressin receptor and AQP2 gene (Table 1.2) [117,119-121]. All mutations in 
association to dominant NDI are located in the cystolic C-terminus of AQP2, a 
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region which is critical for AQP2 translocation to the plasma membrane [117, 119-
121].   
 
Since AQP3 and AQP4 are expressed in the same cells as AQP2, the former are 
thought to facilitate basolateral exit of water which gains entry through AQP2 
apically. AQP3 knock-out studies have enlightened the understanding of the 
physiological roles of AQP3 in the renal system [122]. AQP3 knock-out mice were 
found to display NDI like phenotypes [123]. Furthermore deletion of AQP3 was 
accompanied with diminished AQP2 expression which resulted in the reduction of 
the permeability of the basolateral membrane of the cortical collecting duct and 
lead to polyuria where the daily urine output was elevated ten-fold [122]. On the 
contrary, AQP4 knock-out mice only showed mild urinary concentrating defects 
[5]. 
 
AQP6, 7 and 8 are also expressed in the kidneys. However their extent of 
contribution to renal pathology is yet to be established. AQP11 is expressed in the 
intracellular vesicles in proximal tubules. Knockout mice models of AQP11 
developed cyst formation which was similar to polycystic kidney disease [124].  
The onset of vacuolization and cyst formation set in within three weeks of birth and 
developed into renal failure in mice [124].  More recently, a mutation within the 
AQP11 gene, C227S, was identified as a cause for the disruption
 of the protein‟s 
function that resulted in severe proximal tubule injury leading
 
to renal failure [125].  
All these experimental evidence highlight the important pathophysiological roles of 
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AQPs in renal diseases and hence modulating the expression of these proteins 
would provide valuable information and will enable further understanding of the 
mechanisms involved.   
 
1.1.6 Inhibitors of aquaporins 
Having established the importance of AQP in pathological states, the necessity to 
be able to modulate their expression is recognized. Initially, mercurial compounds 
were shown to block certain AQPs such as AQP1 [126] but not AQP4 [127-128]. 
However more recently, Yukutake et al [128] suggested that the water permeability 
of the M23 isoform of AQP4 was reduced by Hg
2+
. Yet toxicity of mercurial 
compounds has great limitations on their therapeutic value. Tetraethylammonium 
(TEA) was also suggested as an AQP1 inhibitor by molecular dynamic modelling 
[129-130], although it was not seen in all assays [131]. Furthermore TEA was also 
shown to be non specific as it could also block a variety of K
+
 channels and other 
membrane proteins. Arylsulfonamides, including acetazolamide, a carbonic 
anhydrase inhibitor that is commonly used to reduce CSF production have been 
suggested as pharmacological blockers of AQP1 and 4. Ma et al [132] reported that 
acetazolamide reduced osmotic permeability via interaction with AQP1. Yet Yang 
et al [131,133] found no evidence that acetazolamide inhibited AQP1 or 4. This has 
generated considerable controversy. A small inhibitory effect of bumetamide, a 
loop diuretic that blocks the Na-K-Cl co-transporter, on AQP4 water permeability  
has lead to the development of other related molecules based on the structure of 
bumetamide [134]. The arylsulfonamide AqB013 which has been reported by Yool 
32 
 
et al [135] to block both AQP1 and 4 is such an example although its therapeutic 
potential remains to be tested. The AQP inhibitors found thus far are handicapped 
by toxicity, low efficacy, and lack of specificity [136]. In addition these studies 
also highlight the lack of AQP activators. Hence there is a need to find suitable 
molecules that could inhibit as well as activate AQPs. 
 
1.2 MicroRNAs 
1.2.1 The discovery of microRNAs  
Unknown to many, the idea of RNA based gene regulation was coined as early as 
the 1960‟s.  Based on the observation that during cell differentiation, a pool of 
genes can be activated whereas at the same time another set of genes can be 
inactivated, Britten and Davidson [137] proposed the presence of “activator" RNAs 
transcribed from redundant genomic regions that could form complexes with 
regulatory DNA sequences to activate a battery of protein coding genes. The first 
study on RNA based gene regulation however only sprouted in 1993 where a 21-
nucleotide RNA molecule, lin-4, was shown to control the developmental timing of 
Caenorhabditis elegans (C. elegans) by post-transcriptional regulation of the gene 
lin-14.  Lin-4, a non-coding RNA molecule was observed to bind to the 3 ′ UTR of 
the lin-14 gene [138-139]. Yet, the importance of this 21-nucleotide long RNA 
molecule was not fully understood at that point of time. Rather it was believed to 
be an isolated event occurring in the C. elegans as the lin-4 sequence was not 
conserved in other species. It took another seven years before the second RNA 
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molecule, let-7, which was highly conserved in many species, was shown to 
regulate the developmental timing in C. elegans. [140]. Since then more and more 
studies have emerged and these small nucleotides are now being recognised as a 
separate class of small RNA molecules known as microRNAs (miRNAs). 
 
1.2.2 Biogenesis of miRNAs  
miRNAs are 17-24 nucleotides long endogenous molecules of non-coding RNA. 
They are commonly found along the non-coding regions of the genome such as the 
3‟UTR as well as the intragenic or intergenic regions [141]. The nucleotides are 
often transcribed from the genome by RNA polymerase II to produce single 
stranded transcripts that can be several kilobases long (Figure 1.5A). These 
transcripts also known as primary miRNAs (pri-miRNAs) contain the 7-
methylguanosine cap and a poly(A) tail which are unique for RNA polymerase II 
transcripts  [142-143]. The pri-miRNAs can fold back to form hairpin loops (Figure 
1.5B) and depending on the number of miRNAs within the transcribed region, the 
transcript can exist as single hair-pin structures or a cluster of miRNAs [144-145].  
The hairpin loop structures are processed in the nucleus by the RNASE III enzymes 
Drosha and Pasha, to generate ~70-nucleotide stem loop structures with 5 ′ 
phosphate and a 3 ′ hydroxyl ends. This stem-loop structure is referred to as the 
precursor miRNAs (pre miRNAs). The pre miRNAs are then transported to the 
cytoplasm via a nuclear membrane protein, Exportin5/Ran GTP [146-147]. Once in 
the cytoplasm the pre miRNAs are further processed by an enzyme complex 
consisting of another RNAse III enzyme (Dicer). The two strands of this duplex 
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form a pre-complex with RNA-induced silencing complex (RISC) components. 
The enhanced flexibility of the 5′ antisense terminus facilitates the directional 
unwinding of the duplex from the 5′ antisense end to promote the formation of the 
more stably activated RISC [148-149]. The miRNA strand, having the low internal 
stability at the 5′ end (antisense strand), is retained within the RISC and this 
activated miRNA–RISC complex (miRISC) is the main component of the miRNA 



























Figure 1.5: (A) Biogenesis of 
miRNAs. Transcription of 
miRNA from the precursor 
gene to form pri- and pre-
miRNA occurs in the nucleus 
and the processing of pre-
miRNA to mature miRNA 
takes place in the cytoplasm. 
The active miRNA–RISC 
complex formed will then 
select the target mRNA for 
inactivation. Image obtained 
from Kim et al [150]. (B) 
Primary miRNA transcripts. 
miRNAs can be transcribed 
individually or as a cluster.   
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1.2.3 Mode of action of miRNAs  
Once the miRNA is incorporated into the RISC complex, it helps the RISC to 
identify and bind specific mRNAs that would have complementary sequences. The 
RISC complex will cleave the mRNAs if the complementarity between the miRNA 
and the target mRNA is of perfect match (Figure 1.6). Suppose the 
complementarity is imperfect, as often seen in mammals, the translation process is 
inhibited [151]. However, imperfect match has also resulted in translational arrest 
and degradation of mRNA as in the case of let-7 and lin-4 in C. elegans, as 
observed by Bagga et al [152]. This makes it possible for a single miRNA to bind 
to many mRNAs and to regulate a large number of genes. Usually, a single miRNA 
is estimated to target about 200 different transcripts [153]. Most miRNAs are 
thought to inhibit the translation process by binding mRNAs at the 3‟UTR. 
However more recent reports suggest their ability not only to inhibit translation but 
also to modulate transcription [154-157]. miRNAs binding to the promoter regions 
of a gene have been shown to both activate as well as inhibit transcription [156-
157]. Gene activation is believed to take place via the interaction of miRNAs and 
their target genes at the 5‟ non-coding regulatory regions. Janowski et al [157] 
showed that transfection of short double stranded RNAs which were 
complementary to the progesterone receptor promoter, increased mRNA and 
protein expression of the progesterone protein in breast cancer cells. miR-373 was 






Figure 1.6: Mode of action of miRNAs. The mature miRNA is assembled into a 
ribonucleoprotein complex (RISC). Degradation of the target mRNA occurs when 
the miRNA and the target mRNA are perfectly matched whereas upon partial 
complimentarity the target mRNA is stored away into complexes known as p-
bodies. Hence translational inhibition takes place. Transcriptional modualtion is 











1.2.4 miRNAs as endogenous regulators of diseases  
It is well known that miRNAs play important roles in the developmental regulation 
in mammals. Thus it comes as no surprise that dysregulation of the miRNA 
expression is observed in patho-physiological conditions. This naturally opens up 
the avenue to study and possibly treat various diseased conditions by modulating 
miRNA expression profiles. MiRNA profiling studies on various cancer samples 
showed that their expression patterns vary dramatically across the different tumour 
types [158]. The authors also noted that miRNA profiling data provided more 
accurate information in classifying the various differentiated stages of the tumours 
when compared to the mRNA data. Thus the potential of using miRNA profiling in 
cancer diagnosis becomes evident. A reduction in the overall expression of most 
miRNAs in tumours has been reported [158-159]. In fact, Kumar et al [160] 
showed that global repression of miRNA maturation promotes cellular 
transformation and tumorigenesis. Knockdown of miRNA processing enzymes, 
Drosha and Dicer in a lung cell line caused a global reduction in the miRNA 
expression, thus mimicking a tumour state. These knockdown cells showed 
increased colony formation in vitro and enhanced tumour growth in vivo [160].  
 
While this study was done at a global level, on a closer look, the spread and 
invasion of cancer cells have been attributed to the increased expression of 3 
different miRNAs: miR-10b, -373 and -520c [161-162]. MiR-373 and 520c were 
shown to target CD44, a metastasis suppressor protein and down regulate its 
expression [162]. Nevertheless, another study showed that miR-127, normally 
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downregulated in cancer cells can be activated in order to function as a tumour 
suppressor [163].  Implications of miRNA deregulation do not stop at cancer alone. 
Alzheimer‟s, diabetes, hypertension, cardiovascular disease and cerebral ischemia 
are some of the many maladies they are implicated with. In fact absence of certain 
miRNAs in the brain results in neuronal degeneration and death in mice models 
resulting in symptoms reminiscent of those seen in humans with neurodegenerative
 
disorders [164]. Using rat models of cerebral ischemia, it has been found that 114 
brain-specific miRNAs were differently expressed and several of these miRNAs 
were present in both the brain and blood [165]. These plethora of information serve 
to establish the involvement of miRNAs in diseased conditions and the possibility 
of regulating them for treatment. 
 
1.3 Bioinformatics databases: miRNA target prediction  
The functions of miRNAs in cellular processes are thought to be so diverse that in 
most cases their targets have not been experimentally identified. Thus to obtain 
meaningful interpretations of the action of miRNAs, in silico methods have been 
designed to identify potential targets of miRNA. In order to appreciate the miRNA 
target prediction methodologies it is vital to understand the biology behind miRNA 
activity. The binding of the mature miRNA to its target mRNA initiates 
translational inhibition. It has been reported that the 5‟ end of the miRNA (2-7 
bases) binds with the 3‟ UTR region of the target mRNA [166]. If the 5‟ end of the 
miRNA pairs sufficiently well with the 3‟UTR then the pairing at the 3‟ end of 
miRNA to the target is not essential [167]. However if the 5‟ end of miRNA 
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binding is insufficient there should be sufficient pairing in the 3‟ end for the 
interaction to take place [167]. The miRNA prediction methods available exploit 
this mechanism to find potential targets. They validate the ability of the miRNA to 
bind to the 3‟ UTR region of the target gene using sequence comparisons, 
thermodynamic calculations and statistical evaluations.  
 
The miRNA prediction methods have been implemented as computer algorithms so 
that existing sequences of miRNAs can be compared across different genomes in a 
fairly short amount of time and in an accurate manner [168]. There are also 
databases that list the predicted miRNA targets. Before proceeding further it is 
important at this stage to differentiate between algorithms and databases involved 
in finding potential targets of miRNA. MiRNA target prediction algorithms are 
collections of computer codes which take in a list of miRNAs and target sequences 
to predict their potential binding sites. MiRNA target prediction databases act as 
online repositories of these prediction data. These databases use one or more 
miRNA target prediction algorithms to obtain the potential targets of miRNAs and 
store that data so that investigators can conduct searches in them and retrieve the 
necessary information from them. The prediction data contained in the databases 
differ from each other depending on the algorithm used, the parameters of the 
algorithm such as threshold values, the input list of miRNA and the target 




Several of the commonly used databases are MicroCosm Targets (http://www 
.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/) [169], microRNA.org (http:// 
www.microrna.org/microrna/home.do) [170] and TargetScan (http://www. 
targetscan.org) [171]. Most miRNA target prediction databases fundamentally used 
the miRanda algorithm (http://www.microrna.org/miranda_new.html) as a common 
platform and worked around it with their own filtering or stringency selection 
based on a set of p-values and cut-off points or in combination with other software. 
The miRanda algorithm carries out the miRNA target prediction in two steps. 
Firstly, it does a local alignment between known mammalian miRNA sequences 
and the 3′ UTRs and the protein coding regions from human, mouse and rat 
genomes [172]. The alignment is then scored based on sequence complementarity 
where a miRNA with perfect complementation gets a greater score compared to 
one that does not have perfect complementarity. The alignments identified, are then 
filtered according to their respective cut-off score. The next stage involves the 
identification of the thermodynamic stability of each of the resulting duplexes and 
this is done using the Vienna RNA package which consists of a set of software 
tools for the prediction and comparison of RNA secondary structures [173]. Similar 
analyses were carried out for zebrafish and fugu fish genomes using known as well 
as predicted miRNAs. The conserved sets from the mammalian and the fish group 
were then compiled to generate smaller set of super-conserved vertebrate targets 
[172]. Other algorithms available for the prediction of miRNA
 
targets also include 
TargetScanS, PicTar, and DIANA-microT and these use
 
different filters or 
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statistical models for target identification [174]. For detailed reviews see [168, 175- 
177]. 
 
1.3.1 MicroCosm Targets 
The miRNA target prediction by MicroCosm Targets,  a web resource developed 
by the Enright laboratory at the Wellcome Trust Sanger Institute was also 
previously known as miRBase Targets. In MicroCosm target, the miRNA and the 
target gene sequences are retrieved from miRBase Sequence database and 
EnsEMBL respectively [169, 178]. The miRBase Sequence database contains only 
experimentally validated miRNAs. These miRNAs are scanned against the 3' UTRs
 
from 37 animal genomes available in EnsEMBL [174,179]. Potential binding sites 
are identified using the miRanda algorithm [172]. Although initial hits where the 
seed sequence had more than one nucleotide mismatch were omitted from further 
analysis [169], the selection option is now less stringent as there are more reports 
indicating the presence of mismatches in the seed region [180]. Thus those  
miRNAs that pass the criteria are then sorted through the use of Vienna RNA 
folding program to estimate their thermodynamic stability [173]. Only targets that 
are conserved in at least two species are selected for entry into the database [169].   
 
1.3.2 TargetScan 
The TargetScan database uses TargetScanS [176, 181-182] which is a modified 
version of the original TargetScan algorithm for its prediction. It takes a multistep 
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approach to predict potential targets of a miRNA. TargetScanS uses RNAfold and 
RNAeval which are two components of the Vienna RNA package [173]. The 
TargetScanS algorithm uses both comparative sequence analysis and 
thermodynamics-based modeling to predict miRNA targets. It utilizes the 
orthologous 3‟ UTRs from human, mouse, rat, chicken and dog and the miRNAs 
conserved in these organisms, to search for regions of perfect complementarity to 
the seed sequences of the miRNAs [171, 181]. It considers a six base seed starting 
from the second base of the 5‟ end of the miRNA. Once a perfect complementary 
match is found the algorithm extends the identified basepair sequence to either side 
stopping at mismatches. Subsequent base pairing between the 3‟ region of the 
miRNA and the 3‟UTR is identified using the RNAfold program [173]. Then using 
RNAeval, the folding free energy of the miRNA:mRNA duplex is calculated. 
Finally the interactions are assigned a score based on the number of seed matches 
in the untranslated region and the free energy values, sorted according to 
predetermined cut-off values [171].    
 
1.3.3 MicroRNA.org 
MicroRNA.org (http://www.microrna.org/microrna/home.do) is another miRNA 
database that uses the miRanda algorithm to obtain its own set of predictions [170]. 
Apart from using the miRanda algorithm, microRNA.org also incorporates 
expression profiles derived from comprehensive sequencing projects of mammalian 
tissues and cell lines, both from the normal and diseased states [170]. Thus 
MicroRNA.org not only allows for the prediction of targets and their region of 
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interaction for a particular miRNA, but it also provides information about its 
expression in various tissues [183]. However, in this analysis only the 3‟UTR 
region of the mRNA has been used for the prediction of miRNA target sites. Since 
the targets predicted by the currently available algorithms differ depending on 
many factors, the ideal choice would be to select putative targets of a particular 
miRNA given by at least one algorithm. However since this would result in a 
substantial list of potential targets to evaluate, the practical and the logical approach 
would be to first select the targets which are being identified by several or all 
algorithms. Nevertheless, the predicted targets will have to be validated using the 
wet laboratory protocols [184-185]. 
 
1.3.4 RegRNA (A Regulatory RNA Motifs and Elements Finder)  
RegRNA is a web based software (http://regrna.mbc.nctu.edu.tw/) that could be 
used to identify sequence and structural homologs of the regulatory RNA motifs 
and elements against an input mRNA sequence. The program uses a compilation of 
known regulatory RNA motifs from various RNA motif databases as well as 
literature based searches. The regulatory RNA motifs supported by the server 
include motifs in mRNA 5‟ and 3′ UTRs, motifs involved in mRNA splicing, 
splicing donor/acceptor sites, transcriptional regulation, riboswitches, inverted 
repeats and miRNA target sites [186]. In the case of miRNA prediction, RegRNA 
utilises two different databases, miRBase and miRNAMap [186-187]. In fact 
miRNAMap uses miRanda to detect the miRNA target sites. While the pool of 





are identified from the genomes of human, mouse, rat and dog using RNAz; a 
computational tool for predicting non-coding
 
RNA structures based on comparative 
sequence analysis [188].   
 
1.3.5 Experimental validation of target predictions 
Although prediction programs churn out lots of data, these bioinformatics databases 
serve as an excellent starting point to collate and screen for possible miRNA targets 
[189]. However the basic knowledge of miRNA function is still inadequate. The 
information obtained needs to be further validated via experimental techniques. The 
first step in studying the effects of miRNA on gene modulation is the detection of 
the miRNA expression itself. miRNA cloning is often used to discover novel 
miRNAs in which the cloning frequency of miRNAs is used to quantify their 
relative abundance, but it is not very accurate [185, 190-192]. Northern blotting is 
another routine methodology that has been known as the „gold standard‟ in the 
study of miRNA expression, but such approach is very time-consuming and 
requires high amounts of RNA samples and radioactive probes [193]. Moreover, 
the very short length and low abundance of mature miRNAs makes the sensitivity 
of northern analysis is relatively low. 
 
To overcome the sensitivity issues techniques like real-time PCR is widely used for 
the detection of specific miRNAs of interest [194-195]. Yet a limitation of such 
approach is the size of mature miRNAs that resembles the size of PCR primers and 
this makes it impossible to apply the standard RT-PCR protocol directly. Instead 
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stem-loop primers can be used [194]. The double-stranded structure of the stem-
loop primers enhances specificity and efficiency by preventing non-specific 
binding to other RNA molecules and increasing the thermal stability of the primer-
RNA duplex respectively.  Another method often used to detect miRNAs is in situ 
hybridisation. Such techniques provide important information about the relative 
abundance of the miRNAs as well as their localization [196-197]. Nevertheless 
such methods are costly and limited to specific miRNAs, thus it does not give an 
overall picture of miRNA expression. 
 
The most widely used methodology at present is miRNA microarrays which can 
overcome most of these setbacks [192, 194, 198-199]. MiRNA microarray 
technology is based on the nucleic acid hybridization between the target miRNA 
and their corresponding complementary probes with high specificity and 
sensitivity. There are several platforms available for miRNA microarrays, one of 
which utilizes the locked-nucleic-acid (LNA)-modified oligonucleotide probes 
[200]. The sensitivity of such LNA-modified probes was found to be increased by 
at least ten-fold [198, 200-201]. The emergence of increasing miRNA profiling 
studies is providing vital information of the miRNAs and their roles in many 
biological processes as well as pathogenesis of several diseases [138, 140, 202-
206]. Amalgamating mRNA and miRNA sequences and expression data will 





The most fundamental challenge in miRNA studies lies in the validation of 
miRNA-target prediction. This step is critical since there must be sufficient 
experimental evidence to confirm the miRNA-target mRNA interaction. Target 
interaction of predicted miRNAs can be validated by the use of luciferase reporter 
systems. Anti or precursor miRNAs are co-transfected with luciferase reporter 
plasmids containing the target recognition sites. This technique works in a way by 
which the binding of a miRNA to its specific mRNA target site will suppress or 
enhance the reporter protein production thereby affecting its activity which is then 
measured and compared to appropriate control(s) [205]. After confirming the 
interaction at mRNA level, it is necessary to bring the investigation further to 
protein level. This is because if the predicted mRNA is a true target of that specific 
miRNA, then the modulation of the given miRNA should correlate to the protein 
expression from the mRNA target. Such validation can be done easily by 
performing Western blot analysis using a specific antibody against that protein 
[207]. Alternatively, ELISA or immuno-cytochemistry can also be used to study 
the differential protein expression.  
 
Once the regulation of a given miRNA on its target mRNA has been confirmed, it 
is also possible to demonstrate this interaction with respect to its biological 
functions. Biological assays such as cell proliferation, cell differentiation, cell death 
and also signalling pathways of interest can be performed depending on the process 
in which the target protein is involved [206-209]. On top of these, several groups 
have also used animal models to investigate the effects of a specific miRNA on the 
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development or progression of diseases.  Esau et al [210] were able to identify 
miR-122 as a key regulator of cholesterol and fatty-acid metabolism. Targeting an 
anti-miRNA against it into the rat liver showed changes in the levels of expression 
of the target genes, suggesting that miR-122 may be an attractive therapeutic target 
for metabolic diseases. This study highlighted the possibility of using a single 
miRNA as a key regulator of a process and also showed the possibility of 
modulating the expression level of a miRNA itself through the introduction of anti-
miRNA molecules. In fact, long lasting reduction in plasma cholesterol has been 
observed in non-human primate models upon systemic delivery of Locked Nucleic 
Acids (LNA™) - anti miR-122 [211].  
 
With the several technologies available for miRNA studies and because each of 
them has its own drawback, it is imperative to carefully select the most suitable 
approach which best fits the experimental conditions and the purpose of the study.  
 
1.4 Objectives of this study 
Thus far the importance of AQPs in normal as well as pathophysiological 
conditions has been well established. Among the 13 isoforms reported, classical 
AQPs 1, 2 and 4 are extensively studied by various groups and these studies have 
more than often highlighted lack and the need for proper modulators of these 
channels. Known inhibitors of AQPs are often too harmful for in vivo 
administration and clearly there are no activators. However in recent years, the 
existence of naturally occurring endogenous gene regulators has created a lot of 
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interest. miRNAs have been identified as endogenous regulators of gene expression 
and de-regulation of miRNA expression is being currently censured for almost all 
pathological states. The expression patterns of miRNAs are being explored to 
diagnose, accurately classify and even treat pathological conditions. Thus in this 
study the use of miRNAs as regulators of AQP gene expression was investigated. 
Considering the importance given to classical AQPs 1, 2 and 4, the first part of the 
study aimed to identify and eventually validate miRNAs that could be used as 
modulators for these genes. Utilizing in silico prediction programs and the above-
mentioned experimental methods possible, miRNA modulators were identified and 
validated.   
 
Having seen miRNA based regulation of AQPs 1, 2 and 4, the next aim of the study 
was to test the potential of these validated miRNAs in a disease condition. 
Interestingly among the validated miRNAs, miR-320a was identified as a common 
regulator (miR-320a) for AQP1 and AQP4. One of the major diseases AQPs are 
implicated with is cerebral edema caused by changes in AQP1 and AQP4 
expression. Due to the lack of treatment options, changes in the cerebral water 
content often increased mortality rates. Since ischemic models were readily 
available in our laboratory and miR-320a was observed to be conserved in rats as 
well, the second part of this study investigated the effectiveness of miR-320a in 




During the course of the study, a report by Hirt et al [212] highlighted that the M1 
isoform of AQP4 could be more relevant in terms of contributing to edema in an 
ischemic setting. Two isoforms (M1 and M23) that differ at the amino terminus of 
AQP4 have been reported to be expressed in the brain and they are thought to arise 
from two alternative promoters. While miR-320a was identified as a translational 
regulator of AQP4, to differentially regulate AQP4 M1 a transcriptional modulator 
was needed. The ability of miRNAs to regulate transcription had recently been 
highlighted by a few reports. Thus the third part of the study explored the 
possibility of using miRNAs to selectively regulate the AQP4 M1 promoter 
activity. The M1 promoter clones together with mutation and deletion constructs 
were generated and their interaction with selected miRNAs was studied.  
 
Having explored the prospects of AQP1 and AQP4 regulation in an ischemic 
setting, it was only natural to turn the attention to the remaining AQP implicated to 
play important roles in ischemic brain; AQP9. AQP9, an aquaglyceroporin, is often 
postulated to function as a metabolite channel in the brain, transporting lactate. In 
the absence of oxygen, lactate is considered as a precious and efficient fuel source 
and aids in minimizing the extent of cell death. Since the trigger in apoptosis is 
often associated with changes in cell volume and energy status, an AQP9 regulator 
will ensure sufficient fuel source for the cells. Thus in the last section of this study 



















2.1.1 Cell lines and culture reagents 
Astrocytoma (CRL 1718), HeLa (CCL2) and Caki (HTB-47) cells were obtained 
from the American Type Cell Culture (ATCC, USA).  
 
2.1.1.1 Saline  
NaCl (0.9%, w/v) was diluted in sterile deionised water and autoclaved. Once 
cooled it was stored at room temperature. 
 
2.1.1.2 Trypsin 





2.1.1.3 Sterile glycerol  
Glycerol was autoclaved and used for stocking cells.  
 
2.1.1.4 Basal  RPMI  (1L)  
RPMI      16.2g 
L-glutamine      0.4g 




Penicillin-streptomycin    1% 
(50U-50mg/ml) 
 
2.1.1.5 Basal DMEM (1L)  
DMEM      17.4g 
L-glutamine      0.4g 
Sodium bicarbonate     1.74g 
Penicillin-Streptomycin    1% 
(50U-50mg/ml) 
 
2.1.1.6 Complete RPMI (1L)  
Basal RPMI      900ml 
Fetal Bovine Serum (FBS)    100ml 
 
2.1.1.7 Complete DMEM (1L)  
Basal DMEM     900ml 
Fetal bovine serum (FBS)    100ml 
 
2.1.1.8 Freezing medium (100ml)  
Basal DMEM or RPMI    30ml 
Fetal bovine serum (FBS)    70ml 
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Powdered medium, together with L-glutamine and sodium bicarbonate were 
dissolved in deionised water. The pH was adjusted to 7.3 with 5M NaOH and 
sterile-filtered with a 0.22µm filter.  FBS (if required) and penicillin-streptomycin 
were added aseptically and the medium was stored in 4
o
C. Before use the medium 
was warmed to 37
o
C in a water bath. Cells were stocked with freezing medium and 




2.1.1.9 Glucose free basal RPMI 
Glucose free basal RPMI (Invitrogen, Carlsbad, CA, USA.) was used for oxygen 
glucose deprivation studies. 
 
2.1.1.10  Opti-mem  
Opti- mem medium (Invitrogen, Carlsbad, CA, USA.) was used for transfection 
studies. 
 
2.1.2 Reagents for DNA extraction  
2.1.2.1 DNA extraction  





NaOH (8mM) was prepared using sterile deionised water and stored at room 
temperature.  
 
2.1.2.3 10X Tris-borate-edta (TBE) buffer 
Tris base       108g   
Boric acid       55g  
0.5M EDTA (pH 8.0)    40ml 
Tris base and boric acid was dissolved in 960ml of deionised water before the 
addition of 40ml of EDTA, pH 8.0. The 10X TBE buffer was stored in room 
temperature. The solution was diluted to 1X with deionised water and used as 
running buffer for DNA gel electrophoresis.  
 
2.1.2.4 Ethidium bromide 
Ethidium bromide was dissolved in deionised water at a concentration of 10mg/ml 
and stored at room temperature away from light. The final working concentration 
was 0.1µg/ml. 
 
2.1.2.5 DNA gel (1%) 
Electrophoresis grade agarose   0.5g 
1X TBE Buffer     50ml 
Ethidum bromide (10mg/ml)    1ul   
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Powdered agarose was mixed with 1X TBE buffer and heated to 100
o
C, to dissolve 
completely. It was then cooled to about 60
o
C prior to the addition of ethidum 
bromide.  
 
2.1.3 Reagents for RNA extraction  
2.1.3.1 Ethanol 
Ethanol (75%, v/v) was diluted in sterile deionised water. 
 
2.1.3.2 DEPC treated water 
DEPC      0.2ml 
Deionised water     100ml 
In a fume hood, DEPC was added to the water and mixed vigorously. The solution 
was autoclaved to inactivate the DEPC and stored in room temperature. 
 
2.1.3.3 Deionised formamide 
Formamide (500ml) was stirred with 500mg Dowex XG8 resin for 1 hr and filtered 
through Whatman No.1 paper. Deionised formamide was stored at room 




2.1.4 Reagents for RNA agarose gel electrophoresis  
2.1.4.1 MOPS running buffer (10X) 
MOPS (pH 7.0)     0.4M 
Sodium acetate     0.1M 
EDTA (pH 8.0)     10mM 
10X MOPS was prepared using DEPC treated water and sterile-filtered with a 
0.22µm filter. The solution was diluted with DEPC treated water to 1X MOPS for 
gel running. 
 
2.1.4.2 RNA sample buffer (per sample) 
Deionised formamide    10µl 
37% formaldehyde     3.5µl 
10X MOPS      2µl  
 
2.1.4.3 RNA loading buffer 
Glycerol      50% (v/v) 
Bromophenol blue     0.4% (w/v) 
EDTA (pH8.0)     1mM 
 
2.1.4.4 RNA agarose gel (1%) 
Electrophoresis grade agarose   0.5g 
Deionised water     43.5ml 
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37% formaldehyde     1.5µl 
10X MOPS      5ml 
Ethidum bromide (10mg/ml)    1ul   
Powdered agarose was mixed with water and heated to 100
o
C, to dissolve 
completely. It was then cooled to about 60
o
C before the addition of 37% 
formaldehyde, 10X MOPS and ethidum bromide (section 2.1.2.4).  
 
2.1.5 Reagents for RNA polyacrylamide gel electrophoresis  
2.1.5.1 15% Denaturing polyacrylamide gel  
Urea       7.2g 
40% Acrylamide     5.63ml 
10X TBE Buffer     1.5ml 
Deionised water     0.95ml 
TEMED      7.5µl 
10% Ammonium persulfate (APS)                  37µl 
Acrylamide and 10X TBE buffer together with urea, were heated to 60
o
C. Once 
urea dissolved, deionised water, TEMED and APS were added the the mixture and 
the gel was cast immediately.   
 
2.1.5.2 RNA sample buffer (per sample) 




Deionised Formamide (section 2.1.3.3)  10μl  
RNA Loading Buffer (section 2.1.4.3)   3μl  
Ethidum bromide (10mg/ml)    1ul   
 
2.1.6 Agilent RNA 6000 nano kit 
 RNA Nano Chip 
Agilent RNA 6000 Nano Gel Matrix  
Agilent RNA 6000 Nano Marker  
Agilent RNA 6000 Ladder 
RNA Nano Dye Concentrate 
Electrode Cleaners 
Spin Filters 
The individual components for the set up and running of the bioanaylser were 
available as the Aglient RNA 6000 Nano kit. Upon arrival of the kit, the Agilent 
RNA 6000 Ladder was heat denatured for 2min at 70°C and cooled down 
immediately on ice. It was stored as 2µl aliquots in RNase-free vials at -70°C.   
 
2.1.7 Reagents for protein extraction  
2.1.7.1 Protein wash buffer 
Guanidine- HCl in 95% ethanol   0.3M 
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Powdered guanidine- HCl was purchased from Gibco, USA and dissolved in 95% 
ethanol. The buffer was used to wash protein pellets prior to dissolving them with 
the solubilisation buffer (section 2.1.7.2)  
 
2.1.7.2 Protein pellet solubilisation buffer 
Urea       7M   
Thiourea      2M   
Chaps      2% (w/v)         
Dithiothreitol (DTT)    1% (v/v)  
Protease Inhibitor     1% (v/v) 
Nuclease Inhibitor     1% (v/v) 
The individual components of the buffer were purchased from Amersham 
Biosciences.    
 
2.1.8 Reagents for Tris-Tricine SDS-PAGE 
2.1.8.1 Gel stock buffer 
Tris-HCL, pH8.4     3M 
 
2.1.8.2 Cathode buffer (upper electrode buffer)  
Tris base      0.1M 
Tricine      0.1M 
SDS, pH 8.25     1% 
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2.1.8.3 Anode buffer (lower electrode buffer)  
Tris base      0.1M 
Tricine      0.1M 
SDS, pH 8.25     1% 
 
2.1.8.4 2X SDS PAGE loading buffer 
Tris-HCL, pH6.8     100mM 
Glycerol      20% (v/v) 
SDS       4% (w/v) 
2-mercaptoethanol     2% 
Bromophenol blue     0.2% (w/v) 
 
2.1.8.5 Tris-Tricine SDS-PAGE gel  
    12%          5% 
Resolving gel (ml)            Stacking gel (ml) 
Acrylamide, 40%                    3.00          0.625 
Gel buffer       3.33          1.25 
(section 2.1.8.1)  
10% SDS                            0.10          0.05  
Glycerol      1.10            - 
Deionised water     2.40          2.85 




Ammonium persulfate            0.10                      0.10  
(10% APS) 
TEMED and 10% APS were added to the gel mixture just prior to the casting of the 
gel.   
 
2.1.9 Reagents for Western Blotting  
2.1.9.1 Transfer buffer  
Tris base      48mM 
Glycine       39mM 
Methanol      15% (v/v) 
 
2.1.9.2 Phosphate buffered saline (PBS)  
NaCl       8g 
KCl       0.2g 
Na2HPO4.7H2O      2.68g 
KH2PO4      0.24g 
The solutes were dissolved in 1L of sterile deionised water and the pH was adjusted 
to 7.4. 
 
2.1.9.3 PBST buffer  




2.1.9.4 Blocking solution 
Skim milk (5%, w/v) was diluted with PBST buffer prior to use. 
 
2.1.10 Reagents for Immuno Cyto-Chemistry 
2.1.10.1 PBS buffer with fetal bovine serum 
5% FBS was prepared in 1X PBS and stored at -20
 o
C in 1ml aliquots.  
 
2.1.10.2 Fluorescein coupled secondary antibody  
Fluorescein coupled horseradish peroxidise-conjugated goat anti-rabbit was used 
for immuno cyto-chemistry studies. (Bio-rad, USA). 
 
2.1.10.3 Nuclear stain  
Hoechst 33342, a nuclear stain, was used in immuno cyto-chemistry studies. 
(Biotium, USA).  
 
2.1.10.4 Mounting medium 
An aqueous mounting medium was used to mount the coverslips fixed with cells 
onto microscope slides (Dako, USA). 
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2.1.11 Cell viability assay   
2.1.11.1 MTT solution 
3-(4,5-dimethylthiazole-2-yl)-2,5,-diphenyl tetrazolium bromide (MTT) was 
dissolved in saline to prepare a stock concentration of 5.5mg/ml. It was filtered and 
stored at 4
o
C in the dark. Working concentration was 0.5mg/ml.  
   
2.1.12 Cytotoxicity assay  
2.1.12.1 Lactate dehydrogenase assay 
Release of the cytoplasmic enzyme lactate dehydrogenase (LDH) into the culture 
medium was used as a measure of cytotoxicity.  Presence of LDH was determined 
using a detection kit (Roche Molecular Biochemicals). 
 
2.1.13 Reagents for reverse transcription (RT)  
2.1.13.1 RT mixture for mRNA 
10X Taqman RT buffer     1µl 
25mM MgCl2     2.2µl 
DeoxyNTPs mixture    2µl 
50µM Random hexamers    0.6µl 
20 U/µl RNase inhibitor     0.2µl 
50 U/µl MultiScribe™ Reverse transcriptase  0.25µl 
DEPC treated water     1.75µl 
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The individual components were obtained from the Taqman RT Reagents kit 
(Applied Biosystems, Carlsbad, CA, USA.). 
 
2.1.13.2 RT mixture for miRNA 
10X RT buffer      1.5µl 
100mM DeoxyNTPs mixture   0.15µl 
20 U/µl RNase inhibitor     0.19µl 
50 U/µl MultiScribe™ Reverse transcriptase  1µl  
Nuclease free water     4.16µl 
The individual components for the miRNA RT mixture were obtained from the 
Taqman miRNA RT kit (Applied Biosystems, Carlsbad, CA, USA). 
 
2.1.14 Reagents for quantitative real-time polymerase chain reaction (PCR) 
2.1.14.1 Taqman assay for mRNA  
2X Taqman PCR Master Mixture   12.5µl 
20X primer-probe      1.25µl 
DEPC treated water     6.25µl 
 
2.1.14.2 SYBR green assay for mRNA 
2X SYBR Green PCR Master Mixture  12.5µl 
Forward primer (300nM)    2.5µl  
Reverse primer (300nM)    2.5µl 
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DEPC treated water     2.5µl 
The real-time PCR master mixture reagents and primer-probes were obtained from 
Applied Biosystems (Carlsbad, CA, USA.). Gene specific forward and reverse 
primers for Sybr Green assays were purchased from 1
st
 Base (Singapore). 
 
2.1.14.3 Taqman assay for microRNA 
2X TaqMan Universal PCR Master Mixture 10µl     
(No AmpErase UNGa) 
Taqman miRNA probe      1µl 
Nuclease free water     7.67µl 
The TaqMan Universal PCR Master Mixture reagent was obtained from the 
Applied Biosystems (Carlsbad, CA, USA.).  
 
2.1.15 Reagents for Cloning 
2.1.15.1 Reverse transcription (RT) 
Random hexamer       1μl (100pmol)     
5X Reaction Buffer      4μl 
RiboLock™ RNase Inhibitor   1μl (20U/μl) 
dNTP Mixture, 10 mM each   2μl 
RevertAid™ Reverse Transcriptase   1μl (200U/μl) 
RNase free water      Top up to 20μl 
The individual components for the RT mixture were obtained from the 
RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas, Lithuania). 
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2.1.15.2 Polymerase chain reaction (PCR) 
10X Taq buffer with MgCl2  2.5μl 
dNTP mixture  2.5μl  
Forward Primer (1 OD stock)  2.5μL 
Reverse Primer (1 OD stock)  2.5μL 
Taq DNA Polymerase (2 units/μL)  1μL 
Nuclease free water      Top up to 25µl 
 
2.1.15.3 Ligation 
2.1.15.3.1 Ligation of TA cloning vector  
TOPO® vector      1μl 
Salt Solution      1μl 
Nuclease free water     Top up to 6μl 
The individual components for TA ligation were obtained from TOPO® TA 
Cloning Kit for Sequencing (Invitrogen, USA). 
 
2.1.15.3.2 Ligation of luciferase vector 
2X DNA Ligation buffer    5μl 
T4 DNA Ligase (5U/μL)    1μl 
Nuclease free water     Top up to 10μl 




2.1.15.4 Luciferase vectors 
The various luciferase vectors used in this study are as follows: 
pRL-CMV Vector (Promega, Madison, USA) 
pGL3-Promoter Luciferase Reporter Vector (Promega, Madison, USA) 
pGL-4 Luciferase Reporter Vector (Promega, Madison, USA) 
pMIR-REPORT™ Luciferase miRNA Expression Reporter Vector  (Ambion, 
USA) 
 
2.1.15.5 Competent cells 
50μl of chemically competent TOP10 E. coli cells were used for each 
transformation procedure (Invitrogen, USA). 
 
2.1.15.6 Ampicillin 
Powedered ampicillin (Sigma, USA) was dissolved in sterile water to make 
concentrated stocks of 100mg/ml. The stocks were aliquoted into small volumes 
and stored at -20
o
C. Working concentration for ampicilin was 100µg/µl. 
 
2.1.15.7 Lysogeny broth (LB) 
Tryptone       1% (w/v) 
NaCl       1% (w/v) 
Yeast Extract      0.5% (w/v) 
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The pH of the LB Broth was adjusted to 7.0 using 1M NaOH prior to autoclaving. 




2.1.15.8 LB agar plates 
Powdered agar (Gibco) at a final concentration of 1.3% (w/v) was mixed with the 
LB broth and autoclaved. The mixture was cooled to approximately 55
o
C prior to 
the addition of the antibiotic ampicillin (section 2.1.15.6). 20ml of the molten agar 
was poured into each 90mm sterile petri dish and allowed to set at room 
temperature. The LB agar plates were sealed using parafilm and stored at 4
o
C in an 
inverted position. All plates were pre-warmed at 37
o
C for 1 hr before use.  
 
2.1.15.9 Plasmid isolation reagents 
2.1.15.9.1 Resuspension buffer 
Glucose      50mM 
Tris-HCL (pH 8.0)     25mM 
EDTA (pH 8.0)     10mM 
The resuspension buffer without glucose was sterilised by autoclaving and cooled 








2.1.15.9.2 Lysis buffer 
NaOH      0.2M 
SDS       1% (w/v) 
Freshly prepared lysis buffer was used for plasmid extraction. 
 
2.1.15.9.3 Precipitation buffer 
Potassium acetate     3M 
Glacial acetic acid     1.5% (w/v) 





Powdered RNase dissolved in sterile nuclease free water at 10mg/ml. The solution 
was heated to 60
 o






2.1.16 Reagents for restriction enzyme digestion 
10x Restriction Enzyme Buffer    2μl 
H2O        Top up to 20μl 
Restriction Enzyme     1 U 
The restriction enzymes used in this study were purchased from Promega (USA). 




2.1.17 Reagents for sequencing 
2.1.17.1 Cycle sequencing reaction 
Terminator Ready Reaction Mixture   4μl 
Sequencing Buffer     4μl 
Primer (5 OD)     1μl 
Nuclease free water     Top up to 20μl 
 
2.1.17.2 Purification of extension products 
3M Sodium acetate  (pH 4)     3μl 
95% Ethanol     62.5μl 
Nuclease free water     14.5μl 
 
2.1.18 Reagents for miRNA array 
2.1.18.1 miRNA dephosphorylation (per sample) 
Spike –in miRNA       2μl 
CIP Buffer        0.5μl 
CIP Enzyme       0.5μl 
 
2.1.18.2 miRNA labelling (per sample) 
Labelling buffer     3μl 
Hy
3
 Fluorescent label    1.5μl 
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DMSO      2μl 
Labelling Enzyme     2μl 
 
2.1.18.3 Wash buffers  
2.1.18.3.1 Wash buffer A 
20X Salt buffer     60ml 
10% Detergent solution    12ml 
Sterile water      528ml 
Wash buffer A together with two containers was pre warmed overnight to 56
 o
C 
prior to use. 
 
2.1.18.3.2 Wash buffer B 
20X Salt buffer     20ml 
Sterile water      380ml 
 
2.1.18.3.3 Wash buffer C 
20X Salt buffer     2ml 




2.1.19 Reagents for mRNA array 
2.1.19.1 Reverse transcription master mixture 
T7 Oligo(dT) Primer    1μl 
10X First Strand Buffer    2μl 
dNTP Mixture     4μl 
RNase Inhibitor     1μl 
ArrayScript      1μl 
 
2.1.19.2 Second strand master mixture 
Nuclease-free Water    63μl 
10X Second Strand Buffer    10μl 
dNTP Mixture     4μl 
DNA Polymerase      2μl 
RNase H      1μl 
 
2.1.19.3 In vitro transcription mixture 
T7 10X Reaction Buffer    2.5μl 
T7 Enzyme Mixture     2.5μl  




2.1.20 Animal experiments 
2.1.20.1 Animals  
Male Sprague-Dawley rats (~200-300g) were obtained from the Laboratory Animal 
Centre (National University of Singapore, Singapore) and maintained on an ad 
libitum intake of standard laboratory chow and drinking water. All animals were 
handled according to the guidelines (Howard-Jones, 1995) given by the Council for 
International Organization of Medical Sciences (CIOMS) on animal 
experimentation (WHO, Geneva, Switzerland) and the National University of 
Singapore (IACUC/NUS) guidelines for handling laboratory animals. 
 
2.1.20.2 Anaesthesia 
37% ketamine (75mg/kg) and xylazine (10mg/kg) dissolved in saline was used to 
anaesthasize the rats. 
 
2.1.20.3 Tetrazolium – blue stock solution  
Tetrazolium-Blue     0.4g 
DMSO      5ml 
Deionized water     95ml 
 
2.1.20.4 Triphenyltetrazolium chloride (TTC) stain 
2, 3, 5-Tetrazolium-Blue stock solution   10ml 
0.2M Na2 HPO4     16ml 
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0.2M NaH2PO4     4ml 
8mM MgCl2      10ml 
 The suspension was allowed to stand at room temperature and protected from light 
until the tetrazolium blue powder had completely dissolved to produce a pale-
yellow solution. It was stored at 4
o
C away from light. 
 
2.2 Methods        
2.2.1 Cell Culture 
Astrocytoma cells were cultured in RPMI and while HeLa and Caki cell lines were 
cultured using Dulbecco‟s Modified Eagle‟s medium (DMEM). The medium was 
supplemented with 10% fetal bovine serum, 50U of penicillin and 50µg/ml of 
streptomycin. All cells were cultured in T-75 flasks and maintained in a 37
o
C 
incubator with 5% CO2. 
 
2.2.2 Transfection 
2.2.2.1 siRNA/miRNA transfection 
SiPORT NeoFX transfection reagent (Ambion, USA) and Opti-MEM (Gibco, 
USA) was complexed at a ratio of 1:49µl and incubated for 10min at room 
temperature. The siRNA/miRNA (Ambion, USA) was diluted to the appropriate 
concentration in 50µl Opti-MEM. The diluted transfection reagent and the siRNA 
were then  mixed at a ratio of 1:1 and incubated at room temperature for further 
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20min. Cells were seeded at a density of 5 x 10
4
per well in 24-well plates. The 
100µl of siRNA/miRNA-transfection reagent mixture was added dropwise to the 
wells. After 24 hrs of incubation, 500µl of complete medium was added to the 
wells. Transfection was stopped at 48 hrs. Wells treated with negative control 
siRNA/miRNA (Ambion, USA), composed of scrambled siRNA/miRNA 
fragments, were used to analyse the percentage of gene knockdown in the 
siRNA/miRNA treated wells. 
 
2.2.2.2 miRNA and reporter plasmid transfection 
For miRNA target interaction studies, anti or precursor miRNA was co-transfected 
with luciferase reporter plasmids containing the target recognition sites. For 
miRNA transfection, lipofectamine transfection reagent (Invitrogen, USA) and 
Opti-MEM (Gibco, USA) was complexed at a ratio of 1.5:150µl and incubated for 
10min at room temperature. The anti or precursor miRNA (Ambion, USA) was 
diluted to a concentration of 50nM in 150µl Opti-MEM. The diluted transfection 
reagent and the miRNA complex were then  mixed at a ratio of 1:1 and incubated at 
room temperature for further 20min. Cells were pre-seeded 24 hrs earlier at a 
density of 7 x 10
4
/per well in 24-well plates. The wells were washed with 300µl of 
Opti-MEM followed by the addition of 300µl of the miRNA-transfection reagent 
mixture. The cells were left in the 37°C CO2 incubator for 3 hrs. Towards the end 
of the 3 hrs incubation, preparation for plasmid transfection was done. For plasmid 
transfection, lipofectamine transfection reagent and Opti-MEM was complexed at a 
ratio of 3:150µl and incubated for 10min at room temperature. The luciferase 
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plasmid (section 2.1.15.4) was diluted to a concentration of 200nM in 150µl Opti-
MEM. 10ng of pRL-CMV (Promega, Madison, USA) vector was used to determine 
transfection efficiency. The diluted transfection reagent and the plasmids were then 
mixed at a ratio of 1:1 and incubated at room temperature for further 20min. At the 
end of the 3 hrs incubation the cells, the medium was aspirated and the cells were 
washed again with Opti-MEM. 300µl of the plasmid - transfection reagent mixture 
was then added to the cells. The cells were left in the 37°C CO2 incubator for 
another 3 hrs. At the end of the 3 hrs, the medium was replaced with complete 
medium (DMEM or RPMI) and the cells were left to grow for 48 hrs, following 
which luciferase assays were performed. 
 
2.2.3 Luciferase assay 
To study the miRNA and its target gene interaction, the Dual-Luciferase® Reporter 
(DLR) assay system was used (Promega, Madison, USA). This assay allows the 
simultaneous expression and measurement of two individual reporter enzymes 
within a single system. The Firefly luciferase expression is used to correlate the 
effect of miRNA and its target interaction, while the activity of the co-transfected 
Renilla luciferase provides an internal control that serves as the baseline response. 
Firefly and Renilla luciferases, because of their distinct evolutionary origins, have 
dissimilar enzyme structures and substrate requirements. These differences make it 
possible to selectively discriminate between their respective bioluminescent 
reactions. 48 hrs after transfection, the medium was aspirated and the cells were 
washed with PBS. 100μl of passive lysis buffer was added to each well and the 
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cells were left on a shaker for 10min with gentle agitation. The cells were then 
collected and centrifudged at maximum speed for 2min. The cell lysate was 
transferred into a separate tube. 50μl of the cell lysate was transferred into a white 
optical plate in a luminometer. Upon addition of 50μl Dual-GloTM Luciferase 
substrate, the firefly luciferase activity was measured. To quench the firefly 
luciferase activity and read the Renilla luciferase activity, 50μl of Stop & GloTM 
reagent was added and the luminescence measured.  
 
2.2.4 MTT Assay 
This is a colorimetric assay which measures the reduction of MTT into an insoluble 
formazan product by the activity of mitochondrial enzymes in viable cells. Cell 
viability under the different experimental conditions was determined by this 
technique. At the end of a treatment procedure, concentrated MTT was added into 
each well to a final concentration of 0.5mg/ml. After 60min incubation at 37°C in 
the dark, the MTT-containing medium was removed and the formazan crystals 
were dissolved in 200μl dimethyl sulfoxide (DMSO) (MP Biomedical, USA.) with 
gentle shaking (10min) to ensure complete dissolution of the crystals. 100μl of the 
dissolved crystal solution was transferred to 96-well plate after which the 
absorbance intensities were measured at a wavelength of 550nm using a multi-plate 
scanning spectrophotometer (Bio-Rad, Model 680 Microplate Reader). 100μl 
DMSO was used as a blank. Viability of the treated cells was expressed as a 




2.2.5 LDH Assay 
The cytotoxicity detection kit is a fast and simple colorimetric alternative to 
quantitate cell death based on measurement of LDH that is released from damaged 
cells. LDH is a stable cytoplasmic enzyme present in all cells and rapidly released 
into the medium upon loss of membrane integrity which would result in cell death. 
At the end of a treatment procedure, culture medium was collected and centrifuged 
for 10min at 14000rpm, in order to remove any cellular debris. 100μl of the 
supernatant was transferred to a 96-well plate. Each treatment was done in 
triplicates. The LDH activity in the supernatant was determined using the LDH 
cytotoxicity detection kit purchased from Roche Applied Science (USA). 100μl of 
the reaction mixture, prepared according to the manufacturer‟s protocol, was added 
to the supernatant and mixed well.  Following a 30min incubation at room 
temperature, the relative absorbance was measured at 490nm using the multi-plate 
scanning spectrophotometer (Bio-Rad, Model 680 Microplate Reader). Total LDH 
activity in cells was determined by lysing the cells with 2% Triton X-100 (BDH 
Chemical, England) in basal medium and subjecting the supernatant to the assay. 
Cytotoxicity of the treated cells was expressed as a percentage of the total cellular 
LDH activity.  
 
2.2.6 Isolation of total cellular RNA from cells/brain tissue 
For cell culture, upon completion of a treatment, medium from 24-well plates was 
aspirated. The wells were washed with saline and 1ml of TRizol® reagent was 
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aliquoted into three wells of a 24-well plate. The reagent was pipetted up and down 
to mix and lyse the cells before they were pooled into a 1.5ml eppendorf tube. For 
tissues such as rat brain, 100mg of tissue was weighed out and placed in 1ml of 
TRIzol® reagent (Invitrogen, USA). The sample was homogenised until a fine 
consistency with no visible pieces were achieved. This was then used for RNA 
extraction. Total RNA was isolated from brain/cells according to manufacturer‟s 
instructions. Briefly, 200µl of saturated chloroform was added to the tube and 
mixed vigorously before it was centrifuged at 14,000rpm for 15min at 4
o
C. The 
aqueous phase was transferred to a new tube. The remaining organic phase was 
subjected to protein extraction according to the manufacturer‟s protocol (section 
2.2.10). DNase I (3µl) was added to the aqueous phase and it was incubated at 37
o
C 
with for 20min before the addition of 500µl of isopropanol. The mixture was mixed 
vigorously and left overnight at -80
o
C. Total RNA was pelleted by centrifuging at 
14,000rpm for 15min at 4
o
C. The pellet was washed by centrifuging it with 1ml of 
ice-cold 75% ethanol at 14,000rpm for 10min at 4
o
C. The supernatant was 
discarded and the resultant pellet was air dried before it was solubilised in 20µl of 
DEPC treated water. The RNA concentration was determined by ND-1000 
Spectrophotometer (Nanodrop™, Thermo Fisher Scientific, USA.) at 260nm and 




2.2.7 Checking RNA integrity  
2.2.7.1 RNA gel electrophoresis 
Ribonucleic acids were separated by electrophoresis in agarose gels containing 
formaldehyde. This is necessary to determine the integrity of the RNA isolated. 
Molten RNA gel (section 2.1.4.4) was poured into a horizontal gel-casting tray and 
an appropriate „comb‟ was inserted immediately to create wells for sample loading. 
Once the gel solidified, the „comb‟ was removed and the gel was submerged into 
the electrophoresis tank containing 1X MOPS running buffer. RNA samples (0.4-
1.0µg) were mixed with the sample buffer (section 2.1.4.2) and 2µl of RNA 
loading buffer (section 2.1.4.3) and incubated for 10min at 65
o
C in a water bath 
prior to loading into the gel. Electrophoresis was carried out at 100V for about 30 
min and the migration of the bands was viewed using a UV illuminator. 
 
2.2.7.2 Denaturing polyacrylamide gel electrophoresis 
Denaturing ployacrylamide gel electrophoresis was used to analyse the integrity of 
small RNAs. Molten RNA gel (section 2.1.5.1) was poured into a vertical gel-
casting tray and an appropriate „comb‟ was inserted immediately to create wells for 
sample loading. Once the gel solidified, the „comb‟ was removed and the gel was 
submerged into the electrophoresis tank containing 1X TBE running buffer. The 
gel was pre-run for 30min at 100V. Meanwhile the RNA samples (5-10µg) were 
mixed with the sample buffer (section 2.1.5.2) and heated up to 95
o
C for 5min in a 
water bath. The samples were chilled immediately and briefly centrifuged prior to 
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loading into the gel. Electrophoresis was carried out at 100V for about 1.5h and the 
migration of the bands was viewed using a UV illuminator. 
 
2.2.7.3 BioAnalyser 
The Aglient RNA 6000 Nano kit was used to determine RNA quality of samples 
used for mRNA and miRNA arrays.  
 
2.2.7.3.1   Preparation of gel matrix 
550µl of gel matrix (section 2.1.6) was loaded onto a spin filter and centrifuged for 
10min at 4000rpm. The filtered gel matrix was stored at 4
o
C for up to one month as 
65µl aliquots. 
 
2.2.7.3.2   Addition of dye to gel matrix 
The RNA 6000 Nano dye was equilibrated to room temperature in the dark, for 
30min before use. The dye concentrate was vortexed for 10s and pulsed down. 1μl 
of the RNA 6000 Nano dye concentrate was added to a 65μl aliquot of the filtered 
gel matrix (section 2.1.6). The components were vortexed thoroughly and visually 
inspected to ensure proper mixing of the gel matrix and the dye. The mixture was 
centrifuged for 10min at 14000 rpm and protected from light until use. The gel-dye 




2.2.7.3.3   Loading of gel-dye mixture and the nano marker onto the chip  
Prior to the loading of the gel-dye mixture, the RNA nano-chip was assembled onto 
the chip priming station according to the manufacturer‟s instructions (Aglient, 
USA). Using a plunger-clip system, 9µl of the gel-dye mixture was loaded onto the 
first well labelled „G‟. The plunger was held down for about 30s by a clip and 
released to observe for pressurization within the wells of the chip. Following which 
another 9µl of the gel-dye mixture was loaded into the remaining wells labelled as 
„G‟. The remaining 13 wells (12 sample wells and 1 RNA ladder well) were each 
filled with 5µl of Nano marker (section 2.1.6).  
 
2.2.7.3.4   Loading of RNA ladder and RNA samples onto the chip  
Once the gel-dye matrix and the nano marker were loaded successfully, the RNA 
ladder and samples were added within the next 5min, in order to prevent 
evaporation of the pre-loaded reagents. Prior to loading, the ladder aliquots were 
thawed on ice and to minimize secondary structures, the RNA samples were heat 
denatured at 70 °C for 2min. 1μl of the RNA ladder as well as the samples were 
loaded into the respective wells. The chip and its contents were vortexed using an 
adapted vortexer for 1min at 2400rpm. 
 
2.2.7.3.5   Running of the Agilent 2100 bioanalyser  
The Agilent 2100 Bioanalyser was switched on for about 15min to warm up the 
system. Before the start of each run, the electrodes were cleaned with 350μl RNase 
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Zap followed by 350μl RNase free water and air dried for about 10s. The chip 
loaded with the RNA samples were inserted into the bioanalyser and the integrity 
of the RNA samples were examined using the 2100 Expert software.   
 
2.2.8 Reverse transcription (RT) 
2.2.8.1 RT of mRNA  
200ng of total RNA (100ng/µl) was reverse transcribed using 8µl of RT mixture 
(section 2.1.13.1) to generate 10µl of first strand complementary DNA (cDNA). 
Synthesis of cDNA was carried out in a PCR machine (Perkin-Elmer, Germany) at 
25°C for 10min; 37°C for 60min followed by 95°C for 5min. 
 
2.2.8.2 RT of miRNA  
10ng of total RNA (2ng/µl) was reverse transcribed using 7µl of miRNA RT 
mixture (section 2.1.13.2) and 3ul of miRNA specific primers to generate 15µl of 
RT product.  Synthesis was carried out using a PCR machine (Perkin-Elmer, 
Germany) at 16°C for 30min; 42°C for 30min followed by 85°C for 5min. The 





2.2.9 Quantitative real-time PCR (qPCR) 
2.2.9.1 qPCR (mRNA)  
Changes in gene expression upon a particular treatment were determined using 
real-time PCR technology. Two detection systems that are available are the 
Taqman and SYBR green assay methods. Taqman assay makes use of gene specific 
primers and fluorescent probes whereas SYBR green assay uses two (forward and 
reverse) gene specific primers and a DNA intercalating dye. Sequences for gene 
specific primers were designed using the PrimerExpress 2.0 software and the 
respective mRNA strands. The primers were designed to yield amplicons of about 
200bp. Ribosomal RNA (18S) was used as an internal calibrator. 20µl of the 
Taqman (section 2.1.14.1) or SYBR green assay (section 2.1.14.2) was mixed with 
5µl of RT product (section 2.2.8.1) and loaded into 96 well optical plates. The 
plates were sealed with a clear plastic cover and the PCR reaction was carried out 
on ABI PRISM 7900 cycler with thermal cycling conditions of 50°C for 2min, 
95°C for 10min followed by 40 cycles at 94°C  for 15s and 60°C for 1min per 
cycle. All reagents and consumables needed for the PCR reaction were purchased 
from Applied Biosystems, USA. 
 
2.2.9.2 qPCR (stem-loop) 
8.67µl of the Taqman miRNA mixture (section 2.1.13.2) was mixed with 1.33µl of 
miRNA RT product (section 2.2.8.2) and loaded into 384 well optical plates. The 
plates were sealed with a clear plastic cover and the PCR reaction was carried out 
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on ABI PRISM 7900 cycler with thermal cycling conditions of 30°C for 2min, 
95°C for 10min followed by 40 cycles at 94°C  All reagents and consumables 
needed for the PCR reaction was purchased from Applied Biosystems, USA. The 
miRNA specific primers were purchased as MicroRNA Assay kits (Applied 
Biosystems, USA). 
 
2.2.10 Extraction of total protein from cells/brain tissue  
Total protein from brain tissue/cells were extracted, according to the 
manufacturer‟s protocol, from the remaining organic phase after chloroform 
extraction (see section 2.2.6) (Invitrogen, USA). Briefly, 300µl of 100% ethanol 
was added to the organic phase and the samples were mixed by inversion. The 
samples were stored at room temperature for 3min and sedimented at 12000rpm for 
5min at 4°C. The supernatant was transferred to a fresh tube and 1.5ml of 
isopropanol was added. After 30min incubation at room temperature, the protein 
was precipitated by centrifugation at 12000rpm for 10min at 4°C. The supernatant 
was discarded and the pellet was washed 3X with 1ml of 0.3M guanidine 
hydrochloride in 95% ethanol (section 2.1.7.1). During each wash cycle, the pellet 
was kept in the wash solution for 20min at room temperature and centrifuged at 
7500rpm for 5min at 4°C. After the final wash, the pellet was vortexed and stored 
in 2ml of 100% ethanol for 20min and centrifuged at 7500rpm for 5min at 4°C. The 
supernatant was discarded and the pellet was vacuum-dried and dissolved in the 




2.2.11 Determination of protein concentration 
Bradford‟s reagent (Bio-Rad, USA) was diluted 5X using sterile deionised water. 
2μl of the protein sample and 1ml of the diluted Bradford‟s reagent was then added 
to1ml of the diluted reagent and incubated at room temperature for 15min prior to 
absorbance measurement at a wavelength of 595nm. Bovine serum albumin (2-
10μg) was used to generate the standard graph and the concentration of the 
unknown protein samples was determined from it. 
 
2.2.12 Tris-Tricine SDS-PAGE 
The protein extracted from cells or tissues were separated using Tris-tricine SDS-
PAGE. PAGE was carried out according to Schagger et al [213].  For preparation 
of resolving (12%) and stacking (4%) see section 2.1.8.5. The resolving gel was 
prepared first and allowed to set before the stacking gel was cast.  A 1mm „comb‟ 
was placed at the top of the stacking gel to create wells for sample loading. The gel 
was assembled in a vertical electrophoresis unit and filled with the upper and lower 
buffers (section 2.1.8.2 & 2.1.8.3). 40ug of protein samples were mixed with 2X 
sample buffer (section 2.1.8.4) and heated for 10min at 100
o
C. The samples were 
loaded onto the gel and electrophoresis was carried out at 120V for about 1.5 hrs. 
 
2.2.13 Western Blot 
The SDS-PAGE gel (section 2.2.12) was carefully removed and soaked in transfer 
buffer (section 2.1.9.1) for 15min. Nitrocellulose membrane (Amersham 
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International, UK) cut to the dimensions of the gel, 2pieces of scotchbrite and 2 
sheets of 3MM paper were soaked in the transfer buffer for 30min. They were then 
assembled on the blotting panel in the following order: scotchbrite, 3MM paper, 
gel, nitrocellulose membrane, 3MM paper and scotchbrite. Precaution was taken to 
ensure that air bubbles were not present between the membrane and the gel. The 
blotting assembly was then secured in the transfer apparatus and filled with pre-
cooled transfer buffer. Electro-blotting was carried out for 110V for 1 hrs. At the 
end of blotting, the apparatus was disassembled and the membrane was blocked for 
60min in blocking solution (section 2.1.9.4). This was followed by 1hr incubation 
with affinity purified, polyclonal anti-AQP (anti- AQP 1, 4 and 9)  or β-actin; 
(Santa cruz, USA) antibodies at a dilution of 0.5µg/ml in 0.5% blocking solution. 
After three washes of 10min each in PBST (section 2.1.9.3), the membranes were 
incubated for 1 hr at room temperature with horseradish peroxidise-conjugated goat 
anti-rabbit (Bio-Rad, USA) secondary antibodies at a dilution of 1:10000 in 0.5% 
blocking solution. The membranes were then washed 2X for 20min each in PBST 
and visualised via enhanced chemiluminescence (Supersignal; Pierce, USA) with 
variable exposures (Kodak-MS film). Films of western blot were scanned and 
labelling intensities of the bands were quantitated using Image J software.  
 
2.2.14 Immuno Cyto-Chemistry (ICC)  
To visualize changes in protein expression upon miRNA transfection, ICC 
techniques were employed. The cells were seeded on coverslips which were placed 
in 24-well plates. Cell seeding and transfection with anti or pre miRNAs and the 
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plasmid constructs were carried out as described in section 2.2.2.2. 48 hrs after 
transfection, the cells were washed with PBS to remove traces of medium. The 
cells were then fixed to the coverslips using 1ml of 4% formaldehyde for 30min. 
The cells were then washed with PBS and permeabilised using 0.1% Trition X for 
20min. The cells were washed again prior to the addition of 5% FBS (section 
2.1.10.1). 1ml of 5% FBS was used as a blocking solution for 30min. After 30min, 
the wells were washed with PBS and the coverslips were removed from the wells 
and placed on a clean surface. 50µl primary antibody (anti-AQP) at a concentration 
of 1µg/ml was overlayed on top of each coverslip and incubated for 1 hr at room 
temperature. After the incubation the coverslips were washed three times for a total 
duration of 15 min in PBS. 50µl of FITC coupled horseradish peroxidise-
conjugated goat anti-rabbit (Bio-Rad, USA) secondary antibody at a dilution of 
1:200 was overlayed on the coverslips for 1 hr in the dark which was followed by 
three washes in PBS for 15min. 50µl Hoescht nuclear stain (section 2.1.10.3) was 
overlayed on the coverslips for 3min, followed by another three washes in PBS for 
15min. Each coverslip was then mounted (section 2.1.10.4) face down onto a 
microscope slide and the images were captured using a fluorescence microscope 
(Carl Zeiss LSM510 META).  
 
2.2.15 Oxygen glucose deprivation (OGD)  
OGD simulates ischemia-like conditions and this was achieved by placing the cells 
in medium without glucose, serum and in an incubation chamber (maintained at 
37°C) whereby oxygen was displaced with nitrogen. On the day of the treatment, 
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basal RPMI 1640 medium (Gibco, USA) without glucose was deoxygenated for 
30min by bubbling nitrogen gas into it. This medium was used to wash the pre-
seeded cells (cells subjected to siRNA treatment (section 2.2.2.1). After washing, 
300μl of the same medium was added to the wells. The OGD chamber which was 
maintained at 37°C with a nitrogen gas flow rate of 1.3L/min was flushed with 
nitrogen gas for 10min prior to the transfer of culture plates. The cells were 
subjected to OGD treatment. Corresponding control cell cultures were maintained 
in 300μl basal RPMI medium with glucose (Gibco, USA) and were incubated at 
37°C with 5% CO2. At the end of each time point, the medium was replaced with 
fresh basal RPMI 1640 medium containing glucose. The cells were allowed to 
recover at 37°C in a 5% CO2 incubator for 16-18 hrs before further studies. 
 
2.2.16 Extraction of DNA from cells  
DNA from astrocytoma cells was extracted to facilitate cloning of AQP4 promoter 
regions. Briefly, 1.0ml of DNAzol® Reagent (Invitrogen, USA) was added to one 
T-25 flask. The cells were lysed by agitating the flask and the lysate was collected 
into an eppendorf tube. To minimize shearing of the DNA molecules, the lysate 
was pipetted using wide-bore tips. DNA from the lysate was precipitated by the 
addition of 0.5ml of 100% ethanol. The samples were mixed by inversion and 
stored at room temperature for 1-3min. The DNA became visible as a cloudy 
precipitate. The DNA was collected by spooling it with a pipette tip and transferred 
to a clean tube. The sample was washed twice with 1.0ml of 75% ethanol by 
inverting the tubes 3-6 times. After each wash, the tubes were left to stand 1min to 
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allow the DNA to settle to the bottom and the ethanol was removed by pipetting. 
The tubes were then air dried for about 15s and the DNA pellet was dissolved in 8 
mM NaOH. The concentration and purity of genomic DNA was determined using 
Nanodrop (Nanodrop Tech, Rockland, Del). The DNA sample was stored at -20°C. 
1μl of a 10x diluted DNA sample was used to perform PCR in a 25μl volume.  
 
2.2.17 DNA gel electrophoresis 
Nucleic acids were separated by electrophoresis in 1% agarose gels. This is 
necessary to determine the integrity of the DNA isolated as well as to analyse PCR 
products. Molten DNA gel (section 2.1.2.5) was poured into a horizontal gel-
casting tray and an appropriate „comb‟ was inserted immediately to create wells for 
sample loading. Once the gel solidified, the „comb‟ was removed and the gel was 
submerged into the electrophoresis tank containing 1X TBE running buffer. DNA 
samples were mixed with the 6X loading buffer (Fermentas, Lithuania) prior to 
loading into the gel. 100 basepairs or 1 kilo basepair markers (Fermentas, 
Lithuania) were used according to the requirement.  Electrophoresis was carried out 
at 100V for about 40min and the migration of the bands was viewed using a UV 
illuminator (Cell Biosciences, USA). 
 
2.2.18 First strand cDNA synthesis for cloning  
Total RNA from various cell lines were used to reverse transcribe mRNAs 
encoding AQP genes. Briefly, the individual components of the Fermentas 
91 
 
RevertAid™ H Minus First Strand cDNA Synthesis Kit (section 2.1.15.1) were 
thawed on ice. 1µg of total RNA and 1µl (100 pmol) of random hexamers were 
aliquoted into a sterile PCR tube containing RNase free water. The volume was 
adjusted to 12µl. The contents in the tube were mixed gently, centrifuged briefly 
and incubated at 65°C for 5min. The tube was then chilled on ice. The remaining 
components of the Fermentas RevertAid™ H Minus First Strand cDNA Synthesis 
Kit were added to the tube. The contents were mixed and centrifuged briefly. The 
PCR tube was incubated at 25°C for 10min followed by 60min at 42°C. The 
reaction was terminated by heating at 70°C for 5min. 1μl of the cDNA was directly 
used to perform PCR in a 25μl volume.  
 
2.2.19 Polymerase chain reaction (PCR) 
Depending on the region of interest, the template used for PCR was either genomic 
or complementary DNA. The PCR reaction was prepared in thin-walled PCR tubes 
on ice according to section 2.1.15.2. 1μl of the template was added and the contents 
were briefly centrifuged. The PCR cycling conditions were set depending on the 
melting temperatures (Tm) of the primers used and the size of the product 
amplified. Typically the annealing temperature was set 5
o
C below the primer Tm 
for 45s while the extension temperature was kept at 72
o
C. At the end of the run, 
10μl of the product was analysed on a 1% DNA agarose gel (section 2.1.2.5). Once 
the desired fragment size is obtained, the fragment is excised out with a clean, 




2.2.20 DNA gel extraction 
The excised DNA/PCR fragment from the agarose gel was weighed and QG buffer, 
(Qiagen, Germany), volume equivalent to 3 times the weight of the gel was added. 
The gel and buffer mixture was incubated at 50°C for about 10min. Once the gel 
slice had completely dissolved, 1 gel volume of isopropanol was added and mixed. 
The sample was applied to a QIAquick spin column and centrifuged at maximum 
speed for 1min. The flow-through was discarded and the column was washed with 
0.75ml of PE buffer (Qiagen, Germany) by centrifuging at maximum speed for 
1min. The QIAquick column was transferred into a clean 1.5ml microcentrifuge 
tube and the DNA was eluted with 20µl of nuclease free water by centrifuging for 
2min at maximum speed. 2µl of the DNA was loaded onto a 1% agarose gel to 
check its integrity. The remaining DNA extract was used directly for cloning or 
stored at   –20°C.   
 
2.2.21 Ligation and transformation 
Ligation reactions were carried out with a vector: insert molar ratio of 
approximately 1:3 to increase the ligation efficiency. Generally 50ng of plasmid 
vector was used for each reaction (section 2.1.15.3). The reaction mixture was 
incubated at room temperature for 30min before the addition of competent cells. 
Competent cells (Invitrogen, USA) from -80°C were thawed on ice. The ligation 
mixture was added to 50μl of the competent cells and mixed gently. The tube was 
kept in ice for 30min. The cells were then heat-shocked at 42°C for 90s, transferred 
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to a 10ml falcon tube with 250μl SOC medium (Invitrogen, USA). The cells were 
incubated for 1 hr at 37°C before plating them on LB-agar plates (section 2.1.15.8) 
containing ampicillin (section 2.1.15.6). The plates were left at 37°C for about 18 
hrs to allow for the colonies to grow. Single colonies were then picked using sterile 
toothpicks and re-grown for 18 hrs in 1.5ml LB broth (section 2.1.15.7) containing 
ampicillin. 
 
2.2.22  Plasmid extraction 
Plasmid extraction was necessary for further analysis of cloned fragments. 1.5ml of 
the individually grown colonies were transferred into an eppendorf tube and 
centrifuged at maximum speed for 2min to pellet the cells. The supernatant was 
aspirated and the pellet was resuspended in 100µl of cold resuspension buffer 
(section 2.1.15.9.1). The tube was vortexed vigorously to facilitate efficient 
resuspension. 200µl of freshly prepared lysis buffer (section 2.1.15.9.2) was added 
and the tube was inverted 5-6 times to mix the contents. Following which 150µl of 
cold precipitation buffer (section 2.1.15.9.3) was added to the tube and mixed by 
inversion. This solution neutralizes NaOH in the previous lysis step while 
precipitating the genomic DNA and SDS into an insoluble white, rubbery 
precipitate. The tube was incubated in ice for 10min and centrifuged at maximum 
speed for 10min. The supernatant was transferred to a new tube. 3µl of RNase 
solution (section 2.1.15.10) was added to the supernatant and incubated at 60 °C for 
20min. The tube was then cooled on ice and the plasmid was precipitated with 
450µl of isopropanol at -80°C for 30min and spun at maximum speed for 10min. 
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The supernatant was discarded and 500µl of 70% ethanol was added. After a 10min 
spin at maximum speed, the supernatant was aspirated and the pellet was air dried 
before being resuspended in 25µl of nuclease free water. 
 
2.2.23 Restriction enzyme digestion 
To check for the presence of the cloned fragment in the vector, restriction enzyme 
digestion was carried out. About 1μg of the plasmid (section 2.2.22) was added to 
the restriction enzyme mixture (section 2.1.16). The final volume was adjusted to 
20μl and the tubes were incubated at 37oC overnight. For double digests, buffers 
compatible to both enzymes were used. Following the incubation, the digests were 
analysed on a 1% DNA agarose gel (section 2.1.2.5). If the digested fragment was 
needed for further cloning, the fragment was excised out with a clean, sharp scalpel 
and the DNA was extracted from the gel (section 2.2.20).  
 
2.2.24 miRNA array 
2.2.24.1  Sample labelling  
All the components of the miRCURY LNA microRNA power labelling kit 
(Exiqon, Denmark) were thawed on ice. Total RNA from the sample or tissue of 
interest was extracted and was prepared to a final concentration of 1µg/2µl. Prior to 
miRNA labelling, the sample was treated with Calf Intestinal Alkaline Phosphatase 
(CIP) to faciliate removal of 5‟-phosphates from terminal of the miRNAs. 2µl of 
the CIP mixture (section 2.1.18.1) was mixed with the RNA sample in a PCR tube. 
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The mixture was incubated in a PCR machine at 37°C for 30min to allow the CIP 
enzyme to function optimally, followed by 95°C for 5min to linearize the miRNA 
template and snap cooled in ice to terminate the reaction. The sample was briefly 
spun and 8.5µl of the labelling mixture (section 2.1.18.2) was added to it. The 
miRNAs were labelled with Hy3 fluorophores. Labelling of miRNAs was 
performed in a PCR cycler with heated lid, for 1 hr at 16C followed by 65C for 
15min. The samples were protected from light. At the end of the reaction, the 
samples were pulsed and left at 4C while the hybridization chamber was prepared. 
Hybridization was carried out within 2 hrs of labelling. 
 
2.2.24.2  Sample preparation for hybridization 
The labelled product was diluted by adding 12.5l of nuclease-free water and the 
contents were transferred into a new PCR tube. 25l of 2x hybridization buffer 
(Exiqon, USA) was added to the sample and the contents were vortexed to mix and 
pulsed down. The sample was then denatured at 95C for 2min and snap cooled on 
ice.  Prior to sample loading, pre-wetting of the pipette tips were essential. Hence a 
tube containing 50l 1x hybridization buffer in nuclease free water was prepared 
and incubated at 56C.  
 
2.2.24.3  Setting up of hybridization chamber 
The MAUI hybridization chamber was switched on and pre-heated to 56C. The 
miRNA array chip (miRBase version 11.0) was warmed on the pre-heated block for 
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5min. The chip was then loaded onto a chip holder. A cover was aligned onto the 
exposed surface of the array chip according to the manufacterer‟s instructions 
(Exiqon, Denmark). The exposed chip surface was then sealed with a cover. The 
enclosed chip assembly was placed back into the MAUI hybridization chamber 
until sample loading.  
 
2.2.24.4  Loading of sample for miRNA array 
Prior to sample loading onto the array slide, the pipette tips were pre-wetted with 
the hybridization plus water mixture. 45l of the sample was slowly injected into 
the chip via the chip cover‟s inlet port. Care was taken to avoid introduction of 
bubbles. Sample introduction was stopped when the fluid was observed to reach the 
outlet port of the cover. The excess fluids were wiped away and the ports were 
sealed with an adhesive tape. The enclosed chip assembly was then loaded back 
onto the pre-heated MAUI hybridization chamber. The assembly was enclosed with 
a pre-wet humidity casing and closed shut. The slides were then incubated for 
about 16 hrs at 56C. 
 
2.2.24.5  Washing of miRNA array slides 
At the end of the hybridization process, the enclosed chip assembly was removed 
from the MAUI hybridization chamber and slotted back into the chip holder. The 
holder was then soaked in 400ml of pre-warmed Buffer A. Keeping the holder 
submerged, the cover of the chip was gently peeled away. The exposed chip was 
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then carefully slotted out of the holder and transferred to a rack which was 
immersed in a dish containing 200ml of the prewarmed Buffer A. The chip was 
then rinsed by gently plunging the rack for 2min. Care was taken to ensure that the 
chip was kept submerged throughout the washing procedure. The rack was then 
transferred to 200ml of Buffer B at room temperature and the chip was temporarily 
stored here while the rest of the chips were disassembled and rinsed in a similar 
manner. Once all the chips were collected in Buffer B, they were rinsed by gently 
plunging the rack for 2min. Then they were moved to another dish containing fresh 
Buffer B solution and the procedure was repeated again for 2min. A third wash was 
done in a similar manner using Buffer C. The final wash was done in 200ml 
absolute ethanol for 1min. Following the washes the chips were dried by 
centrifugation at 1000rpm for 5min and scanned immediately at 532nm as the 
fluorophores on the slides are susceptible to degradation by ozone in the 
atmosphere.  
 
2.2.24.6  Scanning of miRNA array chips and data anlaysis 
Scanning of the miRNA array chips was performed using the InnoScan 700 
Microarray scanner (Innopsys, France) and the signal intensity was quantified using 
the Mapix software (Innopsys, France). Background subtraction and normalisation 
were performed on the raw signal intensity data using the internal controls inherent 
in the chips. Signal values lower than 300 were omitted from the analysis. For 
comparison purposes, the data was expressed as relative fold change with respect to 
controls. Statistical comparisons between controls and test samples are performed 
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using Student‟s t-test and ANOVA. A p-value <0.05 was considered to be 
statistically significant. Hierarchical clustering plot was generated using TIGR 
multiple experimental viewer software (http://www.tm4.org/mev/) [214].  
 
2.2.25 mRNA Array 
2.2.25.1  cRNA amplification and purification 
The Illumina® TotalPrep RNA amplification kit was used to amplify and generate 
biotinylated RNA for hybridization with the Illumina® arrays. Reverse 
transcription to synthesize the first cDNA strand was performed with 500ng of total 
RNA which was diluted to a final volume of 11µl with nuclease-free water. 9µl of 
the reverse transcription master mixture (section 2.1.19.1) was added to the RNA 
sample and incubated for 2 hrs at 42C. At the end of incubation, the samples were 
pulsed down and 80µl of the second strand master mixture (section 2.1.19.2) was 
added. The samples were pulsed and incubated further at 16C for 2 hrs. 250μl of 
cDNA binding buffer was added to each sample to purify out the synthesized 
cDNA. The cDNA sample and the binding buffer were mixed thoroughly and 
pulsed down and the solution was transferred onto the cDNA filter cartridge. The 
filter cartridge was centrifuged for 1min at 10,000 x g and the flow-through was 
discarded. The cDNA filter cartridge was then washed with 500µl of wash buffer 
and transferred to a new tube to prevent carry-over of the wash buffer. The cDNA 
was eluted with 20µl nuclease-free water which was pre-warmed to 55°C and 
transferred into a PCR tube. 7.5μl of the in vitro transcription master mixture 
99 
 
(section 2.1.19.3) was added to each PCR tube. After mixing them thoroughly, the 
samples were pulsed down and placed in the thermal cycler at 37°C for up to 14 
hrs. At the end of the incubation, the reaction was terminated with the addition of 
75μl nuclease-free water, bringing the total volume to 100μl. The amplified cRNA 
was purified to remove the excess enzymes, salts and unincorporated nucleotides. 
350μl of cRNA binding buffer was added to each cRNA sample followed by 250μl 
of 100% ethanol. The components were mixed by pipetting the mixture up and 
down 3 times and transferred onto the cRNA filter cartridge. The filter cartridge 
was centrifuged for 1min at 10,000 x g and the flow-through was discarded. The 
cRNA filter cartridge was then washed with 650µl of wash buffer and transferred to 
a new tube to prevent carry-over of the wash buffer. The cRNA was eluted with 
200µl of nuclease-free water pre-warmed to 55°C. The cRNA concentration was 
determined by ND-1000 Spectrophotometer (Nanodrop™, Thermo Fisher 
Scientific, USA.) at 260nm and the integrity was determined by RNA gel 
electrophoresis.  
 
2.2.25.2  mRNA hybridization 
The labelled cRNA was quantitated and 750ng of it (section 2.2.25.1) was used for 
hybridization to an array according to the Illumina Sentrix humanref-8 beadchip 
protocol. A maximum of 5µl of cRNA was mixed with a 10µl GEX-HYB 
hybridization solution (Illumina Inc., San Diego, USA). The preheated 15µl assay 
sample was dispensed onto the large sample port of each array and incubated for 18 
hrs at 58°C. Microarrays were then washed twice in E1BC buffer (Illumina Inc., 
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San Diego, USA) at room temperature for 5 minutes. After blocking for 5 min in 4 
ml of 1% (w/v) Blocker Casein in phosphate buffered saline Hammarsten grade 
(Pierce Biotechnology Inc., Rockford), array signals were obtained after a 10-min 
incubation in 2ml of 1µg/ml Cy3-streptavidin (Amersham Biosciences, 
Buckinghamshire, UK) solution and 1% blocking solution. After a final wash in 
E1BC buffer, the arrays were dried and scanned. 
 
2.2.25.3  Scanning of mRNA array chips and data anlaysis 
Scanning of the mRNA array chips was performed using the BeadArray Reader 
and the signal intensities were quantified using the BeadStudio software. 
Background subtraction and normalisation were performed on the raw signal 
intensity data using the internal controls inherent in the chips. Signal values lower 
than 300 were omitted from the analysis. For comparison purposes, the data was 
expressed as relative fold change with respect to controls. Statistical comparisons 
between controls and test samples are performed using Student‟s t-test and 
ANOVA. A p-value <0.05 was considered to be statistically significant. 
Hierarchical clustering plot was generated using TIGR multiple experimental 




2.2.26  Animal model 
2.2.26.1  Transient middle cerebral artery occlusion  
Adult Sprague-Dawley rats were anesthesized intraperitoneally with 37% ketamine 
and xylazine mixture (section 2.1.20.2) and the animal was considered sufficiently 
anaesthesized when there was a complete loss of pedal reflex. The region around 
the neck was shaved and cleaned of fur. The left MCA was temporarily occluded 
without craniectomy using a „suture‟ model of focal ischemia described by Longa 
et al [215]. Briefly, a skin incision was made from the petrous bone to the scapula 
and the neck muscles were dissected to gain access to the common carotid artery 
(CCA). Dissection of the carotid bifurcation and glomus caroticum was performed 
in the vicinity of the vagus nerve and the occipital artery branching off the external 
carotid artery (ECA) was cauterized close behind the carotid bifurcation. The 
internal carotid artery (ICA) was carefully dissected as distal to its entrance to the 
skull as possible. Proximal to this entrance, the ICA gives off a branch, the 
pterygopalatine artery that runs more dorsal and lateral to ECA, which was ligated. 
Subsequently, ECA was ligated as distal as possible but still proximal to its 
branching and the ends of the suture was used to pull the blind end of ECA. 
Temporary vascular clips were applied to CCA and ICA, and an incision was made 
in the ECA. A 4/0 monofilament fibre (Ethicon, Belgium), previously coated with 
poly-lysine, was carefully inserted into and through the lumen of ECA until it was 
wedged intracranially, which was usually 17mm from the bifurcation. Eventually, 
the stump of ECA was clipped together with the suture inside and the clip on CCA 
was released. After 60min, the suture was gently pulled through the ligature (to 
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allow reperfusion to take place) and cut, leaving approximately 3mm of the fibre 
within the ECA stump. The ligature was tightened and the wound was closed using 
3/0 silk sutures. All arterial ligations described above were done using 5/0 silk 
sutures (Aesculaps AG & Co, Tuttlingen).  
 
2.2.26.2  Laser-doppler flowmetry 
To confirm appropriate suture placement during transient MCAo, cerebral cortical 
perfusion was monitored by laser-Doppler flowmetry (OxyFlo, Oxford Optronix) 
pre-occlusion, immediately post-occlusion and at the time of reperfusion. The 
region of the rat‟s head above the skull was shaved and cleaned of fur before an 
incision was made. A small hole was bored into the skull using a 2mm-burr and 
dental drill and a 1mm-needle probe was placed in the hole, directly over the 
territory of the MCA (2mm caudal to the bregma and 6mm lateral to the midline). 
The signals were digitized using a 4-channel Powerlab 4SP (ML760) and 
recordings were displayed with Chart 5 software (ADInstruments Pty Ltd, 
Australia). 
 
2.2.26.3  Injection of miRNAs 
Anti/Pre miR-320 was injected into ischemic rats via the intracerebro-ventricular 
cavity. 50 pmol of the miRNA was complexed with the siPORT NeoFix 
transfection agent (Ambion, USA) and the injections were administered 
immediately after reperfusion. 24 hrs after reperfusion, the rats were sacrificed and 
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their brain was examined for the extent of the infarct using a TTC stain (section 
2.1.20.4). 
 
2.2.26.4  Histological analysis of cerebral ischemia   
Whole rats brains were cut coronally into 2mm slices and incubated in TTC stain 
(section 2.1.20.4) for 45 min. Healthy brain tissue turned purple on staining, 
leaving a white unstained area, which represented the infarcted region. Infarct 
volume was calculated according to the formula given below: 
VI = Σ IA x Thickness of slice / 1 + ASF 
where 
VI    = Infarct Volume 
IA    = Infarcted Area 
ASF = Average Swelling Factor 
and  
ASF = [ Σ(IH-NIH)/Σ(IH+NIH)] / number of slices 
where 
IH    = Infarcted Hemisphere 
NIH = Non-Infarcted Hemisphere 
 
2.2.27 Statistical analysis 
All data were presented as mean ± SEM and „n‟ indicates the number of repeats for 
that experiment. Statistical comparisons between controls and test samples were 
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performed using F-test for analysis of variance followed by t-test with 

























MicroRNAs regulating aquaporins  










Of the 13 aquaporins (AQPs) reported to be present in the mammals, AQPs 1, 2, 4, 
5, 6 and 8 are grouped as classical aquaporins since they are considered to function 
primarily as bidirectional water-selective transporters [3]. Among these, AQPs 1, 2 
and 4 constitute the most thoroughly examined classical AQPs that function in 
water homeostasis. All three AQPs function effectively in the kidneys whereas in 
the brain AQP1 and 4 are known to be present [17, 20, 31]. The physiological roles 
of several of these AQPs have been revealed by the use of knock-out mice models. 
About 60-80% of the filtrate entering the Bowman's capsule is reabsorbed at the 
proximal tubules where extensive AQP1 expression is noted. AQP1 knockout 
animal models revealed the animals‟ inability to concentrate their urine because of 
low water permeability in the proximal tubule, resulting in defective near-isosmolar 
fluid absorption in the proximal tubule [115, 216]. Furthermore, impaired water 
permeability along the thin descending limb of Henle due to AQP1 knockout, 
resulted in defective countercurrent multiplication. In the brain, AQP1 is associated 
with cerebrospinal fluid production and knock-out models showed a 25% reduction 
in cerebrospinal fluid production [92, 217].  
 
Expression of AQP2 however is extensive in the kidney and not detected in the 
brain. AQP2 is expressed intracelluarly in the principal cells of the collecting duct 
cells and gets translocated to the apical membrane in response to vasopressin [21-
23]. However, vasopressin independent regulation of AQP2 expression has been 
reported too [218]. An inducible mouse model with mutated AQP2 gene showed 
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that urine osmolality decreased from approximately 2,000 to less than 500 mOsm, 
reflecting conditions of severe nephrogenic diabetes insipidus [219]. Others have 
also shown that mice lacking AQP4 also manifest impaired urine concentrating 
function [220-221] where water permeability in the collecting duct was reduced by 
4 fold [221]. Yet the expression of AQP4 is predominant in the brain and AQP4 
knockout models were shown to be less susceptible to cytotoxic brain edema 
although the lack of its expression made the animals vulnerable to vasogenic brain 
edema [90-91]. 
 
Knowledge of the functional roles of AQPs 1, 2 and 4 has implicated them with 
various pathological conditions as well. Expression of AQP1 and 4 is often 
associated with cerebral edema following ischemia, trauma, tumors, inflammation 
and metabolic disturbances. Brain tissue from surgical patients with contusional 
edema showed upregulation of AQP1 expression [222]. In cultured human 
astrocytes, gliosarcoma and renal epithelial cells, the levels of AQP1 protein 
expression were elevated by hypertonicity [223-225]. The expression of AQP4 was 
also increased in oedematous human brain tumours [226].  
 
In humans, conditions such as hypercalcemia, hypokalemia, ischemic acute renal 
failure or ureteral obstruction are common and often result in urinary concentrating 
defects and polyuria [227]. In severe situations they can result in acquired 
nephrogenic diabetes insipidus. Studies have highlighted that under such 
conditions, there are extensive changes in the AQP expression profiles of classical 
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AQPs 1, 2 and 4 [227-229]. Immunoblotting and densitometry of membrane 
fractions revealed a significant decrease in AQP2 expression in kidney inner 
medulla of hypercalcemic rats to 45.7 ± 6.8%. Parallely an increase in urine 
production to a maximum of 25.3 ± 1.9 ml/day was observed. Li et al [227] 
observed severe downregulation of classical AQPs 1, 2 and 4 in kidneys with 
ureteral obstruction. This was also seen in vasopressin-deficient Brattleboro rats 
suggesting a vasopressin-independent downregulation of AQP2 gene [218]. 
 
On the contrary to AQPs 1, 2 and 4, the functional roles of the other classical AQPs 
are not clearly understood yet. AQP5 is predominantly expressed in the lungs, 
salivary and airway submucosal glands [230-231]. Although knockout of AQP5 
caused defective secretion of saliva and airway mucus production, in the lungs, a 
major organ, lack of its expression did not impair active fluid absorption [230]. 
Hence the exact role of AQP5 is not clear. Likewise the functional role of AQP6, 
proposed to function as an intracellular chloride channel [39] is not evident. AQP8 
knockout studies were not conclusive either. Thus unlike AQPs 1, 2 and 4 the 
importance of AQPs 5, 6 and 8 in physiological and pathophysiological conditions 
is yet to be established.  
 
Having seen the functional importance of AQPs 1, 2 and 4 and their roles in human 
pathophysiologies, there is a need to possess modulators that could regulate the 
expression of these genes either individually or in combinations. Several studies 
have also highlighted this urgent need. One of the most recent breakthroughs in 
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science is the identification of miRNAs which are endogenous regulators of gene 
expression. In silico analysis of databases such as TargetScan, MicroRNA.org and 
MicroCosm Targets revealed large numbers of miRNAs that could potentially 
target all AQPs (AQP0-12) in human, rat and mouse (Table 3.1). Thus sensing the 
need to regulate AQP1, 2 and 4, and the lack of modulators against them, this study 
investigated the ability to exploit the naturally occurring phenomenon of miRNA 
based gene regulation. Using bioinformatics based prediction programs possible 
miRNAs for AQP1, 2 and 4 were identified and selected for further validation 
studies. 
 
3.2 Bioinformatics predictions of miRNAs targeting AQPs 
As mentioned earlier, the initial screening process through the TargetScan, 
MicroRNA.org and MicroCosm Targets databases yielded a large list of miRNAs 
for AQP genes. Although all these programs use the miRanda algorithm for 
prediction, differences in the selection stringency for factors such as the source of 
target sequence information, preference for a perfect seed complementarity or for a 
relaxed complementarity, the extent of conservation against the different species, 
interaction specificity between the 5‟ and 3‟ end of the miRNA with its target 
sequence and variations in the supplementary programs used in the analysis, 
eventually lead to differences in the list of target(s) obtained from the various 
databases. Since variations in the output of prediction programs are expected [184], 
and no prediction program was considered to be superior to the other [161], the 
prediction data was pooled in order to obtain a comprehensive list of miRNAs 
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(Supplementary Table 1). A total of 537 miRNAs were predicted to target the 
human AQP genes 0-12 (Supplementary Table 1). From this huge source of data, 
human miRNAs that could target AQPs 1, 2 and 4 were sorted out. miRNAs 
predicted to target four or more AQPs were excluded from the selection. However 
many of these miRNAs were not exclusive to AQPs 1, 2 and 4 only. They were 
also predicted to target other AQPs. Thus to further streamline the list, if the 
prediction contained more than one other AQP not of interest, (AQPs other than 1, 
2 and 4) then the miRNA was also omitted. For instance, miR-101 predicted to 
target AQPs 1, 5 and 10 was omitted while miR-124 predicted to target AQPs 1, 2 
& 11 was chosen. This selection procedure reduced the list to 182 miRNAs (Table 
3.2) 
 
3.3 Screening of miRNAs expressed in Caki cell line 
From the consolidated list of miRNAs (Table 3.2) an attempt was made to validate 
some of the predictions and screen for possible modulators against AQPs. Given 
the importance of AQPs 1, 2 and 4, this study focussed on these three classical 
AQPs. Co-expression of target gene and its miRNA is often considered an 
important criterion when miRNA based gene regulation is considered. Expression 
of various AQP isoforms including AQPs 1, 2 and 4 has been extensively reported 
in the kidneys. Thus to study the regulation of AQPs 1, 2 and 4 by miRNAs, a 
human kidney cell line Caki (HTB-47™) was chosen. Prior to pursuing the 
validation studies, expression of AQPs 1, 2 and 4 and the expression profile of the 
miRNAs present in Caki cells was established. Total RNA was extracted from the 
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Caki cells using the single-step Trizol technique (section 2.2.6). The purity of the 
RNA was determined using a nano-drop and both 260/280 and 260/230 ratios were 
well within the 1.8-2.0 range. The integrity of the RNA was then checked using a 
bioanalyzer (Figure 3.1). The results showed two distinct sharp peaks 
corresponding to the 18S and 28S. This was an indication of good quality total 
RNA. Gene specific primers were used to test for the presence of AQPs 1, 2 and 4 
in the Caki cell line (Table 3.3).  Expression of all 3 genes were detected in the cell 
line. For miRNA profiling, 1µg of the total RNA was used. A specific and highly 
sensitive miRCURY LNA
TM
 microRNA array system was used for the profiling 
experiments (section 2.2.24). A total of 405 miRNAs were detected. After 
background filtering, an overall of 328 miRNAs were found to be expressed in the 
Caki cells (Table 3.4).  
 
3.4 Validation of miRNA array 
Although profiling experiments enables one to understand the global miRNA 
expression in a system, revalidation studies are necessary and quantitative PCR is a 
common technique used to revalidate profiling results. To validate the miRNA 
array results, about 50 miRNAs were selected for validation. Selection of these 50 
miRNAs was done such that they were representative of the entire signal intensity 
range observed in the miRNA array. This selection technique was used since 
random sampling was prosposed to be a better method for validation rather than the 
common procedure of choosing the most highly expressed genes [226].  The 
authors showed that random sampling was a better reflection of the results obtained 
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from the entire array compared to validating only the highly expressed genes. For 
each miRNA, specific stem-loop primers were used to reverse transcribe 10 ng of 
total RNA and the products were then subjected to quantitative PCR (Table 3.5). 
The expression of miR- 144, 346, 409-5p and 548-5p were not detected in the 
array. Thus these four miRNAs including a no template control (NTC) were used 
as negative controls for the stem-loop PCR. Generally, PCR detection of these 
miRNAs co-related with that of the miRNA array. miRNAs that were detected in 
the array were also detected via stem-loop PCR while expression of miR- 144, 346, 
409-5p and 548-5p were undetermined (Table 3.5).  
 
3.5 Selection of miRNAs for further interaction studies  
Having validated the Caki miRNA expression profile, the next logical move was to 
establish whether the 182 miRNAs selected earlier (Table 3.2), were also expressed 
in Caki cells. Thus a comparison between the Caki miRNA array data (Table 3.5) 
and the selected miRNAs (Table 3.2) was made. From the list of 182, 60 miRNAs 
were found to be expressed in Caki cells and were selected for further studies 
(Table 3.6). Comparison of the signal intensities showed that most of this miRNAs 
were poorly expressed in Caki cells. Ten miRNAs (miR-16, -17-5p, -103, -125b -
146a, -181a, -197, -210, -320a and -498) were found to be highly expressed in Caki 
cells with average signal intensities greater than 1000. Thus these ten miRNAs 
were chosen for further studies. The predicted interaction sites of the miRNAs were 
mapped to the 3‟UTR region of their AQP targets.  miR-146a, -103 and -320a were 
predicted to target the 3‟UTR of AQP1 (Figure 3.2). miR-125b, -146a, -181a, -197  
112 
 
and -498 were predicted to target the 3‟UTR of AQP2 (Figure 3.3) while miR-16, -
17-5p, -125b, -210 and  -320a were predicted to target AQP4 (Figure 3.4). miR-17-
5p had two recognition sites on the AQP4 3‟UTR. 
 
3.6 Cloning of AQPs 1, 2 and 4 3’UTRs 
The most common method for validating the miRNA: target interaction is through 
the use of reporter gene assays. The 3‟UTR region of the target gene is usually 
cloned downstream a reporter gene such as luciferase. Thus in order to screen and 
validate miRNAs that could modulate AQPs 1, 2 and 4, the next task was to clone 
the 3‟ untranslated regions of these three genes. The sequences of these three genes 
were obtained from the NCBI database and specific primers were designed to 
amplify the entire 3‟ UTR regions (Table 3.7). AQP1, 2 and 4 had 3‟UTRs ranging 
from about 1.9 to 4.1 kb long. Due to the long 3‟UTRs seen for these three genes, 
the regions were amplified as smaller fragments from Caki RNA.  The 3‟ UTR of 
AQP1 was generated as 4 fragments (AQP1 A-D) (Figures 3.5 & 3.6), AQP2 as 3 
fragments (AQP2 A-C) (Figures 3.7 & 3.8) and AQP4 as 5 fragments (AQP4 A-E) 
(Figure 3.9 & 3.10). All these fragments were sub-cloned into TOPO vector (Figure 
3.11) and sequenced for verification. Once the sequences were verified as the 
correct AQP 3‟UTR, restriction sites were introduced at the ends of the fragments. 
This was done by re-designing the ends of the original primers with specific 
restriction sites such as (SpeI/HindIII, SpeI/SacI or SpeI/MluI) (Table 3.7). The 
fragments were then re-amplified using the new primers and sub-cloned into TOPO 
vectors once again. The sequences including the presence of the restriction sites 
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were verified by sequencing. The correct fragments were then excised using the 
appropriate restriction enzymes and sub-cloned into pMIR luciferase vector (Figure 
3.12) and sequenced for verification for the final time.  
 
3.7 Interaction studies of miRNAs with predicted targets 
Reporter assays to study the interaction between the miRNAs and their targets, are 
often performed in HeLa cells. It is a common cell line often used due to the fact 
that the cells are easily transfectable. However, prior to transfection, it was 
necessary to establish the expression of the selected miRNAs (miR-16, -17-5p, -
103, -125b -146a, -181a, -197, -210, -320a and -498) in this cell line as well. Thus 
using stem-loop PCR the expression of the ten miRNAs in HeLa cells were 
determined. The expression of all ten miRNAs (miR-16, -17-5p, -103, -125b -146a, 
-181a, -197, -210, -320a and -498) were detected in HeLa (Table 3.8).  The AQP - 
3‟UTR constructs were then co-transfected together with their respective anti or pre 
miRNAs into the cells. Changes in the luciferase activity were measured 48 hrs 
after transfection. Significant changes in luciferase expression were observed in 
several of the constructs (Figure 3.13).  
 
When the AQP1 3‟UTR constructs were co-transfected with anti miR-146a, a 87% 
increase in relative luminescence was noticed (Figure 3.13). While in the presence 
of pre miR-146a, the reporter gene expression was suppressed. A similar 
expression profile was seen when miR-103 and miR-320a levels were modulated. 
This suggests that all three miRNAs (miR-146a, -103, and -320a) could regulate 
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AQP1 expression. However miR-146a was seen to be the strongest modulator, 
followed by miR-320a and miR-103. miR-146a was also predicted to target the 
AQP2 3‟UTR. Neverthelss reporter assays did not show any significant modulation 
in gene expression between the anti and pre treated cells (Figure 3.13). Interestingly 
miR-125b was predicted to be a common modulator for AQP2 and AQP4. Co-
transfection of the anti and pre miR-125b with the respective constructs showed 
differential gene regulation in both AQP2 and AQP4.  Anti miR-125b upregulated 
the gene expression of AQP2 and AQP4 while pre miR-125b downregulated the 
expression. Among the other miRNAs (miR-197, -181a and -498) tested for AQP2, 
miR-197 seemed to be a possible regulator of AQP2 as well. Suppression of miR-
197 caused a 50% increase in relative luminescence while with pre miR-197 a 50% 
reduction in relative luminescence was observed. This phenomenon was not 
evident with miR-181a and miR-498.   
 
Lastly miR-16, -17-5p, -210 and -320a were also predicted to regulate AQP4 
expression. Furthermore miR-17-5p was predicted to interact at two different sites 
in the AQP4 3‟UTR. miR-16, -17-5p and -320a were able to regulate the reporter 
gene expression. Anti miR-16, -17-5p and -320a upregulated reporter gene 
expression and the strongest regulation was seen with anti miR-320a where a 100% 
increase in relative luminescence was observed. With the addition of the pre 
miRNAs the suppression of gene expression was observed in all three cases. 
However it must be highlighted that the regulation of reporter expression was by 
miR-17-5p was observed only at the second recognition site (Figure 3.13). The 
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predicted interaction at the first site was not evident from the reporter assays. The 
anti and pre miR-210 transfection did not cause a significant change in the reporter 
expression as well. Since anti and pre miR-210 treatment did not show significant 
regulation of the reporter gene, AQP4 was probably not a direct target of miR-210.  
 
The results obtained thus far suggest that miRNA based AQP gene regulation is 
possible. So far two miRNAs (miR-146a and -103) have been identified as 
modulators of AQP1 expression. Furthermore, miR-197 has been shown to be able 
to regulate AQP2 while miR-16 and 17-5p could be used to regulate AQP4 
expression. This allows for the independent regulation of each of the three classical 
AQPs. In addition to these, miR-125b has been been shown to be a common 
modulator of AQP2 and AQP4. It might be a useful modulator in conditions 
leading to polyuria. Another common modulator identified in this study was miR-
320a. miR-320a was able to modulate the expression of both AQP1 and AQP4 
simultaneously and it appreared to be a strong regulator of AQP4. Since AQP1and 
AQP4 are often implicated in cerebral edema, a common regulator such as miR-
320a would be of great use. While this study highlights the presence of miRNA 
based modulators against AQPs, further investigations are needed to determine the 







Table3.1: Number of miRNAs obtained from the three different databases against each AQP gene. Gene sequence for AQP10 of 
Rattus norvegicus was not available for prediction. Union refers to the unification of all the miRNAs from the three databases, 
MicroCosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/) (version 4), MicroRNA.org (http://www.microrna 
.org/) (Sept 2008 release), TargetScan (http://www. targetscan.org/) (Release 5.1) against each AQP target.    
 MicroCosm Targets MicroRNA.org TargetScan Union 
 Human Mouse Rat Human Mouse Rat Human Mouse Rat Human Mouse Rat 
AQP0 13 8 4 64 13 - 70 42 27 86 56 28 
AQP1 10 12 1 71 6 15 113 87 47 120 99 47 
AQP2 1 26 17 110 20 5 200 120 62 201 143 76 
AQP3 30 31 13 167 32 11 69 38 24 91 78 35 
AQP4 8 23 11 181 27 27 219 153 97 222 183 106 
AQP5 54 33 15 12 28 7 - - - 63 51 15 
AQP6 19 10 20 101 11 6 96 22 21 105 30 39 
AQP7 56 19 6 13 11 2 4 6 5 60 30 10 
AQP8 59 44 22 17 35 10 49 18 9 90 70 30 























AQP10 20 - - 3 - - 57 25 - 82 25 - 
AQP11 81 53 45 43 55 20 35 19 12 103 89 56 
AQP12 14 19 - 55 20 - 8 4 5 20 29 5 
118 
 
Table 3.2: Selected miRNAs that were predicted to target AQP genes. From the 
initial prediction list, all miRNAs predicted to target AQPs 1, 2 or 4 (in any 
combinations) were shortlisted. miRNAs targeting 4 or more AQPs were then 
omitted. From the remaining pool of miRNAs those targeting more than one AQP 







hsa-miR-7/7ab 2 hsa-miR-203 2 & 4 
hsa-miR-10      2 & 10 hsa-miR-210 4 
hsa-miR-16 4 & 8  hsa-miR-220b 0 & 2 
hsa-miR-17-5p 4 & 9 hsa-miR-224 4 & 9 
hsa-miR-103 1 & 11 hsa-miR-291b-3p 1 
hsa-miR-124/506 1, 2 & 11 hsa-miR-296-5p 2 
hsa-miR-125a-3p 1, 2 & 8 hsa-miR-298.h 1, 2 & 8 
hsa-miR-125b 2, 3 & 4 hsa-miR-302a 2, 4 & 9 
hsa-miR-127-5p 2 hsa-miR-320/320abcd 1 & 4 
hsa-miR-135a* 1 hsa-miR-325/325-5p 2, 4 & 11 
hsa-miR-136 0, 1 & 2 hsa-miR-329/362-3p 2 & 3 
hsa-miR-137 2 & 8 hsa-miR-331-5p 4 & 5 
hsa-miR-139-5p 1 & 6 hsa-miR-337-5p 0 & 4 
hsa-miR-140-5p 4 & 9 hsa-miR-338/338-3p 1, 2 & 10 
hsa-miR-142-3p 2, 4 & 11 hsa-miR-338-5p 2 & 4 
hsa-miR-142-5p 4 hsa-miR-339-3p 2 
hsa-miR-143 2 hsa-miR-342/342-3p 4 & 12 
hsa-miR-144 1 & 4 hsa-miR-346 1, 4 & 5 
hsa-miR-145 4 hsa-miR-362-5p 4 
hsa-miR-146a 1, 2 & 9  hsa-miR-369-5p 4 
hsa-miR-153 4 hsa-miR-371-3p 2 & 11 
hsa-miR-154 1 & 4 hsa-miR-376c 2 & 12 
hsa-miR-181a  2 & 9 hsa-miR-383 1 & 2 
hsa-miR-185/882 2 & 9 hsa-miR-384/384-3p 4 
hsa-miR-187 4 hsa-miR-410 4 & 9 
hsa-miR-188-3p 2 & 4 hsa-miR-411 4 
hsa-miR-196a/b 4 & 11 hsa-miR-412.hr 1 & 10 
hsa-miR-197 0 & 2  hsa-miR-431 4 










4 hsa-miR-579 0, 2 & 4 
hsa-miR-455/455-3p 2 & 4 hsa-miR-580 4 & 8 
hsa-miR-483/483-5p 2 & 7 hsa-miR-581 2 & 5 
hsa-miR-487a 4 has-miR-582-3p/1267 1 & 4 
hsa-miR-489.h 4 hsa-miR-582-5p.h 2 & 4 
hsa-miR-492 2 & 7 hsa-miR-584 4 
hsa-miR-495/1192 4, 6 & 10 hsa-miR-586 4 & 9 
hsa-miR-498 2 hsa-miR-588 1, 2 & 4 
hsa-miR-499/499-5p 3 & 4 hsa-miR-589 4 & 6 
hsa-miR-501-5p 2 & 6 hsa-miR-591 1 
hsa-miR-502-5p 4 & 5 hsa-miR-592 1, 4 & 6 
hsa-miR-509-5p/3p 2 & 11 hsa-miR-592/599 1 & 2 
hsa-miR-510 1, 2 & 9 hsa-miR-595 4 & 9 
hsa-miR-512-3p/1186 4 & 9 hsa-miR-596 1 & 3 
hsa-miR-513b 2 & 4 hsa-miR-601 0 & 1 
hsa-miR-515-3p/519e 2 & 9 hsa-miR-606 4 & 10 
hsa-miR-520gh 2, 4 & 8 hsa-miR-607 4 & 9 
hsa-miR-532/532-5p 2 & 9 hsa-miR-610 1 & 9 
hsa-miR-543 4 & 9 hsa-miR-616 4 & 9 
hsa-miR-548b-3p 4 & 8 hsa-miR-619 1, 2 & 8 
hsa-miR-548g 4 hsa-miR-628-5p 4 & 6 
hsa-miR-548m 4 & 9 hsa-miR-632 1, 4 & 5 
hsa-miR-548p 0, 2 & 4 hsa-miR-633 4 
hsa-miR-555 2 & 6 hsa-miR-636 2 & 9 
hsa-miR-556-5p 1, 4 & 8 hsa-miR-638 1 & 7 
hsa-miR-558 1, 4 & 8 hsa-miR-640 4 
hsa-miR-568 2 hsa-miR-644 1, 4 & 11 
hsa-miR-569 4 & 11 hsa-miR-648 1 & 9 
hsa-miR-570 4 & 11 hsa-miR-649 2 
hsa-miR-571 4 hsa-miR-650 2 & 10 
hsa-miR-575 1, 3 & 4 hsa-miR-651 4 & 10 
hsa-miR-576-5p 3 & 4 hsa-miR-654-3p 4 & 9 









hsa-miR-656 4 hsa-miR-1225-5p 4 
hsa-miR-657 1 & 2 hsa-miR-1226/1838 1 
hsa-miR-658 2 hsa-miR-1227 4 
hsa-miR-661 2, 4 & 6 hsa-miR-1228 1 
hsa-miR-664.hr 4 hsa-miR-1231 2, 4 & 6 
hsa-miR-709/1827 2 & 6 hsa-miR-1236 1, 3 & 4  
hsa-miR-758 3 & 4 hsa-miR-1237 1, 2 & 10 
hsa-miR-767-3p 1, 2 & 6 hsa-miR-1244 4 
hsa-miR-767-5p 0, 1 & 2 hsa-miR-1245 0 & 4 
hsa-miR-875-3p.h 1 & 2 hsa-miR-1248 2 &10 
hsa-miR-876-5p 1, 2 & 4 hsa-miR-1251 4 & 10 
hsa-miR-888 4 & 11 hsa-miR-1254 2 & 6 
hsa-miR-891b 0 & 1 hsa-miR-1255b 2 & 10 
hsa-miR-892b 2 & 4 hsa-miR-1256 2, 4 & 9 
hsa-miR-921 2 & 4 hsa-miR-1257 4 & 9 
hsa-miR-922 4 & 8 hsa-miR-1262 1, 2 & 6 
hsa-miR-924 2, 4 & 11 hsa-miR-1266 2 
hsa-miR-935 4 & 12 hsa-miR-1272 4 & 6 
hsa-miR-936 4 hsa-miR-1273 1 
hsa-miR-938 4 & 6 hsa-miR-1276 1 & 2 
hsa-miR-944 4 hsa-miR-1278 2 
hsa-miR-1178 2 & 4 hsa-miR-1283 4 
hsa-miR-1182 1 & 9 hsa-miR-1294 0, 2 & 4 
hsa-miR-1183 4 hsa-miR-1298 1 & 4 
hsa-miR-1197 2 & 8 hsa-miR-1305 4 
hsa-miR-1200 2 hsa-miR-1322 4 & 6 





























Figure 3.1: RNA integrity analysis. Total RNA extracted from Caki cells were 
subjected to integrity analysis using an Agilent Bioanalyzer. The figures show the 
gel (left) and electropherogram (right) versions of the RNA ladder and Caki 
sample. The two distinct 18S and 28S peaks seen in the Caki sample 









Table 3.3: Validation of AQPs 1, 2 and 4 expression in Caki cell line. The table 
reflects the threshold cycle (CT) values of AQP1, 2 and 4 detected in Caki cell line. 
Data shown are the mean ± SD, n=3.  
Gene Threshold cycle (CT) values 
AQP1 22.65 ± 0.080 
AQP2 28.12 ± 0.130 
AQP4 29.27 ± 0.153 
























Table 3.4: miRNA profiling of Caki cells. 1ug of total RNA was used to profile 
the miRNA expression in Caki cells. A total of 405 miRNAs were detected. 
miRNAs with average signal intensity less than 300 were filtered of as background 
and the remaining 328 miRNAs are listed below.  
miRNA Average signal 
intensity 
miRNA Average signal 
intensity 
hsa-let-7a 10196.88 hsa-miR-20b 376.75 
hsa-let-7b* 419.75 hsa-miR-21 54717.88 
hsa-let-7b 9532.13 hsa-miR-21* 1557.38 
hsa-let-7c* 1002.88 hsa-miR-22 12593.25 
hsa-let-7c 10787.75 hsa-miR-22* 671.75 
hsa-let-7d* 691.75 hsa-miR-23a 38014.88 
hsa-let-7d 4381.50 hsa-miR-23a* 570.75 
hsa-let-7e 8281.00 hsa-miR-23b 32094.25 
hsa-let-7f 21542.63 hsa-miR-24 64852.88 
hsa-let-7g 6316.13 hsa-miR-24-1* 11988.63 
hsa-let-7i 4703.50 hsa-miR-25 1470.88 
hsa-miR-7 995.10 hsa-miR-25* 4054.38 
hsa-miR-7-2* 442.38 hsa-miR-26a 6679.25 
hsa-miR-9 571.75 hsa-miR-26b 22429.50 
hsa-miR-9* 639.88 hsa-miR-27a 7081.75 
hsa-miR-10a 6260.50 hsa-miR-27a* 1571.25 
hsa-miR-10a* 523.25 hsa-miR-27b 308.88 
hsa-miR-10b 2054.75 hsa-miR-28-5p 1228.88 
hsa-miR-15a 1250.88 hsa-miR-28-3p 527.75 
hsa-miR-15b 6855.13 hsa-miR-29a 37087.50 
hsa-miR-16 18087.50 hsa-miR-29b 10977.75 
hsa-miR-17 1601.13 hsa-miR-29b-1* 612.88 
hsa-miR-18a 512.38 hsa-miR-29c 2970.25 
hsa-miR-18b 547.13 hsa-miR-30a 64966.88 
hsa-miR-19a 28593.00 hsa-miR-30a* 668.38 
hsa-miR-19b 42623.00 hsa-miR-30b 43782.13 
hsa-miR-20a 5860.75 hsa-miR-30c 34937.88 
hsa-miR-20a* 437.63 hsa-miR-30d 6226.88 





miRNA Average signal 
intensity 
miRNA Average signal 
intensity 
hsa-miR-30e* 1898.75 hsa-miR-130b* 340.88 
hsa-miR-31 11054.75 hsa-miR-132* 362.13 
hsa-miR-31* 615.50 hsa-miR-135b 724.38 
hsa-miR-32 576.00 hsa-miR-138 4356.63 
hsa-miR-32* 8087.63 hsa-miR-138-1* 17130.13 
hsa-miR-34a 18857.75 hsa-miR-138-2* 541.63 
hsa-miR-34b 25544.00 hsa-miR-140-3p 1040.38 
hsa-miR-34c-5p 305.13 hsa-miR-141 618.38 
hsa-miR-92a 473.88 hsa-miR-146a 13185.00 
hsa-miR-92b 613.63 hsa-miR-146b-5p 15837.13 
hsa-miR-93 3667.88 hsa-miR-146b-3p 2015.00 
hsa-miR-96 870.75 hsa-miR-147b 629.88 
hsa-miR-98 404.00 hsa-miR-148b 2163.75 
hsa-miR-99b 1414.75 hsa-miR-149* 8479.88 
hsa-miR-99b* 1152.13 hsa-miR-151-5p 1733.25 
hsa-miR-100 3641.88 hsa-miR-151-3p 1374.00 
hsa-miR-101 2049.75 hsa-miR-152 1061.25 
hsa-miR-103 2372.38 hsa-miR-155* 391.25 
hsa-miR-106a 1731.25 hsa-miR-155 3500.13 
hsa-miR-106b 9130.00 hsa-miR-181a 8718.63 
hsa-miR-106b* 405.75 hsa-miR-181a* 701.25 
hsa-miR-107 2070.00 hsa-miR-181a-2* 1191.88 
hsa-miR-122 545.88 hsa-miR-181b 515.88 
hsa-miR-122* 1190.75 hsa-miR-182 993.20 
hsa-miR-124 744.75 hsa-miR-183 1710.63 
hsa-miR-125a-5p 9595.63 hsa-miR-183* 4026.38 
hsa-miR-125b 4999.00 hsa-miR-184 4251.75 
hsa-miR-125b-1* 1404.25 hsa-miR-185 509.50 
hsa-miR-125b-2* 949.00 hsa-miR-185* 1201.50 
hsa-miR-126 551.38 hsa-miR-186 1050.63 
hsa-miR-129-5p 1252.13 hsa-miR-187* 1636.25 
hsa-miR-129* 1512.00 hsa-miR-190 383.88 
hsa-miR-130a 3234.50 hsa-miR-191 5520.75 




miRNA Average signal 
intensity 
miRNA Average signal 
intensity 
hsa-miR-193a-3p 1663.38 hsa-miR-302e 550.50 
hsa-miR-193b 9826.25 hsa-miR-320a 2257.88 
hsa-miR-193b* 825.75 hsa-miR-320b 1866.25 
hsa-miR-194 1097.25 hsa-miR-320c 2098.38 
hsa-miR-195* 391.13 hsa-miR-320d 1483.50 
hsa-miR-196a 1528.38 hsa-miR-331-3p 4970.63 
hsa-miR-196a* 6031.38 hsa-miR-335 502.75 
hsa-miR-196b 1382.25 hsa-miR-337-3p 439.13 
hsa-miR-197 1134.67 hsa-miR-339-5p 7981.50 
hsa-miR-198 924.50 hsa-miR-339-3p 313.50 
hsa-miR-200a 2900.50 hsa-miR-340 3880.25 
hsa-miR-200b 3525.50 hsa-miR-340* 746.75 
hsa-miR-200b* 344.63 hsa-miR-342-3p 508.88 
hsa-miR-200c* 338.75 hsa-miR-345 325.13 
hsa-miR-203 528.13 hsa-miR-361-5p 2351.38 
hsa-miR-206 1179.00 hsa-miR-361-3p 482.38 
hsa-miR-208a 1310.88 hsa-miR-363* 1957.63 
hsa-miR-208b 488.00 hsa-miR-365 8039.00 
hsa-miR-210 2771.75 hsa-miR-370 1673.25 
hsa-miR-212 326.50 hsa-miR-374a 5109.63 
hsa-miR-214 2637.25 hsa-miR-374b 680.75 
hsa-miR-215 1587.88 hsa-miR-374b* 1862.88 
hsa-miR-220b 695.63 hsa-miR-375 1646.25 
hsa-miR-221 4019.75 hsa-miR-377 580.13 
hsa-miR-221* 731.75 hsa-miR-377* 702.38 
hsa-miR-222 14541.25 hsa-miR-378 981.88 
hsa-miR-296-3p 397.75 hsa-miR-381 631.25 
hsa-miR-297 980.13 hsa-miR-382 1524.75 
hsa-miR-298 1735.13 hsa-miR-412 356.13 
hsa-miR-299-3p 1184.50 hsa-miR-422a 338.75 
hsa-miR-300 1724.38 hsa-miR-423-5p 5125.50 
hsa-miR-301a 2290.75 hsa-miR-423-3p 10293.38 




miRNA Average signal 
intensity 
miRNA Average signal 
intensity 
hsa-miR-425 800.25 hsa-miR-519e* 2393.50 
hsa-miR-429 1626.13 hsa-miR-520d-5p 911.13 
hsa-miR-452 545.50 hsa-miR-525-5p 1281.50 
hsa-miR-455-5p 645.13 hsa-miR-532-5p 449.00 
hsa-miR-483-5p 825.63 hsa-miR-542-3p 881.63 
hsa-miR-483-3p 857.63 hsa-miR-548e 1005.63 
hsa-miR-485-3p 1375.63 hsa-miR-549 9575.63 
hsa-miR-487b 2242.88 hsa-miR-550 27543.13 
hsa-miR-488 599.13 hsa-miR-551a 883.25 
hsa-miR-490-3p 2442.75 hsa-miR-551b 32883.75 
hsa-miR-491-3p 36487.38 hsa-miR-551b* 736.75 
hsa-miR-493* 320.13 hsa-miR-552 1725.75 
hsa-miR-494 18173.63 hsa-miR-553 882.13 
hsa-miR-498 4248.63 hsa-miR-574-5p 3607.50 
hsa-miR-502-5p 626.38 hsa-miR-574-3p 2313.63 
hsa-miR-505* 1752.38 hsa-miR-576-5p 678.13 
hsa-miR-506 372.88 hsa-miR-576-3p 6487.25 
hsa-miR-508-5p 522.88 hsa-miR-578 331.38 
hsa-miR-509-3-5p 695.13 hsa-miR-583 5146.00 
hsa-miR-509-5p 2647.00 hsa-miR-584 325.25 
hsa-miR-510 1145.63 hsa-miR-589 5198.00 
hsa-miR-513a-3p 853.63 hsa-miR-593 323.13 
hsa-miR-513a-5p 8372.38 hsa-miR-597 539.38 
hsa-miR-513b 1082.88 hsa-miR-600 3913.38 
hsa-miR-514 451.75 hsa-miR-601 402.00 
hsa-miR-516a-5p 2775.50 hsa-miR-602 2597.38 
hsa-miR-516b 1786.25 hsa-miR-615-3p 1722.25 
hsa-miR-518a-5p 2236.13 hsa-miR-617 2405.25 
hsa-miR-519a 625.13 hsa-miR-620 4220.63 
hsa-miR-519c-5p 610.38 hsa-miR-625 1242.13 
hsa-miR-519d 10913.50 hsa-miR-627 435.88 







miRNA Average signal 
intensity 
miRNA Average signal  
intensity 
hsa-miR-629 474.25 hsa-miR-923 64931.50 
hsa-miR-629* 423.00 hsa-miR-933 63002.38 
hsa-miR-630 766.75 hsa-miR-934 1617.50 
hsa-miR-634 2797.50 hsa-miR-937 4309.00 
hsa-miR-636 918.25 hsa-miR-938 735.38 
hsa-miR-637 608.00 hsa-miR-939 7624.63 
hsa-miR-638 339.75 hsa-miR-943 607.38 
hsa-miR-642 1521.88 hsa-miR-1184 716.625 
hsa-miR-647 1508.13 hsa-miR-1201 4474.5 
hsa-miR-656 335.38 hsa-miR-1244 427.75 
hsa-miR-657 599.75 hsa-miR-1246 64930.5 
hsa-miR-659 862.38 hsa-miR-1248 1748.625 
hsa-miR-664* 1283.75 hsa-miR-1252 723.25 
hsa-miR-665 8959.63 hsa-miR-1253 662.625 
hsa-miR-668 39256.38 hsa-miR-1255a 9409.75 
hsa-miR-671-5p 715.88 hsa-miR-1258 514 
hsa-miR-708 549.13 hsa-miR-1259 59236.375 
hsa-miR-720 64930.63 hsa-miR-1260 1720.75 
hsa-miR-744 656.25 hsa-miR-1261 665.625 
hsa-miR-765 13002.25 hsa-miR-1264 22358.875 
hsa-miR-767-5p 459.75 hsa-miR-1265 12368.625 
hsa-miR-768-5p 10377.88 hsa-miR-1270 448.5 
hsa-miR-768-3p 34964.25 hsa-miR-1272 491.25 
hsa-miR-769-5p 333.13 hsa-miR-1274a 38591.5 
hsa-miR-874 824.88 hsa-miR-1274b 2154.625 
hsa-miR-877 548.00 hsa-miR-1275 2117.375 
hsa-miR-886-3p 64046.75 hsa-miR-1280 64449.5 
hsa-miR-886-5p 22209.50 hsa-miR-1284 804.875 
hsa-miR-887 441.50 hsa-miR-1285 28635.125 
hsa-miR-888* 21082.50 hsa-miR-1290 64778.75 
hsa-miR-890 2491.25 hsa-miR-1291 445.625 
hsa-miR-891a 4303.13 hsa-miR-1297 1148.25 





























miRNA Average signal 
intensity 
miRNA Average signal 
intensity 
hsa-miR-1300 924.5 hsa-miR-1321 3262.5 
hsa-miR-1304 1538.375 hsa-miR-1826 64744.00 
hsa-miR-1308 47898 hsa-miR-1827 6897.63 
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Table 3.5: Validation of miRNAs using stem-loop PCR. Cycle threshold (CT) 
values of selected miRNAs in Caki cells are shown here. CT values for respective 
miRNAs were determined from 10ng of Caki total RNA, reverse transcribed using 
miRNA specific stem-loop primers. NTC refers to non template controls. 18s 
expression was used as positive control. Data shown are the mean ± SD, n=3.  
miRNA  CT values (Caki) miRNA  CT values (Caki) 
miR-21 21.88 ± 0.060 miR-342 30.61 ± 0.113 
miR-1280 21.95 ± 0.038    miR-182 30.66 ± 0.234 
miR-146a 23.94 ± 0.023 miR-886-3p 30.83 ± 0.185 
miR-16 24.78 ± 0.160 miR-152 30.87 ± 0.114 
miR-27a 24.91 ± 0.045 miR-185 30.91 ± 0.063 
miR-365 25.82 ± 0.174 miR-29b 30.99 ± 0.083 
miR-125a 25.91 ± 0.068 miR-301 31.64 ± 0.353 
miR-17-5p 25.93 ± 0.076 miR-668 31.89 ± 0.102  
miR-181a 26.72 ± 0.230 miR-494 31.91 ± 0.032 
miR-197 26.74 ± 0.274 miR-708 32.27 ± 0.156 
miR-498 26.87 ± 0.152 miR-101 32.87 ± 0.169  
miR-103 26.91 ± 0.045 miR-602 32.89 ± 0.070 
miR-320a 26.93 ± 0.211 miR-665 33.39 ± 0.164 
miR-768-3p 27.04 ± 0.078 miR-190 33.89 ± 0.054 
miR-125b 27.19 ± 0.041 miR-551b 34.50 ± 0.291 
miR-106a 27.22 ± 0.083 miR-943 35.30 ± 0.115 
miR-221 27.91 ± 0.091 miR-375 35.87 ± 0.153 
miR-181b 27.93 ± 0.066 miR-765 35.98 ± 0.112 
miR-20a 27.94 ± 0.044 miR-206 36.09 ± 0.102 
miR-29c 28.46 ± 0.059 miR-125b-1* 36.45 ± 0.113 
miR-939 28.56 ± 0.281 miR-485-3p 36.55 ± 0.291 
miR-135b 28.90 ± 0.078 miR-184 36.83 ± 0.177 
miR-192 28.95 ± 0.028 miR-144 Undetermined  
miR-331 29.24 ± 0.215  miR-346 Undetermined  
miR-378 29.54 ± 0.242 miR-409-5p Undetermined  
miR-9 29.77 ± 0.287 miR-548-5p Undetermined  
miR-186 29.89 ± 0.060 18S 12.77 ± 0.079 
mir-22 29.92 ± 0.083 NTC  Undetermined  
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Table 3.6: miRNAs expressed in Caki cell line and predicted to target AQPs 1, 
2 or 4. Of the 182 miRNAs shortlisted earlier, 60 of them were expressed in Caki 







hsa-miR-7/7ab 2 hsa-miR-489.h 4 
hsa-miR-10      2 hsa-miR-498 2 
hsa-miR-16 4  hsa-miR-502-5p 4 
hsa-miR-17-5p 4 hsa-miR-509-5p/3p 2  
hsa-miR-103 1  hsa-miR-510 1 & 2 
hsa-miR-124/506 1 & 2  hsa-miR-513b 2 & 4 
hsa-miR-125a-3p 1 & 2  hsa-miR-532/532-5p 2  
hsa-miR-125b 2 & 4 hsa-miR-575 1 & 4 
hsa-miR-136 1 & 2 hsa-miR-576-5p 4 
hsa-miR-140/140-5p/ 
876-3p 
4  hsa-miR-578 2 & 4 
hsa-miR-142-5p 4 hsa-miR-581 2  
hsa-miR-146a 1 & 2 hsa-miR-584 4 
hsa-miR-181a 2 hsa-miR-589 4  
hsa-miR-185/882 2 hsa-miR-595 4  
hsa-miR-188-3p 2 & 4 hsa-miR-601 1 
hsa-miR-196a/b 4 hsa-miR-636 2  
hsa-miR-197 2  hsa-miR-638 1  
hsa-miR-203 2 & 4 hsa-miR-656 4 
hsa-miR-210 4 hsa-miR-657 1 & 2 
hsa-miR-220b 2 hsa-miR-664.hr 4 
hsa-miR-298.h 1& 2 hsa-miR-767-5p 1 & 2 
hsa-miR-302a 2 & 4 hsa-miR-892b 2 & 4 
hsa-miR-320/320abcd 1 & 4 hsa-miR-921 2 & 4 
hsa-miR-339-3p 2 hsa-miR-938 4 & 6 
hsa-miR-342/342-3p 4  hsa-miR-1227 4 
hsa-miR-412.hr 1  hsa-miR-1236 1 & 4 
hsa-miR-432 2  hsa-miR-1244 4 
hsa-miR-455/455-3p 2 & 4 hsa-miR-1248 2  
hsa-miR-483/483-5p 2  hsa-miR-1272 4  




1    AAGGGGTCTGGCCCGGGCATCCACGTAGGGGGCAGGGGCAGGGGCGGGCGGAGGGAGGGG 
61   AGGGGTGAAATCCATACTGTAGACACTCTGACAAGCTGGCCAAAGTCACTTCCCCAAGAT 
121  CTGCCAGACCTGCATGGTCAAGCCTCTTATGGGGGTGTTTCTATCTCTTTCTTTCTCTTT 
181  CTGTTTCCTGGCCTCAGAGCTTCCTGGGGACCAAGATTTACCAATTCACCCACTCCCTTG  
241  AAGTTGTGGAGGAGGTGAAAGAAAGGGACCCACCTGCTAGTCGCCCCTCAGAGCATGATG  
301  GGAGGTGTGCCAGAAAGTCCCCCCTCGCCCCAAAGTTGCTCACCGACTCACCTGCGCAAG  
361  TGCCTGGGATTCTACCGTAATTGCTTTGTGCCTTTGGGCACGGCCCTCCTTCTTTTCCTA 
421  ACATGCACCTTGCTCCCAATGGTGCTTGGAGGGGGAAGAGATCCCAGGAGGTGCAGTGGA  
481  GGGGGCAAGCTTTGCTCCTTCAGTTCTGCTTGCTCCCAAGCCCCTGACCCGCTCGGACTT 
541  ACTGCCTGACCTTGGAATCGTCCCTATATCAGGGCCTGAGTGACCTCCTTCTGCAAAGTG    
601  GCAGGGACCGGCAGAGCTCTACAGGCCTGCAGCCCCTAAGTGCAAACACAGCATGGGTCC 
661  AGAAGACGTGGTCTAGACCAGGGCTGCTCTTTCCACTTGCCCTGTGTTCTTTCCCCAGGG 
721  GCATGACTGTCGCCACACGCCTCTGTGTACATGTGTGCAGAGCAGACAGGCTACAAAGCA 
781  GAGATCGACAGACAGCCAGGTAGTTGGAACTTTCTGTTCCCTATGGAGAGGCTTCCCTAC 
841  ACAGGGCCTGCTATTGCAGAATGAAGCCATTTAGAGGGTGAAGGAGAAATACCCATGTTA 
901  CTTCTCTGAGTTTTAGTTGGTCTTTCCATCTATCACTGCATTATCTTGCTCATTCTTCAG 
                                                       |||||||||| 
                                hsa-miR-146a 3’  UUGGGUACCUUAAGUC  
     AAGAGU  5’  
     |||||| 

















                                                      :||||||| :| 
                             hsa-miR-320a 3' agcGGGAGAGU-UG                                               
     GGUCGAAaa  5'                                               
     ||||||   
1681 CAGCTTCTCAGTTTCTGCCTGGGCAATGGCCAGGGGCCAGGAGTGGGGAGAGTTGTGATG 
            hsa-miR-103  3’ AGUAUCGGGACAUGUU---ACGACGA    5’   




Figure 3.2:  3’ UTR sequence of the AQP1 gene. The sequence was obtained 
from NCBI (NM_198098.1). The predicted binding of selected miRNAs (miR-
146a, -320a, -103) to the 3‟UTR of AQP1 is mapped in this figure in purple. The 














1    GGGCCGCCAGCGGCCTCTAAGGCCCCGACGGACGCTTGTGAGGCCCGAGGCAGAAGGGCC 
61   CACCCCGTCCCTCCTCTCCCGCAGGTCTGAAGTTGGCCCCCCAGCGCAGAGTAGCTGCTT 
121  CCTGGACGTGCGCGCCCAGGCCAGTGCTGTGAGCAGGCGGGGAGGAGGCTGCCGGAGGGA 
181  GCCCTGAGCCTGGCAGGTCCCCTGCCCTGAGGCTGTGAGCAGCTAGTGGTGGCTTCTCCA 
                                                            || | 
                                         hsa-miR-125b    3' AGUGU  
   UCAAUCCCAGAGUCCCU  5’  
    |       |:||||||  
241  GCCTTTTTCAGGGAACTGGGAACTTAGGGGACTGAGCTGGGGAGGGAGGCAGGTGGGTGG 
301  TAAGAGGGAAACTCTGGAGAGCCTGCACCCAGGTACTGAGTGGGGAGTGTACAGACCCCT 
361  GCCTTGGGGGTTCCGGGAATGATGCAACTGGTTTTACTAGTGTGCAAGTGTGTTCATCCC 
                                                     | : : 
                                   hsa-miR-146a   3’ UUGGGUACCUUA 
     AGUCAAGAGU  5’ 
       |||||||  
421  CAAGTTCTCTTTTGTCCTCACATGCAGAGTTGTGCATGCCCCTGAGTGTGAACAGGTTTG 
481  CCTACGTTGGTGCAAGTGTGCATGGCTGGGGACTTCTCACTTCCCCTTGCACCCCTTCCT 
541  CCCCAACCTGCAATAAATCCGCTTCTCCTGCAGTGGATGAGTGTGGGTGCCAGTCCTCCT 
601  CAGGAGAAGGGGAAGGGAAGGAGGCCACTTTGAGAGGGCTGAAGGGAGGGCCTTGATTTC 
661  CAGCCGCAATCTGGCTCCTCCTGGAAAATTTCCCCCACCTGCAGCGCTGGGCCCCAAGGC 
721  TTGCCAAGACTCATTGCTGGAGGTAGAGAGGTGTCAACCAGAGAACAGCTCCCCTAGACA 
                     hsa-miR-197  3'  CGACCCACCUCUUCCACCACUU 5’ 
                                             |      |||||||  
781  TGGCCTCTGGAAAAAGGAAATCTTTGGTGGCCAAAGATTTCCTTTCTGTGGTGAGGGAGA 
841  ACCTCTCCAAAGAGGAAGCAGGCATATGAGTGCGCACGCCTTCACGTGTGTGTATGCTGT      
901  GTGTGCCCGGGACCCCCGTCTCCAGGGGTGCCCCAGACCCAGAGATTAGCCTCCCACTTC 
961  GGCGCAGAAAACAAAAGCCCTTTGTGGGACCCGGGCCTTTGTCTTGGGTGAGGGGAGATT 
3’  CUUUUUGCGGGGGACCGAACUUU  5’  hsa-miR-498                       













               hsa-miR-miR-181a   3'    UGAGUGGCUGUCGCAACUUACAA’5                     

































Figure 3.3:  3’ UTR sequence of the AQP2 gene. The sequence was obtained 
from NCBI (NM_000486). The predicted binding of selected miRNAs (miR-125b, 
146a, -197, -181a, -498) to the 3‟UTR of AQP2 is mapped in this figure in purple. 




















1    CTAGAAGATCGCACTGAAAGCAGACAAGACTCCTTAGAACTGTCCTCAGATTTCCTTCCA 
61   CCCATTAAGGAAACAGATTTGTTATAAATTAGAAATGTGCAGGTTTGTTGTTTCATGTCA 
121  TATTACTCAGTCTAAACAATAAATATTTCATAATTTACAAAGGAGGAACGGAAGAAACCT 
181  ATTGTGAATTCCAAATCTAAAAAAAGAAATATTTTTAAAATGTTCTTAAGCAAATATATA 
241  CCTATTTTATCTAGTTACCTTTCATTAACAACCAATTTTAACCGTGTGTCAAGATTTGGT 
301  TAAGTCTTGCCTGACAGAACTCAAAGACACGTCTATCAGCTTATTCCTTCTCTACTGGAA 
361  TATTGGTATAGTCAATTCTTATTTGAATATTTATTCTATTAAACTGAGTTTAACAATGGC 
421  AAAATACAGTATGTCACAGTCATGCACATTCAAGAGAGAAAATATAACAAGTTCTTTTAT 
481  GAGCAATCCCTTATGCATAGACTACCTTGGCAAAAGAGCATTAGCAAGTGTCACTGCTCA 
541  TCAGTTACTTCCTTCCATTTATATCACAAATACCCAAGTTTCAATTCTAACTTCATTTCA 
601  TGGTATTTCTTCCTCCTCAATGCCCAAGGTAATGTGGGACTAAAGCCCAGAAATTTGAAA 
661  AGAATATTCAGAAATCCTTCCCAAATCATAAGGGCACCTATTGAGATTCAAGACAAGCAG 
721  ACTCGTAAAATCTTGTAGAGGCAGAGGCAAAGTTATCATCATACAAAAATCACAAACAAA 
781  AAGGAGATCTGTATTCGGGTATCAAACGGTTGATCTGTTTTCAGTGCACACCCTCAAATG 
841  CACCACACCAGTTTTACGATCTAAGCTTTTAACCCCTTTACCACTTTGCTTATTTTTAAA  
901  AAATTTATTGGCAAAACTGGGGATTTTGTTTGTAACTTTGGTTATCTATATTTAAACATT 












              hsa-miR-125b      3'    AGUGUUCAAUCCCAGAGUCCCU  5’ 














    hsa-miR-17-5p     3'    GAUGGACGUGACAUUCGUGAAAC  5’ 







                       hsa-miR-210   3' AGUCGGCGACAGUGUGCGUGUC 5'   





                                                           |::| 
                                      hsa-miR-17-5p  3'  GAUGGACG  
     UGACAUUCGUGAAAC  5’  
       |     |||||| 
2941 GATTCCTACACTTTATTTCTGCCATTGATGCTTTTCCTAAACCCTTATACTATCTTTTTA 
             hsa-miR-16    3'        GCGGUUAUAAAUGCACGACGAU  5’ 
                                        | |  |  |  |||||||  
3001 TTATCTGAGCCTTTTCCTAATGCAGCTCATAGGTGCTAGCTAGAGCTGCTGCTCAAGAAA 











                                                 |:||||  | | | |   
                              hsa-miR-320a    3' AGCGGGAGAGU-UGG 
      GUCGAAAA 5'   











      
Figure 3.4:  3’ UTR sequence of the AQP4 gene. The sequence was obtained 
from NCBI (NM_004028). The predicted binding of selected miRNAs (miR-125b, 
17-5p, -16, -210 and -320a) to the 3‟UTR of AQP4 is mapped in this figure in 
purple. The miRNA seed region is highlighted in red.  
 




Table 3.7: Primer list for amplification of 3’UTR of AQPs 1, 2 ad 4. The table 
lists the specific primers used to amplify the 3‟UTR regions of AQPs 1, 2 and 4 
into TOPO vectors. For directional cloning into pMIR vectors, the primers were re-




Sequence of primers used for TOPO cloning 
(5’ to 3’) 
Restriction  sites 
introduced for 
directional cloning 
AQP1 A Forward AGGGTGGAGATGAAGCCCAA Spe1 
AQP1 A Reverse AGCAGGTGGGTCCCTTTCTT Mlu1 
AQP1 B Forward AGCAGGTGGGTCCCTTTCTT Spe1 
AQP1 B Reverse GTAGCCTGTCTGCTCTGCAC Mlu1 
AQP1 C Forward CACACGCCTCTGTGTACATGT Spe1 
AQP1 C Reverse AAGGCTGTGGCCAGGGGTCA Mlu1 
AQP1 D Forward CATTTGAGCAGCTGAAT Spe1 
AQP1 D Reverse AACATATAATGAAATTCCAACTCCAAA Mlu1 
AQP2 A Forward TGGGCTCCCTCCTCTACAACTA Spe1 
AQP2 A  Reverse CATGCACACTTGCACCAACGTA Spe1 
AQP2 B Forward CAATCTGGCTCCTCCTGGAAAAT Spe1 
AQP2 B Reverse AAGATAGGGCACACATTCAGGG Sac1 
AQP2 C Forward GACAGCCACTTGGCCTCACTAC Spe1 
AQP2 C Reverse CCTGCCTCTGTCTGGTTTGGTG Sac1 
AQP4 A Forward GTTGACCGGGGAGAGGAGAA Spe1 
AQP4 A Reverse GCATTTGAGGGTGTGCACTGAAA HindIII 
AQP4 B Forward CCCTCAAATGCACCACACCA Spe1 
AQP4 B Reverse TTTAGGCACCTGCGGTATGC Mlu1 
AQP4 C Forward GCATACCGCAGGTGCCTAAA Spe1 
AQP4 C Reverse GTCTCCTGGGAGCAGCACTA HindIII 
AQP4 D Forward CCAGGAGACCACTGCTGACA Spe1 
AQP4 D Reverse ACATGCTGCAATCAGAGGCC Mlu1 
AQP4 E Forward TGTTGACACCAACCTCACGT Spe1 










Figure 3.5: Schematic representation of the AQP1 3’UTR. The solid black line 
represents the 3‟UTR region of AQP1 (not drawn to scale). The first nucleotide of 
the 3‟UTR region has been re-numbered as 1. P(A) represents the poly A signal on 
the gene. The dotted line represents the coding region of AQP1. The 3‟UTR of 
AQP1 was amplified as four separate fragments (A-D) using sequence specific 










        
 
Figure 3.6: Amplification of AQP1 3’ UTR. The entire 3‟ UTR of the gene was 
amplified using sequence specific primers. Lane 1: 100 bp marker. Lanes 2-5: 
Fragments A-D respectively.   
       1                                                                             1867 P(A) 
258        B            776    
    A       
1193       D           1856 
  C  279  1250    734
 
    
 
               1             2             3             4            5 
    500 bp 







Figure 3.7: Schematic representation of the AQP2 3’UTR. The solid black line 
represents the 3‟UTR region of AQP2 (not drawn to scale). The first nucleotide of 
the 3‟UTR region has been re-numbered as 1. P(A) represents the poly A signal on 
the gene. The dotted line represents the coding region of AQP2. The 3‟UTR of 
AQP2 is amplified as three separate fragments (A-C) using sequence specific 















Figure 3.8: Amplification of AQP2 3’ UTR. The entire 3‟ UTR of the gene was 
amplified using sequence specific primers. Lane 1: 1 Kb marker. Lanes 2-4: 




     A             505   682           B                1656 2072   C             2989 
                  1                                                                                                                        3260  P(A)  
    500 bp 
              1             2              3              4          
  1000bp 










Figure 3.9: Schematic representation of the AQP4 3’UTR. The solid black line 
represents the 3‟UTR region of AQP4 (not drawn to scale). The first nucleotide of 
the 3‟UTR region has been re-numbered as 1. P(A) represtents the poly A signal on 
the gene. The dotted line represents the coding region of AQP4. The 3‟UTR of 
AQP4 is amplified as five separate fragments (A-E) using sequence specific 
primers. The forward primer for fragment A sits about 64bp upstream of the 3‟UTR 

















Figure 3.10: Amplification of AQP4 3’ UTR. The entire 3‟ UTR of the gene was 
amplified using sequence specific primers. Lane 1: 100 bp marker. Lanes 2-6: 
Fragments A-E respectively.  Fragment E although is about 850bp, appears to have 
migrated slightly lower than the other fragments, possibly due to differences in gel 
composition in that lane. 
 
                        1                                                                      4144 P(A) 
       E       4135 
823       B         1715 
           A     
2589 D      3286 
  C  841 2597 1694
 
    
          1             2            3          4         5           6 
    500 bp 








Figure 3.11: Image of the pCR4-TOPO vector. The pCR4-TOPO vector was 
used for sub-cloning of the amplified PCR products. PCR products from the 
agarose gel were purified and ligated together with the vector prior to 













Figure 3.12: Image of the pMIR-Report
TM
 Luciferase vector. The pMIR-
Report
TM
 Luciferase vector was used for reporter gene studies. Gene fragments 
previously sub-cloned into the pCR4-TOPO vector were excised using the 
appropriate restriction enzymes. The same enzymes were also used to linearize the 
pMIR-Report
TM
 Luciferase vector. The fragments were then separated on an 
agarose gel and purified out prior to ligation. Ligation was performed at a insert to 







Table 3.8: Stem-loop PCR for miRNA expression levels in HeLa cells. Cycle 
threshold (CT) values of selected miRNAs in HeLa cells. CT values for respective 
miRNAs were determined from 10ng of HeLa total RNA, reverse transcribed using 
miRNA specific stem-loop primers. NTC refers to non template controls. 18s 





miR-16 23.48 ± 0.419 
miR-17-5p 23.90 ± 0.062 
miR-103 24.25 ± 0.449 
miR-125b 26.02 ± 0.522 
miR-146a 29.49 ± 0.569 
miR-181a 28.83 ± 0.298 
miR-197 28.53 ± 0.205 
miR-210 25.61 ± 0.125 
miR-320a 27.41 ± 0.221 
miR-498 27.93 ± 0.135 









Figure 3.13:  Relative luminescence of the various AQP constructs. The luciferase reporter constructs containing the 3‟UTR 
regions of the AQPs 1, 2 and 4 were co-transfected with the respective anti or pre miRNAs into HeLa cells. The relative luciferase 
activities were normalised against the respective negative controls. Statistical analyses were done using t-tests *, p < 0.05, **, p < 0.01 
















































































MicroRNA 320a as a novel endogenous 










microRNAs (miRNAs) regulate mRNA expression by binding to the 3‟ 
untranslated region (UTR) [131]. Yet as simple as it sounds, identifying targets for 
miRNAs remains a challenging task mainly because each miRNA has hundreds of 
mRNA targets [227]. Due to this complexity in regulation, of the hundreds of 
miRNAs identified in the human species, only a handful have been assigned their 
specific targets. In this study, thus far, several miRNAs were observed to be 
capable of modulating AQPs 1, 2 and 4 (Chapter 3). However, there arises a 
question as to whether the interaction observed between the miRNA and its target 
(as a reporter assay), can also be seen in an in vitro system such as a cellular study 
or an in vivo system and if so, whether manipulation of the miRNA provides any 
therapeutic potential in disease conditions.  
 
Comparison of miRNA profiles between normal and diseased samples allows the 
identification of crucial miRNAs that are altered during disease conditions and 
enables one to search for possibilities of altering these expression profiles in an 
attempt to normalize or reduce the patho-physiological conditions of the disease. 
Changes in the expression of miRNAs have been reported in several diseases [150, 
228-229] including cerebral ischemia [157, 230-231]. Cerebral ischemia is a highly 
debilitating condition and ischemia induced edema further increases complications 
and morbidity [232]. The movement of water into and out of an ischemic brain is 
thought to be mainly modulated by AQPs, especially AQPs 1 and 4. In the brain 
AQPs 1, 3, 4, 5, 8 and 9 expression have been reported with AQPs 1, 4 and 9 being 
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expressed abundantly [233]. However it is the importance of AQPs 1 and 4 
regulation in edema that have been highlighted in several studies [83-84, 234]. 
AQP4 knockouts in mice showed increased protection against cytotoxic edema 
caused by water intoxication and permanent focal cerebral ischemia whereas in 
conditions leading to vasogenic brain edema it had a deleterious effect [83-84]. 
siRNA based studies have paralleled these findings in which AQP4 knockdown 
was shown to reduce the amount of water influx but yet delay its clearance in 
astrocytes during hypoxic and subsequent reoxygenation events [235]. Expression 
of AQPs 1 and 4 were induced in astrocyte cells surrounding the edematous region 
[87]. These findings serve to relay the importance of modulating both AQPs 1 and 
4 during cerebral edema. Yet with the exception of mercury, gold, lithium and 
ammonium quaternary compounds no other natural modulators of AQPs are 
available for in vivo use [124, 129].  
 
Earlier in the study, several miRNA based modulators for AQPs 1and 4 were 
identified (Chapter 3). Therefore this section of the study aimed to determine the 
applicability of miRNA based gene modulation in in vitro and in vivo systems. For 
this study, miR-320a was considered as an ideal choice for reasons that it 
exclusively targets AQPs 1 and 4 which are highly implicated in cerebral edema. 
Furthermore from the in silico predictions, miR-320a was observed to be conserved 
in mammals (rats) and also targets rat AQPs 1 and 4. This was an important 
consideration so that the study can be extended into an in vivo system.  
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4.2 Selection of miR-320a and affirmation of interaction with 
AQPs 1 and 4 
In this section of the study, we chose to access the applicability of miRNA based 
gene modulation in in vitro and eventually in in vivo systems. In foresight of 
extending the study into animal models, miR-320a was chosen as it was conserved 
in mammals (rat) and was also predicted to target rat AQPs 1 and 4 (Table 4.1). 
Furthermore, an ischemic rat model was readily available in the lab to assess the 
applicability of miR-320a based modulation of AQPs 1 and 4 in a disease 
condition. Direct interaction between AQP1, AQP4 and miR-320a were shown 
previously using luciferase reporter studies (Chapter 3). To re-affirm the interaction 
seen between AQP1, AQP4 and miR-320a, mutational studies were performed. The 
seed region of the miR-320a recognition sites on AQPs 1 and 4 3‟UTR were 
mutated using PCR primers. This involved designing primers which included 
several nucleotide changes in the seed region (see Figure 4.3 legend). The mutated 
fragments were then sub-cloned into the luciferase reporter plasmids as described 
previously (Section 3.6). The AQPs 1 and 4 3‟UTR constructs (mutated and non-
mutated) were co-transfected with anti or pre miR-320a into HeLa cells. As seen 
previously, cells transfected with anti miR-320a exhibited an increase in the 
relative luciferase expression. Likewise, pre miR-320a caused a reduction in 
luciferase expression (Figure 4.1). Site-directed mutagenesis of the miR-320a seed 
region located on the recognition site of the AQPs 1 and 4 3‟UTR abolished 
interactions between the miRNA and its AQP targets (Figure 4.1). These results 
indicated that miR-320a was indeed a direct target of AQP1 and AQP4. 
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4.3 Validation of AQPs 1, 4 and miR-320a expression in 
astrocytoma cells.  
Prior to proceeding with the in vitro studies, it was necessary to establish whether 
co-expression of AQPs 1, 4 and miR-320a were seen in the brain. Thus brain 
predominant astrocytoma cells were used to determine their expression. To 
determine the inherent cellular expression levels of AQPs 1 and 4 mRNA, 100ng of 
total RNA was reverse transcribed using random hexamers and the expression 
levels were quantified by real-time PCR. To determine the expression level of miR-
320a, 10ng of total RNA was reverse transcribed using specific stem-loop primers 
and the expression level was verified using real-time PCR (Table 4.2). Both AQPs 
1 and 4 and miR-320a were expressed in astrocytoma cells.  
 
4.4 miR-320a modulates AQPs 1 and 4 mRNA expression 
Thus far, direct interaction between AQP1, AQP4 and miR-320a had been 
established using reporter assays. However it is not known whether modulating 
miR-320a levels would have a resultant effect on the inherent AQP1 and AQP4 
mRNA levels. Thus in vitro studies were performed to determine this. Human 
astrocytoma cells were transfected with miR-320a inhibitor (anti miR-320a) and 
precursor (pre miR-320a) independently at various concentrations from 1 nm to 30 
nm (Figures 4.2 & 4.3). The transfections were carried out for a period of 48 hrs. 
After which the total RNA was extracted and the relative miR-320a levels were 
determined using stem-loop PCR. Optimal modulation of miR-320a levels were 
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observed at 30nm concentrations over 48 hrs (Figure 4.2 & 4.3). At 30nm, in anti 
miR-320a transfected cells relative expression of miR-320a level was about 0.204 ± 
0.052. This signified about 80% reduction in expression compared to normal cells 
(Figure 4.2). Likewise, introduction of 30nm pre miR-320a increased miR-320a 
levels by about 180 fold (Figure 4.3). Thus for all subsequent studies miRNA 
transfections were performed at 30 nm. The corresponding changes in the AQP1 
and AQP4 mRNA levels were determined using real-time PCR. Transfection of 
anti miR-320a increased AQP1 and AQP4 expression while pre miR-320a 
decreased their expression (Figure 4.4).  
 
4.5 miR-320a modulates AQPs 1 and 4 protein expression 
Astrocytoma cells transfected with anti and pre miR-320a were also probed for 
AQP1 and AQP4 protein. The changes in the AQP1 and AQP4 mRNA expression 
were reflected in the protein expression (Figure 4.5). Transfection of anti miR-320a 
caused an increase in both AQP1 and AQP4 protein expression whereas pre miR-
320a resulted in suppression of the protein expression (Figure 4.5).  Changes in 
AQP1 and AQP4 were also visible in cells where AQP1 and AQP4 were 
overexpressed (Figure 4.6). The AQP1 and AQP4 CDS were amplified from total 
RNA using specific primers and cloned into the respective existing 3‟UTR 
constructs. The luciferase CDS present in the constructs were excised at the 
BamHI/SpeI restriction sites and replaced with AQP1 or AQP4 CDS. This plasmid 
was then used to over-express AQP1 and AQP4 protein in astrocytoma cells. These 
cells were treated with anti or pre mir-320a and the changes in AQP1 and AQP4 
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protein expression were captured using immuno cyto-chemistry techniques. Anti 
miR-320a caused further increase in AQP1 and AQP4 expression while pre miR-
320a caused a reduction in AQP1 and AQP4 protein expression (Figure 4.6). 
 
4.6 Viability of astrocytoma cells during OGD conditions   
Having shown in vitro modulation of AQP1 and AQP4 by miR-320a under normal 
conditions, there was a need to understand changes in their expression during 
ischemic conditions. During ischemic stroke, the cells are deprived of oxygen and 
glucose and eventually die. Thus in vitro ischemic conditions were simulated by 
maintaining them in oxygen and glucose deprived conditions for a period of 1 to 8 
hrs. Cell viability was measured using colorimetric MTT assay (section 2.2.4) and 
cytotoxicity was measured using the LDH assay (section 2.2.5). With increased 
duration of OGD, the total number of surviving cells reduced gradually (Figure 
4.7). Similarly LDH assay showed increasing cytotoxcity levels in the culture with 
increased exposure to OGD (Figure 4.8).  About 70% cell viability together with 
about 27% cytotoxicity were achieved after 6 hrs of OGD. Thus the 6 hrs time 
point was considered to cause moderate death and chosen for all further 
experiments.    
 
4.7  Changes in AQPs 1 and 4 expression in OGD conditions   
Having established that the 6 hrs OGD timepoint was suitable for subsequent 
experiments, the effect of this treatment on AQPs 1 and 4 expression was studied. 
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Real-time analysis showed that AQPs 1 and 4 mRNAs were upregulated after 6 hrs 
of OGD (Figure 4.9). Analysis of total protein extracted from the same pool of cells 
also reflected an upregulation in the protein expression of both AQPs 1 and 4 
(Figure 4.10). miRNA profiling of the astrocytoma cells showed 148 miRNAs to be 
expressed (Table 4.3).  84 of the 148 miRNAs were differentially expressed due to 
exposure to 6 hrs of OGD. Interestingly, miR-320a was one of the most 
significantly affected miRNAs and its expression was suppressed in the cells 
subjected to OGD (Table 4.3). 
  
4.8  Modulation of AQPs 1 and 4 in OGD conditions  
The results obtained thus far, indicate that changes in AQP1 and AQP4 expression 
occurs during simulated ischemic conditions.  Modulation of AQP1 and AQP4 is 
considered crucial during edematous and ischemic conditions. Since miR-320a was 
shown to be able to modulate AQP1 and AQP4 expression under normal 
conditions, its functionality during OGD was tested.  Thus astrocytes were 
subjected to OGD in the presence of anti and pre miR-320a, following which the 
changes in the AQP1 and AQP4 expression levels were quantitated. Decreasing 
miR-320a levels during OGD with anti miR-320a further elevated both AQP1 and 




4.9  Changes in AQPs 1, 4 and miR-320a expression in ischemic 
rat models 
Bioinformatic predictions for miR-320a showed that interaction between miR-320a 
and AQP1 and AQP4 were conserved in mammals. Hence prior to studying their 
interaction in other mammalian systems, the expression levels of AQP1 and AQP4 
mRNA as well as miR-320a needed to be validated. In this study, rat models were 
used. Thus the basal expression of  AQP1 and AQP4 mRNA as well as miR-320a 
in rat brain were determined using real-time and stem-loop PCR respectively 
(Table 4.4). 100ng of total RNA from rat brain samples showed higher expression 
levels for all 3 transcripts when compared to astrocytoma cells (Table 4.4). To 
determine the correlation between AQP1, AQP4 and miR-320a expression in-vivo, 
ischemic rat models were used. Cerebral ischemia was induced in rats by occluding 
the middle cerebral artery for 60 min. 24 and 48 hrs after restoration of reperfusion 
the animals were sacrificed. Expression levels of AQP1, AQP4 and miR-320a were 
determined from these MCAo brain samples. An increase in AQP1 and AQP4 
mRNA expression from 24 to 48hrs was mirrored by a decrease in the miR-320a 
expression (Figure 4.12).  
 
4.10  Modulation of AQPs 1 and 4 in ischemic animal models 
To understand the impact of modulation of AQP1 and AQP4 during ischemia ICV 
injections of anti or pre miR-320a were administered to ischemic rats immediately 
after MCAo. In anti miR-320a injected rats, relative expression of miR-320a levels 
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were about 0.452 ± 0.23, which signifies about 55% reduction in expression 
compared to ischemic rats. Likewise in pre miR-320a injected rats, miR-320a 
expression increased to 9.26 ± 2.31 (Table 4.5). Administration of anti miR-320a 
resulted in a reduction in the infarct volume while pre miR-320a caused a further 
increase in infarct volume (Figures 4.13 & 4.14). Real-time analyses showed that 
AQP1 and AQP4 expression were increased with a corresponding reduction in 
infarct volume, suggesting that the increased expression was facilitating edema 
clearance or recovery (Figure 4.15).  Translational modulation of AQP1 and AQP4 
were reflected in the protein expression as well (Figure 4.16). An N-methyl-D-
aspartate antagonist MK-801 is often used as a positive control for recovery from 
ischemia in animal models. When MK-801 was injected as described by Armugam 
et al [222], the animals exhibited increased expression of AQP1 and AQP4 with a 
concomitant reduction in expression of miR-320a (Figure 4.17). These findings 
suggest that upregulation of AQP1 and AQP4 during ischemia could be 
contributing to reduction in infarct volume possibly by edema clearance and this 
could have a beneficial outcome in survival. 
 
4.11 mRNA profiling of astrocytoma cells treated with anti and pre 
miR-320a 
The results obtained thus far showed that miR-320a could modulate AQP1 and 
AQP4 expression and its functionality could be applied in a disease setting with 
potential therapeutic outcomes. However modulating the expression of a single 
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miRNA in a cell is bound to cause changes in the global gene expression. To 
understand the impact of modulating miR-320a expression, an mRNA array was 
performed. Total RNA extracted from anti or pre miR-320a treated cells were 
subjected to mRNA array analysis. Differences in global expression between 
treatments were observed (Figure 4.18). The AQP1 and AQP4 expression data 
extracted from the mRNA array (Table 4.6) correlated with the real-time results 
obtained in this study (Figure 4.4). Recent studies have established miR-320a as 
inhibitors of the cell cycle gene (POLR3D) and the transferrin receptor gene 
(TFRC) [155, 232] The AQP1 and AQP4 gene expression profiles were similar to 
that of these known targets of miR-320a (Table 4.6).  
 
miRNApath, a pathway software [233-234], was used to gauge the impact of miR-
320a modulation. 145 pathways were affected with as many as 1500 target genes. 
Of these affected pathways, majority of them were involved in metabolic processes 
(Figure 4.19). To narrow down the list, 22 pathways (in relation to ischemia) were 
selected. Within these selected pathways 172 genes were predicted to be targets of 
miR-320a. Expression profiles of these 172 predicted targets were compared with 
our anti and pre miR-320a array. Seventy seven genes (including AQP1 and AQP4) 
were found to be upregulated in response to anti miR-320a while they were 
downregulated in response to pre miR-320a treatments (Table 4.6), suggesting that 





Table 4.1: Predicted binding sites of miR-320a in 3’UTR of AQP1 and AQP4. 
The miR-320a binding sites for human and rat AQP1 and AQP4 are indicated. 
Targets were obtained from TargetScan (ver 5.0; 22-24)/ microRNA.org (ver 
January 2008; 25). The underlined nucleotides were subsequently mutated (see 
Figure 4.1 legend) for the 3‟UTR-miRNA binding studies. 
          3' agcGGGAGAGU-UGGGUCGAAaa 5'       hsa-miR-320a 
                :|||||||  :|||||||   
nt  1666: 5' gauUCCUCUCAUUUCCAGCUUcu 3'       AQP1 
          3' agcgggagaguuggGUCGAAAa 5'        rno-miR-320a 
                           |||||||    
nt  553:  5' uggcaaggaagggaCAGCUUUg 3'        Aqp1 
         3' agcGGGAGAGU-UGGGUCGAAaa 5'    rno-miR-320a 
               :|||||||  :|||||||   
nt 1516: 5' gacUCCUCUCAUUUCCAGCUUcu 3'    Aqp1 
         3' AGCGGGAGAGU-UGG--GUCGAAAA 5'  hsa-miR-320 
            |:||||  | | | |  :||||||| 
nt 3585: 5' UUGCCCCAUAAGAGCAGUAGCUUUU 3'  AQP4 
       3'  AGCGGGAGAGUUGGGUCGAAAA  5’      rno-miR-320a 
                          |||||||                                   
nt 3416:  5' UCACUUCCUUUACGUCAGCUUUU  3’      Aqp4 
 
 
Table 4.2: Validation of AQPs 1, 4 and miR-320a expression in astrocytoma 
cell line. The table reflects the threshold cycle (CT) values of AQP1, AQP4 and 
miR320a detected in astrocytoma as well as HeLa cells. Data shown are the mean ± 
SD, n=3.  
 Threshold cycle 
(CT) values 
AQP1 30.29 ± 0.064 
AQP4 24.11 ± 0.101 
miR-320a 27.24 ± 0.150 
18s  9.12 ± 0.201 





Figure 4.1: Relative luminescence in plasmid constructs containing miR-320a 
target sites. miR-320a target regions in the 3‟UTR of AQP1 and AQP4 were 
identified using TargetScan and microRNA.org. These regions were cloned into 
luciferase reporter plasmids. Mutated 3‟ UTR constructs were generated using site-
directed mutagenesis. The miRNA recognition sites at cDNA corresponding to 
3‟UTR (underlined) were mutated as follows: AQP1 (5‟-
CTGATTCCTCTCATTTAATTTGGCT-3‟) and AQP4 (5‟-TTGCCCCATAAG 
AGCAGTCGTCCGG-3‟). The plasmid constructs together with anti or pre miR-
320a were co-transfected into HeLa cells. Luciferase luminescence readings were 
obtained 48 hrs post transfection. Relative luminescence was obtained by 
normalizing value against control plasmids, pMIR-REPORT
TM
 without any 3‟UTR 
insert. Statistical analyses were performed using t-tests *, p < 0.05, compared to 
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Figure 4.2: Percentage expression of miR-320a in astrocytoma cells 
transfected with anti miR-320a. Astrocytoma cells were transfected with anti 
miR-320a in order to knockdown cellular miR-320a expression. Transfection was 
carried out over a timepoint of 48 hrs with varying concentrations of anti miR-
320a, ranging from 0.5 nm to 30 nm. Resultant miR-320a expression was expressed 
















































Figure 4.3: Relative expression of miR-320a in astrocytoma cells transfected 
with pre miR-320a. Astrocytoma cells were transfected with pre miR-320a in 
order to overexpress cellular miR-320a levels. Transfection was carried out over a 
timepoint of 48 hrs with varying concentrations of pre miR-320a, ranging from 0.5 
nm to 30 nm. Resultant miR-320a expression was expressed over negative controls 











































Figure 4.4: Quantitation of AQPs 1 and 4 mRNA in astrocytoma cell line 
transfected with anti or pre miR-320a. Relative mRNA expression of AQP1 and 
AQP4 in astrocytoma cell line transfected with anti or pre miR-320a at a 
concentration of 30 nM. Statistical analyses were done using t-tests *, p < 0.05 and 
**, p < 0.01 compared to respective negative controls. Data shown are the mean ± 




Figure 4.5: AQPs 1 and 4 protein expression in astrocytoma cell line 
transfected with anti or pre miR-320a. Changes observed in mRNA expression 
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Figure 4.6: AQP immuno-reactivites in astrocytoma cells transfected with anti 
or pre miR-320a. Human astrocytoma cells were co-transfected with AQP1 or 
AQP4 plasmids and anti or pre miR-320a. The cells were fixed and 
immunolabelled with either anti-AQP1 or anti-AQP4 antibodies (green) and 
nuclear stain DAPI (blue) (Magnification 40x). Anti miR-320a treated cells showed 
increased immunoreactivity for AQP1 and AQP4 while pre miR-320a treated cells 

















Figure 4.7: Viability of astrocytoma cells subjected to OGD at various 
timepoints. Human astrocytoma cells were subjected to OGD for various intervals 
of time. Following the treatment, the cells were allowed to recover overnight and 
the viability of the surviving cells was then measured using MTT assay (section 










































Figure 4.8: Cytotoxicity in astrocytoma cells subjected to OGD at various 
timepoints. Human astrocytoma cells were subjected to OGD for various intervals 
of time. Following the treatment, the cells were allowed to recover overnight and 
the cytotoxcity levels of the cells were measured using LDH assay (section 2.2.6). 


































Figure 4.9: Expression of AQPs 1 and 4 mRNA in astrocytoma cells subjected 
to 6 hrs OGD. Total cellular RNA was used to quantify AQP1 and AQP4 mRNA 
levels. The changes in expression were compared against cells grown under normal 
conditions and plotted as relative expression of AQP1 and AQP4 mRNA. 
Statistical analyses were done using t-tests **, p < 0.01 compared to control. Data 





Figure 4.10: Expression of AQPs 1 and 4 protein in astrocytoma cells 
subjected to 6 hrs OGD. Total cellular protein was probed for AQP1 and AQP4. 
Upregulation of AQP1 and AQP4 protein were observed. The changes in protein 
expression were compared against cells grown under normal conditions. Β-actin 










































Table 4.3: miRNA profile of astrocytoma cells (CRL
1718
) subjected to 6hrs 
OGD. Raw mean signal intensity of all the detected miRNAs in astrocytoma cells 
(miRbase database ver 9.1). miRNAs that were significantly expressed (t-test; p-
value<0.05)  upon 6 hours OGD is in bold font. Signal log ratios (SLR) for 6 hours 
OGD (vs control) are also tabulated. miR-320a expression is italicised. SD; 
standard deviation.  
miRNA p-value Control 6 hrs OGD SLR  
  Mean SD Mean SD  
hsa-miR-486-5p 2.98E-09 383 46 19 3 -4.33 
hsa-miR-21 1.02E-06 9,654 695 21,013 1,814 1.12 
hsa-miR-99b 6.48E-06 1,170 83 694 48 -0.75 
hsa-miR-34c-3p 7.06E-06 5,476 510 2,607 271 -1.07 
hsa-miR-9 1.48E-05 1,298 224 3,771 460 1.54 
hsa-miR-424 2.53E-05 57 6 171 32 1.57 
hsa-miR-27a 4.10E-05 1,282 111 2,201 218 0.78 
hsa-miR-191 5.21E-05 1,583 92 952 91 -0.73 
hsa-miR-320a 6.53E-05 3,379 283 2,204 178 -0.62 
hsa-miR-29b 7.66E-05 4 2 36 7 3.05 
hsa-miR-768-3p 9.59E-05 245 27 147 12 -0.73 
hsa-miR-27b 1.12E-04 1,202 144 2,105 238 0.81 
hsa-miR-768-5p 1.12E-04 268 32 154 10 -0.80 
hsa-miR-9* 1.31E-04 244 59 779 129 1.67 
hsa-miR-210 1.41E-04 268 19 187 15 -0.52 
hsa-miR-15a 1.63E-04 315 51 881 44 1.48 
hsa-miR-301a 2.11E-04 9 3 28 6 1.61 
hsa-miR-20a 2.36E-04 273 22 465 60 0.77 
hsa-miR-145 2.73E-04 613 66 358 52 -0.78 
hsa-miR-222 2.99E-04 7,738 438 5,994 391 -0.37 
hsa-miR-328 2.99E-04 65 13 30 4 -1.13 
hsa-miR-26b 3.53E-04 54 17 229 34 2.08 
hsa-miR-30d 3.68E-04 681 39 545 21 -0.32 
hsa-miR-423-5p 4.44E-04 853 57 500 66 -0.77 
hsa-let-7g 5.87E-04 568 124 1,219 230 1.10 
hsa-miR-376c 6.72E-04 34 8 72 9 1.08 
hsa-miR-199a-3p 6.81E-04 42 11 93 17 1.14 
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hsa-miR-454 7.74E-04 10 3 26 5 1.38 
hsa-miR-30e 8.88E-04 83 18 152 22 0.88 
hsa-miR-345 9.23E-04 144 27 74 6 -0.96 
hsa-miR-98 1.07E-03 22 7 58 11 1.37 
hsa-miR-497 1.09E-03 107 12 74 7 -0.53 
hsa-miR-20b 1.15E-03 17 5 50 8 1.58 
hsa-miR-1228 1.33E-03 43 15 10 1 -2.13 
hsa-miR-181a 2.27E-03 2,235 266 1,588 177 -0.49 
hsa-miR-106b 2.52E-03 583 77 861 59 0.56 
hsa-miR-29a 2.72E-03 3,640 462 5,020 414 0.46 
hsa-miR-1225-3p 3.02E-03 26 7 9 4 -1.51 
hsa-miR-125b 3.13E-03 14,686 1,458 11,442 944 -0.36 
hsa-miR-92a 3.24E-03 1,728 184 1,246 155 -0.47 
hsa-miR-187* 3.41E-03 45 9 27 4 -0.71 
hsa-miR-19b 3.48E-03 97 32 228 24 1.23 
hsa-miR-148b 3.68E-03 7 3 24 8 1.79 
hsa-miR-455-3p 4.85E-03 108 19 72 8 -0.57 
hsa-miR-29c 5.00E-03 55 29 155 37 1.48 
hsa-miR-484 6.20E-03 193 18 121 26 -0.67 
hsa-miR-28-5p 6.29E-03 42 11 69 6 0.73 
hsa-miR-149* 6.96E-03 452 50 283 62 -0.67 
hsa-miR-937 7.00E-03 26 9 11 4 -1.31 
hsa-miR-22* 8.59E-03 9 4 32 6 1.82 
hsa-miR-923 8.65E-03 656 100 472 64 -0.48 
hsa-miR-130a 8.67E-03 361 51 268 32 -0.43 
hsa-miR-425 1.14E-02 185 26 138 19 -0.42 
hsa-miR-99a 1.16E-02 4,354 605 3,346 221 -0.38 
hsa-miR-487b 1.19E-02 43 9 65 7 0.60 
hsa-miR-663 1.20E-02 1,319 133 1,087 88 -0.28 
hsa-miR-125b-2* 1.23E-02 53 14 31 4 -0.76 
hsa-miR-152 1.26E-02 33 9 56 9 0.76 
hsa-miR-140-3p 1.29E-02 141 24 102 13 -0.47 
hsa-miR-379 1.29E-02 23 10 47 5 1.04 
hsa-let-7d* 1.67E-02 71 19 43 8 -0.72 
hsa-miR-10b 1.78E-02 34 10 55 10 0.72 
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hsa-miR-128 1.79E-02 134 21 178 8 0.41 
hsa-let-7i 1.83E-02 2,432 271 3,178 473 0.39 
hsa-miR-28-3p 1.87E-02 25 5 34 4 0.42 
hsa-miR-485-3p 1.87E-02 29 5 20 4 -0.53 
hsa-miR-125a-5p 2.05E-02 2,025 471 1,389 193 -0.54 
hsa-miR-495 2.11E-02 23 12 48 6 1.08 
hsa-let-7f 2.14E-02 4,949 663 6,572 1,059 0.41 
hsa-miR-489 2.35E-02 22 8 12 3 -0.86 
hsa-miR-107 2.47E-02 1,040 106 848 101 -0.29 
hsa-miR-299-5p 2.49E-02 17 3 26 6 0.60 
hsa-miR-92b 2.57E-02 432 74 327 45 -0.40 
hsa-miR-365 2.58E-02 16 8 37 10 1.18 
hsa-miR-1238 2.68E-02 27 6 15 7 -0.88 
hsa-miR-181d 2.70E-02 25 11 46 10 0.84 
hsa-miR-30b 2.89E-02 1,002 161 1,319 204 0.40 
hsa-miR-575 2.95E-02 58 14 39 6 -0.57 
hsa-miR-324-3p 3.23E-02 27 9 16 5 -0.75 
hsa-miR-22 3.29E-02 985 119 814 75 -0.28 
hsa-miR-18a 3.32E-02 15 8 32 4 1.04 
hsa-miR-17 3.48E-02 356 48 437 53 0.29 
hsa-miR-197 3.59E-02 84 24 54 13 -0.63 
hsa-let-7b 3.73E-02 10,680 1,230 8,843 1,006 -0.27 
hsa-miR-195 5.11E-02 1,326 173 1,602 213 0.27 
hsa-miR-638 5.61E-02 6,105 488 5,213 677 -0.23 
hsa-miR-151-5p 5.82E-02 848 68 766 43 -0.15 
hsa-miR-26a 5.86E-02 3,974 304 4,382 280 0.14 
hsa-miR-103 7.26E-02 1,078 57 955 99 -0.17 
hsa-miR-155 7.46E-02 61 27 92 12 0.60 
hsa-miR-30a 7.73E-02 512 64 596 66 0.22 
hsa-miR-331-3p 8.47E-02 44 10 33 5 -0.39 
hsa-miR-382 8.58E-02 29 6 37 5 0.33 
hsa-miR-940 9.58E-02 29 13 18 9 -0.70 
hsa-miR-377 9.62E-02 156 73 86 29 -0.86 
hsa-miR-151-3p 1.01E-01 231 35 197 12 -0.23 
hsa-miR-185 1.09E-01 203 21 224 14 0.14 
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hsa-miR-134 1.10E-01 28 4 33 4 0.21 
hsa-miR-100 1.14E-01 6,056 583 5,208 821 -0.22 
hsa-miR-132 1.16E-01 72 12 59 12 -0.28 
hsa-miR-1237 1.18E-01 21 7 15 5 -0.51 
hsa-let-7e 1.22E-01 1,774 365 2,283 544 0.36 
hsa-miR-143 1.32E-01 207 28 234 24 0.18 
hsa-miR-127-3p 1.37E-01 139 23 120 10 -0.22 
hsa-miR-532-5p 1.43E-01 35 9 43 5 0.29 
hsa-miR-106a 1.52E-01 340 48 395 60 0.22 
hsa-miR-16 1.52E-01 10,198 988 11,075 790 0.12 
hsa-miR-296-5p 1.58E-01 25 11 15 8 -0.74 
hsa-miR-181b 1.99E-01 172 25 199 35 0.21 
hsa-miR-494 2.10E-01 80 17 92 14 0.21 
hsa-miR-25* 2.16E-01 32 7 26 7 -0.28 
hsa-miR-922 2.36E-01 1 1 20 39 3.75 
hsa-miR-30c 2.48E-01 900 129 1,004 132 0.16 
hsa-miR-744 2.53E-01 32 6 28 5 -0.20 
hsa-miR-342-3p 2.57E-01 24 9 29 4 0.27 
hsa-let-7d 2.70E-01 6,386 899 7,093 962 0.15 
hsa-miR-671-5p 3.39E-01 35 10 40 6 0.21 
hsa-miR-23a 3.53E-01 10,517 1,242 9,839 718 -0.10 
hsa-miR-378 3.53E-01 32 7 28 5 -0.19 
hsa-miR-130b 3.60E-01 130 25 116 13 -0.16 
hsa-let-7b* 3.76E-01 60 17 52 6 -0.21 
hsa-miR-563 3.79E-01 3 2 46 93 3.79 
hsa-miR-193a-5p 4.08E-01 139 19 128 22 -0.12 
hsa-miR-23b 4.18E-01 8,971 1,151 8,428 734 -0.09 
hsa-miR-15b 4.24E-01 1,893 310 2,008 113 0.08 
hsa-miR-203 4.25E-01 10 20 3 2 -1.58 
hsa-miR-361-5p 4.43E-01 481 55 453 65 -0.09 
hsa-miR-181c 4.68E-01 138 31 124 12 -0.15 
hsa-miR-106b* 4.69E-01 32 10 26 8 -0.26 
hsa-miR-550* 4.74E-01 30 10 25 4 -0.27 
hsa-miR-574-5p 4.75E-01 70 27 77 15 0.14 
hsa-miR-34a 4.96E-01 145 10 141 7 -0.04 
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hsa-miR-193a-3p 5.23E-01 39 62 13 6 -1.54 
hsa-miR-503 5.40E-01 32 7 34 5 0.10 
hsa-miR-25 5.95E-01 1,568 118 1,528 111 -0.04 
hsa-miR-221 6.08E-01 5,640 437 5,505 286 -0.03 
hsa-miR-574-3p 6.32E-01 102 28 107 19 0.08 
hsa-miR-324-5p 6.46E-01 36 9 37 5 0.06 
hsa-miR-23a* 7.02E-01 29 12 29 3 0.02 
hsa-miR-518d-3p 7.68E-01 7 3 35 69 2.25 
hsa-miR-432 8.07E-01 26 7 26 5 0.03 
hsa-miR-93 8.18E-01 766 74 754 83 -0.02 
hsa-let-7c 8.25E-01 11,443 1,582 11,212 1,488 -0.03 
hsa-miR-24-2* 8.76E-01 53 83 23 3 -1.18 
hsa-miR-24 9.17E-01 2,898 241 2,908 154 0.00 
hsa-miR-424* 9.54E-01 40 10 40 10 0.02 
hsa-let-7a 9.61E-01 12,220 1,280 12,166 1,026 -0.01 













Figure 4.11: Relative AQPs 1 and 4 expression in cells transfected with anti or 
pre miR-320a and subjected to 6 hrs of OGD. Cells were transfected with anti or 
pre miR-320a 48 hrs prior to OGD. All values were expressed relative to negative 
controls. Statistical analyses were done using t-tests *, p < 0.05 and **, p < 0.01 
compared to control. Data shown are the mean ± SD, n=3.  
 
 
Table 4.4: Expression levels of AQP1, 4 and miR-320a in rat brain. Threshold 
cycle (CT) values of AQP1, AQP4 and miR320a detected in rat brain samples.  
Data shown are the mean ± SD, n=3.  
 Threshold Cycle 
(CT) values 
AQP1 25.29 ± 0.205 
AQP4 20.59 ± 0.291 
miR-320a 25.01 ± 0.133 
18s 9.45 ± 0.089 
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Figure 4.12: Quantitation of AQPs 1 and 4 mRNA in ischemic rat brain. 
Relative AQP1, AQP4 and miR-320a expression levels in ischemic brain were 
determined using qRT-PCR. Ischemia was induced for 60 min and the animals 
were sacrificed at 24 and 48 hrs later. Statistical analyses were done using t-tests *, 
p < 0.05 and **, p < 0.01 compared to normal control brain. Data shown are the 




Table 4.5: Expression level of miR-320a in ischemic rat injected with anti or 
pre miR-320a. Changes in miR-320a expression levels in ischemic rat brain 
samples were quantitated using stem-loop qRT-PCR. Relative expression of miR-
320a was expressed in relation to the respective anti and pre negative controls. Data 
shown are the mean ± SD, n=10.  
 
Treatment Relative expression level of miR-
320a 
Anti miR-320a 0.452 ± 0.23 



































Figure 4.13: Histological analysis of brain sections. TTC stained coronal brain 
sections (2 mm thick) of rats injected with 50 pmoles of anti or pre miR-320a. ICV 
injections were given immediately after the removal of the suture (n = 10). 
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Figure 4.14: Percentage infarct volume of rat treated with anti or pre miR-
320a. Infarct volumes were expressed as a percentage of the control ± SEM. 
Statistical analyses were performed using t-tests *, p < 0.05 and **, p < 0.01 
































Figure 4.15: Quantitation of AQPs 1 and 4 mRNA levels in rats injected with 
anti or pre miR-320a. Data shown are the mean ± SD, n = 10. Statistical analyses 
were performed using t-tests *, p < 0.05 and **, p < 0.01 compared to respective 






Figure 4.16: Quantitation of AQPs 1 and 4 protein levels in rats injected with 
anti or pre miR-320a. Total cellular protein was probed for AQP1 and AQP4. 
Upregulation of AQP1 and AQP4 protein were observed in anti miR-320a injected 
samples. Downregulation of AQP1 and AQP4 protein were observed in pre miR-
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Figure 4.17: Relative expression of AQPs 1, 4 and miR-320a in MK-801 
administered ischemic (MCAo) rats. Rats with MCA occlusion were injected 
with MK-801 to reduce cerebral infarct. All values were expressed relative to 
ischemic rats. Statistical analyses were performed using t-tests, **, p < 0.01. Data 






























Figure 4.18: Heatmap of mRNA profile of 
astrocytoma treated with anti and pre miR-
320a. mRNA profiling of human astrocytoma 
cells treated with 30 nm anti or pre miR-320a (t-
test, p≤ 0.05). Differential global expression was 
observed between treatments. Signal values 
lower than 300 were omitted from the analysis. 
For comparison purposes, the data was 
expressed as signal log ratio with respect to 
controls. Statistical comparisons between 
controls and test samples are performed using 
Student‟s t-test and ANOVA. A p-value <0.05 
was considered to be statistically significant. 
Heatmap was generated using TIGR multiple 





Table 4.6: miR-320a targets. Targets for miR-320a were obtained from 
miRNApath database. 77 genes have been found to be differentially regulated in 
our mRNA profiling of human astrocytoma cells treated with anti or pre miR-320a 
(t-test, p≤0.05). Of these, 2 gene marked with * constitute the validated targets 








validated target from Kim et al [155]. 
 Fold change (mRNA) vs control 
Gene Symbol Anti miR-320a Pre miR-320a 
AQP1* 1.43 ± 0.011 0.84 ± 0.001 
AQP4* 1.21 ± 0.010 0.91 ± 0.013 
TFRC
#
 1.79 ± 0.173 0.93 ± 0.021 
POLR3D
##
 2.07  ± 0.051 0.76 ± 0.049 
STX12 1.369 ± 0.134 0.934 ± 0.021 
VAMP2 1.110 ±0.022 0.899±0.047 
STX16 1.166±0.018 0.955±0.004 
GOSR1 1.506±0.003 0.857±0.113 
FLNC 1.288±0.109 0.900±0.006 
GRB2 1.248±0.11 0.723±0.041 
PRKCG 1.144±0.023 0.983±0.003 
MAPK7 1.294±0.111 0.920±0.054 
RAP1B 1.366±0.169 0.904±0.087 
RASA1 1.106±0.006 0.959 ±0.001 
SRF 2.308±0.344 0.808±0.103 
STK4 1.334±0.032 0.878±0.067 
CACNA1F 1.112±0.002 0.926±0.100 
TAOK2 1.230±0.186 0.671±0.143 
EREG 1.046±0.003 0.935±0.014 
GRB2 1.248±0.176 0.730±0.002 
PLCG1 1.174±0.069 0.852±0.119 
RPS6KB1 1.474±0.227 0.961±0.041 
CAMK2D 1.121±0.022 0.939±0.010 
SPRED2 1.554±0.145 0.933±0.008 
IFNA13 1.044±0.001 0.984±0.038 
JAK2 1.064±0.005 0.776±0.113 
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CCND2 1.338±0.111 0.911±0.009 
CSNK1A1 1.594±0.201 0.961±0.021 
CSNK1E 1.597±0.217 0.835±0.093 
CSNK2A1 1.219±0.104 0.922±0.004 
CSNK1A1L 1.126±0.082 0.973±0.022 
WNT11 1.091±0.061 0.900±0.047 
CAMK2D 1.116±0.044 0.843±0.107 
ADCY2 1.149±0.026 0.952±0.023 
ERBB2 1.090±0.115 0.896±0.158 
GNAS 1.028±0.010 0.789±0.204 
SLC25A5 1.027±0.009 0.794±0.021 
ITPKA 2.265±0.311 0.789±0.162 
ATP2A2 1.249±0.048 0.784±0.143 
CALM1 1.208±0.010 0.655±0.241 
E2F4 1.514±0.116 0.817±0.119 
SP1 1.225±0.063 0.884±0.026 
ZFYVE9 1.048±0.002 0.975±0.017 
CCR4 1.237±0.019 0.962±0.006 
EDA 1.233±0.082 0.926±0.011 
TNFRSF17 1.155±0.0114 0.919±0.012 
TNFRSF19L 1.361±0.121 0.9245±0.017 
TNFSF11 1.102±0.087 0.939±0.101 
ITGB1 1.616±0.119 0.8140.013 
CDH2 6.906±0.542 0.914±0.004 
HLA-DPA1 2.347±0.226 0.886±0.103 
NCAM2 1.052±0.005 0.926±0.001 
CFL1 1.061±0.001 0.832±0.172 
FGD1 1.114±0.025 0.744±0.119 
TIAM2 1.104±0.006 0.952±0.011 
MYH10 1.217±0.011 0.724±0.116 
PFN1 1.179±0.102 0.780±0.103 
FADD 1.799±0.125 0.795±0.034 
FYN 1.117±0.089 0.787±0.052 
TUBB4 1.052±0.005 0.986±0.014 
PRKCZ 1.158±0.046 0.980±0.008 
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CGN 2.064±0.163 0.840±0.022 
MPP5 1.391±0.218 0.968±0.002 
VIM 1.122±0.032 0.877±0.012 
MMP9 1.049±0.011 0.960±0.044 
PLAUR 3.891±0.317 0.958±0.008 
SERPINF2 1.075±0.028 0.958±0.001 
SERPING1 1.238±0.053 0.859±0.021 
SLIT3 1.116±0.032 0.980±0.001 
E2F1 1.348±0.121 0.710±0.100 
SMC1L2 1.095±0.055 0.942±0.021 
YWHAH 1.081±0.012 0.881±0.003 
CCNB1 1.073±0.011 0.420±0.114 
CDC25B 1.086±0.003 0.908±0.011 
P2RX5 1.065±0.018 0.894±0.105 
VDAC1 1.088±0.031 0.707±0.152 













Figure 4.19: Pathways affected by miR-320a modulation. miRNApath software 
predicted ~1500 target genes for miR-320a [233]. These genes were involved in 
145 pathways listed by Kegg Pathway database [234]. The 145 pathways were 






































Animal model studies conducted so far indicates that upregulation of AQP1 and 
AQP4 expression using miR-320a could provide beneficial outcomes in ischemic 
conditions (Chapter 4). While both AQP1 and AQP4 are implicated in cerebral 
edema formation in the event of ischemia, AQP4 is always considered to play a 
greater role. Expression of AQP4 is found predominantly in the central nervous 
system especially in the brain [29, 32]. Its localization patterns in various cellular 
components of the brain such as the glial membranes, the subarachnoidal space, 
osmosensory areas, ventricles and the blood capillaries suggest its importance in 
regulating fluid balance in the central nervous system [29, 32]. However more 
recently, Hirt et al [212] suggested that the M1 isoform of AQP4 could be of more 
importance than the M23 isoform.  
 
Two AQP4 transcripts; M1 and M23 transcribed from two alternative promoters 
have been reported in humans [29]. Transcription of M1 (the larger transcript) is 
thought to be controlled by the promoter located upstream of exon 0 of the AQP4 
gene whereas transcription of the shorter transcript, AQP4 M23 is controlled by the 
promoter located upstream of exon 1 (Figure 5.1). Hereafter, the promoter located 
at exon 0 and exon 1 will be referred to as the M1 promoter and M23 promoter 
respectively. Water permeability studies showed that the M1 isoform conducted 
water at a higher rate than the M23 isoform [29, 235]. Quantitative immunoblot and 
immunofluorescence studies showed that expression of AQP4 M1 was eight fold 
higher than M23 [236]. On the contrary, although Hirt et al [212] observed higher 
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expression of M23 mRNA levels in normal mice brain, under ischemic conditions 
the expression of AQP4 M1 isoform predominated. Expression of AQP4 M1 
transcript and protein were reported to increase further in ischemic brain [212]. It is 
possible that the expression of the M1 isoform is triggered due to its increased 
water permeability characteristics as ischemia often leads to changes in the cerebral 
water content.  
 
Earlier it was showed that targeting the 3‟UTR of AQP4 (as well as AQP1), with 
miR-320a can result in changes in the infarct volume in the ischemic brain (Chapter 
4). However, as a translational regulator, miR-320a does not differentiate between 
the two isoforms. Both the M1 and M23 isoforms only differ at the amino end of 
the transcripts. Although miRNAs are known to mediate translational silencing in 
the cytoplasm, recent evidence suggests that some miRNAs may also regulate gene 
expression at the transcriptional level [154-157]. Several studies have identified 
miRNA recognition sites proximal to known transcription start sites or at gene 
promoters and have shown the ability of miRNAs to regulate the transcription of 
the target gene [154-157]. Given the importance of the AQP4 M1 isoform, in this 
section, the possibility of identifying miRNAs that could selectively modulate the 
M1 promoter was investigated.  
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5.2 Identification of miRNAs binding to AQP4 M1 promoter 
region 
AQP4 gene has been shown to have two alternative promoters (Figure 5.1). In this 
study, the focus was on the promoter of the longer isoform AQP4 M1 (NCBI 
AF026814). Prediction of miRNAs binding to the M1 promoter was done using the 
RegRNA program [186]. Unlike databases like microRNA.org or TargetScan 
which only predict interaction with the 3‟UTR, RegRNA allows the user to 
incorporate the promoter regions of the genes of interest. A total of 35 miRNAs 
were predicted by RegRNA to bind to the M1 promoter (Table 5.1). As an updated 
version (version 11) of the miRNA array system was available, the miRNA 
profiling was repeated for astrocytoma cells. Compared to the 148 miRNAs 
detected earlier in the study (Table 4.3), the newer version detected 293 miRNAs 
(Table 5.2). All 148 miRNAs detected in the array version 8 (Chapter 4), were also 
detected in the version 11. On top of these an additional 145 new miRNAs were 
detected in version 11. Out of the 35 miRNAs that were predicted to target the M1 
promoter, ten of them (hsa miR-1184, -1280, -130a/b, -130b*, -1301, -140-5p, -
152, -668, -744 and -939) were identified to be expressed in astrocytoma cells 
(Table 5.2). Based on the expression levels, the top 50% of the miRNAs were 
chosen for further evaluation. The 5 highly expressed miRNAs were hsa miR-668, 
-1280, -130a, -152, and -939 (Table 5.1). Stem-loop PCR was performed to re-
validate the expression of these 5 miRNAs in astrocytoma cells (Table 5.3) as well 
as in an unrelated cell line; HeLa (HTB-47). Consistent with the miRNA array 
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results, all 5 miRNAs were also detected in astrocytoma cells however only miR-
130a and miR-1280 were observed to be expressed in HeLa.     
 
5.3 Evaluation of promoter activity of AQP4 M1 
Based on the prediction data obtained from RegRNA, the recognition sites of the 5 
miRNAs (hsa miR-668, -1280, -130a, -152 and -939)  on the promoter of AQP4 
M1 were mapped (Figure 5.2). Interestingly miR-130a and miR-152 were predicted 
to interact at the same region. However miRNA expression data showed that miR-
130a was expressed at a much higher level than miR-152 (Table 5.2). It‟s 
noteworthy that these miRNAs do not target the promoter of AQP4 M23 (data not 
shown). In order to evaluate the effect of these 5 miRNAs on the AQP4 M1 
promoter activity, the entire 2.1Kb promoter region upstream of exon 0 was 
amplified using sequence specific primers (Table 5.4) and cloned into a promoter-
less luciferase vector pGL4.10 (Figure 5.3). The five miRNAs predicted to bind 
this promoter region were sequentially downregulated using their respective anti 
miRNAs (Figures 5.4 & 5.5). Sequential removal of miR-668 and miR-1280 with 
the respective anti miRNAs decreased the M1 promoter activity. Interestingly 
inclusion of anti miR-130a/152 caused a surge in promoter activity. This promoter 
activity decreased when anti miR-939 was introduced. These findings suggested 
that miR-668, -1280, 939 could have opposing effects when compared to miR-
130a/152. Thus to study the effects of these miRNAs on the M1 promoter, several 
5‟ miRNA deletion constructs, consisting of sequential deletions of the predicted 
miRNA target sites, were also generated (Figure 5.6). The constructs were 
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transfected into astrocytoma cells and their respective promoter activity was 
determined using luciferase reporter assays. The activity of the deletion constructs 
reflected the observations seen with anti miRNA treatment. Among the different 
promoter deletion constructs, loss of the miR-668 binding site did not result in any 
significant change in luciferase activity. Unlike miR-668, deletion of miR-1280 
resulted in a 32% reduction in luciferase activity suggesting that it behaves as an 
activator. Deletion of miR-130a/152 recognition site however, resulted in a 30% 
increase in the promoter activity (Figure 5.7). Hence they could be considered as 
potential suppressors. Loss of miR-939 recognition site resulted in only a 10% 
reduction in promoter activity, which was somewhat similar to miR-668 (Figure 
5.7).   
 
5.4 Effect of miRNA modulation on the promoter activity of 
AQP4 M1. 
The loss of the miRNA binding sites was seen to affect the AQP4 M1 promoter 
activity. To ascertain these observations, the inherent miRNAs levels were 
modulated and the resultant effects on the promoter activity of AQP4 M1 were 
studied. The whole promoter construct was co-transfected together with the anti or 
pre miRNAs into astrocytoma cells. Introduction of anti miR-130a caused a 60% 
increase in the AQP4 M1 promoter activity whereas anti miR-152 treated cells only 
showed a 25% increase. The opposite profile was noted when the precursor forms 
(pre miR-130a and -152) where transfected into the cells (Figure 5.8). Transfection 
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of anti miR-668, -1280 and -939 caused a decrease in the promoter activity with 
significantly lowest activity observed in the presence of anti miR-1280. 
Introduction of the precursor forms (pre miR-668, -939 and -1280) caused an 
increase in the promoter activity. To observe the effect of these transfections on the 
protein level, promoter constructs containing the AQP4 CDS were separately co-
transfected with the anti and pre miRNAs into astrocytoma cells. The changes in 
the AQP4 protein expression were then captured using FITC labelled goat anti-
rabbit antibodies. Changes in AQP4 protein expression reflected that of the 
luciferase readings (Figure 5.9). 
 
5.5 Effect of miR-130a and miR-1280 on the promoter activity of 
AQP4 M1 
The findings so far show that modulation of miR-130a and mir-1280 had the 
greatest effect on the AQP4 M1 promoter activity (Figure 5.8). Real-time analyses 
performed earlier revealed that that only miR-130a and 1280 are expressed in HeLa 
cell lines (Table 5.3). Thus this cell line was used to study the effects of just miR-
130a and 1280 on the AQP4 M1 promoter construct. The miR-130a and 1280 
recognition sites were mutated using sequence specific primers (Table 5.4). The 
construct with mutations at both the miR-1280 and miR-130a recognition sites was 
used as the reference in this study (Figure 5.10). In the presence of miR-1280 
recognition site (miR-130a mutant) a marginal activation of promoter activity was 
seen. However, in the presence of miR-130a recognition site (miR-1280 mutant) a 
188 
 
strong repression in promoter activity was observed (Figure 5.11). These results 
suggest that miR-1280 functions as a weak activator whereas miR-130a acts as a 
strong repressor of the promoter. 
 
5.6 Intracellular modulation of AQP4 M1 transcript by miR-130a 
miR-130a had been identified as a strong modulator of the promoter of AQP4 M1. 
To understand the in vitro effects of miR-130a, astrocytoma cells were transfected 
with anti or pre miR-130a. The changes in the miR-130a expression levels were 
determined using stem-loop quantitative PCR while the expression levels of AQP4 
transcripts was determined using real-time quantitative PCR. Transfection of anti 
miR-130a resulted in miR-130 relative expression levels decreasing to 0.114 
±0.063 while pre miR-130a increased the relative expression levels to 210.9.4 ± 
13.55 (Table 5.5). Changes in the miR-130a expression levels resulted in 
differential expression of AQP4 M1 transcript while the M23 transcript levels 
remained unchanged (Figure 5.12). These findings support the hypothesis that miR-
130a could be used as a specific regulator of the promoter of AQP4 M1. mRNA 
profiling of anti or pre miR-130a treated samples showed that previously validated 
targets (MEOX2, ATXN1, HOXA5, MAFB, TAC1) of miR-130a were also 




5.7 Modulation of the promoter activity of AQP4 M1 by miR-
130a in the presence of an E box repressor.  
Previous reports on the promoter of AQP4 M1 suggested the presence of 
suppressor elements [237-238]. Umenishi et al [237] considered an E-box region to 
play a crucial role in the transcriptional suppression of the promoter. Mapping the 5 
selected miRNAs in the AQP4 M1 promoter region showed that E box 1 (E1) and 
E box 2 (E2) were closer to the miR-130a and miR-939 recognition sites 
respectively (Figure 5.2). Thus miR-130a recognition site lies between E1 and E2. 
Since suppressor activity with miR-130a was observed, several deletion/mutation 
constructs were created such that they spanned the two E-boxes and miR-130a 
(Figure 5.14). The contribution by miR-939 recognition site was ignored as miR-
939 had already been verified to be absent in the HeLa cells used in this experiment 
(Table 5.3). Promoter activity analysis showed, as seen by Umenishi et al [237], E1 
had marginal effect on the transcriptional capacity while E2 acted as a strong 
repressor (Figure 5.15). However our observation of miR-130a being a repressor 
was also evident. In fact we observed that even in the presence of the E2 
repression, loss of miR-130a recognition site can significantly increase 
transcriptional activity. Furthermore the transcriptional activity of the promoter, in 






Table 5.1: miRNAs predicted to target the promoter of AQP4 M1. The list of 
predicted miRNAs was obtained from RegRNA (release 1.0). Using miRNA 
profiling data of astrocytoma cells and the prediction list, the miRNAs expressed in 
astrocytes were shortlisted (highlighted in bold). Given the huge range of signal 
intensities (ranging from 300 – 64675), we first shortlisted the top 70% of the total 
miRNAs for further studies (highlighted in bold underline).     
miRNAs predicted to target the promoter of AQP4 M1 
hsa-miR-1184   hsa-miR-152 hsa-miR-644 
hsa-miR-1202  hsa-miR-18a*  hsa-miR-654-5p  
hsa-miR-1207-5p  hsa-miR-1913 hsa-miR-663 
hsa-miR-1226*  hsa-miR-214* hsa-miR-668 
hsa-miR-1255b  hsa-miR-220c hsa-miR-744 
hsa-miR-1262  hsa-miR-324-3p   hsa-miR-766 
hsa-miR-1266  hsa-miR-346 hsa-miR-767-5p  
hsa-miR-1280  hsa-miR-453  hsa-miR-92b* 
hsa-miR-130a/b hsa-miR-518c* hsa-miR-939 
hsa-miR-130b*  hsa-miR-541 hsa-miR-940 
hsa-miR-1301 hsa-miR-596  














Table 5.2: miRNA profiling of astrocytoma cells. 1 ug of total astrocytoma RNA 
was used to profile miRNA expression. A total of 293 miRNAs were detected. Raw 
signal intensities were averaged to provide average signal intensity values. 
miRNAs Average Signal 
Intensity 
miRNAs Average Signal 
Intensity 
hsa-let-7a 57675.50 hsa-miR-20b* 5412.00 
hsa-let-7a* 12328.00 hsa-miR-21* 1710.13 
hsa-let-7b* 2833.25 hsa-miR-21 64525.25 
hsa-let-7b 35360.13 hsa-miR-22* 3903.00 
hsa-let-7c 41872.75 hsa-miR-22 64532.75 
hsa-let-7d* 903.00 hsa-miR-23a* 1696.50 
hsa-let-7d 16646.13 hsa-miR-23a 64529.75 
hsa-let-7e 27117.13 hsa-miR-23b 61966.88 
hsa-let-7f 64569.75 hsa-miR-24 64656.50 
hsa-let-7f-2* 435.25 hsa-miR-24-1* 6700.38 
hsa-let-7g 15774.13 hsa-miR-25* 5011.75 
hsa-let-7i 11921.38 hsa-miR-25 6296.50 
hsa-miR-7 2140.38 hsa-miR-26a 42562.00 
hsa-miR-9* 20515.38 hsa-miR-26b 64587.50 
hsa-miR-9 63247.25 hsa-miR-27a 8096.63 
hsa-miR-10b 2634.00 hsa-miR-28-5p 2636.25 
hsa-miR-15a 20441.13 hsa-miR-29a* 794.63 
hsa-miR-15b 45313.88 hsa-miR-29a 64663.25 
hsa-miR-16 64528.50 hsa-miR-29b 20769.75 
hsa-miR-16-1* 452.00 hsa-miR-29b-1* 614.88 
hsa-miR-16-2* 899.63 hsa-miR-29c 3806.00 
hsa-miR-17 3626.63 hsa-miR-30a 54821.25 
hsa-miR-18a 721.75 hsa-miR-30b 49284.50 
hsa-miR-18b 587.38 hsa-miR-30c 24630.25 
hsa-miR-19a 15826.00 hsa-miR-30d 6084.75 
hsa-miR-19b 13894.00 hsa-miR-30e* 2216.50 






miRNAs Average Signal 
Intensity 
miRNAs Average Signal 
Intensity 
hsa-miR-31 6384.75 hsa-miR-140-3p 3908.38 
hsa-miR-32* 18445.25 hsa-miR-143 20893.00 
hsa-miR-34a 17794.00 hsa-miR-145* 415.50 
hsa-miR-34b 64496.50 hsa-miR-145 2995.88 
hsa-miR-93 16574.50 hsa-miR-146b-3p 2284.25 
hsa-miR-98 2858.88 hsa-miR-148b 2275.00 
hsa-miR-99a* 981.88 hsa-miR-149* 20432.88 
hsa-miR-99a 21533.75 hsa-miR-149 1051.63 
hsa-miR-99b* 3135.13 hsa-miR-151-3p 3623.25 
hsa-miR-99b 5813.88 hsa-miR-151-5p 4251.88 
hsa-miR-100 62049.50 hsa-miR-152 3527.75 
hsa-miR-101 4918.13 hsa-miR-181a* 700.63 
hsa-miR-103 6114.13 hsa-miR-181a 17753.75 
hsa-miR-106a 3079.38 hsa-miR-181b 1834.50 
hsa-miR-106b* 1518.00 hsa-miR-1826 64675.00 
hsa-miR-106b 3286.63 hsa-miR-1827 13111.13 
hsa-miR-107 1899.75 hsa-miR-183* 6203.75 
hsa-miR-122* 918.50 hsa-miR-183 1897.38 
hsa-miR-124 657.13 hsa-miR-184 10822.63 
hsa-miR-125a-5p 54572.13 hsa-miR-185* 1336.63 
hsa-miR-125a-3p 885.75 hsa-miR-185 2086.50 
hsa-miR-125b 64668.25 hsa-miR-186 1022.38 
hsa-miR-125b-1* 3862.25 hsa-miR-187* 1802.13 
hsa-miR-125b-2* 603.75 hsa-miR-190 358.25 
hsa-miR-127-3p 675.88 hsa-miR-191 9639.63 
hsa-miR-129* 2405.00 hsa-miR-193a-3p 11293.88 
hsa-miR-129-5p 1451.63 hsa-miR-193b 24501.25 
hsa-miR-130a 6586.63 hsa-miR-193b* 1467.88 
hsa-miR-130b 3725.38 hsa-miR-195 23275.00 
hsa-miR-138-1* 23535.25 hsa-miR-196a* 5142.88 
hsa-miR-138-2* 1097.38 hsa-miR-196a 536.63 





miRNAs Average Signal 
Intensity 
miRNAs Average Signal 
Intensity 
hsa-miR-197 1388.50 hsa-miR-345 929.63 
hsa-miR-198 1173.25 hsa-miR-361-5p 21288.63 
hsa-miR-200b* 546.25 hsa-miR-363* 4188.50 
hsa-miR-200c* 539.00 hsa-miR-365 9864.00 
hsa-miR-203 768.13 hsa-miR-370 1358.13 
hsa-miR-206 1256.25 hsa-miR-374a 14894.00 
hsa-miR-208a 3954.63 hsa-miR-374b* 3631.88 
hsa-miR-210 2856.25 hsa-miR-374b 2870.25 
hsa-miR-214 1966.00 hsa-miR-375 1778.75 
hsa-miR-218 600.00 hsa-miR-376a* 654.25 
hsa-miR-220b 701.88 hsa-miR-376c 2801.38 
hsa-miR-221 20869.00 hsa-miR-377 4634.63 
hsa-miR-221* 2067.25 hsa-miR-378 4688.50 
hsa-miR-222 64553.00 hsa-miR-379 568.38 
hsa-miR-298 1984.75 hsa-miR-381 1671.00 
hsa-miR-299-3p 2598.38 hsa-miR-382 3460.38 
hsa-miR-300 8077.13 hsa-miR-409-3p 804.00 
hsa-miR-301a 3162.75 hsa-miR-411 680.75 
hsa-miR-302c* 1292.00 hsa-miR-412 729.00 
hsa-miR-320a 9486.88 hsa-miR-422a 1734.25 
hsa-miR-320b 7515.38 hsa-miR-423-5p 7485.38 
hsa-miR-320c 9393.13 hsa-miR-423-3p 16433.13 
hsa-miR-320d 5466.25 hsa-miR-424 10036.25 
hsa-miR-331-3p 3509.38 hsa-miR-425 1718.25 
hsa-miR-335 5100.13 hsa-miR-450a 477.38 
hsa-miR-337-3p 1042.00 hsa-miR-483-5p 1071.63 
hsa-miR-337-5p 901.38 hsa-miR-485-3p 1798.00 
hsa-miR-339-3p 520.63 hsa-miR-487b 15245.75 
hsa-miR-339-5p 19122.50 hsa-miR-488 767.25 
hsa-miR-340 8583.38 hsa-miR-490-3p 918.13 
hsa-miR-340* 2790.50 hsa-miR-491-3p 54910.25 
hsa-miR-342-3p 2459.38 hsa-miR-493* 1425.50 
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miRNAs Average Signal 
Intensity 
miRNAs Average Signal 
Intensity 
hsa-miR-494 37536.63 hsa-miR-583 7005.50 
hsa-miR-497 662.00 hsa-miR-584 2776.63 
hsa-miR-498 5816.75 hsa-miR-589 13900.00 
hsa-miR-502-5p 322.75 hsa-miR-597 1462.63 
hsa-miR-505* 2461.50 hsa-miR-600 8168.50 
hsa-miR-508-5p 1182.50 hsa-miR-601 911.00 
hsa-miR-509-5p 3736.13 hsa-miR-602 946.88 
hsa-miR-510 512.50 hsa-miR-615-3p 714.00 
hsa-miR-513a-5p 9050.13 hsa-miR-617 5758.50 
hsa-miR-513b 633.00 hsa-miR-620 7011.38 
hsa-miR-516a-5p 2072.88 hsa-miR-622 457.75 
hsa-miR-516b 2886.25 hsa-miR-625 2295.25 
hsa-miR-518a-5p 3606.75 hsa-miR-625* 1236.88 
hsa-miR-519c-5p 820.38 hsa-miR-628-3p 9833.38 
hsa-miR-519d 17082.38 hsa-miR-629 1142.13 
hsa-miR-519e 9467.00 hsa-miR-629* 1561.63 
hsa-miR-519e* 5305.50 hsa-miR-630 1711.88 
hsa-miR-520d-5p 983.88 hsa-miR-634 3504.00 
hsa-miR-525-5p 1640.00 hsa-miR-636 883.50 
hsa-miR-542-3p 2271.00 hsa-miR-642 2917.00 
hsa-miR-548e 1187.50 hsa-miR-647 2173.50 
hsa-miR-549 11173.75 hsa-miR-652 443.75 
hsa-miR-550 64611.50 hsa-miR-654-3p 1197.50 
hsa-miR-550* 450.13 hsa-miR-656 485.75 
hsa-miR-551a 397.75 hsa-miR-659 1356.38 
hsa-miR-551b* 760.00 hsa-miR-664 318.63 
hsa-miR-551b 19779.50 hsa-miR-664* 1553.38 
hsa-miR-553 906.25 hsa-miR-665 16882.00 
hsa-miR-574-5p 7654.38 hsa-miR-668 49085.75 
hsa-miR-574-3p 4519.00 hsa-miR-671-5p 1428.25 
hsa-miR-576-5p 1836.75 hsa-miR-708 4635.00 













miRNAs Average Signal 
Intensity 
miRNAs Average Signal 
Intensity 
hsa-miR-744 956.13 hsa-miR-1255a 11699.50 
hsa-miR-765 17903.38 hsa-miR-1258 1381.13 
hsa-miR-768-5p 24411.50 hsa-miR-1259 64590.00 
hsa-miR-768-3p 64536.63 hsa-miR-1260 2684.63 
hsa-miR-769-5p 485.88 hsa-miR-1261 1614.13 
hsa-miR-874 1116.13 hsa-miR-1264 42460.38 
hsa-miR-877 1521.63 hsa-miR-1265 40991.25 
hsa-miR-886-5p 40660.50 hsa-miR-1270 925.13 
hsa-miR-886-3p 64575.00 hsa-miR-1273 646.50 
hsa-miR-887 1600.00 hsa-miR-1274a 13028.38 
hsa-miR-888* 36086.00 hsa-miR-1274b 5276.88 
hsa-miR-891a 7151.75 hsa-miR-1275 1337.38 
hsa-miR-920 2181.63 hsa-miR-1280 63345.38 
hsa-miR-923 64610.00 hsa-miR-1284 2387.25 
hsa-miR-92b 1387.25 hsa-miR-1285 64556.25 
hsa-miR-933 64520.50 hsa-miR-1290 64669.63 
hsa-miR-934 2364.63 hsa-miR-1297 867.38 
hsa-miR-937 5228.50 hsa-miR-1299 3518.00 
hsa-miR-938 721.50 hsa-miR-1300 2075.63 
hsa-miR-939 13863.63 hsa-miR-1301 537.75 
hsa-miR-1184 568.63 hsa-miR-1304 3031.00 
hsa-miR-1201 6130.75 hsa-miR-1308 64668.75 
hsa-miR-1246 64535.25 hsa-miR-1321 5809.00 




Table 5.3: Stem-loop PCR for miRNA expression levels. Cycle threshold (CT) 
values of selected miRNAs in astrocytoma and HeLa cells. CT values for respective 
miRNAs were determined from 10ng of total RNA, reverse transcribed using 
miRNA specific stem-loop primers. NTC refers to non template controls. 18s 
expression was used as positive controls. Data shown are the mean ± SD, n=3.  
    miRNA CT values  
(Astrocytoma) 
CT values  
(Hela) 
miR-130a  28.22 ± 0.217 28.37 ± 0.109 
miR-152 30.82 ± 0.049 Undetermined 
miR-668 32.26 ± 0.107 Undetermined 
miR-939 30.75 ± 0.095 Undetermined 
miR-1280 19.19 ± 0.201 30.12 ± 0.126 
NTC Undetermined Undetermined 
18s 9.23 ± 0.188 9.51 ± 0.216 
 
 
Table 5.4: Sequences of primers used to amplify AQP4 M1 promoter. The 
primer sequences used to amplify the 2.1kb AQP4 M1 promoter is given below. 
The primers used to create the miR-130a and miR-1280 recognition site mutants 
are also listed below. The miRNA recognition site was mutated by changing 
several of the nucleotides within the seed region. The mutated nucleotides are 
underlined.   
 
Primers  Sequence (5’ to 3’) 
AQP4 M1 promoter 
Forward: CCCTGGTCAATTTTAAGCTACTCTGC  
Reverse:  TCATGCCTTCCCCAGCCAGA 3‟ 
miR-130a mutation  
Forward: ACCAAGGTGTCCTGCATTCATTCCTACAGTGGACCA  
Reverse:  TGGTCCACTGTAGGAATGAATGCAGGACACCTTGGT  
miR-1280 mutation  
Forward: TCTAGATGTTTTGTAGAGTAATGTTTTCATAGAT  


















Figure 5.1: AQP4 gene organization. AQP4 gene organization image was 
adapted from Umenishi et al [237]. Exons (0-4) are represented as boxes (not 
drawn to scale). Untranslated regions are shown as dotted boxes. Coding regions 
are diagonally shaded. Black box represents the sequence which codes for the long 
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-1933 AGTACTAATAAGTGTAGGGGTTGGAGCCAATGAGGGTGACCCCTTCTTGATGGGAACAGT 
                    |||| || : |||||     |:||||| 
        miR-668  3' CAUCACCCGGCUCGG-----CUCACUGu  5' 
















 -973 ATTGTTCTAGATGTTGGGTTG-AGTGGTGGGTTCATAGATGTTCATTACATTATTTAAAAG    
                      |||| | ||:||||||                     
     hsa-miR-1280  3' CCCACCGUCGCCACCCU  5’     
 -913 CCATTATAATTAACTATTAGAAAATAAGAGGGCCATACATGCACGAGTGATGACAGAGTG 
 -853 TCATAAATCAGGAATTCTGATTATTCCAATCCCATGCACCTAAGATCTGTTTAAAGAAAA 
 -793 AATAATAATGAGATGGTGATGCAGGTAGCTAATGGTTAGACCCTTCTAGAGTTCACCAAA 
 -733 CTCCTTCGGCAGGGACGTCTTCATAAGCATGCAGCCTGCGCAGCTGCACAAGGTCCTGCC 
                                E Box 1 (E1)  








         3' GGUU--CAAGAC---AGU---ACGUGACU 5' hsa-miR-152   
            ||||  || |||   |||   |||||||  
 -613 TTTTACCAAGGTGTCCTGCATTCATTTTGCACTGGGACCAGTAAATTATAAAATCAGTCC 
                 ||:|||   || |: |||||||| 
             3' uACGGGA--AAAUUGUAACGUGAC 5' hsa-miR-130a   
 -553 TGTCCCTAAGTTTCCAGAGGTTAAATTTACCTACAGTTCCCCATAATTTCCGTCCCCATC 
                   ||||||          ||| |||:|||||| 
           3' gugggGGUCUC----------GGA-GUCGAGGGGU 5' hsa-miR 939 
                         
 -593 CAACTTTGATATTTTTTAAGTTTGCTACTTCTTATCCCCCGAGTTATTAATGTAACAGTC 
 -433 AGGTGAGCACCCTAGAGCAGTCTTTTTTCCTGTATTTCCTATGTTTCCTTATTTTTATTG 
      E-box (E2) 
 -373 TCCAAATCAGTGCTGCCTGTGCTATAAATGGAGCTGCAGTTATATATTGTTCTTATAATG 
 -313 CTTCTTCTCAGATCAAAAACTTCAAACAGAATTCATTGGCTAAAAACTAAATGCACTGAA 
 -253 GTCTCTATCTAAATTCATGTTAACTGCTGGATTATACAAATTCATTTTCTAATAATTGCC 
 -193 CAATTTCAACTACAACATATAACCAAACAAGACAAATTCTGAACAATTCTTCATGGTAGA 
 -133 AAGAATTCAAATAAAGATTTAAGGAAATCCTCATTTTCAAAAATTACTGTCTCAAAAAAA 
  -73 AAAATTAAGTAAATGTTTTTGCATTCCTGAAATGCCCTGTGTCTACAGTGATCAGGTACA 
  -13 GAAAAGCTACTTCAAGTTCAAATATAACTTAGCGATTGCCACATGGTGCAGAATCTTTCC 
  +48 ACCCCTAACACTCCAAAAACCCAATCAGACAAGTGGCCGTAATCTGACTCCCAGCACACA 
 +108 GGGAGCTGCGGGGCAGGCAATGAGAGCTGCACTCTGGCTGGGGAAGGCATG 
 
                          
Figure 5.2: Predicted binding of miRNAs to promoter region of AQP4 M1. 
Predicted binding regions of five of the highly expressed miRNAs (in human 
astrocytes) are shown in purple. The seed regions are highlighted in red. The E 














Figure 5.3: Image of the pGL4.10 Luciferase vector. The AQP4 M1 promoter 
was cloned into the pGL4.10 Luciferase vector. Gene fragments previously sub-
cloned into the pCR4-TOPO vector were excised using the appropriate restriction 





Figure 5.4: Image of the AQP4 M1 full promoter construct. The AQP4 M1 
















Figure 5.5: Relative AQP4 M1 promoter activity. The AQP4 M1 promoter was 
co-transfected into astrocytoma cells with anti miRNAs. The miRNAs predicted to 
bind the promoter region were sequentially removed using the respective anti 
miRNAs. Changes in luciferase activity were measured 48 hrs post transfection. 
Luciferase activity of the full promoter in the presence of all the miRNAs was 
taken as 100%. Statistical analyses were done using t-tests *, p < 0.05 compared to 

































                      Control 
 miR-668                            -              -             -                  - 
miR-1280                                                                     -             -               - 
miR-130a/152                                                                                     -                          - 






Figure 5.6: AQP4 M1 promoter constructs. The luciferase reporter constructs 
containing the flanking regions of the promoter of AQP4 M1 are shown above. The 
full promoter construct contains five miRNA target regions. The deletion constructs 
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Figure 5.7: AQP4 M1 promoter activity analysis. The luciferase reporter 
constructs containing the flanking regions of the AQP4 M1 promoter are shown 
above. The promoter construct of AQP4 M1contains five miRNA target regions. 
Deletion constructs had one or more of the miRNA target regions were removed. 
The luciferase reporter constructs containing the flanking regions of the promoter 
were transfected into astrocytoma cells. Luciferase activity of the full promoter was 
taken as 100%. Luciferase activity of all other deletion constructs was expressed 
relative to the activity of the full promoter. Statistical analyses were done using t-



















Δ miR-668 Δ miR-668 / 
1280
Δ miR-668 / 
1280 / 130a / 
152
Δ miR-668 / 
























Figure 5.8: Effect of miRNA modulation on the promoter activity of AQP4 
M1. The luciferase reporter construct containing the entire 2.1kb promoter was 
transfected into astrocytoma cells with the anti or pre miRNAs. Luciferase 
luminescence readings were obtained 48 hrs post transfection. Relative 
luminescence was obtained by normalizing value against respective negative 
control plasmids. Statistical analyses were done using t-tests *, p < 0.05, **, p < 

































































Figure 5.9: AQP4 immuno-reactivites in astrocytoma cells transfected with 
anti or pre miRNAs.  Human astrocytoma cells were co-transfected with promoter 
- AQP4 CDS constructs together with anti or pre miRNAs. The cells were fixed 
and probed with anti-AQP4 antibodies (green) and nuclear stain DAPI (blue) 
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Figure 5.10: miR-1280/130a mutant constructs. Using miR-668 deletion 
construct (which contains recognition sites for miR-1280 and miR-130a), three 
other plasmids were generated such that they contained miR-1280 and/or miR-130a 
recognition site mutations. Mutated sites are represented by xxxxx. The recognition 
site mutated constructs were transfected into HeLa cells and the relative promoter 
activity of the constructs were obtained with respect to the miR-1280/130a mutant 
construct. The predicted recognition site of miR-939 was not taken into 
consideration as these constructs were transfected into HeLa cells which do not 
















miR-1280 miR-130a Luciferase Gene
xxxxx miR-130a Luciferase Gene
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 Figure 5.11: Activity of miR-1280/130a mutant constructs. The miR-1280 and -
130a recognition site mutated constructs were transfected into HeLa cells and the 
relative promoter activity of the constructs were obtained with respect to the miR-
1280/130a mutant construct. The predicted recognition site of miR-939 was not 
taken into consideration as these constructs were transfected into HeLa cells which 
do not express miR-939. Statistical analyses were done using t-tests *, p < 0.05, **, 









































Table 5.5: Relative expression of miR-130a in anti or pre miR-130a treated 
astrocytoma cells. Total RNA was extracted and the relative expression of the 
miR-130 was determined using stem-loop PCR.  Data shown are the mean ± SD, 
n=3.  
Treatment 
Relative expression level 
of miR-130a 
  Anti miR-130a  0.114 ± 0.063 
  Pre miR-130a  210.9.4 ± 13.55 
 18s 10.12 ± 0.184 























Figure 5.12: Relative mRNA expression of AQP4. Astrocytoma cells were 
transfected with anti or pre miR-130a. The corresponding AQP4 mRNA levels 
were also determined. Specific primers were used to differentiate between the two 













































Figure 5.13: Experimentally validated targets of miR-130a. Total RNA 
extracted from human astrocytoma cells treated with 30 nm anti or pre miR-130a 
was subjected to mRNA profiling. The oligonucleotide array was performed 
according to the manufacturer‟s protocol using 500 ng of total RNA (Illumina, 
SanDiego, USA) Signal log ratio of experimentally validated targets of miR-130a 










































Figure 5.14: Suppressor region on AQP4 M1. The luciferase reporter constructs 
containing the suppressor regions of the promoter of AQP4 M1 postulated by 
Umenishi et al [237] are shown above. This region consists of the miR-130a 
recognition site flanked by two E-boxes. The predicted recognition site of miR-939 
was not taken into consideration as these constructs were transfected into HeLa 
















E box 1 miR-130a Luciferase Gene
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Figure 5.15: Relative promoter activity of suppressor region. The graph shows 
an increase in promoter activity as miR-130a sites are mutated. An increase in 
activity was also noted when the second E box (E2) region was deleted. The 
relative activity of the various constructs was expressed with respect to the 
construct with all the predicted suppressor regions (E1/miR-130a/E2). Luciferase 
luminescence readings were obtained 48 hrs post transfection. Statistical analyses 
were done using t-tests *, p < 0.05, **, p < 0.01, compared to control. Data shown 















































Figure 5.16: Modulation of AQP4 M1 promoter using miR-130a. Relative 
promoter activity of suppressor region. The graph shows changes in the promoter 
activity as miR-130a levels are modulated. However this effect was abolished when 
the miR-130a sites where mutated. The relative activity of the various constructs 
was expressed with respect to the negative controls. Luciferase luminescence 
readings were obtained 48 hrs post transfection. Statistical analyses were done 

































































The studies thus far, have focussed on the importance of regulating AQPs 1 and 4. 
Given their important functions in the brain, the potential of miRNA based 
regulation of AQPs 1 and 4 was shown using in vitro studies and in vivo ischemic 
model. Apart from AQP1 and 4 the expression of AQPs 3, 5, 6, 8, 9 and 11 have 
been reported in the rodent brain cells. Yet in in vivo studies of the brain AQPs 1, 4 
and 9 have been found to be more relavant to ischemic conditions [239-240]. 
Unlike AQP1 and 4, AQP9 is classified as an aquaglyceroporin. Thus it is 
permeable to water and glycerol. However, the osmotic water coefficient for AQP9 
is lower than that of a pure water channel like AQP4 [112]. Apart from water and 
glycerol transport, AQP9 is also known to facilitate transport of metalloid 
(arsenite), purines (adenine), pyrimidines (uracil and chemotherapeutic agent 5-
fluorouracil) and monocarboxylates (lactate and β- hydroxybutyrate) [43, 52-53,  
112, 241].   
 
In the brain, expression of AQP9 has been reported in glial cells and predominately 
in catecholaminergic neurons [95, 242]. It is known that catecholaminergic neurons 
are not directly involved in the regulation of systemic osmotic pressure, but are 
implicated in energy balance [243-244]. Thus, AQP9 was hypothesized to play a 
role in brain energy homeostasis [245].  Interestingly, as observed for AQPs 1 and 
4 where an increase in expression was noted upon ischemia, the level of AQP9 
expression was also upregulated [96]. Yet the increase in AQP9 expression was 
independent of edema formation [96]. This observation further seems to strengthen 
215 
 
the postulation that the role of AQP9 in the brain could be inclined towards being a 
metabolite channel.  
 
Glucose converted into lactate by astrocytes has been proposed to be extruded out 
into the extracellular space and eventually taken up by the neurons. Tsukaguchi et 
al [53] showed that AQP9 was permeable to lactate and thus AQP9 has been 
proposed to facilitate shuttling of lactate between astrocytes and neurons. During 
ischemia, a 15 min obstruction in blood supply results extracellular pH to drop 
from 7.2 to about 6.4–6.8 while the intracellular pH falls from 7.05 to 6.4. 
Interestingly, acidosis has been shown to increase the AQP9 lactate permeability 
rates by four fold [53]. This increase in permeability rates is possibily a survival 
mechanism. Schurr et al [246] showed that when hippocampal slices are subjected 
to hypoxia in the presence of lactate about 85% recovered their synaptic function 
whereas only 40% recovered when exposed to glucose. This suggests that during 
ischemia lactate might be a more efficient fuel source for the cells. However the 
increase in AQP9 expression during ischemia was seen only after 24 hrs [96]. A 
modulator to increase the expression of AQP9 at an earlier timepoint may be 
beneficial in terms of reducing cell death.  
  
Thus the regulation of AQP9, not forgetting AQPs 1 and 4, is important for proper 
brain functioning as well as for survival during conditions such is ischemia. A 
greater role in fluid homeostasis was postulated for AQPs 1 and 4 and it has been 
shown that modulation of these classical AQPs 1 and 4 using miR-320a can indeed 
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reduce the infarct volume in ischemic models. While regulation of AQPs 1 and 4 
lessened the detrimental effects caused by water accumulation, increasing the 
energy source to the nutrient depleted neurons could also lessen the extent of cell 
death. In fact it is the depletion of the energy source that triggers the entire cell 
death cascade where changes in the intracellular ionic concentrations result in water 
fluxes.  Thus this chapter attempts to identify potential AQP9 miRNA modulators 
that could be used for further studies in cerebral ischemia. 
 
6.2 AQP9 profile in ischemic rat models 
Ribeiro et al [96] reported that the level of AQP9 expression in cerebral edema did 
not correspond to the extent of water accumulation. They observed significant 
upregulation of AQP9 at the later phases of ischemia and this lasted up to 7 days. 
An ischemic rat model was generated in the lab with several reperfusion timepoints 
of 0 to 48 hrs (Figure 6.1). Real-time PCR studies on ischemic rat brain samples 
showed that although differential expression of AQP9 was noted at the early 
timepoints, the expression was mainly down regulated (Figure 6.1). An increase in 
AQP9 expression was noted at 6 hrs of reperfusion and it peaked at 12 hrs. The 18 
hrs timepoint showed a sharp decrease in AQP9 expression followed by gradual 
increase at 24 hrs and 48 hrs.  AQP9 protein quantitation also showed a similar 
trend in expression (Figure 6.2). To understand the effect of AQP9 downregulation 
(during ischemia) on cell viability, ischemic conditions were simulated in an in 
vitro study.  Oxygen-glucose deprivation (OGD) studies were performed in 
astrocytoma cells treated with AQP9 siRNA. The cells were treated with AQP9 
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siRNA 48 hrs prior to subjecting them to OGD for a period of 1-6 hrs. MTT cell 
viability studies showed that knockdown of AQP9 caused increased cell death 
compared to that of control cells (Figure 6.3). These findings suggested that 
expression of AQP9 was crucial during OGD conditions. Having a regulator to 
increase the expression of AQP9 early in ischemia may be beneficial in cell 
survival.  
 
6.3 Selection of miRNAs for further interaction studies  
To identify AQP9 based miRNA regulators, the original pool of data 
(Supplementary Table 1) was used. The miRNAs predicted to target human AQP9 
were shortlisted. A total of 130 miRNAs were predicted to target the 3‟ UTR of 
AQP9 by the three databases MicroCosm Targets, MicroRNA.org and TargetScan 
(Table 6.1). Since the focus of this study was to identify miRNAs that could 
regulate AQP9 in the brain, the predicted list was compared against the 
astrocytoma miRNA profile (see Table 5.2). Of the 130 miRNAs only 48 of them 
were seen to be expressed in astrocytoma cells (Table 6.2). Ten of the miRNAs 
(miR-18a, -18b, -181a*, -379, -409-3p, -488, -510, -636, -769-5p, and -1301) were 
found to be poorly expressed with array signal intensities below 1000 (Table 6.2). 
Thus these miRNAs were not used for further studies. Interstingly among the 
remaining 38 miRNAs, miR-22, -23a, -93, -106b, 129-5p, -151-5p, -181a, -185, -
331-3p, -365, -494 and -877 were found to be conserved in mammals (Table 6.3). 




6.4 Cloning of AQP9 3’UTR 
The recognition sites of the 12 miRNAs on the AQP9 3‟UTR were mapped (Figure 
6.4).  miR-93 and miR-106b were found to have the same seed region and thus they 
were classified as one miRNA family. Both these miRNAs were predicted to 
interact the the same region on the AQP9 3‟UTR. Thus only miR-106b was 
mapped on the sequence (Figure 6.4). Interestingly, the predictions for miR-181a 
and miR-887 and the predictions for miR-23a and miR-494 overlapped in the 
3‟UTR. However it was observed the predicted binding for miR-181a and miR-494 
was stronger than that of miR-887 and miR-23a respectively. AQP9 gene specific 
primers were designed using NCBI primer blast software (Table 6.4). The 3‟ UTR 
of AQP9 was amplified as a single fragment from total RNA obtained from 
astrocytoma cells (Figures 6.5 & 6.6). The fragment was sub-cloned into TOPO 
vectors and sequenced for verification prior to the introduction of specific 
restriction sites (Spe1/HindIII). The fragments with the restriction sites were then 
excised and sub-cloned into pMIR luciferase vectors and sequenced for verification 
for the final time.  
 
6.5 Profile of selected miRNAs in ischemia 
Of the 12 miRNAs found to be conserved in rats and humans, the five most highly 
expressed miRNAs (miR-22, -23a, -181a, -365 and -494) were chosen for further 
evaluation.The expression patterns of miR-22, -23a, -181a, -365 and -494 over the 
various reperfusion time-points in ischemic brain were determined using stem loop 
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qPCR. Real-time analysis showed that these 5 miRNAs were differentially 
regulated during ischemia (Figures 6.7 – 6.11). While miR-22, -181a, -365 and -
494 had similar expression profiles with respect to AQP9 expression at various 
reperfusion timepoints, the profile of miR-23a was quite different. This could be 
due to the weak interaction predicted for miR-23a. Thus for further validation 
studies the miRNAs with profiles that seem to correlate strongly to AQP9 were 
chosen. Hence miR-22, -181a, -365 and -494 were chosen for validation studies.  
 
6.6 miRNA interaction studies on AQP9 3’UTR 
To study the interaction of miR-22, -181a, -365 and -494 with the AQP9 3‟UTR, 
reporter assays were performed in astrocytoma cells. Prior to interaction studies, 
the expression of the selected miRNAs (miR-22, -181a, -365 and -494) and the 
AQP9 gene in astrocytoma cells were established. Real-time analysis showed that 
all 4 miRNAs and AQP9 were expressed in astrocytoma (Table 6.5). The AQP9 
3‟UTR constructs were then co-transfected together with their respective anti or pre 
miRNAs. Interestingly only anti and pre miR-22 treatment showed differential 












Figure 6.1: Relative AQP9 mRNA expression in ischemic rat brains. Ischemic 
rat models with various reperfusion timepoints were generated. Total RNA was 
extracted from the brain and AQP9 mRNA levels were quantiated using real-time 










































Figure 6.2: Relative AQP9 protein expression in ischemic rat brains. Ischemic 
rat models with various reperfusion timepoints were generated. Total protein was 
extracted from the brain and AQP9 protein was probed using rat anti-AQP9 
antibodies. β-actin was used as loading control (insert). The graph represents 










































Figure 6.3: Percentage of survival in astrocytoma treated with AQP9 siRNA 
and subjected to OGD treatments. Prior to OGD, the AQP9 expression in 
astrocytoma cells was knockdown using siRNAs. Percentage of surviving cells was 
determined relative to control non-transfected cells subjected to OGD. Statistical 
analyses were done using t-tests *, p < 0.05, **, p < 0.01 compared to respective 






























Table 6.1: miRNA predictions for AQP9 from MicroCosm Targets/ 
MicroRNA.org /TargetScan. miRNA target predictions for human AQP9 gene 
from all three sources are shown here. The human AQP9 gene sequence was 
retrieved from the NCBI GenBank database AQP9 (NM_020980). A total of 130 
miRNAs were predicted to bind to the 3‟UTR of AQP9 by these databases. 
miRNAs miRNAs miRNAs 
hsa-miR-17- 5p hsa-miR-219-2-3p hsa-miR-514 
hsa-miR-18ab hsa-miR-224 hsa-miR-515-3p/519e 
hsa-miR-22 hsa-miR-290-5p/292-5p hsa-miR-517b 
hsa-miR-20a/b   hsa-miR-296/296-3p 
hsa-miR-518d-5p/519b-
5p/519c-5p/520c-5p/526a 
hsa-miR-23ab hsa-miR-300 hsa-miR-519d  
hsa-miR-93  hsa-miR-302ac/520f hsa-miR-520a-5p/525-5p 
hsa-miR-96/1271 hsa-miR-302f hsa-miR-520f 
hsa-miR-105.h hsa-miR-324-5p hsa-miR-522 
hsa-miR-106a  hsa-miR-330-3p hsa-miR-525-5p 
hsa-miR-106b  hsa-miR-331/331-3p hsa-miR-532/532-5p 
hsa-miR-129-5p  hsa-miR-344-5p/484 hsa-miR-532-3p 
hsa-miR-135 hsa-miR-365 hsa-miR-543 
hsa-miR-146 hsa-miR-379 hsa-miR-544 
hsa-miR-146b-5p  hsa-miR-380 hsa-miR-545 
hsa-miR-149 hsa-miR-409-3p hsa-miR-548a-3p/548ef 
hsa-miR-151 hsa-miR-410 hsa-miR-548abcd-5p 
hsa-miR-154 hsa-miR-432 hsa-miR-548c-3p 
hsa-miR-181a/b/c/d hsa-miR-433 hsa-miR-548m 
hsa-miR-181a* hsa-miR-485-3p hsa-miR-548n 
hsa-miR-181c* hsa-miR-488 hsa-miR-548o/1323 
hsa-miR-182 hsa-miR-491/491-3p hsa-miR-549 
hsa-miR-185/882 hsa-miR-493 hsa-miR-550 
hsa-miR-188/188-5p hsa-miR-494 hsa-miR-576-3p 
hsa-miR-192* hsa-miR-508-3p hsa-miR-577 
hsa-miR-193a/193a-5p hsa-miR-510 hsa-miR-586 
hsa-miR-198 hsa-miR-511.h hsa-miR-587 
hsa-miR-199/199-5p hsa-miR-512-3p/1186 hsa-miR-590/590-3p 
hsa-miR-205 hsa-miR-512-5p hsa-miR-595 




miRNAs miRNAs miRNAs 
hsa-miR-607 hsa-miR-648 hsa-miR-1185 
hsa-miR-608 hsa-miR-654-3p hsa-miR-1207-5p 
hsa-miR-609 hsa-miR-659 hsa-miR-1224/1224-5p 
hsa-miR-621 hsa-miR-660 hsa-miR-1256 
hsa-miR-623 hsa-miR-671-5p hsa-miR-1257 
hsa-miR-625 hsa-miR-768-3p hsa-miR-1263 
hsa-miR-628-3p hsa-miR-768-5p hsa-miR-1275 
hsa-miR-636 hsa-miR-769-5p hsa-miR-1286 
hsa-miR-637 hsa-miR-770-5p hsa-miR-1293 
hsa-miR-610 hsa-miR-802.h hsa-miR-1301 
hsa-miR-611 hsa-miR-877 hsa-miR-1303 
hsa-miR-612/1285 hsa-miR-885-5p hsa-miR-1321 
hsa-miR-616 hsa-miR-889 hsa-miR-1825 
hsa-miR-617 hsa-miR-943  
















Table 6.2: Astrocyte miRNAs predicted to target AQP9. From the prediction list 
of 130 miRNAs, 48 were expressed in astrocytoma cells. Of these 48 miRNAs, 38 
of them had showed signal intensities greater than a 1000. miRNAs with signal 






hsa-miR-17 3626.625 hsa-miR-488 767.25 
hsa-miR-18a 721.75 hsa-miR-491-3p 54910.25 
hsa-miR-18b 587.375 hsa-miR-494 37536.63 
hsa-miR-20a 5021.5 hsa-miR-510 512.5 
hsa-miR-22 64532.75 hsa-miR-519d 17082.38 
hsa-miR-23a 64529.75 hsa-miR-525-5p 1640 
hsa-miR-23b 61966.88 hsa-miR-548e 1187.5 
hsa-miR-93 16574.5 hsa-miR-549 11173.75 
hsa-miR-106a 3079.375 hsa-miR-550 64611.5 
hsa-miR-106b 32866.38 hsa-miR-576-3p 10528.75 
hsa-miR-129-5p 1451.625 hsa-miR-617 5758.5 
hsa-miR-149 1051.625 hsa-miR-620 7011.375 
hsa-miR-151-5p 4251.875 hsa-miR-625 2295.25 
hsa-miR-181a* 700.625 hsa-miR-628-3p 9833.375 
hsa-miR-181a 17753.75 hsa-miR-636 883.5 
hsa-miR-181b 1834.5 hsa-miR-654-3p 1197.5 
hsa-miR-185 2086.5 hsa-miR-659 1356.375 
hsa-miR-198 1173.25 hsa-miR-671-5p 1428.25 
hsa-miR-300 8077.125 hsa-miR-768-3p 64536.63 
hsa-miR-331-3p 3509.375 hsa-miR-768-5p 24411.5 
hsa-miR-365 9864 hsa-miR-769-5p 485.875 
hsa-miR-379 568.375 hsa-miR-877 1521.625 
hsa-miR-409-3p 804 hsa-miR-1275 1337.375 







Table 6.3: Conserved miRNAs predicted to target AQP9. A total of 12 miRNAs 
were found to be conserved in mammals. Conserved miRNAs were selected to 
study AQP9 regulation so that the study can be extended to in vivo models. The 
miRNAs are listed based on ascending signal intentsities.  































1    TGGCATGCTCAGCTCTGGATTTGCAGTCAGTTTGGGATTCTCTTCAGAAAGATGGCATCT 
61   AAGTGTCTGTGTTCTTGTAAGCCTGAGGTGGAATCCACCCAGTTTTGTCTGCTAGCCATA 
121  TGGGACATCTAATTGGAAAAGCATCTGCATAAAAGTTTGGAAACAATGACCACTTCTCTA 
181  CCATTGTCCCCCACCCCCACCCCCCAGAATAACGCTGACTGTCCCCTGAAACAGCCTTCT 
                 ||||                               
                             hsa-miR-185    3' AGUCCUUGACGGAAAGAG 
     GAGGU 5'    
     ||||  
241  CTCCTGCCCTGTTTATTTCATCCTCGATGGGAATTCTTGCTAGGTAAGCACTAATAACTC 
       | | :| |   |||||||    
      3'   UGAUCUGACACUCGAGGAGCU   5'  hsa-miR-151-5p 
301  GGCATCTTGACGATAGTCCCATTTGGGTGGTTTCAGCTGCACTATCTGTATGAAATGGTG 
361  TCACCAAAACCCTTTTCTTCAGTATCGACAAAGATTACATTCTGAGTACCAACCAAACCC 
421  TAAATTGAAAGACAAAACTATGGTTTCAGTCAACATATTCATGAATTAGGGAGCTAATGG 
481  GTTAAGCTTCCAGTTCCCGCTATGCTACTGGATTTGTATAAATACTGATATTCTCCAAAC 
541  CTAGTGGTGTAGGGAGCAAGAGAATGCAGCTGGAAGGCACAAGGGGAGGACATTGTGGCA 
601  TTCAGAAACTGCAGGAGACAAGATGAATTTGAGAAGCCAAATGGAATTTTTAATGGAAAC 
661  CATTTATCAGATTAATCTCTTGCTCTCCTGCATTTTAGAGGACACCAATTAATTTCCTGG 
721  TCTTTAGTATATAATAACCTAAAATACCATTGTAACCTCAGTCATGAAAAATACATCACT 
781  CTGTCTTTTTAGCTCAAATGTATTTTCCTAATTGCCCACTTGAGAACAGACATTTGACAA 
841  GTTATATCAACGACTGTGCTTGTCCATTATTTTACACATGCCCTAGAAGCCAAAACTGAA 
901  AGCCACTGGATCCTGGTCTAGCTGAATCTTCAGAGTGGGAGGTCTCCAAAAAGATATTAC 
961  CTTATTGGGCTTAACAATTCACAAGGCACTTTCACACCCATTATCTAATTTAATCCTCAT 
                     |:|  ||  ||||||| 
            3' UAGACGUGACAGU--CGUGAAAU 5' hsa-miR-106b  
1021 AATGACTATGTGAGGCAAATGCCACATTGCCATTTTTCAGATAAAGAAACAAAATCTTAG 
          hsa-miR-181a  3'  UGAGUGGCUGUCGCAACUUACAA   5’ 
                               |||:|| |  ||||||||| 
1081 GGAAGATAAGTTGAGTTGTCCAAGAGCACACTGAAAGTTGAATGTTATCTAATGCATTCC 
                                                  : :    :   :||| 
                                hsa-miR-887   3'  GGGACGCGGUAGAGG 
     AGAUG   5’ 
     |||| 
1141 TCTACCTTTCAGAAGATCAGTAGCTGGCTGAGAATCTTTGCCAAATCTTCCTTGCTAGCC 
 
3' UGUCAAGAAGUUGACCGUCGAA 5'   hsa-miR-22          





1321 GAAAGTGGTAGCAATTTAATCATAACTTTCATTTGCTGAAAAACATTATGAGAAGGCCTC  
1381 CCTTCCTAAGCCACCTCTGGTCTTGCTAAGTCTTGATCTTGCTTCCTGCCAGCACCAAAC 
                                                               | 
                                       hsa-miR-331-3p  3’  AAGAUC                          
AGAUCCUAUCCGGGUCCCCG    5’     
      |||  ::||||||       
1441 ATTACATTCAGGGGATTTCCTCTGGCTCAGTCTTTTCCCCTTGAAGTTCTCTAATAGATG 
 
        hsa-miR-331-3p  3’   AAGAUCCUAUCCGGGUCCCCG    5’     
                             |        ||  |||||||              
1501 TTACTTTTGACAAAAGATCGCCTATGAGTTACAAGCACCAGGGGATGCTCTACATCAAGG 
         3' CGUUCGGGUCUGGC-GUUUUUC 5'   hsa-miR-129-5p 
               || :|| ||:| ||||||| 
1561 GATGCACCTTCAGTCAAACTGTCAAAAAGCCCAGAATTCCCAAAGGCATTAGGTTTCCCA 
                                       ||||   |  |||||| 
                hsa-miR-365  3'   UAUUCCUAAAAAUCCCCGUAAU  5’   
          hsa-miR-23a   3' CCUUUAGGGACCGUUACACUA 5'  
                             |          ||||||| 
1621 ACTGCTTTGTGCTGATATCAGAACAGCAGAAATTAAATGTGAAATGTTTCTGATGACTTA 
                                 ||  ||   :|||  ||||||| 
                 hsa-miR-494  3' CUCCAAAGGGCAC-AUACAAAGU 5' 
1681 TGTTCTACAATCTATGGACATACGGGATTTTTTTTTCTTGCTTTGAAGCTACCTGGATAT 
1741 TTCCTATTTGAAATAAAATTGTTCGGTCATTGTTGAAAAAAAAAAAA 
            
   
Figure 6.4:  Sequence of the 3’ UTR of the AQP9 gene. The sequence was 
obtained from NCBI (NM_020980). The predicted binding of selected miRNAs to 
the 3‟UTR of AQP9 is shown in purple. The miRNA seed region is highlighted in 
red. To distinguish between two overlapping miRNA regconition sites, one set of 
miRNA and the predicted region are underlined. Seed region of miR-23a is 








Table 6.4: Primers used for amplification of AQP9 3’UTR. The table lists the 
specific primers used to amplify the 3‟UTR regions of AQP9 into TOPO vectors. 
For directional cloning into pMIR vectors, the primers were re-designed with the 




Sequence of primers used for TOPO 
cloning 





AQP9 Forward TTGTAAGCCTGAGGTGGAAT SpeI 










Figure 6.5: Schematic representation of the AQP9 3’UTR. The solid black line 
represents the 3‟UTR region of AQP1 (not drawn to scale). The first nucleotide of 
the 3‟UTR region has been re-numbered as 1. P(A) represtents the poly A signal on 
the gene. The dotted line represents the coding region of AQP1. The 3‟UTR of 









         1                                             1758 P(A) 




















Figure 6.6: Amplification of AQP9 3’ UTR. The entire 3‟ UTR of the AQP9 gene 
was amplified using sequence specific primers. Lane 1: 100 bp marker and lane 2: 
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Figure 6.7: Profile of miR-22 in ischemic brain samples. The profiles of the 
miR-22 against the AQP9 mRNA expression in ischemic rat brains at various 
timepoints are shown here. Total RNA was extracted from the brain and miR-22 






































































Figure 6.8: Profile of miR-23a in ischemic brain samples. The profiles of the 
miR-23a against the AQP9 mRNA expression in ischemic rat brains at various 
timepoints are shown here. Total RNA was extracted from the brain and miR-23a 




































































Figure 6.9: Profile of miR-181a in ischemic brain samples. The profiles of the 
miR-181a against the AQP9 mRNA expression in ischemic rat brains at various 
timepoints are shown here. Total RNA was extracted from the brain and miR-181a 





































































Figure 6.10: Profile of miR-365 in ischemic brain samples. The profiles of the 
miR-365 against the AQP9 mRNA expression in ischemic rat brains at various 
timepoints are shown here. Total RNA was extracted from the brain and miR-365 





































































Figure 6.11: Profile of miR-494 in ischemic brain samples. The profiles of the 
miR-494 against the AQP9 mRNA expression in ischemic rat brains at various 
timepoints are shown here. Total RNA was extracted from the brain and miR-494 





































































Table 6.5: Validation of miRNAs and AQP9 expression levels in astrocytoma 
cells. Cycle threshold (CT) values of selected miRNAs in astrocytoma cells. CT 
values for respective miRNAs were determined from 10ng of astrocytoma total 
RNA, reverse transcribed using miRNA specific stem-loop primers. 100ng of total 
RNA was used to quantitate AQP9 mRNA exression. NTC refers to non template 
controls. 18s expression was used as positive control. Data shown are the mean ± 
SD, n=3.  
 
    miRNA 
CT values 
(Astrocytoma) 
miR-22 24.38 ± 0.219 
miR-494 29.90 ± 0.062 
miR-181a 24.88 ± 0.149 
miR-365 25.72 ± 0.122 
AQP9 27.40 ± 0.239 






















Figure 6.12: Relative luminescence of AQP9 constructs. The luciferase reporter 
constructs containing the 3‟UTR regions of the AQP9 were co-transfected with the 
respective anti or pre miRNAs into astrocytoma cells. The relative luciferase 
activities were normalised against the respective negative controls. Statistical 
analyses were done using t-tests *, p < 0.05, **, p < 0.01 compared to respective 




















































7.1 Prediction of miRNAs regulating AQPs 
The main objective of this study was to identify miRNAs that could target AQPs 
and serve as regulators of their gene expression. The first report to establish 
miRNA target interaction showed that lin-4 regulated lin-14 translation via an 
antisense RNA-RNA interaction [138]. However this report involved many 
laborious techniques such as physical genetic mapping, Rnase protection assays 
and northern blots. Perhaps this could be a possible cause for the long lag time til 
the next report on miRNAs emerged [140]. Nevertheless in the past decade, 
computational approaches have become invaluable tools in miRNA based studies 
[247-248]. Web-based-miRNA databases have emerged and they have published 
miRNA sequences (e.g. miRBase Sequences database) [169, 178] as well as 
potential miRNA target genes (e.g. miRBase Targets database; [171]. Many pri-
miRNA transcripts are computationally predicted to undergo folding into elaborate 
stem-loop structures. In addition, computational algorithms have been developed to 
predict pre-miRNAs [186] and to search for homologous conserved miRNA genes 
in several animal species. Thus in this study several of these well established 
databases were used as a starting point to predict miRNAs targeting AQPs. The 
amount of data generated from these online depositories was huge (Table 3.1) and 
within human species itself over 500 miRNAs were predicted to target the AQP 
genes (supplementary Table 1).  
 
Since computational methods could result in false-positive predictions, target 
validation in biological system is inevitable to complete the study of target 
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prediction [247]. A reporter assay is the most common method used to check the 
interaction between miRNA and its target mRNA directly. In a standard reporter 
assay, the putative target sites are fused to a reporter construct (e.g. luciferase) and 
reporter expression is measured in the absence and presence of the cognate miRNA 
[205]. Regulation of AQPs 1, 2, 4 and 9 by miRNAs were shown using such 
reporter systems. Several miRNAs such as miR-103, -146a (AQP1), miR-125b, -
197 (AQP2) and miR-16, -17-5p and 125b (AQP4) were shown as potential 
regulators. Additional experimental techniques such as quantitative real-time PCR 
(qRT-PCR), western blot or immunocytochemistry were often performed to 
examine the reciprocal expression of predicted miRNA, mRNA target genes and 
protein levels [205, 207]. Thus several of these techniques were utilized throughout 
the course of this study to further strengthen the findings.    
 
7.2 Importance of regulating AQPs 1, 4 and 9 expression in the 
brain.  
The focus of the in vitro and in vivo studies performed, centred around AQPs 1, 4 
and 9. These three water channels are often studied in relation to brain pathologies 
such as trauma injury and ischemia. In this study, to test the efficacy of a miRNA 
in an in vivo system, an ischemic model was used. Many events are triggered in the 
brain in response to the disruption of blood flow [249]. The lack of oxygen causes 
ionic pump failure which in turn disrupts the maintenance of ionic gradients across 
cell membranes. This leads to the influx of Na
+
 into the cell and Cl
-
 follows. Water 
can follow the entry of these ions osmotically, and edema will be imminent. This 
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initial type of edema following ischemia is termed as “cytotoxic” edema. Cytotoxic 
edema causes cell death as the influx of water eventually ruptures the cell 
membrane, and leads to necrotic cell death. Since astrocytes outnumber neurons 20 




 into astrocytes is primarily responsible 
for cytotoxic edema [249].  
 
Morphological changes in neurons and astrocytes were noted within 30 minutes of 
cerebral occlusion [250]. However, compared to the neurons, astrocytes showed 
severe swelling, disintegration and nuclear pyknosis [250]. In addition astrocytes 
are involved in clearance of K
+
 ions and glutamate, which could also cause osmotic 
overload that in turn promotes water inflow. Although fluid influx into the cells 
does not result in any change in the brain volume, the observable increase in cell 
size results in an average reduction of the extracellular space from the normal 20% 
down to 4 to 10% [251]. The primary route of water movement has been known to 
be through the AQPs. Water intoxication studies, simulating cytotoxic edema, 
showed that compared to AQP4 null mice, the wild type mice exhibited extensive 
astrocyte swelling within 30 minutes. By the end of the hour, only 8% of the 
AQP4
+/+
 mice survived while 76 % of the AQP4
-/-
 mice remained alive [90].  
 
Since cytotoxic edema depletes the ions and water from the extracellular space, this 
establishes new osmotic gradients between the extracellular and intravascular space 




 ions and water, 
achieved by either increasing the expression of transcellular ion channels and 
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transporters and AQP water channels (resulting in ionic edema), or the opening of 
tight junctions between endothelial cells (resulting in vasogenic edema) permits the 
flux of solute and water down their concentration gradients [249-250]. Ionic and 
vasogenic edema occur in the context of altered endothelial cell permeability. 
However ionic edema is distinguished from vasogenic edema by the absence of 
large molecular proteins [253]. Ionic edema fluid is protein poor because tight 
junctions of the blood-brain barrier are intact. Vasogenic edema is often thought to 
occur at the late phase of cerebral edema when the integrity of the blood brain 
barrier (BBB) is compromised. On the other hand, changes in BBB integrity were 
seen as early as 4 hrs upon ischemia and were shown to last for weeks [254-255]. 
Focal cortical freeze injury is a well-established and highly reproducible model of 
vasogenic brain edema. Using AQP4 null mice models, it was shown that the 
expression of AQP4 was crucial in edema clearance [91]. AQP1 expression was 
increased after subarachnoid hemorrhage in human astrocytes [256] while 
intracerebral hemorrhage rodent models showed increased expression in the 
cortical endothelial cells [257]. 
 
Another predominant process known as programmed cell death or apoptosis is 
inevitable and occurs as a consequence of cerebral ischemia. Apoptosis, a highly 
regulated process that involves a complex cascade of events within the dying cell is 
thought to occur predominantly at the penumbra region. The severity of the 
detrimental effect following cerebral ischemia can be reduced by reducing the 
extent of cell death in this region. The key morphological changes observed in an 
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apoptotic cell are cell shrinkage, also termed as apoptotic volume decrease (AVD), 
nuclear condensation and DNA fragmentation [258-259]. Several studies have 
shown that the initial influx of sodium ions into a cell and the efflux of potassium 
ions out of the cell are crucial for apoptosis. Changes in ion concentrations results 
in the changes in the cellular volume of the cell. Efflux of potassium ions out of the 
cell creates a hypertonic environment which results in the flow of water out of the 
cell, a process from which the term AVD arose. AVD has been considered crucial 
in allowing the cell to attain the required intracellular ionic concentration which is 
important in triggering the caspase enzymes. AVD is thought to occur via AQPs 
present in the cells. A few studies have shown that these water channels exhibit 
increased expression and pro-longed half life in cells undergoing hypertonic stress 
[260] and sterically blocking of these AQP1 helped to rescue cells from cell 
shrinkage, loss of mitochondrial permeability and caspase 3 activation [261].  
 
Unlike AQP1 and AQP4 which are implicated in contributing to the formation of 
the edema itself. AQP9 is considered to play a key role in cellular energy balance. 
Changes in AQP9 expression was seen in ischemic models. AQP9 protein was 
upregulated on reactive astrocytes in the border of the infarct after transient middle 
cerebral artery occlusion in mice [88]. In contrast to AQP4, AQP9 showed a 
significant induction at 24 hrs, with expression increasing gradually with time, 
without correlation to swelling [89], suggesting that AQP9 does not play a role in 
edema formation after transient cerebral ischemia in the mouse. Interestingly 
Hwang et al. [262] reported that AQP9 expression was induced at 6 hrs hours after 
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occlusion in the pyramidal neurons. Pyramidal neurons do not express AQP9 
channel in physiological conditions. These findings suggest that AQP9 expression 
was affected by metabolic challenges (decrease of glucose and oxygen) [263]. It 
has been postulated that the increase the permeability of AQP9 during lactic 
acidosis is to facilitate the uptake of excess lactate by astrocytes. They are also 
thought to facilitate shuttling of lactate between the AQP9 and the neurons which 
can be used as an energy substrate [264].  
 
In our ischemic profile AQP9 expression remained low at the early phases of 
ischemia for up to 3 hrs. siRNA based studies revealed that a downregulation of 
AQP9 resulted in increased cell death. Since AQP9 expression is considered crucial 
for cell viability, the use of a regulator to activate AQP9 expression could improve 
survival outcome. In this study, based on changes in miRNA profiles in ischemic 
rat models and reporter assays, miR-22 was identified as a possible regulator of 
AQP9 expression. Further work needs to be done to identify whether in vivo 
modulation of miR-22 using pre miR-22 could result in upregulation of AQP9 at 
the early timepoints. Interestingly a sharp peak in AQP9 mRNA and protein 
expression was observed at the 12 hrs time point which was followed by a sudden 
drop in at 18 hrs.  A study by Lim et al [265] on miRNAs in ischemic stroke 
revealed a siginifcant change in the general miRNA expression in rats at the 12 hrs 
timepoint. Clustering analysis showed that the early timepoints of 0, 1, 3 and 6 hrs 
clustered separately from the later timepoints of 12, 18 and 24 hrs. Thus this 
massive change in total cellular miRNA expression could have resulted in the sharp 
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increase in AQP9 expression seen at 12 hrs.  However it is not understood why the 
18 hrs timepoint resulted in such a drastic drop in AQP9 expression and how it 
contributes to the progression of ischemia. Yet with the use of miR-22, the 
functional importance of this event can be determined in further studies.  
 
Thus while the extent of ischemic damage in the brain depends on multiple factors, 
AQPs seem to play an important role. Given the implication of AQPs in AVD as 
well as cerebral edema, modulating their expression could possibly facilitate the 
rescuing of neurons perhaps via the termination of the apoptotic cascade or via 
inhibition of water uptake [261]. This will result in reducing the area of the 
penumbra region and have better neurological outcomes for patients. Several 
studies have implicated a role for AQP 1, 4 and 9 in cerebral edema, while most of 
them had used knockout mice models and siRNA based transfection techniques 
against AQPs 1 & 4, none have studied the silencing effects of AQP9. The miRNA 
modulators identified in this study can serve as potential regulators of AQPs 1, 4 
and 9. In particular, miR-320a was identified as a common regulator of AQPs 1 and 
4. Modulation of miR-320a reflected changes in AQP1 and AQP4 mRNA as well 
as protein expression in both in vitro and in vivo conditions (Chapter 4). The use of 
miR-320a was tested in an ischemic in vivo model with beneficial outcomes in 




7.3 Upregulation of AQP1 and AQP4 expression in edema – a 
survival mechanism?  
Many of the studies seen so far not only highlight the importance of regulating 
AQPs 1, 4 and 9 in the brain, but they also show the temporal evolution of AQPs 1, 
4 and 9 expression differs between the types of stroke, the various stages and 
timepoints. For instance, Kikuchi et al [266] reported that edaravone attenuates 
cerebral ischemic injury by suppressing AQP4 expression while Li et al [267] 
showed neuregulin administration eased the ischemic injury by upregulating AQP4 
expression. Yet both studies noted a significant reduction in cerebral edema. Given 
the bi-directional nature of these water channels, it is often not clear whether their 
increased expression contributes or alleviates cerebral edema.  
 
Enhanced expression of AQP1 is observed in pathological states and it is thought to 
augment susceptibility to pathological volume changes and promote edema 
formation. Increased AQP1 gene and protein expression was also observed in 
cerebral edema induced by traumatic brain injury [268].  Even though AQP1 in the 
choroid plexus epithelia contributes to only 25% of the total cerebrospinal fluid 
production, diminishing its expression improved survival rates drastically from 
25% to 87% in ischemic rats [92]. Furthermore reduction in AQP expression has 
been reported to enhance the resistance of cells against apoptotic stimulus [268]. 
During apoptosis cellular volume decrease is thought to be mediated via AQP1 
[261]. The initial upregulation of AQP1 expression followed by an inactivation of 
the water channel is considered crucial for the proper progression of apoptosis. This 
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suggests that AQP1 expression is biphasic and highlights the need for a modulator 
that could alter its expression accordingly.  
 
Changes in AQP4 expression with respect to cerebral edema were reported in 
several studies. These studies report a peak in the accumulation of cerebral water 
content which can occur anywhere from 24 hrs to 3 days post MCAo [90, 269].  
Ribeiro et al [96] reported a biphasic trend where the water content peaked at 1 and 
4 hrs post MCAo. Interestingly although a range of timings have been reported 
these observations correlated with the increase in AQP4 gene expression levels. 
These authors proposed that the early upregulation of AQP4 is associated with the 
increase in cerebral edema. Moreover, AQP4 null mice exhibited 35% reduction in 
cerebral water content upon the induction of ischemia [96].  
 
Although the use of knockout models implicated different roles for AQPs in 
cytotoxic and vasogenic edema [90-93], a complete wipe-out of the genes does not 
reflect that of a physiological environment. In a normal or dieased situation, the 
expression of these AQPs are regulated. Thus this study confers the advantage of 
understanding the roles of AQPs, particularly AQP1 and AQP4 in edema formation 
by regulating their expression with miRNAs. In our study we show that 
introduction of anti miR-320a causes a further increase in AQP1 and AQP4 
expression with a consequent reduction in the infarct volume and an introduction of 
pre-miR-320a results in an opposite effect of reducing AQP expression and 
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increasing the infarct volume. Hence the increase in AQP expression at least at the 
24 hrs  reperfusion time point appears to be a part of survival and recovery process.  
 
Interestingly, a recent study by Hirt et al [212] proposed that the early upregulation 
of AQP4 could indeed be a survival mechanism to reduce edema. While thrombin 
preconditioning had no effect on AQP4 expression in normal rats, upon ischemia 
these rats exhibited increased AQP4 expression and reduced cerebral edema, 
suggesting that AQP4 increase might be facilitating edema clearance [212]. In a 
study using a neutral anticoagulant secretory phospholipase A2 (nPLA) from the 
venom of Naja sputatrix as a neurotprotectant, it has been shown that 
administration of nPLA reduced infarct volume in rats subjected to focal transient 
cerebral ischemia. nPLA also alleviated the neuronal damage in organotypic 
hippocampal slices subjected to oxygen glucose deprivation [270]. The authors also 
reported an increase in expression of AQP4 together with several anti-apoptotic and 
pro-survival genes.  
 
Furthermore upregulation in AQP1 and AQP4 expression levels was observed 
when MK-801 was administered to MCAo ischemic models [270]. MK-801 is an 
NMDA antagonist widely used in animal models to rescue or reduce cerebral 
infarct and mimic recovery [271]. Ischemic rats injected with MK-801 exhibited 
increased AQP1 and AQP4 profiles with reduced miR-320a expression, paralleling 
expression patterns of those injected with anti miR-320a. These findings suggest 
that upregulation of AQP1 and AQP4 could possibly assist in edema clearance. A 
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recent report on ischemic human patients with good recovery and good clinical 
outcome (modified Rankin Scale, mRS ≤ 2) also showed a reduction in miR-320 
expression when compared to patients with poor clinical outcome (mRS > 2) [272].  
 
7.4 Other targets of miR-320a and their possible implications  
Administration of anti miR-320a was found to be beneficial in ischemic rats with a 
reduction in infarct volume. While we show that miR-320a can be used to modulate 
the expression of AQP1 and AQP4, one has to accept that introduction of a miRNA 
would have a widespread impact on several other genes. Using miRNApath to 
gauge the impact of miR-320a modulation revealed about 145 pathways being 
affected with as many as 1500 target genes [233-234]. To narrow down the list 22 
pathways (in relation to ischemia) were selected [234]. Within these selected 
pathways 172 genes were predicted to be targets of miR-320a [233].  Expression 
profiles of these 172 predicted targets were compared with our anti and pre miR-
320a array. 77 genes (including AQP1 and AQP4) were found to be upregulated in 
response to anti miR-320a while they were downregulated in response to pre miR-
320a treatments, suggesting that these genes may be affected by miR-320a via the 
RNAi mechanism. From the results shown in Table 4.6, one could hypothesize 
several possible mechanisms that could have aided in the reduction of infarct 
volume due to anti miR-320a administration. 
 
Genes such as protein kinase C gamma (PRKCG) and map kinase 7 (ERK5) and 
tubulin (DUSP4) were upregulated in response to anti miR-320a (Figure 7.1). 
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PRKCG and ERK5 have been reported to target gap junction protein connexin and 
affect its gating status [273]. Dephosphorylation of connexins opens their 
configuration and allows transfer of molecules as well as signaling information 
between adjacent cells whereas phosphorylation of connexins closes their 
conformation, marking them for degradation and internalization. 
Dephosphorylation of connexins during ischemia has been reported and this open 
gating state is thought to propagate ischemic injury. Studies have shown that the 
uncoupling of connexins reduces ischemia related injuries [274]. Upregulation of 
PRKCG and ERK5 by miR-320a might play a role in uncoupling connexins and 
thus rendering protection during ischemia. Cytoskeletal protein DUSP4 interacts 
with Connexin channels and is considered important for translocation of the gap 
junction protein. The increase in DUSP4 could be due to the need for the 
association and internalization of inactive connexin proteins [273]. Although co-
localization of connexin with AQP4 has been reported, the extent of interaction 
between these two proteins is not clear [275-276].  
 
Expression of genes such as janus kinase (JAK) and receptor tyrosine kinase 
(ERBB2) were also increased in response of anti miR-320a. These genes are 
involved in signaling pathways and have an indirect effect on serine/threonine 
protein kinase (AKT) (Figure 7.1). AKT also known as protein kinase B is 
implicated in cell survival, induction of protein production and proliferation. 
ERBB2 interacts with growth factor receptor bound protein-2 (GRB2) to stimulate 
cellular proliferation. Both ERBB2 and GRB2 are predicted targets of miR-320a. 
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Both ERBB2 and GRB2 expression are considered crucial for activation of AKT 
mediated survival pathways [277]. AKT pathway activation can inhibit pro-
apoptotic proteins such as Bcl-2-associated death promoter (BAD) and caspase 9 
(CASP9) and thus promote survival. Influx of Ca
2+
 ions during ischemia directly or 
indirectly triggers a variety of cell responses, one of which is the activation of the 
inflammatory pathway. Activation of AKT pathway results in the inhibition of 
glycogen synthase kinase 3 (GSK-3) which can enhance the operation of various
 
pro-inflammatory signaling molecules [278]. Thus increasing ERBB2 and GRB2 
expression using miR-320a not only enhances proliferation of ischemic cells but it 
also suppresses the inflammatory pathway possibly via AKT activation. 
Furthermore ERBB2 activation is often associated with cell migration, a process 
where AQP1 and AQP4 are also implicated [83, 276]. Increased expression of 
AQP1 and AQP4 are crucial for the formation of cellular processes, subsequent cell 
migration and proliferation [83, 276]. 
 
Several cytoskeletal proteins that aid cell migration or processes such as actin 
remodeling and axon guidance were also upregulated due to anti miR-320a (Figure 
7.1). Some of these proteins with predicted target regions for miR-320a are cofilin 
(CFL1), slit homolog 3 protein (SLIT3) and filamin-A (FLNA). SLIT3 is a 
repulsive axon guidance molecule often expressed and secreted by both endothelial 
cells and vascular smooth muscle cells. They are considered crucial for promoting 
angiogenesis for they have been shown to stimulate blood vessel growth in vivo. 
Apart from angiogenesis SLIT3 also stimulates endothelial cell proliferation and 
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promotes cell motility and chemotaxis [279]. Extensive AQP1 expression has also 
been reported in vascular endothelia. AQP1 null mice transplanted with cerebral 
tumors exhibited reduced vascularity and widespread necrosis suggesting that 
AQP1 expression is crucial for proper angiogensis. The fact that anti miR-320a 
upregulates both AQP1 and SLIT3 gene suggests that ischemic recovery process 
via angiogensis could have been triggered. Angiogenesis requires the controlled 
remodeling of the cytoskeleton and this is evident from the upregulation of 
cytoskeletal proteins such as DUSP4, FLNA and CFL1. FLNA regulates 
reorganization of the actin cytoskeleton by interacting with integrins which was 
also upregulated due to anti miR-320a introduction. Upregulation of these genes 
with the removal of miR-320a in ischemic samples at 24 hrs of reperfusion suggest 









Figure 7.1: Possible pathways/genes affected by miR-320a modulation. Compilation of possible genes affected by miR-320a 
modulation was adapted from KEGG Pathway Database.  












































































7.5 Transcriptional modulation of AQP4 
Apart from translational modulation, miRNAs are also capable of transcriptional 
regulation [154-157]. miRNA-373 has been found to enhance gene expression by 
binding to complementary sequences on the promoter of the E-cadherin gene [156]. 
Li et al [146] demonstrated small RNA induced gene activation (RNAa) using 
synthetic dsRNAs that could target promoter sites and stimulate gene expression. 
The same phenomenon has also been reported by Janowski et al [157].  The crucial 
role played by AQP4 in the brain is well known. Two predominant AQP4 
transcripts (M1 and M23) have been shown to be expressed in the human brain and 
the presence of alternative promoters suggests differential regulation of these two 
isoforms [29, 237]. Yet little is known about the physiological roles of both the 
AQP4 isoforms and most studies do not attempt to differentiate between their 
expression. However a few reports have highlighted the significance of AQP4 M1 
isoform with respect to cerebral water balance. Hirt et al [212] reported that the 
AQP4 M1 isoform significantly increased during conditions such as brain injuries 
and ischemia in edematous tissue. They reported that while the AQP4 M23 
expression was higher under normal conditions, during ischemia the AQP4 M1 
expression increased significantly whereas the AQP4 M23 expression was 
undetermined [206]. What triggers this shift is not understood. Expression of M1 is 
possibly crucial in cerebral homeostasis as its single channel water permeability 
rates are much higher than M23. Furthermore M23 is often implicated with 
structural organisation of the membrane [236, 280]. 
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This study identified the presence of 5 miRNAs (hsa-miR-668, - 1280, -130a, -152, 
and -939) that could function as regulators of the AQP4 M1 promoter activity. Of 
the five, miR-1280 was shown to be a weak activator and miR-130a was seen as a 
very strong repressor. Interestingly, of the five miRNAs tested in this study, only 
miR-130a was conserved in mammals (rat). Expression of AQP4 is biphasic and it 
is often reported to be upregulated at various ischemic timepoints [212, 281] 
whereas a recent report by Lim et al [265] showed that miR-130a was mostly down 
regulated during ischemia. These findings strengthen the observations that miR-
130a plays an important role and can be used to selectively modulate the 
transcription of AQP4 M1. It would be interesting to further study the 
consequences of this modulation with respect to ischemia and cytotoxic edema 
formation since an increase in AQP4 expression at early timepoints of ischemia is 
considered detrimental.  
 
7.6 Conclusion and future prospects of the study. 
In this study, miRNA based endogenous regulators of AQPs 1, 2, 4, and 9 were 
identified. Particular interest was paid to AQPs 1, 4 and 9 as their expression was 
highly implicated in cerebral edema. miR-320a was established as a common 
regulator of AQP1 and AQP4, where it could can directly modulate AQP1 and 
AQP4 gene expression in both in vitro and in vivo conditions. Administration of 
anti miR-320a in ischemic animal models caused an increase in AQP1 and 4 
expression and brought about a reduction in infarct volume. This highlights the 
applicability and potential in miRNA based therapeutics. Apart from translational 
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modulation, transcriptional modulation, a relatively new phenomenon, was shown 
in this study. Using miR-130a, differential regulation of the AQP4 transcripts M1 
and M23 was shown. Furthermore modulation of the promoter activity was shown 
to be possible even in the presence of other transcriptional regulators such as E 
boxes.  
 
Although in this study several miRNA modulators against AQP genes were 
identified, only miR-320a was tested in an in vivo disease setting. Further studies 
are needed to test the applicability of the other miRNAs such as miR-103, -146a 
(AQP1), miR-125b, -197 (AQP2) and miR-16, -17-5p and -125b (AQP4). miR-
146a was seen as a strong regulator of AQP1. However its expression was not 
detected in astrocytoma cells. It was expressed in the kidney cell line, Caki. Thus 
the potential of using miR-146a specifically to manipulate kidney AQPs exists. A 
common regulator such as miR-125b against AQPs 2 and 4 can also be tested in a 
kidney model.  
 
The study on miR-130a established it as a transcriptional modulator of AQP4. 
Using in vitro real-time studies differential regulation of the M1 transcript was 
shown. Hirt et al [212] reported that upregulation of AQP4 was beneficial during 
ischemia and the M1 isoform could play a more important role. Thus the miR-130a 
study can be extended into in vivo settings to see its efficacy in specifically 
regulating AQP4 M1 expression during ischemia. Like miR-320a, the impact miR-
130a modulation on the whole cellular gene expression needs to be studied as well. 
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miRNA based transcriptional modulation is also a relatively new area and the 
mechanism by which the miRNA gets transported back into the nucleus is 
unknown. Thus this also is an area that needs to be explored.  
 
Although the focus of this study centred around AQPs 1, 4 and 9, further studies 
can be done to identify miRNA based regulators for all the other AQPs. The 13 
AQPs can be classified according to their permeability characteristics (classical vs 
aquaglyceroporins), localisation (plasma membrane or intracellular), tissue 
distribution (brain or kidneys) or even disease pathologies (renal diseases, obesity). 
Thus based on these classifications a subset of AQPs can be chosen for further 
studies. This study identified possible miRNA based regulators for AQPs 1, 2 and 
4. Apart from AQPs 1, and 4, expression of several other water channels such as 
AQP6 and AQP11 has also been reported in the kidneys. Although an 
aquaglyceroporin, AQP3 is also implicated in water transport in kidney 
functioning. Hence identifying modulators for these AQPs will be of much use in 
terms of regulating kidney water channels. AQP7, another aquaglyceroporin is 
thought to contribute to obesity problems such as adipocyte fat accumulation. 
Furthermore it seems to work in conjunction with the other aquaglyceroporin, 
AQP9. Plasma glycerol released from adipocytes via AQP7 is taken up via AQP9 
into the liver for gluconeogenesis. In fact, expression of hepatic AQP9 in mice is 
up-regulated upon fasting and down-regulated upon refeeding [57]. Since 
metabolic diseases are of primary concern in many societies, the potential of 




The functional roles of several AQPs such as AQP6, AQP8 and AQP12 are yet to 
be determined as well. Another area where the study could be extended is to 
identify modulators for these AQPs. With the availability of miRNA based 


































8 References  
1. Sidel VW, Solomon AK. Entrance of water into human red cells under an 
osmotic pressure gradient. J. Gen. Physio. (1957) 41: 243–257. 
2. Agre P. Aquaporin water channels. Biosci. Reports (2004) 24:127-163. 
3. Agre P, Sasaki S, Chrispeels MJ. Aquaporins: a family of water channel 
proteins. Am. J. Physiol. Renal Physiol. (1993) 265:463 -476. 
4. Noda Y, Sohara E, Ohta E, Sasaki S. Aquaporins in kidney pathophysiology. 
Nat Rev Nephrol. (2010) 6:168-78.  
5. Verkman AS. Aquaporins: translating bench research to human disease. J. Exp. 
Biol. (2009) 212: 1707-1715. 
6. Yasui M, Hazama A, Kwon TH, Nielsen S, Guggino WB, Agre P. Rapid gating 
and anion permeability of an intracellular aquaporin. Nat. (1999) 402:184–187. 
7. Jahn TP, Moller ALB, Zeuthen T, Holm LM, Klarke DA, Mohsin B, 
Kuhlbrandt W,  Schjoerring JK. Aquaporin homologues in plants and mammals 
transport ammonia. FEBS Lett. (2004) 574: 31–36 
8. Ma T, Yang B, Verkman AS. Cloning of a novel water and urea-permeable 
aquaporin from mouse expressed strongly in colon, placenta, liver, and heart. 
Biochem. Biophys. Res. Commun. (1997) 240: 324–328. 
9. Ishibashi K. New members of mammalian aquaporins: AQP10-AQP12. Handb 
Exp Pharmacol. (2009) 190: 251-262.  
10. Gorelick DA, Praetorius J, Tsunenari T, Nielsen S, Agre P. Aquaporin-11: A 
channel protein lacking apparent transport function expressed in brain. BMC 
Biochem. (2006) 7:14.  
11. Yakata K, Hiroaki Y, Ishibashi K, Sohara E, Sasaki S, Mitsuoka K, Fujiyoshi 
Y. Aquaporin-11 containing a divergent NPA motif has normal water channel 
activity. Biochim Biophys Acta. (2007) 1768: 688–693 
12. Ohta E, Itoh T, Nemoto T, Kumagai J, Ko SB, Ishibashi K, Ohno M, Uchida K, 
Ohta A, Sohara E, Uchida S, Sasaki S, Rai T. Pancreas-specific aquaporin 12 
null mice showed increased susceptibility to caerulein-induced acute 
pancreatitis. Am J Physiol Cell Physiol. (2009) 297: C1368-1378.  
13. Ishibashi K, Hara S, Kondo S. Aquaporin water channels in mammals. Clin. 
Exp. Nephrol. (2009) 13:107–117. 
259 
 
14. Mulders SM, Preston GM, Deen PM, Guggino WB, Van Os CH, Agre P. Water 
channel properties of major intrinsic protein of lens. J. Biol. Chem. (1995) 
270:9010–9016.  
15. Farjo R, Peterson WM, Naash MI. Expression profiling after retinal detachment 
and reattachment: a possible role for aquaporin 0. Invest. Ophthalmol. Vis. Sci. 
(2008) 49: 511–521. 
16. Yang B, Fukuda N, van Hoek A, Matthay MA, Ma T, Verkman AS. Carbon 
dioxide permeability of aquaporin-1 measured in erythrocytes and lung of 
aquaporin-1 null mice and in reconstituted proteoliposomes. J. Biol. Chem. 
(2000) 275: 2686 – 2692.  
17. Zhang R, Skach W, Hasegawa H, van Hoek AN, Verkman AS. Cloning, 
functional analysis and cell localization of a kidney proximal tubule water 
transporter homologous to CHIP28. J Cell Biol. (1993) 120:359-369. 
18. Brown D, Verbavatz JM, Valenti G, Lui B, Sabolic I. Localization of the 
CHIP28 water channel in reabsorptive segments of the rat male reproductive 
tract. Eur. J. Cell Biol. (1993) 61:264–273. 
19. Nielsen S, Smith BL, Christensen EI, Agre P. Distribution of the aquaporin 
CHIP in secretory and reabsorptive epithelia and capillary endothelia. Proc. 
Natl. Acad. Sci. USA. (1993)  90:7275–7279. 
20. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and 
expression of apical membrane water channel of rat kidney collecting tubule. 
Nat. (1993) 361:549–552.  
21. Nielsen S, Digiovanni SR, Christensen EI, Knepper MA, Harris HW. Cellular 
and subcellular immunolocalization of vasopressin-regulated water channel in 
rat kidney. Proc. Natl. Acad. Sci. USA. (1993) 90:11663–11667.  
22. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. 
Vasopressin increases water permeability of kidney collecting duct by inducing 
translocation of aquaporin-CD water channels to plasma membrane. Proc. Natl. 
Acad. Sci. USA. (1995) 92:1013–1017. 
23. Stevens AL, Breton S, Gustafson CE, Bouley R, Nelson RD, Kohan DE and 
Brown D. Aquaporin 2 is a vasopressin-independent, constitutive apical 




24. Sawada S, Takeda T, Kitano H, Takeuchi S, Kakigi A, Azuma H. Aquaporin-2 
regulation by vasopressin in the rat inner ear. Neuroreport. (2002) 13:1127-
1129. 
25. Ishibashi K, Sasaki S, Fushimi K, Uchida S, Kuwahara M, Saito H, Furukawa 
T, Nakajima K, Yamaguchi Y, Gojobori T. Molecular cloning and expression 
of a member of the aquaporin family with permeability to glycerol and urea in 
addition to water expressed at the basolateral membrane of kidney collecting 
duct cells. Proc. Natl. Acad. Sci. USA (1994) 91:6269–6273.  
26. Matsuzaki T, Suzuki T, Koyama H, Tanaka S, Takata K. Water channel protein 
AQP3 is present in epithelia exposed to the environment of possible water loss. 
J. Histochem. Cytochem. (1999) 47:1275–1286.  
27. King LS, Nielsen S, Agre P. Aquaporins in complex tissues. I. Developmental 
patterns in respiratory and glandular tissues of rat. Am. J. Physiol. Gastrointest. 
Liver Physiol.  (1997) 273: 1541–1548.  
28. Hamann S, Zeuthen T, La Cour M, Nagelhus EA, Ottersen OP, Agre P, Nielsen 
S. Aquaporins in complex tissues: Distribution of aquaporins 1–5 in human and 
rat eye. Am. J. Physiol. Cell Physiol. (1998) 274: 1332–1345. 
29. Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P. Molecular 
characterization of an aquaporin cDNA from brain: candidate osmoreceptor and 
regulator of water balance. Proc. Natl. Acad. Sci. USA (1994) 91:13052–13056.  
30. Frigeri A, Nicchia GP, Verbavatz JM, Valenti G, Svelto M. Expression of 
Aquaporin-4 in fast-twitch fibers of mammalian skeletal muscle. J. Clin. Invest. 
(1998) 102: 695–703. 
31. Frigeri A, Gropper MA, Turck CW, Verkman AS. Immunolocalization of the 
mercurial-insensitive water channel and glycerol intrinsic protein in epithelial 
cell plasma membranes. Proc. Natl. Acad. Sci. USA (1995) 92: 4328–4331. 
32. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen 
OP. Specialized membrane domains for water transport in glial cells: high-
resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci.  
(1997) 17: 171–180.  
33. King LS, Agre P. Pathophysiology of the aquaporin water channels. Annu. Rev. 
Physiol. (1996) 58: 619–648.  
261 
 
34. Nielsen S, King LS, Christensen BM, Agre P. Aquaporins in complex tissues. 
II. Subcellular distribution in respiratory and glandular tissues of rat. Am. J. 
Physiol. (1997) 273: 1549–1561. 
35. Matsuzaki T, Suzuki T, Koyama H, Tanaka S, Takata K. Aquaporin-5 (AQP5), 
a water channel protein, in the rat salivary and lacrimal glands: 
immunolocalization and effect of secretory stimulation. Cell Tissue Res. (1999) 
295: 513–521.  
36. Matsuzaki T, Tajika Y, Suzuki T, Aoki T, Hagiwara H, Takata K. 
Immunolocalization of water channel, aquaporin-5 (AQP5) in the rat digestive 
system. Arch.  Histol. Cytol. (2003)  66: 307–315. 
37. Parvin MN, Tsumura K, Akamatsu T, Kanamorin N, Hosoi K. Expression and 
localization of AQP5 in the stomach and duodenum of the rat. Biochim. 
Biophys. Acta (2002) 1542: 116–124. 
38. Liu H, Hooper SB, Arumugam A, Dawson N, Ferraro T, Jeyaseelan K, Thiel A, 
Koukoulas I, Wintour EM. Aquaporin gene expression and regulation in the 
ovine fetal lung. J. Physiol. (2003) 551: 503-514. 
39. Yasui M, Kwon TH, Knepper MA, Nielsen S, Agre P. Aquaporin-6: An 
intracellular vesicle water channel protein in renal epithelia. Proc. Natl. Acad. 
Sci. USA (1999) 96:  5808–5813. 
40. Beitz E, Liu K, Ikeda M, Guggino WB, Agre P, Yasui M. Determinants of 
AQP6 trafficking to intracellular sites versus the plasma membrane in 
transfected mammalian cells. Biol. Cell. (2006) 98:101–109  
41. Ishibashi K, Kuwahara M, Gu Y, Kageyama Y, Tohsaka A, Suzuki F, Marumo 
F, Sasaki S. Cloning and functional expression of a new water channel 
abundantly expressed in the testis permeable to water, glycerol, and urea. J. 
Biol. Chem (1997) 272: 20782–20786.  
42. Kuriyama H, Kawamoto S, Ishida N, Ohno I, Mita S, Matsuzawa Y, Matsubara 
K, Okubo K. Molecular cloning and expression of a novel human aquaporin 
from adipose tissue with glycerol permeability. Biochem. Biophys. Res. 
Commun. (1997) 241: 53–58.  
43. Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P, Rosen BP. Arsenite 
transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. 
Sci. USA (2002) 99: 6053–6058. 
262 
 
44. Laforenza U, Gastaldi G, Grazioli M, Cova E, Tritto S, Faelli A, Calamita G, 
Ventura U. Expression and immunolocalization of aquaporin-7 in rat 
gastrointestinal tract. Biol. Cell (2005) 97: 605–613.  
45. Koyama Y, Yamamoto T, Kondo D, Funaki H, Yaoita E, Kawasaki K, Sato N, 
Hatakeyama K, Kihara I. Molecular cloning of a new aquaporin from rat 
pancreas and liver. J. Biol. Chem. (1997) 272: 30329–30333.  
46. Ishibashi K, Kuwahara M, Kageyama Y, Tohsaka A, Marumo F, Sasaki S. 
Cloning and functional expression of a second new aquaporin abundantly 
expressed in testis. Biochem. Biophys. Res. Commun. (1997) 237: 714–718. 
47. Elkjaer ML, Nejsum LN, Gresz V, Kwon TH, Jensen UB, Frøkiaer J, Nielsen S. 
Immunolocalization of aquaporin-8 in rat kidney, gastrointestinal tract, testis, 
and airways. Am. J. Physiol. Renal Physiol. (2001) 281:1047–1057. 
48. Calamita G, Ferri D, Gena P, Liquori GE, Cavalier A, Thomas D, Svelto M. 
The inner mitochondrial membrane has aquaporin-8 water channels and is 
highly permeable to water. J. Biol. Chem. (2005) 280: 17149-17153.  
49. Ferri D, Mazzone A, Liquori GE, Cassano G, Svelto M, Calamita G. Ontogeny, 
distribution, and possible functional implications of an unusual aquaporin, 
AQP8, in mouse liver. Hepatology. (2003) 38: 947-57.  
50. Calamita G, Ferri D, Bazzini C, Mazzone A, Bottà G, Liquori GE, Paulmichl 
M, Portincasa P, Meyer G, Svelto M. Expression and subcellular localization of 
the AQP8 and AQP1 water channels in the mouse gall-bladder epithelium Biol. 
Cell. (2005) 97: 415–423 
51. Yang B, Zhao D, Solenove E, Verkman AS. Evidence from knockout mice 
against physiologically significant aquaporin-8 facilitated ammonia transport. 
Am. J. Physiol. Cell Physiol. (2006) 291: C417-423 
52. Ishibashi K, Kuwahara M, Gu Y, Tanaka Y, Marumo F, Sasaki S. Cloning and 
functional expression of a new aquaporin (AQP9) abundantly expressed in the 
peripheral leukocytes permeable to water and urea, but not to glycerol. 
Biochem. Biophys. Res. Commun. (1998) 244: 268–274.  
53. Tsukaguchi H, Shayakul C, Berger UV, Mackenzie B, Devidas S, Guggino 
WB, van Hoek AN, Hediger MA. Molecular characterization of a broad 
selectivity neutral solute channel. J. Biol. Chem. (1998) 273: 24737–24743.  
54. Amiry-Moghaddam M, Lindland H, Zelenin S, Roberg B A, Gundersen BB, 
Petersen P, Rinvik R, Torgner IA, Ottersen OP.
 
Brain mitochondria contain 
263 
 
aquaporin water channels: evidence
 
for the expression of a short AQP9 isoform 
in the inner mitochondrial
 
membrane. The FASEB Journal (2005) 19: 1459-
1467 
55. Yang B, Zhao D, Verkman AS. Evidence against functionally significant 
aquaporin expression in mitochondria. J Biol Chem. (2006) 281:16202-16206.   
56. Okada S, Misaka T, Matsumoto I, Watanabe H, Abe K. Aquaporin-9 is 
expressed in a mucus-secreting goblet cell subset in the small intestine. FEBS 
Lett. (2003) 540: 157–162.  
57. Kuriyama H, Shimomurai I, Kishida K, Kondo H, Furuyama N, Nishizawa H, 
Maeda N, Matsuda M, Nagaretani H, Kihara S, Nakamura T, Tochino Y, 
Funahashi T, Matsuzawa Y. Coordinated regulation of fat-specific and liver-
specific glycerol channels, aquaporin adipose and aquaporin 9. Diabetes (2005) 
51:2915–2921. 
58. Ishibashi K, Morinaga T, Kuwahara M, Sasaki S, Imai M. Cloning and 
identification of a new member of water channel (AQP10) as an 
aquaglyceroporin. Biochim. Biophys. Acta (2002) 1576: 335–340. 
59. Hatakeyama K, Yamamoto T. Cloning of a new aquaporin (AQP10) abundantly 
expressed in duodenum and jejunum. Biochem. Biophys. Res. Commun. (2001) 
287: 814-819. 
60. Li H, Kamie J, Morishita Y, Yoshida Y, Yaoita E, Ishibashi K, Yamamoto T. 
Expression and localization of two isoforms of AQP10 in human small 
intestine. Biol. Cell (2005) 97: 823–829. 
61. Ishibashi K, Kuwahara M, Kageyama Y, Sasaki S, Suzuki M, Imai M. 
Molecular cloning of a new aquaporin superfamily in mammals: AQPX1 and 
AQPX2. In S. Hohmann and S. Nielsen (ed.), Molecular biology and 
physiology of water and solute transport. Kluwer Academic/Plenum Publishers, 
New York, 123–126. (2002) 
62. Morishita Y, Matsuzaki T, Hara-Chikuma M, Andoo A, Shimono M, Matsuki 
A, Kobayashi K, Ikeda M, Yamamoto T, Verkman A, Kusano E, Ookawara S, 
Takata K, Sasaki S, Ishibashi K. Disruption of Aquaporin-11 Produces 
Polycystic Kidneys following Vacuolization of the Proximal Tubule. Mol. Cell 
Biol. (2005) 25:7770–7779. 
264 
 
63. Itoh T, Rai T, Kuwahara M, Ko SB, Uchida S, Sasaki S, Ishibashi K. 
Identification of a novel aquaporin, AQP12, expressed in pancreatic acinar cells 
Biochem. Biophys. Res. Commun. (2005) 330: 832–838 
64. Preston GM, Agre P. Isolation of the cDNA for erythrocyte integral membrane 
protein of 28 kDa: member of an ancient channel family. Proc. Natl. Acad. Sci. 
USA (1991) 88:11110–11114. 
65. Stamer WD, Snyder RW, Regan JW. Characterization of the transmembrane 
orientation of aquaporin-1 using antibodies to recombinant fusion proteins. 
Biochem. (1996) 35:16313–16318.  
66. Ishibashi K. Aquaporin subfamily with unusual NPA boxes. Biochim. Biophys. 
Acta – Biomemb. (2006) 1758: 989–993 
67. Verbavatz JM, Brown D, Sabolic I, Velanti G, Ausiello DA, Van HoeK AN, 
Ma T, Verkman AS. Tetrameric assembly of CHIP28 water channels in 
liposomes and cell membranes: a freeze-fracture study. J. Cell Biol. (1993) 
123:605–618. 
68. Kong Y, Ma J. Dynamic mechanisms of the membrane water channel 
aquaporin-1 (AQP1). Proc. Natl. Acad. Sci. USA (2000) 98:14345–14349.  
69. De Groot BL, Grubmuller H. Water permeation across biological membranes: 
mechanism and dynamics of Aquaporin-1 and GlpF. Science (2001) 294: 2353 
– 2357.  
70. Wu B, Beitz E. Aquaporins with selectivity for unconventional permeants. Cell. 
Mol. Life Sci. (2007) 64: 2413 – 2421 
71. Beitz E, Wu B, Holm LM, Schultz JE, Zeuthen T. Point mutations in the 
aromatic/arginine region in aquaporin 1 allow passage of urea, glycerol, 
ammonia, and protons. Proc. Natl. Acad. Sci. USA (2006) 103: 269–274. 
72. Stroud RM, Miercke L J, O‟Connell J, Khademi S, Lee JK, Remis J, Harries W, 
Robles Y, Akhavan D. Glycerol facilitator GlpF and the associated aquaporin 
familyof channels. Curr. Opin. Struct. Biol. (2003) 13: 424 – 431. 
73. Ikeda M, Beitz E, Kozono D, Guggino WB, Agre P, Yasui M. Characterization 
of aquaporin-6 as a nitrate channel in mammalian cells. Requirement of pore-
lining residue threonine 63. J Biol Chem. (2002) 277: 39873-39879. 
74. Nakhoul NL, Davis BA, Romero MF, Boron WF. Effect of expressing the 
water channel aquaporin-1 on the CO2 permeability of Xenopus oocytes. Am. J. 
Physiol. (1998) 274: C543 – 548. 
265 
 
75. Herrera M, Garvin JL. Novel role of AQP-1 in NO-dependent vasorelaxation. 
Am. J Physiol. Renal. Physiol. (2007) 292: F1443-1451 
76. Wang Y, Cohen J, Boron WF, Schulten K, Tajkhorshid E. Exploring gas 
permeability of cellular membranes and membrane channels with molecular 
dynamics. J. Struct. Biol. (2007) 157: 534-544. 
77. Boassa D, Yool A. Single amino acids in the carboxyl terminal domain of 
aquaporin-1 contribute to cGMP-dependent ion channel activation. BMC 
Physiol. (2003) 3: 12. 
78. Minassian DC, Reidy A, Desai P, Farrow S, Vafidis G, Minassian A. The 
deficit in cataract surgery in England and Wales and the escalating problem of 
visual impairment: epidemiological modelling of the population dynamics of 
cataract. Br. J. Ophthalmol. (2000) 84:4–8.  
79. Shiels A, Bassnett S. Mutations in the founder of the MIP gene family underlie 
cataract development in the mouse. Nat Genet. (1996) 12: 212-215. 
80. Francis P, Chung JJ, Yasui M, Berry V, Moore A, Wyatt MK, Wistow G, 
Bhattacharya SS, Agre P. Functional impairment of lens aquaporin in two 
families with dominantly inherited cataracts.  Human Mol. Gene. (2000) 9: 
2329-2334. 
81. Ruiz-Ederra J, Verkman AS. Accelerated cataract formation and reduced lens 
epithelial water permeability in aquaporin-1-deficient mice. Invest. Ophthalmol. 
Vis. Sci. (2006) 47:3960-3967. 
82. Zhang Z, Chen Z, Song Y, Zhang P, Hu J, Bai C. Expression of aquaporin 5 
increases proliferation and metastasis potential of lung cancer. J. Pathol. 221: 
210- 220.  
83. Saadoun S, Papadopoulos MC, Hara-Chikuma M, Verkman AS. Impairment of 
angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nat. 
(2005) 434: 786-792. 
84. Hara-Chikuma M, Verkman AS. Aquaporin-1 facilitates epithelial cell 
migration in kidney proximal tubule. J Am. Soc. Nephrol. (2006) 17:39-45. 
85. Ma T, Verkman AS. Aquaporin water channels in gastrointestinal physiology. 
J. Physiol. (1999) 517: 317-326. 
86. Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di 
W, Wan Y. Curcumin attenuates EGF-induced AQP3 up-regulation and cell 
266 
 
migration in human ovarian cancer cells. Cancer Chemother. Pharmacol. 
(2008) 62: 857-865.  
87. Wang J, Tanji N, Kikugawa T, Shudou M, Song X, Yokoyama M. Expression 
of aquaporin 3 in the human prostate. Int. J. Urol. (2007) 14:1088-1092.  
88. Huang Y, Zhu Z, Sun M, Wang J, Guo R, Shen L, Wu W. Critical role of 
aquaporin -3 in the human epidermal growth factor-induced migration and 
proliferation in the human gastric adenocarcinoma cells. Canc. Biol. Therapy 
(2010) 9: 1000 –1007. 
89. Sugita M, Maeda S, Sagawa M, Shimasaki M, Ueda Y, Sakuma T. Expression 
of AQP1, AQP3 and AQP5 in the human lung cancer tissue. Chest. (2005) 
(Abstract) 
90. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, Chan P, 
Verkman AS. Aquaporin-4 deletion in mice reduces brain edema after acute 
water intoxication and ischemic stroke. Nat. Med. (2000) 6: 159-163. 
91. Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 
facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 
(2004) 18: 1291-1293. 
92. Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT. Reduced 
cerebrospinal fluid production and intracranial pressure in mice lacking choroid 
plexus water channel aquaporin-1. FASEB J. (2004) 19:76-78.  
93. Tang Y, Wu P, Su J, Xiang J, Cai D, Dong Q. Effects of Aquaporin-4 on edema 
formation following intracerebral hemorrhage. Exp. Neurol. (2010) 223: 485-
495.   
94. Suzuki R, Okuda M, Asai J, Nagashima G, Itokawa H, Matsunaga A, Fujimoto 
T, Suzuki T. Astrocytes co-express aquaporin-1,-4, and vascular endothelial 
growth factor in brain edema tissue associated with brain contusion. Acta 
Neurochir. Suppl. (2006) 96: 398-401.  
95. Badaut J, Hirt L, Granziera C, Bogousslavsky J, Magistretti PJ, Regli L. 
Astrocyte-specific expression of aquaporin-9 in mouse brain is increased after 
transient focal cerebral ischemia. J. Cereb. Blood. Flow. Metab. (2001) 21: 477-
482. 
96. Ribeiro MC, Hirt L, Bogousslavsky J, Regli L, Badaut J. Time course of 
aquaporin expression after transient focal cerebral ischemia in mice. J. 
Neurosci. Res. (2006) 83: 1231-1240. 
267 
 
97. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and 
aquaporin 4. J. Neuroinflam. (2008) 5:22. 
98. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, 
Weinshenker BG. Brain Abnormalities in Neuromyelitis Optica. Arch 
Neurol. (2006) 63: 390-396. 
99. Kishida K, Shimomura I, Kondo H, Kuriyama H, Makino Y, Nishizawa H, 
Maeda N, Matsuda M, Ouchi N, Kihara S, Kurachi Y, Funahashi T, Matsuzawa 
Y. Genomic structure and insulin-mediated repression of the aquaporin adipose 
(AQPap), adipose-specific glycerol channel. J. Biol. Chem. (2001) 276: 36251-
36260. 
100. Ishibashi K, Yamauchi K, Kageyama Y, Saito-Ohara F, Ikeuchi T, Marumo F, 
Sasaki S. Molecular characterization of human Aquaporin-7 gene and its 
chromosomal mapping. Biochimi. et biophysica acta (1998) 1399: 62-66. 
101. Hara-Chikuma M, Sohara E, Rai T, Ikawa M, Okabe M, Sasaki S, Uchida S, 
Verkman AS. Progressive adipocyte hypertrophy in aquaporin-7-deficient mice: 
adipocyte glycerol permeability as a novel regulator of fat accumulation. J. 
Biol. Chem. (2005) 280:15493-15496. 
102. Maeda N, Funahashi T, Hibuse T, Nagasawa A, Kishida K, Kuriyama H, 
Nakamura T, Kihara S, Shimomura I, Matsuzawa Y. Adaptation to fasting by 
glycerol transport through aquaporin 7 in adipose tissue. Proc. Natl. Acad. Sci. 
USA (2004) 101:17801-17806. 
103. Skowronski MT, Lebeck J, Rojek A, Praetorius J, Fuchtbauer EM, Frokiaer J, 
Nielsen S. AQP7 is localized in capillaries of adipose tissue, cardiac and 
striated muscle: implications in glycerol metabolism. Am. J. Physiol. (2007) 
292: F956-965. 
104. Sohara E, Rai T, Miyazaki J, Verkman AS, Sasaki S, Uchida S. Defective water 
and glycerol transport in the proximal tubules of AQP7 knockout mice. Am. J. 
Physiol. (2005) 289: F1195-1200. 
105. Prudente S, Flex E, Morini E, Turchi F, Capponi D, De Cosmo S, Tassi V, 
Guida V, Avogaro A, Folli F, Maiani F, Frittitta L, Dallapiccola B, Trischitta V. 
A functional variant of the adipocyte glycerol channel aquaporin 7 gene is 




106. Marrades MP, Milagro FI, Martinez JA, Moreno-Aliaga MJ. Differential 
expression of aquaporin 7 in adipose tissue of lean and obese high fat 
consumers. Biochem. Biophys. Res. Commun. (2006) 339: 785-789. 
107. Hibuse T, Maeda N, Funahashi T, Yamamoto K, Nagasawa A, Mizunoya W, 
Kishida K, Inoue K, Kuriyama H, Nakamura T, Fushiki T, Kihara S, 
Shimomura I. Aquaporin 7 deficiency is associated with development of obesity 
through activation of adipose glycerol kinase. Proc. Natl. Acad. Sci. USA 
(2005) 102: 10993-10998. 
108. Kondo H, Shimomura I, Kishida K, Kuriyama H, Makino Y, Nishizawa H, 
Matsuda M, Maeda N, Nagaretani H, Kihara S, Kurachi Y, Nakamura T, 
Funahashi T, Matsuzawa Y. Human aquaporin adipose (AQPap) gene: 
Genomic structure, promoter analysis and functional mutation. FEBS (2002) 
269: 1814-1826. 
109. Kishida K, Kuriyama H, Funahashi T, Shimomura I, Kihara S, Ouchi N, 
Nishida M, Nishizawa H, Matsuda M, Takahashi M, Hotta K, Nakamura T, 
Yamashita S, Tochino Y, Matsuzawa Y. Aquaporin adipose, a putative glycerol 
channel in adipocytes. J. Biol. Chem. (2000) 275: 20896-20902. 
110. Lee DH, Park DB, Lee YK, An CS, Oh YS, Kang JS, Kang SH, Chung MY. 
The effects of thiazolidinedione treatment on the regulations of 
aquaglyceroporins and glycerol kinase in OLETF rats. Metabol. Clinc. Exper. 
(2005) 54: 1282-1289. 
111. Rojek AM, Skowronski MT, Fuchtbauer EM, Fuchtbauer AC, Fenton RA, Agre 
P, Frokiaer J, Nielsen S. Defective glycerol metabolism in aquaporin 9 (AQP9) 
knockout mice. Proc. Natl. Acad. Sci. USA (2007) 104: 3609-3614. 
112. Carbrey JM, Gorelick-Feldman DA, Kozono D, Praetorius J, Nielsen S, Agre P. 
Aquaglyceroporin AQP9: solute permeation and metabolic control of 
expression in liver. Proc. Natl. Acad. Sci. USA (2003) 100: 2945-2950. 
113. Pallone TL, Edwards A, Ma T, Silldorff EP, Verkman AS. Requirement of 
aquaporin-1 for NaCl-driven water transport across descending vasa recta. J. 
Clin. Invest. (2000) 105: 215-222. 
114. Verkman AS. Dissecting the roles of aquaporins in renal pathophysiology using 
transgenic mice. Sem. Nephrol. (2008) 28: 217-226. 
269 
 
115. King LS, Choi M, Fernandez PC, Cartron JP, Agre P. Defective urinary-
concentrating ability due to a complete deficiency of aquaporin-1. New England 
J. Med. (2001) 345:175-179. 
116. Wang W, Li C, Summer SN, Falk S, Wang W, Ljubanovic D, Schrier RW. Role 
of AQP1 in endotoxemia-induced acute kidney injury. Am. J. Physiol. (2008) 
294: F1473-1480. 
117. Savelkoul PJ, De Mattia F, Li Y, Kamsteeg EJ, Konings IB, van der Sluijs P, 
Deen PM. R254Q mutation in the aquaporin-2 water channel causing dominant 
nephrogenic diabetes insipidus is due to a lack of arginine vasopressin-induced 
phosphorylation. Hum. Mut. (2009) 30: E891-903. 
118. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat. Rev. (2009) 5: 
270-276. 
119. Loonen AJ, Knoers NV, van Os CH, Deen PM. Aquaporin 2 mutations in 
nephrogenic diabetes insipidus. Sem. Nephrol. (2008) 28: 252-265. 
120. de Mattia F, Savelkoul PJ, Kamsteeg EJ, Konings IB, van der Sluijs P, 
Mallmann R, Oksche A, Deen PM; Lack of arginine vasopressin-induced 
phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant 
nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. (2005) 16: 2872-2880. 
121. Kamsteeg EJ, Savelkoul PJ, Hendriks G, Konings IB, Nivillac NM, Lagendijk 
AK, van der Sluijs P, Deen PM. Missorting of the Aquaporin-2 mutant E258K 
to multivesicular bodies/lysosomes in dominant NDI is associated with its 
monoubiquitination and increased phosphorylation by PKC but is due to the 
loss of E258. Pflugers Arch. (2008) 455: 1041-1054. 
122. Ma T, Song Y, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. 
Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. 
Proc. Natl. Acad. Sci. USA (2000) 97: 4386-4391. 
123. Roudier N, Ripoche P, Gane P, Le Pennec PY, Daniels G, Cartron JP, Bailly P. 
AQP3 deficiency in humans and the molecular basis of a novel blood group 
system, GIL. J. Biol. Chem. (2002) 277: 45854-45859. 
124. Morishita Y, Matsuzaki T, Hara-chikuma M, Andoo A, Shimono M, Matsuki 
A, Kobayashi K, Ikeda M, Yamamoto T, Verkman A, Kusano E, Ookawara S, 
Takata K, Sasaki S, Ishibashi K. Disruption of aquaporin-11 produces 
polycystic kidneys following vacuolization of the proximal tubule. Mol. Cell. 
Biol. (2005) 25: 7770-7779. 
270 
 
125. Tchekneva EE, Khuchua Z, Davis LS, Kadkina V, Dunn SR, Bachman S, 
Ishibashi K, Rinchik EM, Harris RC, Dikov MM, Breyer MD. Single amino 
acid substitution in aquaporin 11 causes renal failure. J. Am. Soc. Nephrol. 
(2008) 19: 1955-1964.  
126. Preston GM, Jung JS, Guggino WB, Agre P. The mercury-sensitive residue at 
cysteine 189 in the CHIP28 water channel. J. Biol. Chem. (1993) 268: 17-20. 
127. Hasegawa H, Ma T, Skach W, Matthay MA, Verkman AS: Molecular cloning 
of a mercurial insensitive water channel expressed in selected water-
transporting tissues. J. Biol. Chem (1994) 269: 5497–5500. 
128. Yukutake Y, Tsuji S, Hirano Y, Adachi T, Takahashi T, Fujihara K, Agre P, 
Yasui M, Suematsu M. Mercury chloride decreases the water permeability of 
aquaporin-4-reconstituted proteoliposomes. Biol. Cell (2008) 100: 355-363. 
129. Brooks HL, Regan JW, Yool AJ. Inhibition of aquaporin-1 water permeability 
by tetraethylammonium: involvement of the loop E pore region. Mol. 
Pharmacol. (2000) 57:1021-1026.  
130. Müller EM, Hub JS, Grubmüller H, de Groot BL. Is TEA an inhibitor for 
human Aquaporin-1? Pflugers Arch (2008) 456: 663-669. 
131. Yang B, Kim JK, Verkman AS. Comparative efficacy of HgCl2 with candidate 
aquaporin-1 inhibitors DMSO, gold, TEA+ and acetazolamide. FEBS Lett. 
(2006) 580: 6679-6684.  
132. Ma B, Xiang Y, Mu SM, Li T, Yu HM, Li XJ. Effects of acetazolamide and 
anordiol on osmotic water permeability in AQP1-cRNA injected Xenopus 
oocyte. Acta. Pharmacol. Sin. (2004) 25: 90-97. 
133. Yang B, Zhang H, Verkman AS. Lack of aquaporin-4 water transport inhibition 
by antiepileptics and arylsulfonamides. Bioorg. Med. Chem. (2008) 16: 7489-
7493 
134. Migliati E, Meurice N, DuBois P, Fang JS, Somasekharan S, Beckett E, Flynn 
G, Yool AJ. Inhibition of aquaporin-1 and aquaporin-4 water permeability by a 
derivative of the loop diuretic bumetanide acting at an internal pore-occluding 
binding site. Mol. Pharmacol. (2009) 76: 105-112.  
135. Yool AJ, Brown EA, Flynn GA. Roles for novel pharmacological blockers of 
aquaporins in the treatment of brain oedema and cancer.  Clin. Exp. Pharmacol. 
Physiol. (2009) 37: 403-9. 
271 
 
136. Niemietz CM, Tyerman SD. New potent inhibitors of aquaporins: silver and 
gold compounds inhibit aquaporins of plant and human origin. FEBS lett. 
(2002) 531: 443-447. 
137. Britten RJ, Davidson EH. Gene regulation for higher cells: A theory. Science 
(1969) 165: 349-357. 
138. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 75: 
843 -854.  
139. Wightman B, Ha I, Ruvkin G. Posttranscriptional regulation of the 
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. 
elegans. Cell (1993) 75: 855 -862. 
140. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, 
Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature (2000) 403: 901-906. 
141. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of 
mammalian microRNA host genes and transcription units. Genome Res. (2004) 
14: 1902 -1910. 
142. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes 
are transcribed by RNA polymerase II. EMBO J. (2004) 23: 4051–4060  
143. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from 
capped, polyadenylated transcripts that can also function as mRNAs. RNA 
(2004) 10: 1957–1966  
144. Smalheiser NR. EST analyses predict the existence of a population of chimeric 
microRNA precursor-mRNA transcripts expressed in normal human and mouse 
tissues. Genome Biol. (2003) 4: 403.  
145. Cullen BR. Transcription and processing of human microRNA precursors. Mol. 
Cell (2004) 16: 861-865. 
146. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is aRanGTP-dependent 
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 
(2004) 10: 185-191. 
147. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of 
microRNA precursors. Science (2004) 303: 95-98. 
148. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs 
exhibit strand bias. Cell (2003) 115: 209-216. 
272 
 
149. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and 
human disease. Development (2005) 132: 4653-4662. 
150. Kim VN, Nam JW. Genomics of microRNA. Trends Genet. (2006) 22: 165-
173.  
151. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and 
mRNA degradationby miRNAs and siRNAs. Genes Dev. (2006) 20: 515-524. 
152. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 
(2005) 122: 553-563. 
153. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, 
da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA 
target predictions. Nat. Genet. (2005) 37: 495-500 
154. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya 
R. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. 
Acad. Sci. USA (2006) 103: 17337-17342. 
155. Kim DH, Saetrom P, Snove O, Rossi JJ. MicroRNA-directed transcriptional 
gene silencing in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. (2008) 105: 
16230-16235  
156. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces 
expression of genes with complementary promoter sequences. Proc. Natl. Acad. 
Sci. U.S.A. (2008) 105: 1608-1613. 
157. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR. 
Activating gene expression in mammalian cells with promoter-targeted duplex 
RNAs. Nat. Chem. Biol. (2007) 3: 166-173. 
158. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero 
A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz, HR, 
Golub TR. MicroRNA expression profiles classify human cancers. Nat. (2005) 
435: 834-838. 
159. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel 
MA. Characterization of microRNA expression levels and their biological 
correlates in human cancer cell lines. Cancer Res. (2007) 67: 2456-2468. 
160. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA 
processing enhances cellular transformation and tumorigenesis. Nat. Genet. 
(2007) 39: 673-677. 
273 
 
161. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis 
initiated by microRNA-10b in breast cancer. Nat. (2007) 449: 682-688. 
162. Huang Q, Gumireddy K, Schrier M, Le Sage C, Nagel R, Nair S, Egan DA, Li 
A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, 
Pure E,  Agami R. The microRNAs miR-373 and miR-520c promote tumour 
invasion and metastasis. Nat. Cell Biol. (2008) 10: 202-210. 
163. Yoshimasa S, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones 
PA. Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer 
Cell. (2006) 9: 435-443. 
164. Schaefer A, O'Carroll D, Tan CL, Hillman D, Sugimori M, Llinas R,  
Greengard P. Cerebellar neurodegeneration in the absence of microRNAs. J. 
Exp. Med. (2007) 204: 1553-1558. 
165. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in the blood and 
brain of rats subjected to transient focal ischemia by middle cerebral artery 
occlusion. Stroke. (2008) 39: 959-966. 
166. Ambros V. The functions of animal microRNAs. Nature. (2004) 431: 350-355. 
167. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target 
recognition. PLoS Biol. (2005) 3: e85. 
168. Mazière P, Enright AJ. Prediction of microRNA targets. Drug Discov Today. 
(2007) 12: 452-458. 
169. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. 
miRBase: microRNA sequences, targets and gene nomenclature. Nucl. Acids 
Res. (2006) 34: D140-144. 
170. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org 
resource: targets and expression. Nucl. Acids Res. (2008) 36: D149-153. 
171. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of 
mammalian microRNA targets. Cell. (2003) 115: 787-798. 
172. John B, Enright AJ, Aravin A, Tuschl T, Sander C,  Marks DS. Human 
microRNA targets. PLoS Biol. (2004) 2: e363. 
173. Hofacker IL, Fontana W, Stadler PF, Bonhoeffer S, Tacker M,  Schuster P. Fast 
folding and comparison of RNA secondary structures. Monatshefte fur Chemie. 
(1994) 125: 167-188. 
274 
 
174. Hudder A, Novak RF. miRNAs: Effectors of environmental influences on gene 
expression and disease. Toxicol. Sci. (2008) 103: 228-240. 
175. Zhang Y, Verbeek FJ. Comparison and intergration of target prediction 
algorithms for microRNA studies. J. Integrative Bioinfo. (2010) 7: 3 
176. Wantanabe Y, Tomita M, Kanai A. Computational methods for microRNA 
target prediction. Methods Enzymol. (2007) 427: 65-86  
177. Chaudhuri K, Chatterjee R. MicroRNA detection and target prediction: 
integration of computational and experimental approaches. DNA Cell Biol. 
(2007) 26: 321-327. 
178. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets 
in Drosophila. Genome Biol. (2004) 5: R1. 
179. Birney E, Andrews TD, Bevan P, Caccamo M, Chen Y, Clarke L, Coates G, 
Cuff J,  Curwen V, Cutts T, Down T, Eyras E, Fernandez-Suarez XM, Gane P, 
Gibbins B,  Gilbert J, Hammond M, Hotz, HR, Iyer V, Jekosch K, Kahari A, 
Kasprzyk A, Keefe   D, Keenan S, Lehvaslaiho H, McVicker G, Melsopp C, 
Meidl P, Mongin E, Pettett R, Pottter S, Proctor G, Rae M, Searle S, Slater G, 
Smedley D, Smith J, Spooner W,  Stabenau A, Stalker J, Storey R, Ureta-Vidal 
A, Woodwark KC, Cameron G, Durbin  R, Cox A, Hubbard T, Clamp M. An 
overview of Ensembl. Genome Res. (2004) 14: 925-928. 
180. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for 
microRNA genomics. Nucl. Acids Res. (2008) 36: D154-158.  
181. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. 
Cell. (2005) 120: 15-20. 
182. Grimson A, Farh KKH, Johnston WK, Garrett-Engele, P, Lim LP, Bartel DP.   
MicroRNA targeting specificity in mammals: determinants beyond seed 
pairing. Mol.  Cell. (2007) 27: 91-105. 
183. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer  S, Rice 
A, Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, 
Chiaretti S, Foà R, Schliwka J, Fuchs U, Novosel A, Müller RU, Schermer B, 
Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti 
D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, 
Wernet P, Macino G, Rogler CE, Nagle JW,  Ju J, Papavasiliou FN, Benzing T, 
Lichter P, Tam W, Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, 
275 
 
Zavolan M,  Tuschl T. A Mammalian microRNA expression atlas based on 
small RNA library sequencing. Cell. (2007) 129: 1401-1414. 
184. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos 
Z, Hatzigeorgiou A. A combined computational-experimental approach predicts 
human microRNA targets. Genes Dev. (2004) 18: 1165-78. 
185. Krutzfeldt J, Poy MN, Stoffel M. Strategies to determine the biological function 
of microRNAs. Nat. Genet. (2006) 38: S14-29.  
186. Huang HY, Chien CH, Jen KH, Huang HD. RegRNA: an integrated web server 
for identifying regulatory RNA motifs and elements. Nucl. Acids Res. (2006) 
34: W429-434. 
187. Hsu PWC, Huang HD, Hsu SD, Lin LZ, Tsou AP, Tseng CP, Stadler PF, 
Washietl S, Hofacker IL. miRNAMap: genomic maps of microRNA genes and 
their target genes in mammalian genomes. Nucl. Acids Res. (2006) 34: D135-
139. 
188. Washietl S, Hofacker IL, Stadler PF. From the cover: fast and reliable 
prediction of noncoding RNAs. Proc. Natl. Acad. Sci. USA (2005) 102: 2454-
2459. 
189. Wang X, El Naqa IM. Prediction of both conserved and nonconserved 
microRNA targets in animals. Bioinformatics. (2008) 24: 325-332. 
190. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 
Identification of tissue-specific microRNAs from mouse. Curr. Biol. (2002) 12: 
735–739. 
191. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs 
with probable regulatory roles in Caenorhabditis elegans. Sci. (2001) 294: 858-
862. 
192. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes. RNA. (2005) 3: 241-
247. 
193. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. 
Expression profiling of mammalian microRNAs uncovers a subset of brain-
expressed microRNAs with possible roles in murine and human neuronal 
differentiation. Genome Biol. (2004) 5: R13 
194. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, 
Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Real-
276 
 
time quantification of microRNAs by stem-loop RT-PCR.  Nucleic Acids Res. 
(2005) 33: E179. 
195. Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP. Protocol: a highly 
sensitive RT-PCR method for detection and quantification of microRNAs. 
Plant Methods. (2007) 3: 12. 
196. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de 
Bruijn E, Horvitz HR, Kauppinen S, Plasterk RH. MicroRNA expression in 
zebrafish embryonic development. Sci. (2005) 309: 310–311. 
197. Valoczi A, Varallyay E, Kauppinen S, Burgyan J, Havelda Z. Spatio-temporal 
accumulation of microRNAs is highly coordinated in developing plant tissues. 
Plant J. (2006) 47: 140–151. 
198. Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, 
Muckenthaler MU. A sensitive array for microRNA expression profiling 
(miChip) based on locked nucleic acids (LNA). RNA (2006) 12: 913–920. 
199. Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR. Probing microRNAs 
with microarrays: tissue specificity and functional inference. RNA. (2004) 10: 
1813–1819. 
200. Válóczi A, Hornyik C, Varga N, Burgyán J, Kauppinen S, Havelda Z. Sensitive 
and specific detection of microRNAs by northern blot analysis using LNA-
modified oligonucleotide probes. Nucleic Acids Res. (2004) 32: E175. 
201. Pall GS, Codony-Servat C, Byrne J, Ritchie L, Hamilton A. Carbodiimide-
mediated cross-linking of RNA to nylon membranes improves the detection of 
siRNA, miRNA and piRNA by northern blot. Nucleic Acids Res. (2007) 35: 
E60. 
202. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD, Shimizu M, 
Cimmino A, Zupo S, Dono M, Dell‟Aquila ML, Alder H, Rassenti L, Kipps TJ, 
Bullrich F, Negrini M, Croce CM. MicroRNA profiling reveals distinct 
signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA. 
(2004) 101: 11755–11760. 
203. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H,Endoh H, 
Harano T, Yatabe Y, Nagino M, Nimura Y, MitsudomiT, Takahashi T. 
Reduced expression of the let-7 microRNAs in human lung cancers in 




204. Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, 
Poppema S, van den Berg A. Lack of BIC and microRNA miR-155 expression 
in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer. (2006) 45: 
147–153. 
205. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-
155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J 
Biol Chem. (2006) 281: 18277-18284. 
206. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, 
Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of 
cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. 
Cell. (2007) 20: 303-317.  
207. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, Murphy A, 
Frendewey D, Valenzuela D, Kutok JL, Schmidt-Supprian M, Rajewsky N, 
Yancopoulos G, Rao A, Rajewsky K. Regulation of the germinal center 
response by microRNA-155. Sci. (2007) 316: 604-608. 
208. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van 
Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright 
AJ, Dougan G, Turner M, Bradley A. Requirement of microRNA-155 for 
normal immune function. Science. (2007) 316: 608–611.  
209. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of 
stress-dependent cardiac growth and gene expression by a microRNA. Science. 
(2007) 316: 575–579. 
210. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, 
Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett 
CF, Bhanot S,  Monia BP. miR-122 regulation of lipid metabolism revealed by 
in vivo antisense targeting. Cell Metab. (2006) 3: 87-98. 
211. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, 
Hedtjarn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup 
EM,  Kauppinen S. LNA-mediated microRNA silencing in non-human 
primates. Naure. (2008) 452: 896-899. 
212. Hirt L, Ternon B, Price M, Mastour N, Brunet JF, Badaut J. Protective role of 
early aquaporin 4 induction against postischemic edema formation. J Cereb 
Blood Flow Metab. (2009) 29: 423-433. 
278 
 
213. Schägger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis for the separation of proteins in the range from 1 to 100 kDa. 
Anal Biochem. (1987) 166: 368-379. 
214. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, 
Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov 
A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J. 
TM4: a free, open-source system for microarray data management and analysis. 
Biotech. (2003) 34: 374-378. 
215. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral 
artery occlusion without craniectomy in rats. Stroke. (1989)  20: 84-91. 
216. Schnermann J, Chou CL, Ma T, Traynor T, Knepper MA, Verkman AS. 
Defective proximal tubular fluid reabsorption in transgenic aquaporin-1 null 
mice. Proc. Natl. Acad. Sci. USA (1998) 95: 9660-9664. 
217. Oshio K, Song Y, Verkman AS, Manley GT. Aquaporin-1 deletion reduces 
osmotic water permeability and cerebrospinal fluid production, Acta Neurochir. 
Suppl. (2003) 86: 525–528. 
218. Li C, Wang W, Summer SN, Cadnapaphornchai MA, Falk S, Umenishi F,  
Schrier RW. Hyperosmolality In Vivo Upregulates Aquaporin 2 Water Channel 
and Na-K-2Cl Co-Transporter in Brattleboro Rats Pathophysiology of Renal 
Disease and Progression.  J Am Soc Nephrol (2006) 17: 1657-1664. 
219. Yang B, Zhao D, Qian L, Verkman AS. Mouse model of inducible nephrogenic 
diabetes insipidus produced by floxed aquaporin-2 gene deletion. Am J Physiol 
Renal Physiol. (2006) 291: F465-472. 
220. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. Generation 
and phenotype of a transgenic knockout mouse lacking the mercurial-
insensitive water channel aquaporin-4. J Clin Invest. (1997) 100: 957-962. 
221. Chou CL, Ma T, Yang B, Knepper MA, Verkman AS. Fourfold reduction of 
water permeability in inner medullary collecting duct of aquaporin-4 knockout 
mice. Am J Physiol. (1998) 274: C549-554. 
222. Suzuki R, Okuda M, Asai J, Nagashima G, Itokawa H, Matsunaga A, Fujimoto 
T, Suzuki T. Astrocytes co-express aquaporin-1, -4, and vascular endothelial 
growth factor in brain edema tissue associated with brain contusion. Acta 
Neurochir Suppl. (2006) 96: 398-401. 
279 
 
223. Misawa T, Arima K, Mizusawa H, Satoh J. Close association of water channel 
AQP1 with amyloid-beta deposition in Alzheimer disease brains. Acta 
Neuropathol (2008) 116: 247-260. 
224. Hayashi Y, Edwards NA, Proescholdt MA, Oldfield EH, Merrill MJ. 
Regulation and function of aquaporin-1 in glioma cells. Neoplasia. (2007) 9: 
777-7787. 
225. Jenq W, Ramirez G, Peguero A, Cooper DR, Vesely DL. D-glucose and NaCl 
enhance the expression of aquaporin-1: inhibition of both by cholera toxin. 
Nephron. (2002) 92: 279-286. 
226. Saadoun S, Papadopoulos MC, Davies DC, Krishna S, Bell BA. Aquaporin-4 
expression is increased in oedematous human brain tumours. J Neurol 
NeurosurgPsychiatry. (2002) 72: 262-265. 
227. Li C, Wang W, Knepper MA, Nielsen S, Frøkiaer J. Downregulation of renal 
aquaporins in response to unilateral ureteral obstruction. Am J Physiol Renal 
Physiol. (2003) 284: F1066-1079. 
228. Jung JS, Lee RH, Koh SH, Kim YK. Changes in expression of sodium 
cotransporters and aquaporin-2 during ischemia-reperfusion injury in rabbit 
kidney. Ren Fail. (2000) 22: 407-421. 
229. Earm JH, Christensen BM, Frokiaer J, Marples D, Han JS, Knepper MA, 
Nielsen S. Decreased aquaporin-2 expression and apical plasma membrane 
delivery in kidney collecting ducts of polyuric hypercalcemic rats  JASN (1998) 
9: 2181-2193. 
230. Ma T, Fukuda N, Song Y, Matthay MA, Verkman AS. Lung fluid transport in 
aquaporin-5 knockout mice. J Clin Invest. (2000) 105: 93-100. 
231. Song Y, Verkman AS. Aquaporin-5 dependent fluid secretion in airway 
submucosal glands. J. Biol. Chem. (2001) 276:  41288-41292. 
232. Schaar DG, Medina DJ, Moore DF, Strair RK, Ting Y. mir-320 targets 
transferrin receptor 1 (cd71) and inhibits cell proliferation. Exp. Hemat. (2009) 
37: 245-255  
233. Chiromatzo AO, Oliveira TY, Pereira G, Costa AY, Montesco CA, Gras DE, 
Yosetake F, Vilar JB, Cervato M, Prado PR, Cardenas RG, Cerri R, Borges RL, 
Lemos RN, Alvarenga SM, Perallis VR, Pinheiro DG, Silva IT, Brandão RM, 
Cunha MA, Giuliatti S, Silva WA Jr. miRNApath: a database of miRNAs, 
target genes and metabolic pathways. Genet Mol Res. (2007) 6: 859-865. 
280 
 
234. Kanehisa M, Goto S. Kegg: Kyoto encyclopedia of genes and genomes. Nucleic 
Acids Res. (2000) 28: 27-30. 
235. Fenton RA,Moeller HB, Zelenina M, Snaebjornsson MT, Holen T, MacAulay 
N. Differential water permeability and regulation of three aquaporin 4 isoforms. 
Cell Mol Life Sci. (2010). 67: 829-840. 
236. Silberstein C, Bouley R, Huang Y, Fang P, Pastor-Soler N, Brown D, Van Hoek 
AN. Membrane organization and function of M1 and M23 isoforms of 
aquaporin-4 in epithelial cells. Am J Physiol Renal Physiol. (2004) 287: F501-
511 
237. Umenishi F, Verkman AS. Isolation and functional analysis of alternative 
promoters in the human aquaporin-4 water channel gene. Genomics. (1998) 50: 
373-377. 
238. Arima H, Yamamoto N, Sobue K, Umenishi F, Tada T, Katsuya H, Asai K 
(2003) Hyperosmolar Mannitol Stimulates Expression of Aquaporins 4 and 9 
through a p38 Mitogen-activated Protein Kinase-dependent Pathway in Rat 
Astrocytes. J Biol Chem 278: 44525–44534. 
239. Badaut J, Brunet JF, Regli L. Aquaporins in the brain: from aqueduct to “multi-
duct.”  Metab Brain Dis. (2007) 22: 251–263. 
240. Arciénega II, Brunet JF, Bloch J, Badaut J. Cell locations for AQP1, AQP4 and 
9 in the non-human primate brain. Neuroscience. (2010) 167: 1103-1114.  
241. Ko SB, Uchida S, Naruse S, Kuwahara M, Ishibashi K, Marumo F, Hayakawa 
T, Sasaki S. Cloning and functional expression of rAOP9L a new member of 
aquaporin family from rat liver. Biochem Mol Biol Int. (1999) 47: 309-318. 
242. Badaut J, Petit JM, Brunet JF, Magistretti PJ, Charriaut-Marlangue C, Regli L. 
Distribution of Aquaporin 9 in the adult rat brain: preferential expression in 
catecholaminergic neurons and in glial cells. Neuroscience. (2004) 128: 27-38. 
243. Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. 
Front Neuroendocrinol. (2002) 23: 2-40. 
244. Pénicaud L, Leloup C, Lorsignol A, Alquier T, Guillod E. Brain glucose 
sensing mechanism and glucose homeostasis. Curr Opin Clin Nutr Metab Care. 
(2002) 5: 539-543.  
245. Badaut J, Regli L. Distribution and possible roles of aquaporin 9 in the brain. 
Neuroscience. (2004) 129: 971-981. 
281 
 
246. Schurr A, Dong WQ, Reid KH, West CA, Rigor BM. Lactic acidosis and 
recovery of neuronal function following cerebral hypoxia in vitro. Brain Res. 
(1988) 438: 311-314. 
247. Bentwich I. Prediction and validation of microRNAs and their targets. FEBS 
Lett. (2005) 579: 5904-5910. 
248. Rajewsky N. microRNA target predictions in animals. Nat Genet. (2006) 38: 
S8-13.  
249. Kahle KT, Simard JM, Staley KJ, Nahed BV, Jones PS, Sun D. Molecular 
mechanisms of ischemic cerebral edema: role of electroneutral ion transport. 
Physiology. (2009) 24: 257-265 
250. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, Chen S, Chopp M. 
Progression from ischemic injury to infarct following middle cerebral artery 
occlusion in the rat. Am J Pathol. (1993) 142: 623-635. 
251. Lundbaek JA, Hansen AJ. Brain interstitial volume fraction and tortuosity in 
anoxia. Evaluation of the ion-selective micro-electrode method. Acta Physiol 
Scand. (1992) 146: 473-484. 
252. Mori K, Miyazaki M, Iwase H, Maeda M. Temporal profile of changes in brain 
tissue extracellularspace and extracellular ion (Na+, K+) concentrations after 
cerebral ischemia and the effects of mild cerebral hypothermia. J Neurotrauma 
(2002) 19:1261–1270. 
253. Young W, Rappaport ZH, Chalif DJ, Flamm ES. Regional brain sodium, 
potassium, and water changes in the rat middle cerebral artery occlusion model 
of ischemia. Stroke (1987) 18: 751-759. 
254. Pillai DR, Dittmar MS, Baldaranov D, Heidemann RM, Henning EC, Schuierer 
G, Bogdahn U, Schlachetzki F. Cerebral ischemia-reperfusion injury in rats--a 3 
T MRI study on biphasic blood-brain barrier opening and the dynamics of 
edema formation. J Cereb Blood Flow Metab. (2009) 29: 1846-1855. 
255. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, 
Abo-Ramadan U, Tatlisumak T. The blood-brain barrier is continuously open 
for several weeks following transient focal cerebral ischemia. Neuroscience. 
(2008) 153: 175-181.  
256. Badaut J, Brunet JF, Grollimund L, Hamou MF, Magistretti PJ, Villemure JG, 
Regli L. Aquaporin 1 and aquaporin 4 expression in human brain after 
282 
 
subarachnoid hemorrhage and in peritumoral tissue. Acta Neurochir Suppl. 
(2003) 86: 495-498. 
257. Yatsushige H, Ostrowski RP, Tsubokawa T, Colohan A, Zhang JH: Role of c-
Jun N-terminal kinase in early brain injury after subarachnoid hemorrhage. J 
Neurosci Res (2007) 85: 1436–1448. 
258. Zhang X, Chen Y, Jenkins LW, Kochanek PM, Clark RS. Bench-to-bedside 
review: Apoptosis/programmed cell death triggered by traumatic brain injury. 
Crit Care. (2005) 9: 66-75.  
259. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 
(2007) 35: 495-516. 
260. Leitch V, Agre P, King LS. Altered ubiquitination and stability of aquaporin-1 
in hypertonic stress. Proc Natl Acad Sci U S A. (2001) 98: 2894-2898. 
261. Jablonski EM, Webb AN, McConnell NA, Riley MC, Hughes FM Jr. Plasma 
membrane aquaporin activity can affect the rate of apoptosis but is inhibited 
after apoptotic volume decrease. Am. J. Physiol. (2004) 286: C975–C985. 
262. Hwang IK, Yoo KY, Li H, Lee BH, Suh HW, Kwon YG, Won MH. Aquaporin 
9 changes in pyramidal cells before and is expressed in astrocytes after delayed 
neuronal death in the ischemic hippocampal CA1 region of the gerbil. J 
Neurosci Res. (2007) 85:2470-2479. 
263. Badaut J. Aquaglyceroporin 9 in brain pathologies. Neuroscience. (2010) 
168:1047-1057.  
264. Schurr A. Lactate, glucose and energy metabolism in the ischemic brain. Int J 
Mol Med. (2002) 10: 131-136.  
265. Lim KY, Chua JH, Tan JR, Swaminathan P, Sepramaniam S, Armugam A, 
Wong PT,  Jeyaseelan K. MicroRNAs in cerebral ischemia. Transl. stroke Res. 
(2010) 1: 287-303. 
266. Kikuchi K, Tancharoen S, Matsuda F, BiswasKK, Ito T, Morimoto Y, Oyama 
Y, Takenouchi K, Miura N, Arimura N, Nawa Y, MengX, Shrestha B, Arimura 
S, Iwata M, Mera K, Sameshima H, Ohno Y, Maenosono R, TajimaY, 
Uchikado H, Kuramoto T, Nakayama K, Shigemori M, Yoshida Y, Hashiguchi 
T,Maruyama I, Kawahara K: Edaravone attenuates cerebral ischemic injury by 




267. Li Q, Li Z, Mei Y, Guo Y: Neuregulin attenuated cerebral ischemia-
creperfusion injury via inhibiting apoptosis and upregulating aquaporin-4. 
Neurosci Lett (2008) 443: 155– 159. 
268. Tran ND, Kim S, Vincent HK, Rodriguez A, Hinton DR, Bullock MR, Young 
HF. Aquaporin-1-mediated cerebral edema following traumatic brain injury: 
effects of acidosis and corticosteroid administration. J Neurosurg. (2010) 5: 
1095-1104 
269. Taniguchi M, Yamashita T, Kumura E, Tamatani M, Kobayashi A, Yokawa T, 
Maruno M, Kato A, Ohnishi T, Kohmura E, Tohyama M, Yoshimine T. 
Induction of aquaporin-4 water channel mRNA after focal cerebral ischemia in 
rat. Mol. Brain Res. (2009) 78: 131-137  
270. Armugam A, Cher C, Lim K, Koh D, Howells D, Jeyaseelan K. A secretory 
phospholipase A2-mediated neuroprotection and anti-apoptosis. BMC Neurosci. 
(2009) 10: 120 
271. Bertorelli R, Adami M, Di Santo E, Ghezzi P. Mk-801 and dexamethasone 
reduce both tumor necrosis factor levels and infarct volume after focal cerebral 
ischemia in the rat brain. Neurosci. Lett. (1998) 246: 41- 44  
272. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, 
Jeyaseelan K. Expression profile of microRNAs in young stroke patients. PLoS 
ONE  (2009) 4: E7689 
273. Dbouk HA, Mroue RM, El-Sabban ME, Talhouk RS. Connexins: A myriad of 
functions extending beyond assembly of gap junction channels. Cell Commun. 
Signal (2009) 7: 4  
274. Frantseva MV, Kokarovtseva L, Perez Velazquez JL. Ischemia-induced brain 
damage depends on specific gap-junctional coupling. J. Cereb. Blood Flow 
Metab.(2002) 22: 453-462  
275. Kong H, Fan Y, Xie J, Ding J, Sha L, Shi X, Sun X, Hu G. Aqp4 knockout 
impairs proliferation, migration and neuronal differentiation of adult neural 
stem cells. J. Cell Sci.(2008) 121: 4029-4036  
276. Nicchia GP, Srinivas M, Li W, Brosnan CF, Frigeri A, Spray DC. New possible 
roles for aquaporin-4 in astrocytes: cell cytoskeleton and functional relationship 
with connexin43. J. FASEB (2005) 19: 1674-1676  
284 
 
277. Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM. Grb2 downregulation 
leads to akt inactivation in heregulin-stimulated and erbb2-overexpressing 
breast cancer cells. Oncogene (2000) 19: 6271-6276  
278. Yin W, Signore AP, Iwai M, Cao G, Gao Y, Johnnides MJ, Hickey RW, Chen 
J. Preconditioning suppresses inflammation in neonatal hypoxic ischemia via 
Akt activation. Stroke. (2007) 38: 1017-24. 
279. Zhang B, Dietrich UM, Geng JG, Bicknell R, Esko JD, Wang L. Repulsive 
axon guidance molecule Slit3 is a novel angiogenic factor. Blood. (2009) 114: 
4300-4309. 
280. Sorbo JG, Moe SE, Ottersen OP, Holen T. The molecular composition of 
square arrays. Biochemistry. (2008) 47: 2631-2637.  
281. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, Tan JR, 
Jeyaseelan K. MicroRNA 320a functions as a novel endogenous modulator of 
aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. 































9 Supplementary Data  
Supplementary Table 1: miRNA predictions from MicroCosm /MicroRNA.org 
/TargetScan. miRNA target predictions for human AQP genes from all 3 sources 
are shown. The sequences were retrieved from NCBI GenBank database (AQP0 
(NM_012064), AQP1 (NM_198098), AQP2 (NM_000486), AQP3 (NM_004925), 
AQP4a (NM_001650), AQP4b (NM_004028), AQP5 (NM_001651), AQP6 
(NM_001652), AQP7 (NM_001170), AQP8 (NM_001169), AQP9 (NM_020980), 
AQP10 (NM_080429), AQP11 (NM_173039), AQP12a (NM_198998)) 
miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-let-7/98 6 hsa-miR-27b 0, 1, 5, 6, 10 & 11 
hsa-miR-7/7ab 2 hsa-miR-28-3p 4, 5,  6 & 10 
hsa-let-7g* 11 hsa-miR-28-5p 1, 2, 5 & 6 
hsa-miR-9 0, 1, 2, 4 & 11 hsa-miR-29a/b/c 1, 2, 4 & 11 
hsa-miR-10a      10 hsa-miR-29a* 11 
hsa-miR-10a* 6 hsa-miR-30a-3p 10 
hsa-miR-10b 10 hsa-miR-30b/d 7 
hsa-miR-10b* 6 hsa-miR-33b 8 
hsa-miR-15 2, 4, 8 & 11 
hsa-miR-34a/34b/c-
5p449abc/699 
3 & 8 
hsa-miR-16 4 & 8  hsa-miR-34a* 0 
hsa-miR-16-1* 0 & 11 hsa-miR-34b/ b* 11 
hsa-miR-17-3p 5 hsa-miR-92a-1* 5 
hsa-miR-17-5p 4 & 9 hsa-miR-92b* 7 
hsa-miR-18ab    0, 1, 3 & 9 hsa-miR-96 2, 5, 9 & 10 
hsa-miR-19    2, 4, 5 & 11 hsa-miR-99b 7 
hsa-miR-20a* 3 & 5 hsa-miR-99b* 8 
hsa-miR-21* 5 hsa-miR-100* 5 
hsa-miR-22 2 & 8,  9 hsa-miR-101 1, 5 & 10 
hsa-miR-23a 0, 2, 4, 7, 9 & 11 hsa-miR-101* 7 
hsa-miR-23b 0, 2, 4, 9 & 11 hsa-miR-103 1 & 11 
hsa-miR-24 2, 4, 6, 7 & 10 hsa-miR-105 8 
hsa-miR-25/32/92ab/ 
363/367 
2, 4 & 8 hsa-miR-122 0 
hsa-miR-26b* 7 hsa-miR-124/506 1, 2 & 11 




miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-125a-3p 1, 2 & 8 hsa-miR-148a 4, 7 & 11 
hsa-miR-125b 2, 3 & 4 hsa-miR-148b 7 & 11 
hsa-miR-125b-2* 7 hsa-miR-149 1, 2, 6, 9 & 10 
hsa-miR-127-3p 3 & 10 hsa-miR-150 3 & 7 
hsa-miR-127-5p 2 hsa-miR-150* 11 
hsa-miR-128a 1, 2 , 4 & 11 hsa-miR-151 0 & 9 
hsa-miR-128b 11 hsa-miR-152 7 
hsa-miR-129-1* 5 hsa-miR-153 4 
hsa-miR-129-3p 2 , 4 & 5 hsa-miR-154 1 & 4 
hsa-miR-130a* 7 & 11 hsa-miR-155 4, 6 & 11 
hsa-miR-130b 0 hsa-miR-181a  2 &  9 
hsa-miR-133a/b 0, 1, 2, 3, 5 & 10 hsa-miR-181a*/c* 9 
hsa-miR-135a/b 1, 9 & 12 hsa-miR-181b/d 7, 9 & 11 
hsa-miR-135a* 1 hsa-miR-181c 9 & 11 
hsa-miR-136 0, 1 & 2 hsa-miR-182 2 & 9 
hsa-miR-137 2 & 8 hsa-miR-182* 0 & 12 
hsa-miR-138 8 & 11 hsa-miR-183 0, 4, 5 & 11 
hsa-miR-138-1* 0, 1, 3 & 7 hsa-miR-184 0 
hsa-miR-139-3p 8 & 12 hsa-miR-185/882 2 & 9 
hsa-miR-139-5p 1 & 6 hsa-miR-185* 5 
hsa-miR-140/140-5p/ 
876-3p 
4 & 9 hsa-miR-186 0, 4 & 11 
hsa-miR-141/200a 4, 8, 10 & 11 hsa-miR-187 4 
hsa-miR-142-3p 2, 4 & 11 hsa-miR-187* 12 
hsa-miR-142-5p 4 hsa-miR-188-3p 2 & 4 
hsa-miR-143 2 hsa-miR-188/188-5p 3, 5, 6 & 9 
hsa-miR-144 1 & 4 hsa-miR-191 8 
hsa-miR-145 4 hsa-miR-193a-3p 3 & 7 
hsa-miR-145* 6 hsa-miR-193a-5p 1, 2, 3, 4, 9 & 11 
hsa-miR-146a 1, 2 & 9  hsa-miR-193b 2, 3, 4, 5 & 7 
hsa-miR-146b-3p 1, 2, 3 & 8 hsa-miR-194 3 & 6 
hsa-miR-146b-5p 11 hsa-miR-194* 11 
hsa-miR-147/147a 4, 6 & 8 hsa-miR-195 11 
hsa-miR-147b 5 & 8 hsa-miR-196a/b 4, 8 & 11 
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miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-197 0 & 2  hsa-miR-298.h 1, 2 & 8 
hsa-miR-198 2, 4, 9 & 10 hsa-miR-299-3p 5 & 11 
hsa-miR-199a-3p 2, 3 & 8 hsa-miR-299/299-5p 0 & 12 
hsa-miR-199a/199a-5p 2, 3, 6, 7, 9 & 11 hsa-miR-300 0, 2 & 9 
hsa-miR-200a 8, 10 & 11 hsa-miR-301 0 
hsa-miR-200c 0, 4 & 11 hsa-miR-302a 2, 4 & 9 
hsa-miR-202-5p 11 hsa-miR-302b* 11 
hsa-miR-202/202-3p 0 hsa-miR-302c* 7 & 11 
hsa-miR-203 2 & 4 hsa-miR-302d* 7 
hsa-miR-204/211 1, 2, 3 & 4 hsa-miR-302f 9 
hsa-miR-205 1, 2, 3, 9 & 10 hsa-miR-320/320abcd 1 & 4 
hsa-miR-210 4 hsa-miR-323-3p 3, 4, 7 ,10 & 11 
hsa-miR-212 8 hsa-miR-324-3p 1, 5, 7 & 8 
hsa-miR-214/761 0, 2, 4 & 8 hsa-miR-324-5p 0, 2 , 7, 9 & 10 
hsa-miR-216a 2, 4, 6 & 7 hsa-miR-325/325-5p 2, 4 & 11 
hsa-miR-216b 2, 4, 5 & 7 hsa-miR-326 2, 3, 4, 6 & 8 
hsa-miR-217 5 hsa-miR-328 0, 1, 3, 5 & 10 
hsa-miR-219-1-5p 9 & 11 hsa-miR-329/362-3p 2 & 3 
hsa-miR-219-2-3p 1, 4, 8 & 9 hsa-miR-330-3p 0, 1, 4, 8, 9 & 11 
hsa-miR-220b 0 & 2 hsa-miR-330-5p 2, 3, 4, 5, 6 & 8 
hsa-miR-220c 1, 2, 4 & 7 hsa-miR-331/331-3p 1, 2, 3, 5, 6, 8, 9 & 10 
hsa-miR-221* 8 hsa-miR-331-5p 4 & 5 
hsa-miR-222 3 & 12 hsa-miR-335/335-5p 0 
hsa-miR-222* 8 hsa-miR-337-3p 3, 4 & 8 
hsa-miR-223 6 & 8 hsa-miR-337-5p 0 & 4 
hsa-miR-224 4 & 9 hsa-miR-338/338-3p 1, 2 & 10 
hsa-miR-290-5p/292-
5p/371-5p 
2, 4, 6 & 9 hsa-miR-338-5p 2 & 4 
hsa-miR-291b-3p/ 
519a/519b-3p/519c-3p 
1 hsa-miR-339-3p 2 
hsa-miR-296-3p 5, 8,9 & 10 hsa-miR-339-5p 3, 5, 8 & 10 









miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-344-5p/484 0, 1, 2, 4 & 9 hsa-miR-422a 11 
hsa-miR-345 2, 5 & 9 hsa-miR-423a-3p 8 
hsa-miR-346 1, 4 & 5 hsa-miR-423a/423-5p 0, 1 & 10 
hsa-miR-361-3p 1, 2, 3, 4 & 6 hsa-miR-424 11 
hsa-miR-362-5p 4 hsa-miR-425-5p 3, 4 & 11 
hsa-miR-362-3p 7 hsa-miR-431 4 
hsa-miR-362-5p 0 hsa-miR-431* 8 
hsa-miR-363* 0 & 3 hsa-miR-432 2 & 9 
hsa-miR-365 6, 7 & 9 hsa-miR-432* 7 & 10 
hsa-miR-367 6 hsa-miR-433 9 
hsa-miR-368 2, 8 & 12 hsa-miR-449a/b 8 





hsa-miR-370 1, 2, 3 & 4 hsa-miR-452 8 
hsa-miR-371-3p 2 & 11 hsa-miR-453 1, 4, 10 & 11 
hsa-miR-371-5p 5 hsa-miR-454* 3 
hsa-miR-374b/b* 11 hsa-miR-455/455-3p 2 & 4 
hsa-miR-376c 2 & 12 hsa-miR-483/483-3p 1, 3, 4, 6 & 7 
hsa-miR-377 0, 2, 4, 11 & 12 hsa-miR-483/483-5p 2 & 7 
hsa-miR-377* 11 hsa-miR-485-3p 1, 9 & 12 
hsa-miR-378/422a 1, 6, 8 & 11 hsa-miR-485/485-5p 2, 6 & 11 
hsa-miR-379 6 & 9 hsa-miR-486-3p 0, 2, 3, 4, 6 & 8 
hsa-miR-380 9 & 11 hsa-miR-486-5p 5, 6, 7 & 11 
hsa-miR-380* 7 hsa-miR-487a 4 
hsa-miR-382 6 hsa-miR-487b 12 
hsa-miR-383 1 & 2 hsa-miR-488 0, 1, 3, 4 & 9 
hsa-miR-384/384-3p 4 hsa-miR-489.h 4 
hsa-miR-409-3p 4, 7 & 9 hsa-miR-490-3p 8 
hsa-miR-409-5p 0, 1, 5, 7 & 10 hsa-miR-491/491-3p 3 & 9 
hsa-miR-410 4 & 9 hsa-miR-491/491-5p 0, 1, 2, 3 & 6 
hsa-miR-411 4 hsa-miR-492 2 & 7 
hsa-miR-412.hr 1 & 10 hsa-miR-493-5p 3, 9 & 10 




miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-495/1192 4, 6 & 10 hsa-miR-517b 2, 5 & 9 
hsa-miR-497 11 hsa-miR-517c 5 





0, 2, 4 & 9 
hsa-miR-499-3p 2, 4, 7 & 11 hsa-miR-519a/e 11 
hsa-miR-499/499-5p 3 & 4 
hsa-miR-520a-5p/525-
5p 
2, 3, 4, 6 & 9 
hsa-miR-500/501-3p/ 
502/ 502-3p 
0, 3 & 4 hsa-miR-520d-5p 8 
hsa-miR-501-5p 2 & 6 hsa-miR-520f 9 
hsa-miR-502-3p 7 hsa-miR-520gh 2, 4 & 8 
hsa-miR-502-5p 4 & 5 hsa-miR-522 1, 2, 4, 9 & 12 
hsa-miR-503 8 & 11 hsa-miR-523 8 
hsa-miR-504 0 & 11 hsa-miR-524 5 
hsa-miR-506 11 hsa-miR-526b 5, 6 & 8 
hsa-miR-507/557 0, 1,  4 & 8 hsa-miR-527 8 
hsa-miR-508-3p 9 hsa-miR-532-3p 3,7 & 9 
hsa-miR-508-5p 5,  6 & 7 hsa-miR-532/532-5p 2 & 9 
hsa-miR-509-5p/3p 2 & 11 hsa-miR-539 0, 2, 4, 6 & 8 
hsa-miR-510 1, 2 & 9 hsa-miR-541/654-5p 0, 2 & 6 
hsa-miR-511 2,  4, 9 & 10 hsa-miR-542-5p 8 
hsa-miR-512-3p/1186 4 & 9 hsa-miR-543 4 & 9 
hsa-miR-512-5p 5 & 9 hsa-miR-544 1, 2, 4 & 9 
hsa-miR-513a-5p/3p 2, 4, 6, 10 & 11 hsa-miR-545 0 & 9 
hsa-miR-513b 2 & 4 hsa-miR-548a-3p 1, 4, 9 & 11 
hsa-miR-513c 6,  8 & 9 
hsa-miR-548a/b/c/d-
5p/ 548hij/ 559 
3 & 9 
hsa-miR-514 2, 4, 7, 9 & 11 hsa-miR-548b-3p 4 & 8 
hsa-miR-515-3p/519e 2 & 9 hsa-miR-548c-3p 2, 4, 6, 9 & 11 
hsa-miR-516a-3p 0, 2 & 11 hsa-miR-548d-3p 3,4 & 8 
hsa-miR-516a-5p 8 & 11 hsa-miR-548g 4 
hsa-miR-517a 5 hsa-miR-548l 6 





miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-548n 3, 4 & 9 hsa-miR-581 2 & 5 
hsa-miR-548o/1323 0, 6 & 9 has-miR-582-3p/1267 1 & 4 
hsa-miR-548p 0, 2 & 4 hsa-miR-582-5p.h 2 & 4 
hsa-miR-549 9 & 11 hsa-miR-583 2, 5 & 10 
hsa-miR-550 2,4, 9 & 11 hsa-miR-584 4 
hsa-miR-551a/b 3 & 7 hsa-miR-585 6 
hsa-miR-552 8 hsa-miR-586 4 & 9 
hsa-miR-555 2 & 6 hsa-miR-587 9 & 11 
hsa-miR-556-3p 0, 4 & 7 hsa-miR-588 1, 2 & 4 
hsa-miR-556-5p 1, 4 & 8 hsa-miR-589 4 & 6 
hsa-miR-557 0, 3 & 8 hsa-miR-590/590-3p 0, 4, 9 & 11 
hsa-miR-558 1, 4 & 8 hsa-miR-591 1 
hsa-miR-559 8 hsa-miR-592 1, 4 & 6 
hsa-miR-562 0 hsa-miR-592/599 1 & 2 
hsa-miR-563 2, 7 & 11 hsa-miR-593 1, 3, 6, 8 & 10 
hsa-miR-564 6 hsa-miR-594 11 
hsa-miR-565 10 hsa-miR-595 4 & 9 
hsa-miR-566 6 & 10 hsa-miR-596 1 & 3 
hsa-miR-567 3 & 11 hsa-miR-597 4,6 & 11 
hsa-miR-568 2 hsa-miR-599 10 
hsa-miR-569 4 & 11 hsa-miR-600 0, 2 & 10 
hsa-miR-570 4 & 11 hsa-miR-601 0 & 1 
hsa-miR-571 4 hsa-miR-602 7 
hsa-miR-573 10 hsa-miR-603 0,2,3 & 4 
hsa-miR-574-3p 0 & 7 hsa-miR-605 0, 4, 6 & 9 
hsa-miR-575 1 , 3 & 4 hsa-miR-606 4 & 10 
hsa-miR-576-3p 1, 4, 8 & 9 hsa-miR-607 4 & 9 
hsa-miR-576-5p 3 & 4 hsa-miR-608 1, 2,3 , 6, 8 & 9 
hsa-miR-577 4, 9 & 10 hsa-miR-609 1,8,9 & 11 
hsa-miR-578 2, 4 & 6 hsa-miR-610 1 & 9 
hsa-miR-579 0, 2 & 4 hsa-miR-611 0,8 & 9 





miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-615-5p/3p 2, 3, 6 & 8 hsa-miR-653 3 
hsa-miR-616 4 & 9 hsa-miR-654-3p 4 & 9 
hsa-miR-617 3, 4 & 9 hsa-miR-654-5p 8 
hsa-miR-619 1, 2 & 8 hsa-miR-655 4 & 11 
hsa-miR-620/1270 2, 8 & 9 hsa-miR-656 4 
hsa-miR-621 4, 9 & 11 hsa-miR-657 1 & 2 
hsa-miR-622 4, 5,6 & 8 hsa-miR-658 2 
hsa-miR-623 0, 2, 3, 4, 5, 6 & 9 hsa-miR-659 2, 5 & 9 
hsa-miR-625/625* 11 hsa-miR-660 9 
hsa-miR-626 1, 3 & 6 hsa-miR-661 2, 4 & 6 
hsa-miR-627 0, 2 & 11 hsa-miR-662 5 & 8 
hsa-miR-628-3p 2, 4, 6 & 9 hsa-miR-663a 10 
hsa-miR-628-5p 4 & 6 hsa-miR-663b 1, 3, 4 & 10 
hsa-miR-631 1, 2, 3 & 5 hsa-miR-664.hr 4 
hsa-miR-632 1, 4 & 5 hsa-miR-665 0, 2, 6 & 10 
hsa-miR-633 4 hsa-miR-668 1, 2,  7, 10 & 11 
hsa-miR-634 1, 3 & 5 hsa-miR-671/671-3p 3 
hsa-miR-635 1,3,4,6 & 10 hsa-miR-671-5p 0, 1, 2, 6, 8 & 9 
hsa-miR-636 2 & 9 hsa-miR-674 10 
hsa-miR-637 0, 2, 6, 7, 9 & 12 hsa-miR-675/675-5p 8 
hsa-miR-638 1 & 7 hsa-miR-708 5 
hsa-miR-639 5 hsa-miR-709/1827 2 & 6 
hsa-miR-640 4 hsa-miR-720.h 10 
hsa-miR-642 0,1,2,5,10 & 12 hsa-miR-744 12 
hsa-miR-643 11 hsa-miR-744* 7 
hsa-miR-644 1,4 & 11 hsa-miR-758 3 & 4 
hsa-miR-645 0 & 8 hsa-miR-763/1207-3p 0, 1, 2,  6 & 11 
hsa-miR-646 2,4, 6 & 11 hsa-miR-765 2, 6 & 10 
hsa-miR-648 1 & 9 hsa-miR-766 2, 5, 6 & 10 
hsa-miR-649 2 hsa-miR-767-3p 1, 2 & 6 
hsa-miR-650 2 & 10 hsa-miR-767-5p 0, 1 & 2 





miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-769-3p 5 & 7 hsa-miR-942 0, 2, 4,  & 10 
hsa-miR-769-5p 5, 6 & 9 hsa-miR-943 0, 2, 4, 9 & 10 
hsa-miR-770-5p 0, 4 & 9 hsa-miR-944 4 
hsa-miR-801 8 hsa-miR-1178 2 & 4 
hsa-miR-802 1, 4, 6 & 9 hsa-miR-1179 6 
hsa-miR-872 7 hsa-miR-1182 1 & 9 
hsa-miR-873 2, 6 & 8 hsa-miR-1183 4 
hsa-miR-874 2, 3, 8 & 10 hsa-miR-1184 3 & 10 
hsa-miR-875-3p.h 1 & 2 hsa-miR-1185 6 & 9 
hsa-miR-875-5p 11 hsa-miR-1197 2 & 8 
hsa-miR-876-5p 1, 2 & 4 hsa-miR-1200 2 
hsa-miR-877 2, 3, 7, 9 &10 hsa-miR-1201 2, 6 & 7 
hsa-miR-885-3p 0, 3 & 8 hsa-miR-1205 1, 2, 3 & 10 
hsa-miR-885-5p 0, 4 & 9 hsa-miR-1206 4 
hsa-miR-886-3p 7 hsa-miR-1207-5p 1, 2, 6, 8 & 9 
hsa-miR-886-5p 0, 7 & 10 hsa-miR-1208 10 
hsa-miR-887 10 hsa-miR-1224-5p 0, 2, 4, 6, 8 & 9 
hsa-miR-888 4 & 11 hsa-miR-1224-3p 0, 2 & 6 
hsa-miR-889 3, 4 & 9 hsa-miR-1225-5p 4 
hsa-miR-890 2, 4 ,6 & 8 hsa-miR-1226/1838 1 
hsa-miR-891b 0 & 1 hsa-miR-1227 4 
hsa-miR-892b 2 & 4 hsa-miR-1228 1 
hsa-miR-920 1, 2, 3, 4, 6 & 10 hsa-miR-1231 2, 4 & 6 
hsa-miR-921 2 & 4 hsa-miR-1236 1, 3 & 4 
hsa-miR-922 4 & 8 hsa-miR-1237 1, 2 & 10 
hsa-miR-924 2, 4 & 11 hsa-miR-1238 3 & 4 
hsa-miR-933 2, 10 & 11 hsa-miR-1243 10 
hsa-miR-935 4 & 12 hsa-miR-1244 4 
hsa-miR-936 4 hsa-miR-1245 0 & 4 
hsa-miR-938 4 & 6 hsa-miR-1248 2 &10 
hsa-miR-939 0, 2, 3, 10 & 12 hsa-miR-1249 10 





miRNAs Predicted Targets miRNAs Predicted Targets 
hsa-miR-1252 0,1,2,4,6 & 8 hsa-miR-1280 6 
hsa-miR-1253 1,2,4,8,10 & 11 hsa-miR-1281 6 
hsa-miR-1254 2 & 6 hsa-miR-1283 4 
hsa-miR-1255b 2 & 10 hsa-miR-1286 2, 4, 8 & 9 
hsa-miR-1256 2, 4 & 9 hsa-miR-1288 11 





hsa-miR-1262 1, 2 & 6 hsa-miR-1293 0, 2, 4, 6, 9 & 10 
hsa-miR-1263 9 & 10 hsa-miR-1294 0, 2 & 4 
hsa-miR-1264 2, 4, 10 & 11 hsa-miR-1296 6 
hsa-miR-1265 0 & 3 hsa-miR-1298 1 & 4 
hsa-miR-1266 2 hsa-miR-1300 1,2, 8, 10 & 11 
hsa-miR-1268 6 hsa-miR-1301 3& 9 
hsa-miR-1269 11 hsa-miR-1302 2,4, 6 & 8 
hsa-miR-1272 4 & 6 hsa-miR-1303 9 
hsa-miR-1273 1 hsa-miR-1304 0, 3 & 4 
hsa-miR-1274a 2,6 & 10 hsa-miR-1305 4 
hsa-miR-1274b 10 hsa-miR-1321 0, 3 & 9 
hsa-miR-1275 2, 6 & 9 hsa-miR-1322 4 & 6 
hsa-miR-1276 1 & 2 hsa-miR-1324 0, 1 & 2 








MicroRNA 320a Functions as a Novel Endogenous Modulator
of Aquaporins 1 and 4 as Well as a Potential Therapeutic
Target in Cerebral Ischemia*□S
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Aquaporins facilitate efficient diffusion of water across cellu-
lar membranes, and water homeostasis is critically important in
conditions such as cerebral edema. Changes in aquaporin 1 and
4 expression in the brain are associated with cerebral edema,
and the lack of water channel modulators is often highlighted.
Here we present evidence of an endogenousmodulator of aqua-
porin 1 and 4.We identifymiR-320a as a potential modulator of
aquaporin 1 and 4 and explore the possibility of usingmiR-320a
to alter the expression of aquaporin 1 and 4 in normal and ische-
mic conditions.We show that precursormiR-320a can function
as an inhibitor, whereas anti-miR-320a can act as an activator of
aquaporin 1 and 4 expressions. We have also shown that anti-
miR-320a could bring about a reduction of infarct volume in
cerebral ischemia with a concomitant increase in aquaporins 1
and 4 mRNA and protein expression.
MicroRNAs (miRNAs)2 regulate mRNA expression by
binding to the 3-UTR (1). As simple as it sounds, identifying
targets for miRNAs remains a challenging task mainly
because each miRNA has hundreds of mRNA targets (2).
Increasing this complexity are emerging reports on miRNAs
binding at 5-UTR as well as promoter regions (3–5). Recent
studies also reveal the possibility of miRNAs functioning as
transcriptional or splicing regulators within the nucleus (6)
and being involved in genetic exchange via exosomes with
adjacent cells (7). Because of this complexity in regulation, of
the hundreds of miRNAs identified in the human species,
only a handful have been assigned their specific targets.
Comparison of miRNA profiles between normal and dis-
eased samples allows the identification of crucial miRNAs
that are altered during disease conditions and enables one to
search for possibilities of altering these expression profiles in
an attempt to normalize or reduce the patho-physiological
conditions of the disease. Changes in the expression of
miRNAs have been reported in several diseases (8–10)
including cerebral ischemia (11–13). Cerebral ischemia is a
highly debilitating condition, and ischemia-induced edema
further increases complications and morbidity (14). The
movement of water into and out of an ischemic brain is
thought to be mainly modulated by aquaporins (AQPs),
especially aquaporin 1 (AQP1) and aquaporin 4 (AQP4).
AQPs are a family of transmembrane proteins involved in
transport of water, glycerol, ions, and even CO2 (15, 16). The
13-member family is ubiquitously expressed in almost all
parts of the human body. Often more than one homolog is
found to be present in any tissue or organ. In the brain AQP1,
3, 4, 5, 8, and 9 have been reported, with AQP1, 4, and 9 being
expressed abundantly (17). The importance of AQP1 and
AQP4 regulation in edema has been highlighted in several
studies (18, 19). AQP4 knockouts in mice showed increased
protection against cytotoxic edema caused by water intoxi-
cation and permanent focal cerebral ischemia, whereas in
conditions leading to vasogenic brain edema, it had a dele-
terious effect (18, 19). siRNA-based studies have paralleled
these findings in which AQP4 knockdown was shown to
reduce the amount of water influx but yet delay its clearance
in astrocytes during hypoxic and subsequent reoxygenation
events (20). Expression of AQP1 and AQP4 were induced in
astrocyte cells surrounding the edematous region (21).
These findings serve to relay the importance of modulating
both AQP1 and AQP4 during cerebral edema, yet with the
exception of mercury, gold, lithium, and ammonium quater-
nary compounds, no other natural modulators of AQPs are
available for in vivo use. In this paper we explore the possi-
bility of using endogenous miRNAs as riboregulators to
modulate the expression of AQP1 and AQP4.
EXPERIMENTAL PROCEDURES
Transient Focal Cerebral Ischemia and Quantitation of
Infarct Volume—Transient focal cerebral ischemia was in-
duced in male Sprague-Dawley rats through middle cerebral
artery occlusion (MCAo) as described by Armugam et al. (22).
The animals were handled according to the guidelines of the
Council for International Organization of Medical Sciences
on Animal Experimentation (World Health Organization,
Geneva, Switzerland) and theNational University of Singapore.
The animal protocols were approved (approval code 081/09) by
* This work was supported by National Research Foundation Grant R-184-
002-165-281, National Medical Research Council Grant EDG: R-183-000-
230-275, and National Kidney Foundation Grant NKFRC/2008/10.
□S The on-line version of this article (available at http://www.jbc.org) contains
supplemental Tables S1 and S2.
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Supplemental Material can be found at:
the National University of Singapore Institutional Animal Care
and Use Committee. Transient ischemic stroke was created in
rat models via MCAo for a period of 1 h. After 1 h of occlusion,
the suturewas removed to allow for reperfusion. Intracerebrov-
entricular administration of anti- or pre-miR-320a was carried
out immediately after the removal of suture. For infarct volume
quantitation, whole rat brain slices were stained in 2,3,5-triph-
enyltetrazolium chloride (Sigma) and fixed in 10% buffered for-
malin. Stained brain slices were scanned, and the images were
analyzed using Scion Image analysis software (22).
Transfection of miRNAs in Astrocytoma Cells—Transfection
procedures of miRNAs were adapted from Cheng et al. (23).
Human anti- or pre-miR320a (anti-miR-320a; 5-UUUUCGA-
CCCAACUCUCCCGCU-3 and pre-miR-320a 5-GCUUCG-
CUCCCCUCCGCCUUCUCUUCCCGGUUCUUCCCGGA-
GUCGGGAAAAGCUGGGUUGAGAGGGCGAAAAAGGA-
UGAGGU-3) at 30 nM final concentration (in 50 l of
Opti-MEM) was complexed with 1 l of NeoFx in 50 l of
Opti-MEM (Ambion, Inc.). The cells were transfected with
these complexes and maintained for 48 h prior to subsequent
work.
Oxygen and Glucose Deprivation—Human astrocytoma cells
(CRL-1718TM, ATCC) were cultured in RPMI 1640 medium
(Hyclone Laboratories) supplemented with 10% fetal bovine
serum, 1% L-glutamine, and 1% penicillin-streptomycin
(Invitrogen) and maintained in a 37 °C incubator with 5% CO2.
The cells were seeded at a density of 1.0 105 (24-well plates)
and subjected to oxygen and glucose deprivationwhere the cells
were maintained in an incubation chamber for 6 h at 37 °C, in
the absence of oxygen, glucose, and serum. Oxygen in the
chamber was displaced with a nitrogen gas flow rate of 1.3
liters/min. Corresponding control cell cultures were main-
tained at 37 °C in a 5% CO2 incubator. After 6 h, the cells were
left to recover at 37 °C in a 5% CO2 incubator for 16–18 h prior
to further work.
Extraction of Total RNA and Protein—Total RNA (including
miRNA) and protein were extracted from cells by a single-step
method using TRIzol (Invitrogen) according to the manufac-
turer’s protocol. The concentration and integrity of RNA were
determined using Nanodrop ND-1000 spectrophotometry
(Nanodrop Tech, Rockland, DE) and RNA gel electrophoresis.
Reverse Transcription andReal TimeQuantitative PCR—Re-
verse transcription followed by real time quantitative PCRwere
carried out according to Jeyaseelan et al. (12). Quantitation of
AQP1 and AQP4 mRNAs was performed using SYBR green
assay. Specific primer sequences were generated using Primer-
Express (Applied Biosystems). (AQP1 forward primer, 5-GAC-
ACCTCCTGGCTATTGACTACA-3; AQP1 reverse primer,
5-CCGCGGAGCCAAAGG-3; AQP4 forward primer, 5-
AGCCTGGGATCCACCATC-3; and AQP4 reverse primer,
5-TGCAATGCTGAGTCCAAAGC-3). For miRNA detec-
tion, reverse transcription followed by stem-loop real time
quantitative PCRs were performed according to the manufac-
turer’s protocols using miR-320a-specific primers (Applied
Biosystems). All of the reactions were conducted on anApplied
Biosystems 7900 sequence detection system.
mRNA and ParafloTM MicroRNA Microarray Assay and
Analysis—The oligonucleotide (DNA) microarray was per-
formed according to the manufacturer’s (Illumina, San Diego,
CA) protocol using 500 ng of total RNA. The ParafloTM
microRNA microarray was performed as described by Jeyas-
eelan et al. (12). The raw data were subtracted from control
samples and further filtered for signal log ratio (1 and1)
determination at a detection probability value of0.01.
SDS-PAGE and Western Blot Analysis—40 g of total pro-
teinwas resolved using 12%Tris-Tricine SDS-PAGE andWest-
ern blot was carried out as described by Satoh et al. (24). The
membranes were probed with primary antibodies (rabbit anti-
AQP1 and AQP4; Santa Cruz Biotechnology) at a concentra-
tion of 1g/ml in 0.5% blocking solution. -Actin was used as a
loading control (Bio-Rad). Secondary antibodies (horseradish
peroxidase-conjugated goat anti-rabbit; Bio-Rad) were used
at a dilution of 1:10,000 in 0.5% blocking solution. The mem-
branes were visualized via enhanced chemiluminescence
(SuperSignal West; Thermo Scientific) with variable expo-
sures (Kodak-MS film). Films ofWestern blots were scanned
(Acer SWZ3300U), and the labeling intensities of the bands
were quantitated using ImageJ software (National Institutes
of Health).
Immunocytochemistry—Immunocytochemistry was per-
formed on astrocyte cell cultures treated with anti- or pre-
miR-320a. Briefly, astrocytes co-transfected with either
AQP1 or AQP4 plasmids and anti- or pre-miR-320a were
fixed with 4% formaldehyde in phosphate-buffered saline for
20 min, permeabilized with 0.1% Triton X-100 in PBS for 30
min, and blocked with 5% FBS in PBST for 30 min. AQP1 and
AQP4 (Santa Cruz Biotechnology) were probed according to
the procedure adapted from Satoh et al. (24). FITC-coupled
secondary antibody was used at dilutions of 1:200. DAPI was
used as a nuclear stain. The images were viewed and analyzed
using LSM510 confocal imaging software (Carl Zeiss Micro-
Imaging Inc.)
Luciferase Assays—Gene-specific primers were used to
amplify the miR-320a binding sites predicted on AQP1 and
AQP4 3-UTR (AQP1 forward primer, 5-ATTAACTAGTCA-
TTCCCTAGCA-3; AQP1 reverse primer, 5-TATGAAGCT-
TCAGGCAGGGGGT-3; AQP4 forward primer, 5-ATTAA-
CTAGTTTTCCTAAAGTG-3; and AQP4 reverse primer,
5-TATGAAGCTTTCACAGGCTAT-3). The PCR products
were cloned into the Firefly luciferase expressing vector
(pMIR-REPORTTM; Ambion) at the SpeI and HindIII sites.
Plasmid transfection procedure was adapted from Cheng et al.
(23). HeLa cells were transfected with 50 nM anti- or pre-miR-
320a for 3 h followed by 100 ng/well pMIR-REPORTTM vector
for 3 h. The cells were lysed 48 h later for measurement of
luciferase activity. Dual luciferase assay (Promega) was used to
quantitate the effects of anti- or pre-miR-320a interaction with
the 3-UTR of AQP1 and AQP4. The assay was performed
according to the manufacturer’s protocol. In all experiments,
transfection efficiencies were normalized to those of cells co-
transfected with the Renilla luciferase expressing vector (pRL-
CMV; Promega) at 10 ng/well.
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To assess the miRNAs that could target AQP1 and AQP4, a
bioinformatic search was performed in the Targetscan and
microRNA.org databases (25–28). Only miRNAs conserved in
mammals were selected for this study. The search yielded 14
miRNAs against AQP1 and 25 miRNAs against AQP4 (Table
1). Among these miRNAs only miR-320 was reported to be
differentially expressed in miRNA profiles of both human
stroke patients and rat ischemic models (12, 13). miRNA pro-
filing of human astrocytoma cells also revealed the presence
of miR-320 among the 148 miRNAs detected (supplemen-
tal Table S1).More recently four different transcripts have been
reported in the database for miR-320 (miR-320a, b, c, and d)
(25–28). The sequence of miR-320 previously reported in the
human and rat ischemic profiles (12, 13) matched that of miR-
320a. Variations between the sequences ofmiR-320a, b, c, and d
were only observed at the 5-UTR. The seed region considered
crucial for target binding remains the same for miR-320a, b, c,
and d, and all four isoforms have been predicted to target the
same region on the AQP1 and AQP4 transcripts. Thus in this
study, we focused on miR-320a. The predicted interaction
regions of miR-320a with the 3-UTR of AQP1 and AQP4 in
humans and rats are shown in Table 2.
miR-320a Modulates AQP1 and AQP4 mRNA Expression—
Based on the assumption that miR-320a binds to the 3-UTR of
AQP1 and AQP4, changes in miR-320a levels should be
reflected in AQP1 and AQP4 gene expression. Hence in an
attempt to change the cellular levels of miR-320a, human
astrocytoma cells were transfected with miR-320a inhibitor
(anti-miR-320a) and precursor (pre-miR-320a) independently.
Changes inmRNAandmiRNA levels were determined. In anti-
miR-320a transfected cells, the relative expression miR-320a
levels was0.204 0.052. This sig-
nifies80% reduction in expression
compared with normal cells (Fig.
1A). Simultaneously an increase in
the AQP1 and AQP4 mRNA ex-
pression was observed (Fig. 1B).
Likewise, introduction of pre-miR-
320a increased miR-320a levels by
180-fold and resulted in a reduc-
tion in AQP1 and AQP4 mRNA
expression (Fig. 1, A and B). Total
RNA extracted from anti- or pre-
miR-320a-treated cells were also
subjected to mRNA array analysis.
The AQP1 and AQP4 expression
data extracted from the mRNA
array (supplemental Table S2) cor-
related with the results obtained
in this study. The AQP1 and AQP4
protein production (Fig. 1C) also
correlated with the gene expres-
sion studies (Fig. 1B). Immunocyto-
chemistry showed increased immu-
noreactivity for AQP1 and AQP4 in
astrocytes treated with anti-miR-
320a and reduced immunoreactiv-
ity in cells treated with pre-miR-
320a (Fig. 1D). These findings
FIGURE 1. Expression of AQP1 and AQP4 in astrocytoma cell line transfected with anti- or pre-miR-320a.
A, relativemiR-320a expression in astrocytoma cell line transfectedwith anti- or pre-miR-320a at a concentrationof
30nM.B, relativemRNAexpressionofAQP1, AQP4 in astrocytomacell line transfectedwith anti- or pre-miR-320a at
a concentration of 30 nM. Statistical analyses were done using t tests. *, p  0.05; **, p  0.01 compared with
respective negative controls. Thedata shownare themeans S.D.,n 3.C, AQP1 andAQP4protein expression in
astrocytomacell line transfectedwith anti- or pre-miR-320a. Changesobserved inmRNAexpressionwere reflected
in protein expression aswell.-Actinwas used as a loading control.D, AQP immunoreactivites in astrocytoma cells
transfected with anti- or pre-miR-320a. Human astrocytes were co-transfected with AQP1 or AQP4 plasmids and
anti- or pre-miR-320a. The cells were fixed and immunolabeled with either anti-AQP1 or anti-AQP4 antibodies
(green) andnuclear stainDAPI (blue). Anti-miR-320a-treatedcells showed increased immunoreactivity forAQP1and
AQP4, whereas pre-miR-320a-treated cells showed a reduction in immunoreactivity.
TABLE 1
miRNAs predicted to target 3-UTR of AQP1 and AQP4
Targets were obtained from TargetScan (version 5.0) (22–24) and microRNA.org
(version January 2008; 25). CommonmiRNAs between AQP1 andAQP4 are shown
in bold type. miRNA-320a is underlined.
Gene miRNAs conserved in mammals
AQP1 miR-28/28-5p/708, 125a-3p, 136, 154, 320a/b/c/d, 328, 346, 370, 378/422a, 488, 544,
592/599, 615-3p, 876-5p
AQP4 miR-186, 224, 290-5p/292-5p/371-5p, 320a/b/c/d, 326/330/330-5p, 342/342-3p, 346,
370, 377, 384/384-3p, 410, 411, 421, 431, 488, 494, 494/1192, 505, 539, 542/542-3p,
543, 544, 590/590-3p, 758, 876-5p
TABLE 2
Predicted binding sites of miR-320a in 3UTR of AQP1 and AQP4
The binding sites for human and rat are indicated. The underlined nucleotides were
subsequently mutated (see Fig. 2 legend) for the 3-UTR-miRNA binding studies.
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suggest that miR-320a functions as a modulator of AQP1 and
AQP4 gene expression.
miR-320a Directly Targets AQP1 and AQP4—To validate
direct interaction of miR-320a with AQP1 and AQP4 mRNAs,
their 3-UTR target sites were cloned into firefly luciferase
reporter plasmids independently. These constructs were co-
transfected with anti- or pre-miR-320a into HeLa cells. Cells
transfected with anti-miR-320a exhibited an increase in the
relative luciferase expression. Likewise, pre-miR-320a caused a
reduction in luciferase expression (Fig. 2). Site-directed
mutagenesis of the miR-320a recognition site located on the
AQP1 and AQP4 3-UTR abolished interactions between the
miRNA and its AQP targets. These results indicate that miR-
320a can directly target AQP1 and AQP4.
miR-320a Can Modulate AQP1 and AQP4 in Oxygen- and
Glucose-deprived Conditions—The results obtained thus far
indicate that miR-320a can modulate AQP1 and AQP4 expres-
sion under normal conditions. Modulation of AQP1 and AQP4
is considered crucial during edematous and ischemic condi-
tions. Thus astrocytes were subjected to oxygen and glucose
deprivation for 6 h, in the presence or absence of anti- and
pre-miR-320a, after which the changes in the AQP1 and AQP4
expression levels were quantitated. AQP1 and AQP4 mRNA
and protein expression were up-regulated after 6 h of oxygen
and glucose deprivation (Fig. 3A). Conversely, of the 84 miR-
NAs that were differentially expressed because of oxygen and
glucose deprivation,miR-320awas found to be down-regulated
(supplemental Table S1). Decreasing miR-320a levels during
oxygen and glucose deprivation with anti-miR-320a further
elevated both AQP1 and AQP4 gene expression, whereas pre-
miR-320a suppressed them (Fig. 3B).
Anti-miR-320a Reduces Infarct Volume—To determine the
correlation between AQP1, AQP4, andmiR-320a expression in
vivo, ischemic animalmodels were used. Cerebral ischemia was
induced in rats by occluding the middle cerebral artery for 60
min. 24 h after restoration of reperfusion, the animals were
sacrificed. Expression levels of AQP1, AQP4, and miR-320a
were determined from theseMCAo brain samples. An increase
in AQP1 and AQP4 mRNA expression was mirrored by a
decrease in the miR-320a expression (Fig. 4, A and D). To
understand the impact of modulation of AQP1 and AQP4 dur-
ing ischemia, intracerebroventricular injections of anti- or pre-
miR-320awere administered to ischemic rats immediately after
MCAo. In anti-miR-320a-injected rats, the relative expression
of miR-320a levels was0.452 0.23, which signifies a55%
reduction in expression compared with ischemic rats. Likewise
in pre-miR-320a injected rats, miR-320a expression increased
to 9.26  2.31 (Fig. 4A). Administration of anti-miR-320a
resulted in a reduction in the infarct volume, whereas pre-miR-
320a caused a further increase in infarct volume (Fig. 4, B and
C). Real time analyses showed that AQP1 andAQP4 expression
was increased with a corresponding reduction in infarct vol-
ume, suggesting that the increased expression was facilitating
edema clearance or recovery (Fig. 4D). An N-methyl-D-aspar-
tate antagonist MK-801 is often used as a positive control for
recovery from ischemia in animal models. When MK-801 was
injected as described byArmugam et al. (22), the animals exhib-
ited increased expression of AQP1 and AQP4 with a concomi-
tant reduction in expression of miR-320a (Fig. 4E).
DISCUSSION
AQP1andAQP4AreDirect Targets ofmiR-320a—This study
examined the possibility of exploiting miRNAs as natural
endogenous modulators of AQP1 and AQP4 expression. With
the help of bioinformatics-based databases (25–28) and pub-
lished reports (12, 13), the search was narrowed down to miR-
320a as a possible modulator of AQP1 and AQP4. Recent stud-
ies have established miR-320a as an inhibitor of the cell cycle
gene (POLR3D) and the transferrin receptor gene (TFRC) (4,
29). OurAQP1 andAQP4 gene expression profiles were similar
FIGURE 2. Relative luminescence in plasmid constructs containing miR-
320a target sites.miR-320a target regions in the 3-UTR of AQP1 and AQP4
were identified using TargetScan and microRNA.org. These regions were
cloned into luciferase reporter plasmids. Mutated 3-UTR constructs were
generated using site-directed mutagenesis. The miRNA recognition sites at
cDNA corresponding to 3-UTR (underlined) were mutated as follows: AQP1
(5-CTGATTCCTCTCATTTAATTTGGCT-3) and AQP4 (5-TTGCCCCATAAGAG-
CAGTCGTCCGG-3). The plasmid constructs together with anti- or pre-miR-
320a were co-transfected into HeLa cells. Luciferase luminescence readings
were obtained 48 h post-transfection. Relative luminescence was obtained
by normalizing the values against control plasmids, pMIR-REPORTTM without
any 3-UTR insert. Statistical analyses were done using t tests. *, p 0.05; **,
p 0.01 comparedwith control. The data shown are themeans S.D., n 3.
FIGURE3.ExpressionofAQP1andAQP4 inastrocytomacells subjected to
6 h of oxygen and glucose deprivation (OGD). A, changes in AQP1 and
AQP4mRNA and protein expression in cells subjected to oxygen and glucose
deprivation. Total cellular RNA and protein were used to quantify AQP1 and
AQP4 levels. Up-regulation of AQP1 and AQP4 mRNA and protein (see inset)
were observed. B, relative AQP expression in cells transfected with anti- or
pre-miR-320a and subjected to 6 h of oxygen and glucose deprivation. The
cells were transfected with anti- or pre-miR-320a 48 h prior to oxygen and
glucose deprivation. All of the values were expressed relative to negative
controls. Statistical analyses were done using t tests. *, p 0.05; **, p 0.01
compared with control. The data shown are the means  S.D., n  3. Ctrl,
control.
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to those of these known targets of miR-320a (supplemental
Table S2). This inhibitory effect was reflected in our in vitro
systems (using astrocytes) under both normal and ischemic
environment. The changes seen in AQP1 and AQP4 mRNA
levels caused by the modulation of miR-320a were also
reflected in the protein expression (immunoblotting and
immunocytochemistry) in a target-specific manner. These
observations together with luciferase binding assays demon-
strate that AQP1 and AQP4 modulation is possible with the
manipulation of miR-320a. The ability to modulate these two
water channels can have a major impact on the outcome of
edema-associated pathologies. AQP1 andAQP4 are considered
the major contributors for maintaining cerebral fluid balance.
In the brain, AQP1 is concentrated around the apical mem-
brane of the choroid plexus epithelia andmoderately present in
the hippocampus and ependymal cells (30). Expression of
AQP4 is extensive in the astrocytic processes adjacent to cere-
bral capillaries and in the pial membranes lining the subarach-
noid space (31). The expression of these two water channels at
strategic locations in the brain
emphasizes their importance in cer-
ebral water transport.
Up-regulation of AQP1andAQP4
Expression in Edema: A Survival
Mechanism?—Enhanced expres-
sion of AQP1 is observed in patho-
logical states, and it is thought to
augment susceptibility to patholog-
ical volume changes and promote
edema formation. Increased AQP1
gene and protein expression was
also observed in cerebral edema
induced by traumatic brain injury
(32). Even though AQP1 in the cho-
roid plexus epithelia contributes to
only 25% of the total cerebrospinal
fluid production, diminishing its
expression improved survival rates
drastically from 25 to 87% in ische-
mic rats (33). Furthermore, reduc-
tion in AQP expression has been
reported to enhance the resistance
of cells against apoptotic stimulus
(34). During apoptosis, cellular
volume decrease is thought to be
mediated via AQP1 (35). The ini-
tial up-regulation of AQP1 expres-
sion followed by an inactivation of
the water channel is considered
crucial for the proper progression
of apoptosis. This suggests that
AQP1 expression is biphasic and
highlights the need for a modula-
tor that could alter its expression
accordingly.
Changes in AQP4 expression
with respect to cerebral edemawere
reported in several studies. These
studies report a peak in the accumulation of cerebral water
content that can occur anywhere from 24 h to 3 days after
MCAo (18, 36). Ribeiro et al. (36) reported a biphasic trend
where the water content peaked at 1 and 4 h afterMCAo. Inter-
estingly, although a range of timings have been reported, these
observations correlatedwith the increase inAQP4 gene expres-
sion levels. These authors proposed that the early up-regulation
of AQP4 is associated with the increase in cerebral edema.
Moreover, AQP4 null mice exhibited a 35% reduction in cere-
bral water content upon induction of ischemia (37).
In our study we show that introduction of anti-miR-320a
causes a further increase in AQP1 and AQP4 expression with a
consequent reduction in the infarct volume, and an introduc-
tion of pre-miR-320a results in an opposite effect of reducing
AQP expression and increasing the infarct volume. Hence the
increase inAQP expression, at least at the 24 h reperfusion time
point, appears to be a part of the survival and recovery process.
Interestingly, a recent study byHirt et al. (38) proposed that the
early up-regulation of AQP4 could indeed be a survival mech-
FIGURE 4.Analyses of brain sections ofMCAoccluded rats injectedwith anti- or pre-miR-320a. A, expres-
sion level of miR-320a in ischemic rat injected with anti- or pre-miR-320a. Changes in miR-320a expression
levels in thebrain sampleswerequantitatedusing stem-loop real timequantitative PCR.B, histological analysis
of brain sections. 2,3,5-Triphenyltetrazolium chloride-stained coronal brain sections (2 mm thick) of rats
injectedwith 50pmol of anti- or pre-miR-320a. Intracerebroventricular injectionsweregiven immediately after
the removal of the suture (n  10). Surviving cells stained red, whereas dead cells remained white. C, infarct
volumeof rat treatedwith anti- or pre-miR-320a. Infarct volumes are expressed aspercentagesof the control
S.E.D, AQP1andAQP4mRNA levels in rats injectedwithanti- orpre-miR-320a. Thedata shownare themeans
S.D.,n10.mRNAexpression correlatedwithprotein expression aswell (see inset). E, relativeAQP1, AQP4, and
miR-320a expression inMK-801 administered ischemic (MCAo) rats. The ratswithMCAocclusionwere injected
with MK-801 to reduce cerebral infarct. All of the values were expressed relative to ischemic rats. Statistical
analyses were done using t tests. **, p 0.01. The data shown are the means S.D., n 10. Ctrl, control.
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anism to reduce edema. Although thrombin preconditioning
had no effect on AQP4 expression in normal rats, upon
ischemia these rats exhibited increased AQP4 expression
and reduced cerebral edema, suggesting that AQP4 increase
might be facilitating edema clearance (38). In a study using a
neutral anticoagulant secretory phospholipase A2 as a neu-
roprotectant, it has been shown that administration of secre-
tory phospholipase A2 reduced infarct volume in rats sub-
jected to focal transient cerebral ischemia. Secretory
phospholipase A2 also alleviated the neuronal damage in
organotypic hippocampal slices subjected to oxygen glucose
deprivation (22). The authors also reported an increase in
expression of AQP4 together with several anti-apoptotic and
pro-survival genes.
In this studywehave also observed an up-regulation inAQP1
andAQP4 expression levels whenMK-801was administered to
MCAo ischemic models. MK-801 is an NMDA antagonist
widely used in animal models to rescue or reduce cerebral
infarct and mimic recovery (39). Ischemic rats injected with
MK-801 exhibited increased AQP1 and AQP4 profiles with
reduced miR-320a expression, paralleling expression patterns
of those injected with anti-miR-320a. These findings suggest
that up-regulation of AQP1 and AQP4 could possibly assist in
edema clearance. A recent report on ischemic human patients
with good recovery and good clinical outcome (modified
Rankin scale,2) also showed a reduction in miR-320 expres-
sion when compared with patients with poor clinical outcome
(modified Rankin scale,2) (13).
Other Targets of miR-320a and Their Possible Implications—
Administration of anti-miR-320a was found to be beneficial in
ischemic rats with a reduction in infarct volume. Although we
show that miR-320a can be used to modulate the expression of
AQP1 and AQP4, one has to accept that introduction of a
miRNA would have a widespread impact on several other
genes. Using miRNApath to gauge the impact of miR-320a
modulation revealed 145 pathways being affected with as
many as 1500 target genes (40, 41). To narrow down the list, 22
pathways (in relation to ischemia) were selected (41). Within
these selected pathways 172 genes were predicted to be targets
of miR-320a (40).
Expression profiles of these 172 predicted targets were com-
pared with our anti- and pre-miR-320a array. 77 genes (includ-
ing AQP1 and AQP4) were found to be up-regulated in
response to anti-miR-320a, whereas they were down-regulated
in response to pre-miR-320a treatments, suggesting that these
genes may be affected by miR-320a via the RNAi mechanism.
From the results shown in supplemental Table S2, we could
hypothesize several possible mechanisms that could have aided
in the reduction of infarct volume caused by anti-miR-320a
administration.
FIGURE 5.Possible pathways/genes affectedbymiR-320amodulation.Compilation of possible genes affected bymiR-320amodulationwas adapted from
the KEGG Pathway Database. Green ovals, targets of miR-320a; green rectangles, other genes in pathway; pink ovals, secondary messenger; blue right arrows,
direct interaction; dashed blue right arrows, indirect interaction; broken red right arrows, AQP interaction.
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Genes such as protein kinase C and MAP kinase 7 (ERK5)
and tubulin (DUSP4) were up-regulated in response to anti-
miR-320a (Fig. 5). Protein kinase C and ERK5 have been
reported to target gap junction protein connexin and affect its
gating status (see review in Ref. 42). Dephosphorylation of con-
nexins opens their configuration and allows the transfer ofmol-
ecules as well as signaling information between adjacent cells,
whereas phosphorylation of connexins closes their conforma-
tion, marking them for degradation and internalization.
Dephosphorylation of connexins during ischemia has been
reported, and this open gating state is thought to propagate
ischemic injury. Studies have shown that the uncoupling of
connexins reduces ischemia-related injuries (43). Up-regula-
tion of protein kinase C and ERK5 by miR-320a might play a
role in uncoupling connexins, thus resulting in protection dur-
ing ischemia. Cytoskeletal protein DUSP4 interacts with con-
nexin channels and is considered important for translocation of
the gap junction protein. The increase in DUSP4 could be due
to the need for the association and internalization of inactive
connexin proteins (42). Although co-localization of connexin
with AQP4 has been reported, the extent of interaction
between these two proteins is not clear. Mixed reports about
their interaction exist (44, 45).
Expression of genes such as Janus kinase (JAK) and receptor
tyrosine kinase (ERBB2)were also increased in response to anti-
miR-320a. These genes are involved in signaling pathways and
have an indirect effect on serine/threonine protein kinase
(AKT) (Fig. 5). AKT, also known as protein kinase B, is impli-
cated in cell survival, induction of protein production, and pro-
liferation. ERBB2 interacts with growth factor receptor bound
protein 2 (GRB2) to stimulate cellular proliferation. Both
ERBB2 and GRB2 are predicted targets of miR-320a. Both
ERBB2 and GRB2 expression are considered crucial for activa-
tion of AKT-mediated survival pathways (46). AKT pathway
activation can inhibit pro-apoptotic proteins such as Bcl-2-as-
sociated death promoter and caspase 9 and thus promote sur-
vival. Influx of Ca2	 ions during ischemia directly or indirectly
triggers a variety of cell responses, one of which is the activation
of the inflammatory pathway. Activation of the AKT pathway
results in the inhibition of glycogen synthase kinase 3, which
can enhance the operation of various pro-inflammatory signal-
ing molecules (47). Thus increasing ERBB2 and GRB2 expres-
sion using miR-320a not only enhances proliferation of ische-
mic cells but also suppresses the inflammatory pathway
possibly via AKT activation. Furthermore ERBB2 activation is
often associatedwith cell migration, a process whereAQP1 and
AQP4 are also implicated (44, 48). Increased expression of
AQP1 and AQP4 are crucial for the formation of cellular pro-
cesses, subsequent cell migration, and proliferation (44, 48).
Several cytoskeletal proteins that aid cell migration or pro-
cesses such as actin remodeling and axon guidance were also
up-regulated because of anti-miR-320a (Fig. 5). Some of these
proteins with predicted target regions for miR-320a are cofilin,
slit homolog 3 protein (SLIT3), and filamin A. SLIT3 is a repul-
sive axon guidance molecule often expressed and secreted by
both endothelial cells and vascular smooth muscle cells. They
are considered crucial for promoting angiogenesis, for they
have been shown to stimulate blood vessel growth in vivo. Apart
from angiogenesis, SLIT3 also stimulates endothelial cell pro-
liferation and promotes cell motility and chemotaxis (49).
Extensive AQP1 expression has also been reported in vascular
endothelia. AQP1 null mice transplanted with cerebral tumors
exhibited reduced vascularity and widespread necrosis, sug-
gesting that AQP1 expression is crucial for proper angiogene-
sis. The fact that anti-miR-320a up-regulates both AQP1 and
SLIT3 genes suggests that the ischemic recovery process via
angiogenesis could have been triggered. Angiogenesis requires
the controlled remodeling of the cytoskeleton, and this is evi-
dent from the up-regulation of cytoskeletal proteins such as
DUSP4, filamin A, and cofilin. Filamin A regulates reorganiza-
tion of the actin cytoskeleton by interacting with integrins,
which were also up-regulated because of anti-miR-320a intro-
duction. Up-regulation of these genes with the removal of miR-
320a in ischemic samples at 24 h of reperfusion suggests that
survival mechanisms are triggered and recovery is underway.
Conclusion—In this study, we have established that miR-
320a can directlymodulateAQP1 andAQP4 gene expression in
both in vitro and in vivo conditions.We have also observed that
administration of anti-miR-320a could bring about a reduction
in infarct volume as well as an increase in the expression of
aquaporins 1 and 4 in animalmodels of cerebral ischemia. miR-
320a is generally implicated with anti-angiogenesis. However,
because of the large number of possible targets, its mode of
action is notwell established.Nevertheless, we have highlighted
several other genes that could possibly be targets ofmiR-320a in
cerebral ischemia.
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